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People with severe mental illness (SMI) die on average 10–20 years younger 
than the general population, including those with morbidity relating to cancer. 
People with SMI face specific barriers to attending cancer screening, 
including for cervical cancer and, as a consequence, they are 
underrepresented in cancer screening generally and have poorer survival 
rates following a positive diagnosis. The aim of this PhD was to develop a 
cervical screening ‘informed-choice tool’ for women with SMI. The tool was 
designed to address barriers to cervical screening uptake in order to help 
women with SMI make an informed choice about participating in screening. 
This research focused on three questions: (1) What are, if any, the specific 
design(s) and theoretical underpinning(s) of informed-choice tools developed 
for people with SMI? (2) What are service users’ and clinicians’ experiences 
of using the tool? (3) Does the tool have any impact on service users’ 
decisional conflict to attend screening?  
 
The tool was informed by a realist review of physical health interventions for 
people with SMI and by a systematic review of informed-choice tools for this 
population, which have now been published. A mixed-methods research 
design was used to develop the tool. The usability and acceptability of the 
tool was tested by service users and clinicians in two NHS Trusts using 
semi-structured interviews and the ‘think-aloud’ method. A preliminary 
evaluation of the tool was conducted to assess the impact on service users’ 
decisional conflict to attend cervical screening sessions. Results from the 
evaluation (n = 25) showed that the tool may have an impact on some 
women who are either overdue for their screening or have never attended. 
This work has resulted in a tool which is usable and acceptable by women 
with SMI and may impact on their screening uptake and hence their mortality 
rates from cervical cancer. An animated video has also been developed to 
illustrate the key findings of the tool. The tool and video have since been 
disseminated widely across the NHS and third sector organisations. Future 
research may involve further assessments of the real-world impact of the tool 
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Overview of thesis 
 
In this thesis, a major health inequality is addressed, namely that people with 
SMI are less likely to engage in cancer screening than the general 
population. Lower uptake is partly due to a number of barriers experienced 
specifically by this group. Although cancer screening saves lives, it remains a 
choice. This research aims to empower women with SMI to be better able to 
make an informed choice.  
 
This thesis covers the development, acceptability and usability of a cervical 
screening informed-choice tool for women with SMI. There is a clear need 
for an intervention to support the uptake of cervical screening for this group. 
First, there was no evidence in the existing literature of any individual-level 
intervention for women with SMI regarding cervical screening (Barley et al., 
2016). Second, cervical screening covers more women than any other NHS 
cancer screening programmes and attendance rates in the UK are 
suboptimal; indeed, in 2018, they dropped to a 20-year low. Third and finally, 
women with SMI face barriers to attending cervical screening, which needs 
to be addressed in any intervention targeted at their specific needs.  
 
The primary aim of this research project was, therefore, to design, 
develop and test an informed-choice tool which improves the ability of 
women with SMI to decide whether to attend cervical screening. This 
project includes women’s own experiences of using this tool, as well as 
feedback from clinicians, to ensure that this study provides a robust 
understanding of what women with SMI require from an informed-choice tool 
20 
 
on cancer screening and, how, in practice, they use it. This tool has been 
theoretically underpinned to ensure its appropriateness and acceptability for 
any future trial evaluation. The tool is currently being disseminated in a range 
of clinical settings. 
 
In Chapter One, the background to this research is introduced. A definition 
of ‘SMI’ is provided, followed by a description of the context for the work, 
namely the overall problem of excess morbidity and mortality in the SMI 
population. A discussion of the prevalence, incidence and impact of cancer in 
people with SMI is provided before highlighting the importance of cancer 
screening and discussing the lower uptake of screening by people with SMI 
than in the general population. Lastly, an overview of strategies to improve 
the uptake of cancer screening by women with SMI in the UK is presented. 
This section introduces the concept of making an ‘informed choice’, an 
essential condition for deciding whether to take up any health intervention, 
and the rationale for deciding, in this study, to develop an informed-choice 
tool as opposed to other decision-making tools. 
 
In Chapter Two, the rationale and protocol for this research are outlined 
before moving to a discussion of the research paradigm and methods 
chosen. This research is underpinned by the Medical Research Council 
(MRC) guidance for developing complex interventions (Craig et al., 2013) 
and, as such, five linked studies were conducted, with each subsequent 
study building on the former. An outline of each study and how it maps onto 




In Chapter Three, a realist review of interventions to increase access to or 
uptake of physical health screening in people with SMI is reported (study 
one), followed by a discussion of how the findings of the review informed the 
development of the informed-choice tool. A paper describing this work has 
been published in a peer-reviewed journal (Lamontagne-Godwin et al., 
2018).  
 
In Chapter Four, a systematic review of the design and evaluation of 
informed-choice tools for people with SMI is described (study two). The 
principal aim of this review was to determine the optimum design of an 
informed-choice tool for people with SMI, based on the available evidence. 
The findings from this review informed the development of the tool. This 
review is aligned with step one of the MRC guidance for complex 
interventions (Development phase). A paper describing this study has been 
published in a peer-reviewed journal (Lamontagne-Godwin et al., 2020). 
 
In Chapter Five, a description of the tool’s development and its theoretical 
underpinnings is provided; the tool was developed using the MRC guidance 
(Craig et al., 2013). The barriers and enablers to cancer screening uptake in 
people with SMI (Clifton et al., 2016), which were underpinned by the 
Theoretical Domains Framework (Cane et al., 2012), are also presented 
here, and a discussion of how the components of the tool were developed to 
address these identified barriers is included. Component behaviour change 
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techniques (Michie et al., 2015) were selected and/or refined to promote 
screening behaviour within the tool.  
 
In Chapter Six, the research key stakeholders (service users and service 
user groups, clinicians and public health policymakers) are introduced. The 
importance of their input in the development of the tool is also discussed. 
Involving stakeholders at every stage of the development of the tool was 
important to ensure the acceptability and usability of the tool by women with 
SMI, and therefore, a description of the process of involving these women in 
refining the tool is provided. An overview of the clinicians’ feedback on the 
first draft of the tool is also provided; this feedback was solicited to ensure 
that the content was clinically accurate and appropriate for testing with 
service users.  
 
In Chapter Seven, study three, the objective of which was to test the 
acceptability of the tool with stakeholders, is presented. Service users and 
health professionals were recruited for this purpose from two NHS Trusts 
during the period from September to November 2018.  
 
In Chapter Eight, study four, the objective of which was to test the usability 
of the tool with stakeholders, is presented. The ‘think-aloud’ method (van 
Someren et al., 1994) was used for this purpose. The readability of the tool 
was assessed, and final changes were incorporated to ensure that the tool 
was acceptable to the various organisations who supported its development 
and who will have a role in its dissemination. These organisations, including 
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Jo’s Cervical Cancer Trust and the West London NHS Trust, supported this 
research by facilitating the recruitment of participants and ensuring the 
information contained in the tool conformed with NHS cervical screening 
guidelines (NHS, n.d.; PHE Screening, 2019). A description of how iterative 
changes were made to produce a version of the tool appropriate for 
preliminary evaluation is provided.  
 
In Chapter Nine, study five, a preliminary evaluation of the tool’s impact on 
cervical screening decision-making with women with SMI, is described. This 
evaluation aimed to establish proof of concept of the tool. Two validated 
scales were selected for this purpose: The Stage of Decision-Making scale, 
which measures 1) an individual’s readiness to engage in decision-making, 
2) progress in making a choice and 3) openness to considering or re-
considering options (O’Connor, 2000 – updated 2003), and the Decisional 
Conflict Scale, which measures five dimensions of decision-making 
(ineffective decision-making, feeling uninformed, feeling uncertain, feeling 
unclear about values and feeling unsupported) (O’Connor, 1993 – updated 
2010). Underpinned by the Theory of Planned Behaviour (Azjen, 1991) and 
using a mixed-method design, the data from this study were used to interpret 
qualitative data from stakeholders on the acceptability and usability of the 
tool in studies three and four.  
 
In Chapter Ten, the findings from the five studies comprising this thesis are 
summarised, alongside a reflection on the unique contribution of this 
research to the field of cancer screening for people with SMI. The 
24 
 
methodological strengths and limitations of the methods chosen for 
developing the tool are also discussed. Lastly, the research implications for 
clinical practice and future research are considered.  
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Chapter One – Introduction to the research 
 
This chapter establishes the background for this study. This thesis addresses 
a major health inequality – namely that people with SMI are less likely to take 
up cancer screening than the general population. This is important because 
cancer screening saves lives. In this chapter, a definition of what is meant by 
‘SMI’ is provided and, to give context to the work, the overall problem of 
excess morbidity and mortality in the SMI population is described. A 
discussion about the prevalence, incidence and impact of cancer in people 
with SMI is then presented before highlighting why cancer screening is 
important and discussing the decreased uptake by people with SMI. Finally, 
an overview of the UK landscape in relation to improving the uptake of 
cancer screening in SMI is provided. This includes a discussion of ‘informed 




1.1 Definition of SMI 
 
There is no standard definition and little consistency in how ‘SMI’, the 
abbreviation for severe mental illness, serious mental illness, or severe and 
enduring/persistent mental illness, is defined in research or practice (Mauritz 
et al., 2013; National Institute for Health and Care Excellence (NICE), 2016; 
Center for Behavioral Health Statistics and Quality, 2017). The UK’s National 
Institute for Health and Care Excellence (NICE) includes in its discussion of 
SMI a clinical diagnosis of schizophrenia, schizotypal and delusional 
disorders, bipolar affective disorder, or severe depressive episodes with or 
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without psychotic episodes (NICE, 2016). In the United States, Kessler et al. 
(2003) defined SMI as any DSM-IV (Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition) disorder lasting for at least 12 months 
(American Psychiatric Organisation, 2000), other than a substance use 
disorder, with a Global Assessment of Functioning (GAF) score <60, 
suggesting moderate to severe mental health symptoms. In Europe, Ruggeri 
et al. (2000) have operationalised the National Institute of Mental Health 
criteria for SMI according to the degree of dysfunction (GAF score ≤50 or 70 
depending on the primary diagnosis) and the duration of treatment (≥2 years) 
for any mental illness.  
 
For this research, the definition of severe mental illness as operationalised 
by NICE (2016) was selected, using the 10th revision of the International 
Statistical Classification of Diseases and Related Health Problems (ICD-10) 
(World Health Organization (WHO), 1992). ICD-10 uses specific codes to 
classify each disorder: schizophrenia spectrum disorders [F20.0-F20.9]; 
schizoaffective disorders [F25]; bipolar affective disorder [F31]; major 
depressive disorder, recurrent, severe without psychotic features [F33.2]; 
and major depressive disorder, recurrent, severe with psychotic symptoms 
[F33.3]. Schizophrenia occurs in approximately 1% of the population, with a 
similar percentage for bipolar affective disorder; schizoaffective disorder is 





1.2 Excess morbidity and mortality in SMI  
 
1.2.1 Excess morbidity in people with SMI 
Comorbidity, defined as the presence of more than one distinct condition in 
an individual (Valderas et al., 2009), and multimorbidity, defined as two or 
more chronic conditions in the same individual (Smith et al., 2012), is 
frequently reported in this group (Reilly et al., 2015). Other than 
cardiovascular disease and certain cancers, physical health conditions found 
to be more prevalent in people with SMI include type 2 diabetes and 
metabolic syndrome (Holt and Mitchell, 2015; Mulligan et al., 2017; Osborn 
et al., 2008), tuberculosis, HIV, osteoporosis, poor dentition, impaired lung 
function, sexual dysfunction and obstetric complications (De Hert et al., 
2011).  
 
Metabolic syndrome is defined by the World Health Organization (WHO) 
(1999) as glucose intolerance, diabetes mellitus and/or insulin resistance, 
with two or more of the following: central obesity (waist-to-hip ratio: ≥0.90 in 
men and ≥0.85 in women and/or body mass index >30kg/m2), raised arterial 
pressure (≥140/90 mm Hg), microalbuminuria (≥20 μg/min or albumin: 
creatinine ratio ≥30 μg/mg) and raised plasma triglyceride (≥ 150 mg/dl) 
and/or low HDL-C (High-density lipoprotein – cholesterol<35 mg/dl in men 
and <39 mg/dl in women)]. A systematic review (Mitchell et al., 2013) 
reported a significantly higher prevalence of metabolic syndrome in people 
with SMI than in the general population. Several factors contribute to these 
elevated rates of morbidity, including the metabolic effects of antipsychotic 
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medications, poor diet, the impact of symptoms on motivation and increased 
sedentary behaviour.  
 
In addition to metabolic syndrome and the other conditions mentioned above, 
people living with SMI have five times the risk of dyslipidaemia (imbalance of 
lipids in the bloodstream), three times the risk of hypertension and metabolic 
syndrome, and double the risk of obesity and diabetes compared to the 
general population (Allison et al., 2009; Bradshaw and Mairs, 2014; 
Dickerson et al., 2006; Mangurian et al., 2016). People with SMI are also at 
greater risk of developing bowel cancer, as obesity is an important risk factor 
for this (Bhaskaran et al., 2014; Renehan et al., 2008). 
 
The epidemiological evidence around cancer incidence for people with SMI 
is mixed (Osborn et al., 2013; Weinstein et al., 2016). Some studies have 
found the incidence for this group to be higher than for the general 
population (Lichtermann et al., 2001; McGinty et al., 2012; Pandiani et al., 
2006). Other studies have found it to be lower (Barak et al., 2005, 2008; 
Chou et al., 2011; Grinshpoon et al., 2005; Ji et al., 2013; Lin et al., 2013) or 
equal (Goldacre et al., 2005; Levav et al., 2007, 2009). The potential for 
schizophrenia to serve as a protective factor for cancer has been explored, 
though the evidence is mixed (Catts et al., 2008; Hodgson et al., 2010; 
Tabares-Seisdedos et al., 2011). Biological factors have been brought 
forward to explain the reduced risk (Abel et al., 2006; Goldacre et al., 2005), 
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such as the p53 gene, which produces, through apoptosis,1 the effect of both 
disrupting neurodevelopment and reducing the cancer risk (Park et al., 2004; 
Yang et al., 2004). Another gene, adenomatous polyposis coli, a key tumour 
suppressor gene, may confer susceptibility to schizophrenia and also be 
associated with reduced vulnerability to cancer in schizophrenia (Cui et al., 
2005). Environmental and behavioural factors (such as reduced exposure to 
occupational carcinogens and sun rays and greater physical health 
screening in some environments) were also put forward as potential 
protective factors. Nonetheless, even if there is a decreased risk of cancer 
for people with SMI, many of the risk factors for metabolic and cardiovascular 
diseases, which this group is at increased risk of developing, overlap with 
those for cancer (Hodgson et al., 2010). 
 
In addition, there is a high prevalence of smoking in people with SMI; 
between 30% and 70% of people with SMI smoke, compared with 20% of the 
general population (Peckham et al., 2016). Studies have shown that up to 
70% of psychiatric inpatients are smokers, and of those, approximately 50% 
smoke heavily (20+ cigarettes/day) (Coulthard et al., 2002; Kelly and 
McCreadie 1999). Smoking rates are lower for people with SMI who live in 
the community and have less severe psychiatric symptoms; around 40% of 
this group smoke, almost 30% of whom do so heavily (Farrell et al., 2001; 
O’Brien et al 2002). People with SMI usually start smoking at a younger age 
than smokers with no mental illness (Weiser et al., 2004) and they usually 
 
1 Apoptosis is a type of cell death in which a series of molecular steps in a cell lead to its 




smoke more cigarettes a day than smokers without SMI; up to 50% of people 
with SMI smoke heavily compared with approximately 9% of the general 
population (Jochelson and Majrowski, 2006; Tsoi et al., 2010). People with 
SMI who smoke are less likely to get support to quit and are more likely to 
develop smoking-related illnesses than the general population of smokers 
(Gilbody et al., 2019; Szatkowski and McNeill, 2013). Smoking is the largest 
risk factor for cardiovascular disease and premature death for this group 
(Peckham et al., 2016).  
 
The evidence presented in this section points to excess morbidity in this 
group; high rates of long-term conditions such as diabetes, cancer, 
cardiovascular disease, chronic obstructive pulmonary disease and obesity 
are reported. These can complicate treatment and contribute to poorer 
outcomes (Gilbody et al, 2019; Howard et al., 2010; Kisely et al., 2015; 
Weinstein et al., 2015). These compounding elements may have an impact 
on the excess mortality rate of people with SMI, which is discussed in the 
following section.  
 
1.2.2 Excess mortality in people with SMI 
Within the general population, people with SMI face one of the greatest 
health inequality gaps (Lawrence and Kisely, 2010). Reducing this gap is a 
key public health priority for the National Health Service in England (NHS 
England, 2016a). A reduced life expectancy of 10–20 years for individuals 
with SMI compared to the general population has been reported in the UK 
(Brown et al., 2010; Dutta et al., 2012; Hayes et al., 2017) and in other high-
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income countries, such as the United States, the Nordic countries, Japan 
and Israel (Chesney et al., 2014; Laursen et al., 2007; Nielsen et al., 2013; 
Wahlbeck et al., 2011). A systematic review and meta-analysis, which 
included studies (n = 203) representing 29 countries, found that people with 
SMI have a twofold to threefold increased risk of premature mortality; people 
who have, at some point, been admitted to hospital had a significantly higher 
mortality rate compared to outpatients who have never been admitted 
(Walker et al., 2015). Higher inpatient mortality may be because this 
population tends to have more severe psychiatric symptoms and poorer 
overall health (Crump et al., 2013a). Findings from the review suggest a 
pattern of increased risk of premature mortality in Europe (n = 125), primarily 
Sweden (n = 30) and the UK (n = 18); North America: United States (n = 42) 
and Canada (n = 9); Asia (n = 16); Australia (n = 8); Africa (n = 2) and South 
America (n = 1). Of the 203 studies, the risk ratio on all-cause mortality in this 
group was reported for 148 studies. Of those, 135 studies reported mortality 
for people with SMI as significantly higher than the comparison group, while 
14 studies reported no significant difference. No studies reported a lower 
mortality risk in this group (Walker et al., 2015).  
 
The authors of an earlier systematic review (Saha et al., 2007) reported that 
people with schizophrenia have two-and-a-half times the risk of mortality 
compared with the general population. The data were identified in articles2 (n 
= 37) from 25 countries, primarily in Europe (n = 24); North and South 
America (n = 11); Asia: (n = 9); Australia (n = 2) and the Middle East (n = 1) 
 
2 Some articles reported studies from more than one country. 
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(Saha et al., 2007). Therefore, internationally, there appears to be strong 
evidence of increased mortality. Additionally, the authors found that the 
mortality gap between individuals with schizophrenia and the general 
population increased over the period of the review, which took place between 
1980 and 2006 (Saha et al., 2007).  
 
In the UK, a nationally representative cohort study using primary care 
electronic health records between 2000 and 2014 found that the mortality 
gap between the general population and individuals with bipolar disorder and 
schizophrenia is widening (Hayes et al., 2017); this increasing mortality gap 
has been reported elsewhere (Hodgson et al., 2010; Lomholt et al., 2019; 
Nielsen et al., 2013). Authors highlight the fact that health improvements in 
people with SMI are increasing at a slower rate than in the general 
population, and that health inequalities for this group are growing despite 
significant public health efforts to address this issue. Other factors 
contributing to health inequalities, which can lead to premature mortality, 
include barriers to accessing preventive health services by people with SMI. 
There is also some evidence that addressing negative health behaviours, 
such as smoking, has been more effective in the general population than for 
people with SMI. For people with bipolar disorder, polypharmacy is 
increasingly common and could be contributing to the worsening 
cardiovascular disease mortality compared with the general population over 
the 2010–2014 period. Recent deinstitutionalisation in the UK may have also 
led to reduced support and care for people living with SMI in the community, 
which may be reflected in mortality rates. Finally, austerity measures 
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following the 2008 financial crash may have disproportionately hit people 
with SMI who may lack social safety-nets, which may further worsen their 
health. 
 
Norman and Ryrie (2009) reported that while approximately 40% of 
premature deaths in people with SMI are linked to suicide and accidents, a 
significant cause of the mortality disparity is attributed to preventable and 
treatable long-term physical health conditions, with cardiovascular disease 
and cancer as the first and second leading cause of death, respectively, in 
individuals with SMI (De Hert et al., 2011; Tran et al., 2009). While the 
epidemiological evidence regarding cancer incidence in people with SMI is 
inconsistent, excess cancer mortality in people with SMI has been reported 
consistently. Cancer was, therefore, selected as the disease focus for this 
study.  
 
1.3 Cancer in people with SMI  
 
1.3.1 Excess cancer mortality rates in people with SMI 
Several studies in the UK and other high-income countries have found that 
individuals with SMI have disproportionately higher cancer mortality rates 
than in the general population (Batty et al., 2012; Cook et al., 2014; Crump et 
al., 2013b; Ferron et al., 2011; Howard et al., 2010; Kisely et al., 2012; 
Weinstein et al., 2015). In comparison with the general population, mental 
health service users under the age of 75 in England have death rates that 
are two times higher for cancer (Public Health England, 2018). A prospective 
cohort study of patients with schizophrenia (n = 3470) was undertaken in 
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France (Tran et al., 2009), and during the 11-year follow-up, 14% of patients 
with schizophrenia had died. In this cohort, after suicide (n = 143), cancer 
was the second leading cause of death (n = 74), with a global standardised 
mortality rate of 1.5 (95% CI, 1.2‐1.9). The cancer-related mortality rate was 
almost four times higher than in the general population; breast cancer was 
the most frequent neoplasm for women (n = 11), while for men, it was lung 
cancer (n = 23).  
 
In Australia, Kisely et al. (2013) led a population-based record-linkage 
analysis, comparing mental health patients with the general population of 
Western Australia using an inception cohort. Mental health records were 
linked with cancer registrations and death records from 1988 to 2007. 
Cancer mortality was found to be 30% higher in people with SMI than in the 
general population (Kisely et al., 2013).  
 
Findings from the UK Schizophrenia Commission (2012) indicated that 
people with schizophrenia who develop cancer are three times more likely to 
die than those in the general population. Also in the UK, a data-linkage study 
in South-East London (Chang et al., 2014) found that people with SMI and 
other mental disorders had significantly worse survival rates after a cancer 
diagnosis, independent of the cancer stage at diagnosis.  
 
In Canada, authors reported a significantly higher risk of cancer mortality for 
people with SMI (Kisely et al., 2008). Results from a more recent Canadian 
study showed that among adults presenting with malignancies, use of mental 
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health services before a cancer diagnosis is independently associated with 
worse cancer-specific mortality and all-cause mortality (Klaassen et al., 
2019).   
 
1.3.2 Causes of excess cancer-related mortality 
One key cause of excess cancer-related mortality to consider in this group is 
the inequity of access to specialist medical treatment and care (Kisely et al., 
2013, 2015). A reduced likelihood of undertaking chemotherapy and 
radiotherapy has been reported for a range of cancers in people with SMI 
(Baillargeon et al., 2011; Chang et al., 2014; Irwin et al., 2014, Obuchi et al., 
2014, Weinstein et al., 2016). Additionally, people with schizophrenia have a 
higher rate of complications and mortality following surgery (Cook et al., 
2014); for example, findings have shown that women with SMI undergoing a 
mastectomy are more likely to have complications and longer stays in 
hospital settings (Loh et al., 2006).  
 
Results from a US study led by Weinstein (2015, 2016) on cancer screening, 
prevention and treatment in people with SMI highlight three factors that may 
play a role in reduced rates of oncology treatment uptake. The first is 
fragmented health services, that is the lack of communication between 
primary, oncology and mental health professionals. The second is health 
professionals’ stigmatising behaviour towards people with SMI, for instance, 
when a patient has poor hygiene due to self-neglect or where the symptoms 
of their mental illness make them behave aggressively (Ziedonis et al., 
2007), and the last is ‘diagnostic overshadowing’.  Diagnostic overshadowing 
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is the attribution of an individual’s symptoms to their mental condition when 
such symptoms suggest a comorbid condition, which may also delay 
appropriate diagnosis and treatment, especially for people with psychosis 
(Cook et al., 2014; Howard et al., 2010). In addition, people with SMI are 
more at risk of social isolation (Kilbourne et al., 2008), low income (Ferron et 
al., 2011; Sylvestre et al., 2018) and homelessness (Aubry et al., 2015), 
which all present challenges to the provision of cancer treatment and 
palliative care, as these factors contribute to whether people access 
healthcare services (Cook et al., 2014; Weinstein et al., 2015).  
 
Another important factor which contributes to poorer survival rates of people 
with SMI after a cancer diagnosis is unequal access to cancer screening 
(Chang et al., 2014; Cunningham et al., 2015). A Western Australia data 
linkage study found that people with SMI are more likely to present with 
metastases at diagnosis (7.1%) than the general population (6.1%) (Kisely et 
al., 2013). A delayed cancer diagnosis, which may be due to postponements 
in help-seeking due to mental health symptoms (Cook et al., 2014), may not 
fully explain the mortality differential, but it is an important factor. Among 
women with SMI, delays in help-seeking are particularly problematic because 
women may be at an increased risk of invasive cervical cancer due to the 
prevalence of other risk factors for cervical cancer. These include a lifetime 
incidence of sexual abuse (69%), high rates of smoking and risky sexual 
behaviour associated with manic episodes (Anderson et al., 2016; De Hert et 




This section has highlighted that cancer mortality in people with SMI is higher 
than in the general population, which has been evidenced in studies across 
several countries. One key factor which explains the excess mortality in this 
group is a delayed diagnosis, which may, in part, be due to the reduced 
uptake of cancer screening programmes. Lack of uptake is the risk factor for 
cancer addressed in this thesis; specifically, in relation to cervical screening. 
This is discussed in the following section. 
 
1.4 Low cancer screening uptake in people with SMI 
Screening, and the resulting early detection and treatment, has been shown 
to reduce mortality and morbidity from certain cancers (Kalager et al., 2010; 
Stang and Jöckel, 2018). As a public health intervention, cervical screening 
can achieve reductions in cancer incidence by up to 80% where practised 
effectively (Ogilvie et al., 2013). There is some indication that cervical 
screening contributes to reducing the presentation of malignant (cancerous) 
tumours, the two most common tumours of the cervix being squamous cell 
carcinomas (around 80-85% of cases) and adenocarcinoma (around 15-20% 
of cases) (Wang et al., 2004). Evidence shows that cervical screening is 
more effective for detecting the first tumour type (Sasieni et al., 2009). 
Delayed diagnoses can partly be addressed by attending health screening 
(Kalager et al., 2010), but only if people with SMI attend both screening and 
subsequent appointments at the same rate as the general population. 
Relative to the general population, some health services tend to be 
underused by people with SMI (Druss, 2007), including preventive and 
screening services, such as cancer screening programmes and dental 
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checks (Bardi and Moorley, 2016; Kisely et al., 2015; John et al., 2018; 
Lamontagne-Godwin et al., 2018). This reduced uptake in cancer screening 
can often be explained by the fact that these programmes do not address the 
underlying psychological variables that may influence a person’s decision to 
attend the screening (Bish et al., 2000). As mentioned earlier (section 1.3.2), 
there is a high prevalence of trauma, including physical and sexual abuse, 
among people with SMI (Anderson et al., 2016); this may impact on their 
decision to attend cancer screening (Clifton et al., 2016). A literature review 
of the barriers to cancer screening in SMI is reported in Chapter Five (section 
5.1).  
 
In contrast to their uptake of screening programs, people with SMI access 
non-psychiatric medical care, such as acute and emergency care, at much 
higher rates than individuals without mental illness as a result of the 
increased prevalence of poor physical health (Dismuke and Egede, 2011; 
Jayatilleke et al., 2018). Authors from a UK study reported that in 2013/14, 
people with mental illness had 3.2 times more Accident and Emergencies 
attendance and 4.9 times more emergency inpatient admissions than people 
without mental illness (Dorning et al., 2015). This indicates that people with 
SMI may experience unique obstacles (or ‘barriers’) in their preventive care 
pathway that go beyond access to general healthcare (Xiang, 2015).  
 
Evidence on cancer screening uptake indicates that for a range of cancers, 
screening attendance is significantly lower in people living with SMI 
compared to the general population. Solmi et al. (2019) led a prevalence and 
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comparative meta-analysis of 4.7 million people with mental illness to explore 
world-wide disparities in cancer screening uptake in people with SMI across 
the world in comparison with the general population. Attending cancer 
screening appointments was found to be significantly less frequent in people 
with any type of SMI compared with the general population for any cancer 
(k=37; OR 0·76 [95% CI 0·72–0·79]), breast cancer (k=27; 0·65 [0·60–0·71]), 
cervical cancer (k=23; 0·89 [0·84–0·95]) and prostate cancer (k=4; 0·78 
[0·70–0·86], but not for colorectal cancer (k=8; 1·02 [0·90–1·15]) (Solmi et 
al., 2019). In a prior review conducted by Howard et al. (2010), evidence 
suggested (n = 12 studies: United States (n = 8), one each in Iceland, 
Canada, Australia and the UK) that adults with SMI were less likely than 
other groups to receive screening for a range of cancers (cervical, breast, 
colorectal and prostate cancer). Another review (n = 16 studies: United 
States (n = 10), Canada (n = 4), one in Taiwan and one study that included 
10 European countries; Happell et al., 2012) showed that most studies 
demonstrated a 20–30% reduced likelihood of cervical screening attendance 
in the SMI population. Authors of a subsequent review (Aggarwal et al., 
2013) of breast and cervical screening uptake in the SMI population (n = 19 
studies: Australia (n =1), Canada (n = 2), UK (n = 1), US (n = 15)), which also 
included studies in people with depression and anxiety disorders, reported 
similar findings.  
 
There was considerable overlap between the three reviews, which all 
showed a reduced uptake of cancer screening in people with SMI. Results 
from two Japanese studies (Fujiwara et al., 2017; Inagaki et al., 2018) have 
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also found rates of cancer screening to be 40% lower for people with 
schizophrenia. Authors from a recent cross-sectional study using the UK 
Biobank reported that more severe depressive symptoms were associated 
with reduced participation in cervical and breast screening programmes 
(Niedzwiedz et al., 2020). In the US, the severity of mental health diagnoses 
is strongly associated with lower initial and follow-up breast screening rates 
(Carney and Jones, 2006; Weinstein et al., 2019), while in Denmark, an 
observational study showed a strong association between psychiatric 
morbidity and an increased likelihood of non-participation in breast cancer 
screening (Jensen et al., 2016). 
 
A scoping review of access to screening by people living with SMI from 
London’s African Caribbean communities considered all types of cancer 
screening (MacAttram and Chinegwundoh, 2014). Key findings suggested 
that currently no strategies exist to ensure that people living with mental 
illness are included in cancer screening programmes; involvement in cancer 
screening by this population is unrecorded, the needs of psychiatric inpatient 
groups are not considered and mental health and cancer screening service 
providers do not collaborate. Lastly, the ethnicity of screening attenders is 
not recorded, so it is unclear whether people with SMI in some Black, Asian 
and Minority Ethnic (BAME) groups attend cancer screening to the same 
extent as White British people with SMI. General population studies have 
shown that women from BAME backgrounds are less likely to attend cervical 
and breast screening than White British women (Marlow et al., 2015; Moser 




With regards to bowel cancer screening, a cohort study (n = 80,670) in the 
US (Baillargeon et al., 2011) found that people diagnosed with a mental 
disorder up to two years before their cancer diagnosis were more likely to 
die of any cause (hazard ratio (HR) = 1.33, 95% CI (confidence interval) = 
1.31–1.36) or colon cancer (HR = 1.23, 95% CI = 1.19–1.27). UK uptake of 
cancer screening is lower among the most socioeconomically deprived, 
women with disabilities, black and minority ethnic populations, and those 
with learning difficulties (Duffy et al., 2017).  
 
This section has highlighted the reduced uptake of cancer screening 
programmes in people with SMI, as reported in the UK and internationally. 
The focus of this thesis is cervical screening uptake in women with SMI; the 
following section presents the current evidence specific to this type of 
screening. 
 
1.4.1 Cervical screening uptake in women with SMI: the UK and international 
figures 
Similar to other types of cancer, reduced uptake of cervical screening in 
women with SMI has been reported in several UK and international studies 
(e.g. Abrams et al., 2012; Aggarwal et al., 2013; Druss et al., 2010; Fang et 
al., 2011; Fujiwara et al., 2017; Howard et al., 2010; Inagaki et al., 2018; 
James et al., 2017; Martens et al., 2009; Mo et al., 2014; Tilbrook et al., 




In the UK, based on the primary care records of 1.7 million primary care 
patients, women with schizophrenia were less likely to have had a cervical 
sample taken in the preceding five years (63%) compared with the general 
population (73%) (NHS Employers, 2018). In Canada, Martens et al. (2009) 
reviewed records of women (n = 338 514) and found a 30% decrease in 
cervical screening rates among women with schizophrenia compared to the 
general population. Another Canadian study reported that women with 
psychosis were more than five times less likely to receive adequate cervical 
screening compared with the general population despite their higher rates of 
smoking and a higher number of primary care visits (Tilbrook et al., 2010). 
Given that the study took place in a setting that specifically aimed to provide 
primary care to people with SMI, it is possible that rates of uptake would be 
even lower in other clinical settings. Other studies (Druss et al., 2010; Fang 
et al., 2011) have found lower rates of cervical screening among women with 
SMI, particularly among older women and those living with schizophrenia or 
other psychotic disorders.  
 
A US study (Xiang, 2015) found that serious psychological distress (n = 
1340) was associated with 41% lower odds of being up to date with cervical 
screening among women eligible for screening. Another US study (James et 
al., 2017) found that only 20.2% of women in California with SMI received 
cervical screening during one year compared with 42.3% of Californian 
women in the general population. Women with bipolar disorder were also 
significantly more likely than those with schizophrenia to have been 
screened. In contrast, the authors of a study in Maryland, United States 
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(Abrams et al., 2012) reported higher cervical screening rates in women with 
mental illness compared with controls without a diagnosis of mental illness. 
The authors concluded that a higher rate of screening uptake by women with 
SMI may be because study participants were enrolled in Maryland’s 
Medicaid programme; Maryland is a wealthy US state with a well-funded 
public mental health system. 
 
Eligible SMI patients in a London data linkage study were almost 60% less 
likely to have received cervical screening than women without SMI 
(Woodhead et al., 2016). Having a diagnosis of schizophrenia and receiving 
depot medication (suggesting severe illness) were associated with the lowest 
odds of uptake of cervical screening among women with SMI. A depot 
antipsychotic prescription is a special preparation of the medication which is 
given by injection; it is slowly released into the body over several weeks 
(Royal College of Psychiatrists, 2015). Being prescribed depot injections may 
indicate a difficulty with self-management, which in turn might reduce the 
likelihood of attending cancer screening (Woodhead et al., 2016). Health 
systems vary between countries (even within countries, such as the United 
States), but reduced rates of screening for people with SMI have been found 
in all but the one study discussed above (Abrams et al., 2012).  
 
This section has highlighted the reduced uptake of cervical screening by 
women with SMI in the UK and internationally. The following section 
summarises cervical cancer incidence and risk factors. The UK’s cancer 
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screening programme is then briefly introduced to provide a background to 
the setting of this research. 
 
1.5 Cervical cancer and UK’s cancer screening programme 
 
1.5.1 Cervical cancer: a brief overview 
Cervical cancer is the second most common cancer in women, and the most 
common cancer in women aged 35 and under (Jo’s Cervical Cancer Trust, 
n.d.). Cervical cancer is the fourth most commonly diagnosed cancer and the 
fourth leading cause of cancer-related death; an estimated 527,600 cases 
and 265,700 deaths worldwide were attributed to cervical cancer in 2012 
(Ferlay et al., 2012). In high-income countries, it is the second most 
frequently diagnosed cancer after breast cancer and is the third leading 
cause of cancer-related death after breast and lung cancers (Ferlay et al., 
2012).  
 
Cervical cancer is now a preventable and curable illness following the 
introduction of cervical screening and HPV vaccination programmes 
(Banerjee, 2017) and 100,000 deaths from cervical cancer are estimated to 
have been prevented by the UK national screening programme since its 
initiation in 1988 (Peto et al., 2004). The main risk factor for cervical cancer is 
chronic and persistent infection with human papillomavirus (HPV) (Villain et 
al., 2015), and another risk factor is to never have been screened or being 
under-screened (Lofters et al., 2007). In a data linkage study comparing 
women with SMI to the general population in Western Australia, cancer-
specific mortality for women with SMI was found to be high for 
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gynaecological cancer (risk ratio: 1.26) with a reduced likelihood of surgery, 
especially for resection (surgical removal of tissue) of cervical cancers 
(hazard ratio: 0.73). It is also the highest increased risk of mortality in people 
with schizophrenia (hazard ratio: 1.96) (Kisely et al., 2013). 
 
In England, data suggest higher cervical cancer mortality in women living in 
the most deprived quintile of areas nationally compared with those living in 
the least deprived quintile. Relative survival increases over time: at one year 
there is a 6% gap in relative survival; this gap in relative survival increases to 
11% at the five-year mark (Trent Cancer Registry, National Cancer 
Intelligence Network and the NHS Cervical Cancer Screening Programme, 
2012). In the UK general population, incidence rates for cervical cancer are 
projected to rise between 2014 and 2035 by 43% (Cancer Research UK, 
2014), which is a projected average annual percentage change of 1.65 for 
the same period (Smittenaar et al., 2016). Though the incidence rate is 
projected to fall for the over-75 age group, the overall projected increase in 
cervical cancer incidence is driven by changes in the 25–49 and 50–64 age 
groups (Smittenaar et al., 2016). The following section briefly introduces the 
UK’s cancer screening programmes.  
 
1.5.2 UK cancer screening programmes 
Earlier research has shown that screening can reduce cervical cancer 
mortality and that a reduction in incidence and mortality seems to be 
proportional to the intensity of the screening efforts (Laara et al., 1987; Miller 
et al., 1976). It has been reported that the uptake of new cancer screening 
46 
 
programmes can be low, particularly in the target groups who are most at 
risk of developing cervical cancer (Makuc et al., 1989).  
 
Three universal cancer screening programmes are offered in the UK once 
the required age is reached. These are for bowel, breast and cervical cancer. 
Risk-stratified screening is offered for a range of other cancers, such as lung 
cancer (NHS Choices, 2018). Cervical screening was selected as the focus 
of this research since women aged 25–64 are eligible for cervical screening, 
ensuring a suitably large and diverse sample set. When compared to breast 
screening, which counts women aged 50–70 in its eligibility, and bowel 
screening, where those aged 60–69 form the standard eligibility group and 
those aged 70–75 can be included on request, the decision to focus on 
cervical screening was made with a view that the potential impact of the work 
would be greater due to the larger numbers of people affected.  
 
Attendance rates for cervical screening in the UK have been suboptimal for 
the past two decades, in 2018 dropping to a 21-year low: in England, 71.4% 
of eligible women attended cervical screening (NHS Digital, 2018). This is 
the lowest rate since 1997 and a decrease from 75.7% in 2011 (Jo’s Cervical 
Cancer Trust, 2016).  
 
1.6 Improving access and uptake of cancer screening in SMI 
 





People living with SMI are not consistently being offered appropriate or 
timely physical health assessments – which include cancer screening – 
despite being at an increased risk of poor physical health (Lawrence and 
Kisely, 2010), and therefore, making screening more accessible for people 
with SMI is an important healthcare policy for the UK Department of Health 
(2011) and Public Health England (PHE) (Syson-Nibbs, 2018). PHE has 
been addressing this by undertaking a survey of cancer screening uptake 
among people with SMI using the ‘Health Improvement Network’ database of 
GP records. The results will form a baseline from which change can be 
measured (Public Health England, 2018). In the Five Year Forward View for 
Mental Health (NHS England, 2016b), NHS England has committed to 
leading work to ensure that by 2020/21, 280,000 people living with SMI will 
have had their physical health needs met by increasing early detection and 
expanding yearly access to evidence-based physical care assessment and 
intervention.  
 
To address this reduced uptake of and access to health screening, incentive 
schemes in the NHS, such as the Quality and Outcomes Framework (QOF) 
and the Commissioning for Quality and Innovation (CQUIN) schemes, have 
been utilised (British Medical Association, 2003; NHS England, 2019). For 
instance, under QOF, GPs are incentivised to offer annual physical health 
reviews to people with diagnoses of schizophrenia or bipolar disorder, 
including, since 2006, the offer of age- and gender-appropriate cancer 
screening (British Medical Association, 2006). A QOF indicator [MH-008] 
established in 2010 incentivises GPs to ensure that women with 
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schizophrenia, bipolar affective disorder or other psychoses are given 
cervical screening according to national guidelines (NHS Employers, 2018).  
In the NHS, the care pathways that manage the physical health of people 
with SMI are organised in two ways, depending on whether the patient is 
registered in secondary (mental health services) or primary care only.  
 
Primary care teams are responsible for carrying out annual physical health 
assessments and follow-up care for people with SMI who are not in contact 
with secondary mental health services, including both those whose care has 
always been solely in primary care and those who have been discharged 
from secondary care. This also includes patients with SMI who have been in 
contact with secondary care mental health teams (with shared care 
arrangements in place) for more than 12 months and/or whose condition has 
stabilised (NHS England, 2018). GPs can use an online physical health 
recording template (the ‘Bradford Template’), which includes a review of their 
patient’s blood tests to monitor their cardiovascular and type 2 diabetes 
risk/management, their smoking and alcohol intake habits, their sexual health 
and whether they are up to date on cancer screening (NHS England, 2016c).  
Secondary care teams are responsible for carrying out annual physical 
health assessments and follow-up care for patients with SMI under the care 
of a mental health team for less than 12 months and/or whose condition has 
not yet stabilised and for inpatients. A clinical resource (the ‘Lester tool’) is 
available for secondary care health professionals to assess patients’ 
cardiovascular health (Shiers et al., 2014). The tool is in widespread use to 
support the implementation of the physical health (CQUIN – Commissioning 
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for Quality and Innovation) targets. These targets aim, through remuneration, 
to improve collaborative and effective physical health monitoring and 
management of common physical health conditions and risk factors in people 
with psychotic illnesses (e.g. smoking, lifestyle, obesity, hypertension, 
diabetes and hyperlipidaemia, though not specifically cancer screening). The 
Bradford physical healthcare template is aligned with the Lester 2014 tool 
(NHS England, 2016c). 
 
It is not known whether these measures influence screening uptake by 
people living with SMI. A report (2013) by Rethink – a national mental health 
charity in the UK – found that in some areas, only 30% of people living with 
SMI had received their physical health review, suggesting that the 
incentivisation appears to have been relatively ineffective in some areas. The 
latest figures show little variation: in England, 32.3% of people on the GP 
mental health register on the 31st December 2019 had received their physical 
health review in the preceding 12 months (NHS England, 2020). 
 
Like every adult eligible based on age in the UK general population, people 
living with SMI should receive invitations from the NHS to attend cervical, 
breast and bowel cancer screening. The mental health status of screening 
attendees is not recorded by the NHS cancer screening programmes, 
however, so rates of screening uptake in this population, which are lower 
than for people with SMI, are unknown on a national basis. UK studies have 
therefore relied on datasets created by linking local primary care databases 




1.6.2 Interventions to improve uptake of cancer screening at the patient level 
Whether to take up cancer screening is a health decision faced by most 
people, and recently, more emphasis has been put on to enabling people 
who access health services (including cancer screening) to make an 
informed choice (Jepson et al., 2007; Michie et al., 2004). Deciding whether 
to attend screening involves making an informed choice that includes 
consideration of the advantages and risks of the screening process. In recent 
years, the focus has moved away from solely promoting the benefits of 
screening to providing comprehensive information which enables individuals 
to make an informed choice (Jepson et al., 2005). Consideration of pros and 
cons may be part of most people’s decision-making; however, people with 
SMI may face additional barriers to cancer screening uptake that are specific 
to them and which may affect their decision-making (Clifton et al., 2016).  
 
Systematic reviews on cancer screening in people living with SMI report 
many barriers that are also experienced by the general population and other 
disadvantaged groups (e.g. embarrassment, childcare responsibilities, fear of 
receiving an abnormal result). Evidence suggests that barriers to screening 
uptake in people with SMI vary for different types of screening, at different 
stages of the screening process and between individuals (Clifton et al., 
2016). Several individual-level interventions exist that aim to facilitate 
decision-making in health care, including those targeted at patients and 
clinicians, namely tools to promote shared decision-making and decision 
support tools targeted to patients. The support tools aimed at supporting 
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patients include informed-choice tools and patient decision aids. Both have 
been used for screening decisions, though they have different goals. 
Informed-choice tools seek to support patient autonomy and ensure that 
individuals are neither deceived nor coerced (Jepson et al., 2005), while the 
goal of a patient decision aid is to help patients make a decision and be 
satisfied with it. Given that the intervention in this study is being developed 
for women with SMI, a group that tends to underuse cancer screening 
services, the goals of informed-choice tools were considered to be more 
appropriate than those of a patient decision aid for this population. Each type 
of decision support tool is presented below. 
 
a. Shared decision-making tools 
‘Shared decision-making’ interventions are available to support individuals’ 
decisions (Elwyn et al., 2012; Légaré et al., 2018). These may be regarded 
as an intermediate model that falls between a paternalistic approach and the 
informed-choice model (Charles et al., 1997; Kon, 2010) as they facilitate a 
collaborative process through which a clinician supports a patient to decide 
on their treatment (Elwyn et al., 2010). Shared decision-making interventions 
share similarities with informed-choice tools in that they both seek to clarify 
values, but the decision-making process is different as the decision is shared 
with a health professional (Drake et al., 2009; Duncan et al., 2010; Elwyn et 




b. Decision aids 
The International Patient Decision Aids Standards (IPDAS) collaboration 
(Elwyn et al., 2006; IPDAS, 2005; Joseph-Williams et al., 2013) defines 
decision aids as evidence-based tools designed to help patients make 
specific and deliberate choices among healthcare options (Stacey et al., 
2017). Decision aids describe the decision that must be made and the 
options available and help people to think about the options from a personal 
viewpoint (Stacey et al., 2017); they are used by the patient on their own to 
weigh the pros and cons of a decision, clarify the values underpinning that 
decision and determine what they need to support them to pursue a given 
option. In the general population, decision aids are effective in helping 
people make decisions about a range of health issues, including screening 
(Stacey et al., 2017). Patient decision aids have been developed to guide 
individuals through a cancer screening decision-making process (Martínez-
Alonso et al., 2017; Trikalinos et al., 2014; Volk et al., 2016).  
 
c. Informed-choice tools 
Informed-choice tools aim to provide the individual with the required 
information to allow them to make an informed choice, while also including 
the patient’s values in the decision-making process (Barratt, 2008). These 
tools are a variant on the decision aid idea, sometimes known as ‘decision 
support tools’, and come in various formats, including pamphlets, videos or 
web-based tools such as apps. Informed-choice tools, which are commonly 
delivered online, might include ‘personal stories’, namely testimonies or 
videos of people who have faced a similar decision. These tools often also 
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include exercises that allow participants to explore the advantages and 
disadvantages of a choice (Brunette et al., 2011).  
 
Of the three tools described above, two are potential methods to support 
decision-making around cancer screening: shared decision-making and 
informed-choice tools. People living with SMI commonly report poor 
continuity of care (Biringer et al., 2017) and difficult relationships with health 
professionals, particularly in primary care (Clifton et al., 2016; Ross et al., 
2015), so shared decision-making tools may not be appropriate for everyone 
within this population. In addition, primary care clinicians face time 
constraints to using a shared decision-making tool (Gravel et al., 2006), so 
an informed-choice tool, which could be used independently or with a 
supporter of choice, may be a more suitable format for assisting women with 
SMI in their decision to attend their screening appointment. An informed-
choice tool was therefore the selected format for this research. 
 
1.6.3 The evidence so far on initiatives to increase uptake 
The World Health Organization (2013) has recognised the important role of 
mental disorders in contributing to the global burden of non-communicable 
diseases, such as cancer, and highlighted the need for equitable access to 
healthcare interventions for people with mental illness. Nevertheless, in 
England, there is a lack of support in practice. People with SMI are not 
currently supported to use available health information and advice or to take 
up medical tests and interventions that reduce the risk of preventable health 
conditions (NHS England, 2018). In addition, there is little research on ways 
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to increase cancer screening uptake in this group. A range of initiatives has 
been developed for the general public to address uptake to the NHS Cervical 
Screening Programme, including the Public Health England (PHE) Decision 
aid leaflet ‘NHS Cervical Screening: Helping you Decide’ and ‘An Easy Guide 
to Cervical Screening’, which were developed in collaboration with women 
who have learning disabilities (PHE, 2012, 2013a). Jo’s Cervical Cancer 
Trust3 has several information leaflets on their website for anyone who is 
thinking about attending the cervical screening or has a question about 
cervical cancer.  
 
So far, in the existing literature, no individual-level intervention for women 
with SMI has been identified to increase uptake of or access to cancer 
screening (Barley et al., 2016). Only one published study has reported the 
testing of a shared decision-making intervention to assist formerly homeless 
women in Philadelphia (US) living with SMI to attend breast cancer screening 
(Weinstein et al., 2015, 2019). Authors of a comparative meta-analysis on 
the cancer screening disparities between people with mental illness and the 
general population report the urgent need for the development of tailored 
interventions to increase uptake of cancer screening for this group (Solmi et 
al., 2019). Researchers have also identified the need for interventions to 
support people with SMI to process information concerning cancer and 
cancer screening in order to enable them to recognise the importance and 
benefits associated with cancer screening (Clifton et al., 2016; Mo et al., 





(2014) suggest that tailor-made information about cancer and the benefits of 
screening should be provided in a way that is accessible and easy to 
understand; the intervention should address their beliefs, concerns and 
possible misconceptions about cancer. 
 
An important consideration in screening for people with SMI is that of their 
capacity to decide whether to attend their appointment. The NHS Cancer 
Screening Programme (2009) posits that some people who lack mental 
capacity due to a mental health problem, learning disability or dementia may 
be unable to make an informed decision about whether to attend the 
screening. The Mental Capacity Act (2005) defines the lack of mental 
capacity as the inability to decide at a particular time. Informed consent in the 
medical context can be defined as the process in which a health professional 
educates an individual about the benefits, risks and alternatives of a given 
intervention or procedure (Berg et al., 2001). In contrast, informed choice is 
central to supporting patient autonomy by ensuring that people make choices 
in line with their interests, values and preferences and that these choices are 
based on all relevant information, as well as being free from coercion 
(Jepson et al., 2005; Smith et al., 2010).  
 
The Informed Consent Guidelines on cancer screening (2009, updated 2018) 
under the provisions of the Mental Capacity Act (2005), state that individuals 
must be provided with all practicable help to make their own decisions before 
anyone assumes they are not able to do so. The Mental Capacity Act (2005) 
posits that before a decision is made on whether a person lacks capacity, 
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steps must be taken to allow the person to try to make the decision 
themselves. These steps are listed below: 
 
1) providing the person with all the relevant information they require, 
2) ensuring they have been given information on any alternatives,  
3) checking the information has been presented in a way that is easier for 
them to understand (e.g. using simple language).  
 
A higher proportion of people living with SMI has, relative to the general 
population, difficulty in processing information due to poor concentration, or 
may periodically face executive function issues, including drowsiness or 
cognitive blunting (Castillo et al., 2015; Le et al., 2017). Some people with 
SMI and lower functioning may struggle with understanding health 
information and may have limited numerical literacy, limited computing skills 
and lower literacy, which could impact on how informed-choice tools are 
used (Borzekowski et al., 2009; Clausen et al., 2016, Ferron et al., 2011). 
Every step outlined in the Mental Capacity Act above is therefore critical to 
consider with regards to the development of decision-making tools for people 
with SMI. It has been stated that having a range of information and choices is 
integral to the empowerment of people with SMI (Linhorst, 2006). For those 
with poor decision-making skills and/or unmanaged psychiatric symptoms, or 
those who lack decision-making experience, making even a small choice can 
be empowering (Carling, 1995; Hagner and Marrone, 1995; Linhorst, 2006). 
Research has shown better health outcomes for those with a mental health 
diagnosis as a result of active participation in decision-making (Martin et al., 






This chapter has highlighted that there is a higher mortality rate and reduced 
life expectancy of people with SMI compared to the general population. 
Cancer mortality is higher in this group than in the general population due to 
several factors, one of which is low uptake of cancer screening. Yet, cancer 
screening programmes have been shown to help with early detection and 
reduce the risk of premature mortality. Thus, an intervention that can support 
the uptake of cancer screening among this group is needed. Cervical 
screening was selected as the focus of this research as considerably more 
people are eligible for this, compared to other screening programmes; hence, 
the potential impact of the work is greater. In addition, attendance rates for 
cervical screening among the overall UK population have been falling year 
on year, suggesting that attention is needed in this area. Several 
interventions aimed at the individual were discussed in this chapter, with an 
informed-choice tool deemed the most appropriate for responding to the 
specific needs of people with SMI. This study was therefore designed to 
develop such a tool and to test its usability, readability and acceptability 




Chapter Two – Rationale and outline of the research 
 
This chapter outlines the rationale and protocol for the research. It describes 
the research paradigm that informs the chosen methods and introduces the 
Medical Research Council (MRC) guidance (Craig et al., 2013), which 
provides the overarching framework for the research. Based on this 
guidance, this research project comprises five linked studies, each of which 
is outlined in this chapter. 
 
2.1 The current research  
 
As reported in Chapter One, rates of uptake of cervical screening 
programmes are lower for people with SMI compared to the general 
population. This finding, along with research on barriers to screening that are 
specific to this population (Clifton et al., 2016) illustrates that it may be harder 
for people with SMI compared with the general population to access 
preventive care. To address this, a cervical screening informed-choice tool 
will be developed that is informed by known barriers to cancer screening 
uptake among people with SMI. These barriers have been identified through 
a literature review that is reported in Chapter Five (section 5.1). Moreover, as 
discussed in Chapter One (see section 1.7.2), the optimum design for an 
informed-choice tool for people with SMI is currently unknown. Informed by 
relevant identified barriers to cervical screening for women with SMI, a 
theoretically underpinned cervical screening informed-choice tool will 
therefore be developed to redress this population’s unequal access to and 




2.2 Aims and objectives of the research 
 
The primary aim of this research is to develop and test an intervention to 
surmount or reduce the impact of barriers to cervical screening in women 
with SMI. Based on the literature, an informed-choice tool (thereafter tool) 
appears to be a suitable instrument for achieving this aim. This tool directly 
needs to target the decision to attend cervical screening, a particular health 
behaviour. The evidence shows that going for screening is the best way to 
avoid cervical cancer; nonetheless, it remains a choice whether to do so. The 
primary aim of the tool is therefore to support women to make an informed 
decision regarding cervical screening. The information needs to be provided 
in the tool in a way that is accessible, usable and acceptable to this group, 
and the tool should address barriers to screening and be theoretically 
underpinned to ensure its acceptability and appropriateness for future 
evaluation in a trial. Acceptability can be defined as the perception among 
stakeholders (in this case mental health service users and mental health 
professionals) that an intervention is agreeable to them (Peters et al., 2013). 
Usability testing involves evaluating the intervention through the analysis of 
typical end users interacting with the intervention; this allows for iterative 
modifications (Kushniruk, 2002). Testing the usability of an intervention can 
lead to increased user satisfaction and performance (Alhadreti and Mayhew, 





2.3 Selection of research paradigm 
 
2.3.1 Research paradigms in social research 
Paradigms can be defined as ways to view the world; they summarise 
researchers’ beliefs about their contribution to knowledge (Kuhn, 1996; Rallis 
and Rossman, 2003). Four main paradigms can be distinguished in social 
research: constructivist, positivist, participatory and pragmatist (Creswell, 
2009). Constructivism is associated with qualitative research and is used to 
obtain an understanding of the world from an individual perspective. The 
assumption is that no objective truth exists and that everyone is shaped by 
their experience and environment (Creswell et al., 2011). Positivism is 
associated with quantitative research and aims to test hypotheses to obtain 
objective truth and generalise theories to other contexts (Willig, 2013). The 
main purpose of the participatory paradigm is to explore and interpret the 
views, concerns, and experiences of people from their own perspectives; this 
then allows them to undertake measures to improve their situations (Heron 
and Reason, 1997). The fundamental principle of participatory research is 
Objective one: To develop an informed-choice tool for women with SMI 
which addresses some of the barriers to screening attendance 
Objective two: The informed-choice tool should be theoretically 
underpinned 
Objective three: Acceptability and usability of the tool by stakeholders 
should be tested 
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that it is research ‘with’, rather than ‘on’ people (Heron and Reason, 1986). 
Lastly, the pragmatist approach is defined as a ‘third way’, moving away from 
the traditional opposition between constructivism and positivism. 
 
Within social research, the pragmatist approach is not new (Gage, 1989; 
Patton, 1988); however, its link to the use of mixed methods is more recent 
(Pearce, 2012; Tashakkori and Teddlie, 2010). Constructivism and positivism 
were previously regarded in the literature as irreconcilable approaches 
(Creswell and Plano Clark, 2007; Howe, 1988); however, the pragmatist 
approach is integrally linked to both. Pragmatism has gained considerable 
traction in social research over the last 20 years (Johnson and Christensen, 
2012), and the gradual use of mixed methods (Creswell et al., 2011; Johnson 
et al., 2007) has been interpreted as a ‘third methodological movement’, 
adding to quantitative and qualitative methodologies (Greene, 2008; 
Tashakkori and Teddlie, 2003). The pragmatist approach was selected for 
this research. 
 
2.3.2 The pragmatic paradigm and the use of mixed methods in research 
 
Pragmatism adopts a form of relativism and rejects the need to choose 
between paradigms that are either entirely context-specific or linked to a 
universal value (Coghlan and Brydon-Miller, 2014). Pragmatists emphasise 
the importance of the research question and use all appropriate approaches 
available to understand the problem. They favour the approach of using 
several methods in their inquiries and choosing the most appropriate method 
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for answering the research question (Johnson and Onwuegbuzie, 2004). 
They are not committed to any philosophical view or reality; their beliefs are 
more directly connected to actions (Dewey, 2008). Pragmatists seek a truth 
that is practically useful rather than absolute. They focus on what works at a 
specific time and why research should be conducted in a specific way 
(Creswell and Plano Clark, 2007). Critics posit that the philosophical 
foundations of pragmatism have not been sufficiently examined with 
consideration of the focus in the literature on the practical aspects of the 
pragmatic paradigm, which embraces a plurality of methods. In turn, this 
approach of using multiple methods has been criticised for the lack of 
epistemological consensus surrounding it (Creswell, 2011; Denzin and 
Lincoln, 2011). Pragmatism is often employed in health services research 
(O’Cathain et al., 2007) as it offers a sensitivity to the research context, a 
focus on applied research, and the valuing of different forms of knowledge 
(Long et al., 2018). 
 
Because of its appropriateness for health services research, pragmatism was 
thus selected as the dominant paradigm in which to ground this research. 
For the research enquiry relating to the development of the tool and to 
service users’ and clinicians’ experiences of using the tool, qualitative 
methods were deemed the most appropriate. Quantitative methods were 
selected to investigate the impact the tool had on service users’ decisional 
conflict to attend the screening. Decisional conflict, explained in more detail 
in section 2.5, can be defined as being uncertain about which choice to make 
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when the different options comprise regret, risk or challenge to personal life 
values. 
 
2.4  Development of complex interventions 
 
The tool developed through this work represents a ‘complex intervention’. An 
intervention can be described as complex (Craig et al., 2008; Hawe et al., 
2004) if the conditions listed below are met; the chapter describing the tool in 
relation to these conditions are provided in parentheses: 
 
• interacting behaviours or components are required by those receiving 
or delivering the intervention (Chapter Five), 
• several groups or organisational levels are targeted by the 
intervention (Chapter Six), 
• there is more than one outcome (this chapter) and 
• a degree of flexibility or tailoring of the intervention is permitted 
(Chapter Ten). 
 
Different frameworks, guidance, and theoretical models have been 
recommended to inform the development of a theory-driven complex 
intervention (de Silva et al., 2014; Hurley et al., 2016; O’Cathain et al., 2019). 
The ‘gold standard’ tool in health services research is the Medical Research 
Council (MRC) guidance, which provides a framework for developing and 
evaluating complex interventions (Craig et al., 2013; Moore et al., 2015). The 
MRC guidance for developing and evaluating interventions that contain 
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several interacting components was originally published in 2000 (Campbell 
et al., 2000) and updated in 2008 (Craig et al., 2008), and it has helped 
researchers develop and evaluate several theories and evidence-based 
health interventions (Bobrow et al., 2018; Dowding et al., 2017; Lakshman et 
al., 2014; Troughton et al., 2016). The updated 2008 MRC guidance provides 
a non-linear cyclical framework (Figure 2.1), advising health researchers to 
answer a range of sequential questions regarding the theory of the 
intervention, feasibility and acceptability, effectiveness and cost-
effectiveness, and sustainability of the intervention (Craig et al., 2008; 
Fletcher et al., 2016). The MRC guidance has four phases (Development, 
Feasibility/Piloting, Evaluation and Implementation), and each phase 
includes three steps. Given its widespread use, the MRC guidance was 
selected as the most appropriate framework for this research, which 
addresses elements of the first three phases of the MRC. The fourth phase, 
‘Implementation’, involves the dissemination, translation and monitoring of 
the intervention into routine practice. Dissemination of the tool has begun 
(see Chapter Ten, section 10.4.1) and other aspects of this phase of the 

























Figure 2.1 Key elements of the development, evaluation, and implementation 
process of complex interventions (Craig et al., 2008). 
 
2.5 Overview of the research 
 
This research comprises the conception and design of the tool and five 
related studies, all of which are in line with MRC guidance. An overview of 
each element of the MRC guided research is provided here; subsequent 




Figure 2.2 Mapping out of each study to the MRC guidance for the 
development and evaluation of complex interventions 
 
1) Study one [Chapter Three] 
Identifying the evidence base: Step one of the MRC Development Phase  
This step aims to identify the existing evidence and what is already known 
about similar physical health interventions for people with SMI and the 
methods that have been used to evaluate them (Craig et al., 2013). The 
MRC guidance states that if there is no recent, high-quality recent systematic 
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review of the relevant evidence, one should be conducted (Craig et al., 
2013). Therefore, a systematic realist review of studies was conducted to 
evaluate the effectiveness of interventions developed to increase uptake of 
or access to physical health screening in people diagnosed with an SMI. 
Recent research has described and exemplified how social scientists can 
integrate realist principles across all phases of the MRC guidance (Fletcher 
et al., 2016). Consideration of what part of an intervention works for whom, in 
what circumstances, in what setting and how is deemed useful to the 
development of this tool (Fletcher et al., 2016; Holland et al.,2013; Rycroft-
Malone et al., 2012). Results from the review were published in a peer-
reviewed journal (Lamontagne-Godwin et al., 2018).4  
 
2) Study Two [Chapter Four] 
 
Identifying the evidence base (2): Step one of the MRC Development Phase  
 
In line with this step of the MRC guidance, a systematic review was also 
conducted to identify the specific design(s) and theoretical framework(s) 
used to develop informed-choice tools for people diagnosed with SMI, and 
whether there was any evidence of their effectiveness. The results from the 
review (n = 9 studies) informed the development of the tool. A manuscript of 
the systematic review (n = 10)5 has been published in a peer-reviewed 
 
4 Lamontagne-Godwin, F., et al. (2018) ‘Interventions to increase access to or uptake of 
physical health screening in people with severe mental illness: a realist review’, BMJ Open, 8, 
e019412. http://dx.doi.org/10.1136/bmjopen-2017-019412. 
5 An additional study describing a fourth intervention was included following an update of the 
review in March 2020. 
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journal (Lamontagne-Godwin et al., 2020).6  
 
3) Conception and design of the tool [Chapters Five and Six] 
 
Identifying theory: Step two of the MRC Development phase 
 
The MRC guidance recommends to first understand, from a theoretical 
perspective, the factors that can act as barriers or enablers to performing the 
behaviours that are to be targeted in the intervention. The Theoretical 
Domains Framework (TDF) can be defined as an 
integrative framework, which was developed from a synthesis of 
psychological theories to support the application of theoretical approaches to 
interventions targeting behaviour change (Cane et al., 2012; Phillips et al., 
2015). The TDF has been used previously to explore the behaviours of people 
diagnosed with SMI behind the decision of whether to attend cancer 
screening (Clifton et al., 2016). Using the barriers and enablers identified in 
the Clifton et al. (2016) study ensured that the development of the tool’s 
components was theoretically underpinned. In addition, a literature review of 
the barriers and enablers to cancer screening in people with SMI was 
conducted. The rationale for this review was to explore all possible barriers 
and enablers across different national health systems to ensure none were 
missed. This study also identified the underpinning ‘active ingredients’ of the 
 
6 Lamontagne-Godwin, F., Henderson, C., Lafarge, C., Stock, R. and Barley, E. (2020) ‘The 
effectiveness and design of informed choice tools for people with severe mental illness: A 





tool and how its components were expected to interact synergistically with 
one another to generate the expected outcomes (Bonell et al., 2015).  
 
4) Study Three [Chapter Seven] 
 
Testing procedures: Step one of the MRC Feasibility/Piloting phase  
 
In line with this step of the MRC guidance, user testing was conducted with 
various stakeholders. NICE’s Behaviour Change guidance [PH6] states that 
an intervention should be planned in collaboration with individuals, 
communities, organisations and populations (Holman et al., 2018) and 
should ‘take account of the circumstances in which people live, especially the 
socio-economic and cultural context’ (NICE, 2007). Before testing in clinics, a 
key informants’ group was established that, together with service user 
groups, provided iterative feedback on the tool. Semi-structured interviews 
with women diagnosed with SMI and their health professionals working in 
mental health outpatient settings were then conducted across two NHS 
Trusts to assess acceptability and relevance of the tool and to ensure that 
no information was excluded. Feedback received on the content of the tool 
was transcribed, analysed and incorporated into the tool once the interviews 
were completed.  
 
5) Study Four [Chapter Eight] 
 
Testing procedures (2): Step one of the MRC Feasibility/Piloting phase  
 
The updated version of the tool was then presented to a second group of 
women diagnosed with SMI and health professionals to test its usability 
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using the ‘ think-aloud’ method (van Someren et al., 1994). This is a 
validated method for assessing user experience and the usability of 
interventions that allow for observation of the actual reactions of the 
participant using the tool. The method was used to test an intervention with 
participants who were diagnosed with SMI (Vilardaga et al., 2016). Feedback 
on the tool was transcribed, analysed and incorporated once the interviews 
were completed.  
 
6) Study Five [Chapter Nine] 
 
Understanding the change process: Step three of the Evaluation phase  
 
This step of the MRC guidance aims to establish the proof of concept of 
intervention. The evaluation of the tool is reported in Chapter Nine. Women 
diagnosed with SMI were asked to complete the measures of their 
decisional conflict to attend cervical screening using two validated scales. 
Decisional conflict is generated by four factors: unclear values, the 
perception that an ineffective decision has been made and inadequate 
knowledge and support (Janis and Mann, 1977). In other words, it is a 
reflection of the level of comfort someone faces in making a decision 
(Thompson-Leduc et al., 2016). The data analysis of the preliminary 
evaluation of the tool is reported in this chapter. Analysis of the qualitative 




This chapter presents the rationale for this PhD research, which is the need 
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for the development of an intervention to reduce inequality in cervical 
screening uptake for women living with SMI. The research paradigm and 
the overarching framework for the research have been presented, with each 
element of the research briefly outlined.  The next chapter outlines Study 
One, the realist review, in detail. 
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Chapter Three – Identifying the evidence base: A realist 
review of interventions to increase access to or uptake of 
physical health screening in people with SMI 
 
This chapter describes a realist review that was conducted of interventions 
to increase access to or uptake of physical health screening in people 
with SMI. A discussion of how the results of the review informed the tool is 
also provided. This review is in line with step one of the MRC guidance for 
complex interventions (Development phase), and a paper describing this 
work has been published in a peer-reviewed journal (Lamontagne-Godwin et 
al., 2018).  
 
3.1 Background 
Several systematic reviews have identified effective interventions for 
increasing access to, or uptake of, screening for a range of physical health 
conditions in the general population (Bonfill et al., 2001; Brouwers et al., 
2011; Camilloni et al., 2013; Everett et al., 2011; Jepson et al., 2000). One 
study (Segnan et al., 1998) included in the Camilloni et al. (2013) review 
explicitly excluded women with SMI. It is unclear whether people with SMI 
were excluded from the other studies and, as they are general population 
samples, the expected proportion of people with SMI would be very low; in 
England, 1–2% of the population will, at some point in their lives, receive a 
bipolar disorder diagnosis and 0.72% a diagnosis of schizophrenia (Pini et 
al., 2005; Saha et al., 2005). There is a lack of knowledge about whether the 
interventions are effective for people with SMI specifically. To address this 
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gap in the literature, a realist review of studies was conducted to evaluate 
the effectiveness of interventions developed to increase uptake of or access 
to physical health screening in people diagnosed with an SMI.  
The realist review methodology is a relatively novel method of a systematic 
review that is used especially in health services research. It provides an 
explanatory analysis of complex interventions, aiming to discern what works, 
under what circumstances, for whom, in what respects and how (Pawson et 
al., 2005). It involves identifying underlying causal mechanisms and 
understanding how interventions work (or not) and under what conditions 
(Rycroft-Malone et al., 2012).  
 
As mentioned in the previous chapter (section 2.5), the Development phase 
of the MRC guidance for the development of complex interventions involves 
identifying the existing evidence and what is already known about similar 
interventions and the methods that have been used to evaluate them (Craig 
et al., 2013). If no recent, high-quality systematic review of the relevant 
evidence has been undertaken, the MRC guidance recommends that one 
should be conducted (Craig et al., 2013). This provides the rationale for 
conducting this realist review. 
 
Recent research has described and exemplified how social scientists can 
integrate realist principles across each phase of the MRC guidance (Fletcher 
et al., 2016). Intervention development and modelling, as well as feasibility 
and pilot studies that represent the different phases of the MRC guidance 
(Chapter Two, Figure 2.1) need to take into consideration which contexts are 
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necessary for intervention mechanisms to be activated. In cases where 
interventions are scaled up into routine practice (the Implementation phase 
of the MRC guidance), realist principles can facilitate knowledge about 
longer-term sustainability, as well as benefits and harms (Fletcher et al., 
2016). The realist review methodology was selected over a standard 
systematic review in this research, to find out not only whether screening 
interventions for people with SMI produce the desired outcomes, but also to 
discern the contexts in which they are more likely to be successful. 
 
Guidance on quality assurance and uniform reporting of the results is a key 
phase for any type of primary research that moves towards improving the 
quality and consistency of studies (Wong et al., 2014). Although there is a 
growing acknowledgement of the value of qualitative and mixed-method 
approaches to a systematic review as an alternative to quantitative reviews, 
the quality of such reviews can be hard to assess. The RAMESES project 
(Realist And Meta-narrative Evidence Syntheses: Evolving Standards) has 
produced methodological guidance, publication standards, and training 
resources for those choosing to use the realist approach to a systematic 
review (Wong et al., 2016). This realist review is described in accordance 
with RAMESES and the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses) guidelines. Appendix 1 contains the completed 
PRISMA checklist, which confirms how this review was completed according 




The review question was ‘what works, for whom and why to increase the 
uptake of or access to physical health screening programmes by people 
living with SMI’? The objectives were threefold: to identify and evaluate 
interventions to increase uptake of or access to physical health screening 
programmes by adults with SMI; to examine the use of behaviour change 
models within the identified interventions; and to identify the factors that 




3.2.1 Study selection 
The inclusion criteria used in this review were as follows: 
 Intervention studies of any design 
 Studies of any intervention to promote access to, or uptake of, 
screening for or monitoring of any physical health condition  
 Participants were aged 18 years and over  
 No date restriction was applied in the search 
 Participants had a diagnosis of SMI (psychosis or bipolar disorder 
however diagnosed)  
 For studies where some of the participants had mental health 
disorders other than SMI, a minimum of 50% of participants 
needed to have either a diagnosis of psychosis or bipolar disorder 
 The full text was published in a peer-reviewed journal 
 The study was reported in English  
 
The exclusion criteria included: 
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 Intervention studies aiming to improve the physical health in 
people with SMI, which may involve screening, but where uptake 
or access to screening was not a primary outcome 
 Service evaluations or audits which considered screening but did 
not test any intervention 
 Studies where the mental illness diagnoses were not specified 
 
3.2.2 Terminology 
Any intervention described as promoting either screening or monitoring of 
physical health was included. The UK National Screening Committee defines 
screening as a ‘public health service in which members of a defined 
population (…) are asked a question or offered a test, to identify those 
individuals who are more likely to be helped than harmed by further tests or 
treatment to reduce the risk of a disease or its complications’ (Public Health 
England, 2013b). ‘Monitoring’ was defined as per the Cochrane review by 
Tosh et al. (2014) as a means ‘to obtain information which can then be acted 
on to treat or prevent a physical health problem’. For clarity, the term 
‘screening’ is used throughout the review. Uptake of screening was the 
review’s primary outcome.  
 
3.2.3 Search strategy 
The search strategy was informed by published, related systematic reviews 
(Barley et al., 2016; Holland et al., 2013; Holt and Mitchell, 2015) and was 
checked by a specialist health librarian at the University of West London. 
Searching was conducted in December 2016. An example of a full electronic 
77 
 
search strategy for one database (MEDLINE) is contained in Appendix 2. 
The review protocol is registered on the international prospective register of 
systematic reviews (PROSPERO Registration number: CRD42016047848).  
 
3.2.4 Data sources 
Medline, Embase, Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), PsychINFO, Cochrane Database of Systematic Reviews and 
Database of Abstracts of Reviews of Effectiveness were searched 
independently of each other. Reference chaining of identified studies was 
also conducted. This is a research method that involves looking at 
the references or works cited in key publications on a particular topic, tracing 
a particular topic both forward and backward in time.  
 
3.2.5 Selection of studies 
Titles and abstracts were screened independently by two reviewers [a health 
psychologist and a chartered psychologist with expertise in health 
psychology]. Full texts were retrieved and screened by three reviewers [the 
candidate, a health psychologist and a chartered psychologist with expertise 
in health psychology]. Among the 33 full texts selected was a recent 
systematic review of studies of ‘Strategies to implement physical health 
monitoring in people affected by severe mental illness’ (Ferrara et al., 2015), 
which included 14 studies. Although the focus of the Ferrara et al. (2015) 
review was slightly different from the current one, it contained one study that 
was also included in this review (Hardy and Gray, 2012). It also included two 
studies that were excluded: one was not an intervention study (Hardy et al., 
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2012) and the other tested the validity of a health-monitoring tool 
(Bressington et al. 2014).  
 
It was decided by the reviewing team that health-monitoring (in addition to 
health-screening) tools were also relevant to the review question. The 
rationale for this was that although such studies aimed to improve the quality 
of screening (e.g. more health indicators measured) and ongoing monitoring, 
this often resulted in increased uptake. Identified studies and those included 
in the Ferrara et al. (2015) review were re-screened by two reviewers [a 
health psychologist and a chartered psychologist with expertise in health 
psychology] to select the final set of studies for inclusion. 
 
3.2.6 Study quality assessment 
The quality of randomised controlled trials (RCT) (Druss et al., 2010; Osborn 
et al., 2010) was assessed using the Cochrane tool, the only evidence-based 
tool for measuring the risk of bias of RCT (Higgins et al., 2011). It covers 
seven principles, including a recommendation not to use quality scales, that 
the focus should be on internal validity and that it is necessary to report 
outcome-specific evaluations of risk of bias (Higgins et al., 2011). No similar 
‘gold standard’ tool exists that could be used across the other study designs, 
so each of the non-RCT studies was assessed using a simple checklist 
based on the STrengthening the Reporting of OBservational studies in 
Epidemiology (STROBE) (von Elm et al., 2007) statement and a recent 
review of tools to assess bias in observational studies (Sanderson et al., 
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2007). Each study was rated independently by two reviewers, with 
discrepancies resolved by discussion.  
 
3.2.7 Data extraction 
Each reviewer independently extracted information from up to five articles, 
with one reviewer [health psychologist] reviewing all studies. Data were 
extracted regarding study authors, year of publication, geographical location, 
and setting, participant characteristics, features of the intervention, screening 
(targeted screening or with multiple parameters; when, how and wherein the 
care pathway screening was offered; screening health professional(s) and 
type of service), outcome measures, study design and limitations. Though 
not an inclusion criterion, patient-related outcomes – such as a significant 
reduction in cardiovascular disease risk at follow-up – were included when 
available. They provided important additional information and gave an 
accurate reflection of the effectiveness of the interventions. 
 
3.2.8 Approach to synthesis 
 
The main task of a realist synthesis is to understand the mechanisms by 
which an intervention works (or not). The basic focus of the synthesis 
process is to refine the programme theory, i.e., to determine what works, 
why, in what circumstances, for whom and in what respects. The aim of a 
realist synthesis is not to determine ‘best’ practice, but to describe the 
relationships between interventions and the contexts in which those 
interventions occur. Similarities and differences in the intervention approach 
were identified and summarised across studies into separate clusters. 
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Barriers and enablers to the implementation of each intervention cluster were 
identified and these were then synthesised by theme. Exploration of how and 
why different approaches might have worked was undertaken by searching 
for themes across studies, paying particular attention to disconfirming 
evidence. As there was considerable between-study variation in outcome 




3.3.1 Search results 
The initial electronic search identified 1872 potentially relevant publications; 
six others were identified through reference chaining. Forty-four studies were 
identified as being potentially relevant and were screened by two reviewers. 
Twenty-two of these did not meet the inclusion criteria, and a total of 22 
studies were included. The screening and study selection processes are 





Figure 3.1 PRISMA Flow Diagram (Moher et al., 2009) 
 
3.3.2 Study quality assessment 
While there is no universal definition for study ‘quality’, it involves the extent 
to which the study design, conduct, analysis and presentation are 
appropriate for answering the research question (Higgins et al., 2011). The 
aim of the quality assessment is not to exclude any study from the synthesis, 
but to determine the reliability of the overall body of evidence. A description 
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of the main study weaknesses is presented in Tables 3.1 and 3.2. The most 
common ones were small sample size and lack of generalisability.  
 
3.3.3 Study characteristics 
A range of study designs was employed (pre-post audit n = 9, consecutive 
prospective case series design n = 1, repeat audit n = 1, cross-sectional 
study n = 1, quality improvement n = 4, retrospective audit n = 4, RCT n = 1, 
cluster-randomised feasibility trial n = 1). Study characteristics are detailed in 
Tables 3.1 and 3.2; each study has been given a number in column 1 of the 
tables. The numbering system was used in this chapter and subsequent 
chapters to reference the studies for ease of reading. Studies either 
described the testing of a new tool (e.g. computer programme to support 
clinicians to monitor and screen physical health indicators) to facilitate 
screening for health professionals (1-10) (Table 3.1) or complex health 
services delivery changes (11-22) (e.g. invitation letter from primary care to 
encourage patients to attend screening as part of their physical health check-
up) (Table 3.2). Mental health staff performed ‘in-house’ screening 
(1,7,8,16,18,19,21), ordered screening tests (2-4,6,9,15-17,19,20,22) or 
acted as a broker between the patient and screening service (2,12,14,15). 
 
3.3.4 Study settings 
Studies pertaining to health service delivery changes were conducted in 
multiple settings: community mental health clinics (12,16-17), early 
intervention in psychosis services (15,19-20), primary care (13,22), a 
community drop-in centre (14) and a clozapine clinic (21). Two tools to 
facilitate screening (5,10) and two health service delivery change (11,13) 
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interventions were delivered in primary care. The remainder took place in 
inpatient and outpatient mental health services.  
 
3.3.5 Types of conditions screened  
Two studies (14,22) considered breast cancer screening and one included 
infection preventive services (22). Other than one study (14), which was 
designed to increase rates of mammography uptake, all remaining studies (n 
= 21) considered metabolic syndrome screening by targeting metabolic 
syndrome-related risk factors: blood pressure (1,2,4,5,7-13,15-20,22), 
cholesterol/sugar (1-13,15-17,19,20,22) and BMI (1-13,15-20,22). Two 
studies described national screening programmes (14,22) and 20 studies 
reported the development of ‘in-house’ screening pathways (1-13,15-20). 
Interventions focused on metabolic/cardiovascular screening for all studies. 
One study monitored the uptake of both national cancer screening services 
and metabolic screening (22). The data collection tools (Table 3.2) were 
designed to gather information required to improve metabolic syndrome 
screening (2,3,6,9) or physical health screening (1,4,5,7,8,10). Metabolic 
syndrome screening was evaluated using the following measurements: blood 
pressure, smoking status, waist circumference, fasting blood glucose, BMI 
triglycerides and high-density lipoprotein cholesterol. These measures were 
based on the following clinical guidelines:  
 
1) National Institute for Health and Care Excellence [NICE] 
(5,7,8,10,11,13,15,16)  
2) Maudsley prescribing guidelines (4,8,11,15,20)  
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3) American Diabetes Association (2,3,4,6,9)  
4) U.S. Preventive Services Task Force (12,22)  
5) American Psychiatric Association Practice (1,9)  
6) National Heart, Lung and Blood Institute (2)  
7) de Hert (2009) guidelines (5).  
8) Early Psychosis Prevention and Intervention Centre (19)  
9) Psychotropic Therapeutic Guidelines (21)  
 
3.3.6 Study participants 
All studies targeted adults, though in one study (20) eligible participants were 
14–35 years old. Study populations included participants with schizophrenia 
(1-5,8,9,11,12,14,16-18,22), bipolar disorder (1-3,5,9,12,14,16-18,22), 
schizoaffective disorder (1-3,5,12,14,16-18), other psychotic disorders 
(1,4,5,9,17,18,22) and other mental health disorders (2,9,12,14,16,17,18,22). 
Some studies did not specify the SMI (10,13,19,20) diagnosis, while other 
studies included patients with SMI who were on antipsychotics (3,6,7,15) 












Intervention Screening Method(s) applied Findings Main study 
weaknesses 
Bressington 
et al. 2014 
(1) 








nurses on how 





HIP contains 27 gender-
specific items highlighting 
indicators of physical health 
risk in SU 
Items are divided into four 
categories: measurements, 
blood tests, screening and 
lifestyle indicators. HIP used 
at baseline and at twelve-
month FU9 during routine 
clinical practice. Community 
psychiatric nurses trained to 
use the HIP in a community 








reported exercise & 
reduced prescription  
mean WC10 increased 
at FU 
Absence of 
deterioration in most 
areas of 
cardiovascular risk 
(BMI mean: 25.79 to 
25.66, weight mean: 
66.76 to 66.49) 
At FU, prescriptions 
reduced for diabetes 
(10.8% to 5.4%) and 
hypertension (21% to 
14%) medication 
General improvements 
in health behaviours 
over the 12-month 
period: 7% increase in 
the number of SU 
eating sufficient fruit 
and vegetables, but 
only exercise improved 
to a statistically 
significant level (p = 
0.02) 
No randomisation, 





7 Service user (patient with SMI) = SU 
8 Health Improvement Profile = HIP 
9 Follow-up = FU 
10 Waist circumference = WC 
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staff and SU 
MS screening (WC, BP12, 
fasting blood glucose, 
triglycerides and high-density 
lipoprotein cholesterol) 
Blood tests ordered for 
metabolic monitoring when 
clinicians prescribed 
scheduled second-
generation antipsychotics to 
their inpatients 
During routine clinical 
practice, WC and BP 
measured using standard 
size adult BP cuff available at 
each site. Measurements 
typically conducted in 
patients’ homes by nurses 
and psychiatrists working in 
three Assertive Community 
Treatment teams 
QI13 project 75 (53%) participants 
met the criteria for MS 
Five of these 
diagnoses came from 
the use of adapted 
diagnostic criteria 
using random glucose 
measurements  
Of the 66 participants 
who did not have MS, 
only 9 had no 
metabolic risk factors 
34 met 2 criteria and 
the remaining 23 met 1 
criterion for MS 
No randomisation, 
no control group 
 
 
11 Metabolic syndrome = MS 
12 Blood pressure = BP 











on a general 
psychiatric 
inpatient unit – 
171 at pre-

















Metabolic monitoring (fasting 
blood glucose and lipid). SU 
weight, BP, information 
regarding family history and 
WC not collected as part of 
this study 
Prescribers entering order of 
second-generation 
antipsychotics assess the 
need for metabolic 
monitoring and facilitate 
ordering of appropriate blood 
tests directly via electronic 
pop-up alert 
Retrospective 
chart review of 
notes and tests 






in the availability of 
metabolic monitoring 
data post-intervention: 
12.9% to 47.8% in the 
number of service 
users with both fasting 
glucose level & fasting 
lipid panel 
No randomisation, 
no control group 
Open to time bias 
Gonzalez et 
al. 2010 (4) 











First audit n = 
126 












tool: A4 page 
filed in the 
patients’ 
records, both as 




for the physical 
monitoring and 
as an instrument 
to facilitate later 
data collection 
Blood tests for SU taking 
first-generation 
antipsychotics (full blood 
count, urea and electrolytes, 
liver function test, thyroid 
function test, glycosylated 
haemoglobin, prolactin, 
glucose and lipids) 
Routine blood testing 
ordered by psychiatrists 





audit of patients’ 





selecting every 4th 
file in alphabetical 





improvement in all 
tests (glucose: 24.6% 
to 72.6%, lipids: 7.1% 
to 52.8%, liver 
function: 38.9% to 
79.2%) except HbA1c 
(3.2 to 5.7%) and 
Prolactin (0.8% to 0) 
Implementation of the 
monitoring tool 
achieved in 48% of the 
re-audit sample 
No randomisation, 
no control group 
Did not include 
other measure for 
detection of MS 
and did not include 
electrocardiogram  
Limited time 
between audits to 
allow embedding of 
the intervention 
Other factors may 
have resulted in 
improvements seen 
due to increased 
awareness within 
the service due to 
local policy and 
national guidelines 












to increase level 











Screening for cardiovascular 
disease risk factors (BMI or 
WC, blood glucose, serum 
cholesterol, diet advice, BP, 
exercise recommendations 
and smoking cessation 
guidance) carried out by 
practice nurses as part of 
their routine clinical role 
 
Repeat audit to 
monitor how well 
primary care 
practitioners are 









number of SU 
receiving wide-ranging 
health check 
Pre-training: n = 33, 
8% Post-training: n = 
60, 15%, p = .01 
Increase in number of 
service users receiving 
lifestyle interventions  
No randomisation, 
no control group 
Unclear why other 
26 primary care 
centres did not 
participate 
Did not look at any 



















100 notes of 
community 
mental health 









tool to improve 
identification of 
patients at risk 
of metabolic 
syndrome 
MS screening (BP, weight, 
height, lipid panel, fasting 
glucose and/or glycated 
haemoglobin parameters) 
during routine consultation at 
clinic with SU on second 
generation antipsychotics 
Blood tests ordered and vital 
signs obtained and results 
recorded in the patient 
electronic health system. 
Screening undertaken by 
mental health clinicians in a 





design to evaluate 
the effectiveness 




tool to improve 
identification of 
metabolic 
syndrome risk for 
SU  
Percentage of blood 
tests ordered were 
62% post-intervention 




no control group 
Difficulty obtaining 
WC – parameter 
frequently omitted 
Lack of agreement 
over who is 
responsible for 
ordering blood tests 
and following-up 
results 
Small sample size 
– difficult to 
generalise results  
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Shuel et al. 
2010 (7) 
UK 31 community-








HIP filled out during 
consultation with SU on 
antipsychotics who were 
invited to attend outpatient 
medication management 
clinic at the hospital 
Mental health nurses were 











participated in audit  
Mean number of 
parameters per patient 
requiring intervention 
was 6.1 and a total of 
189 physical health 
issues were identified 
At least one physical 
health issue was 
identified per patient 
High prevalence of 
obesity, poor diet (41% 
of patients) and lack of 
exercise 
14 referrals for 
potentially serious 
conditions including 





no control group 
 
Vasudev et 
al. 2012 (8) 
UK 15 male 







SMI and on 
antipsychotics 
Introduction of a 
physical health 
monitoring sheet 
by the Trust to 
prompt staff to 
do the checks 
Six-monthly physical health 
monitoring (weight, BMI, WC, 
BP, results of blood tests and 
electrocardiogram, diabetic 
status if suffering from 
cardiovascular disease, 
smoking status, calculated 
cardiovascular risk over the 
next ten years, and use of 
alcohol in units per week) of 
all SU in a male medium 
secure forensic psychiatric 
rehabilitation unit  
Nurse took responsibility for 
completing the section on 
weight, BMI, WC, BP and 
smoking status while the rest 
Pre-post audit of 
physical health 
monitoring (12 
months apart)  
 
At re-audit 100% of 
service users had up 
to date records on the 
physical health 
monitoring sheet 
At FU increased 
number of service 
users prescribed 
hypolipidaemic agents 
 Significant reduction 
in cardiovascular 
disease risk at FU  
No randomisation, 
no control group 
Small male-only 
sample  







of the information was 
completed by the junior 
doctor 
Wiechers et 
al. 2012 (9) 
United 
States 
206 adult SU 






antipsychotics   
Metabolic 
Screening 












Documentation in the last 12 
months of any individual 
element of the Metabolic 
Screening Bundle (BP, BMI, 
glucose and lipid panel) for 
patients on antipsychotic 
medication 
Screening performed by 
psychiatry residents in an 
academic medical centre 
outpatient psychiatry clinic 
Audits of the 
Electronic Medical 
Record completed 
at baseline and 
each quarter for 
the following year 
QI intervention 
Rates component 
parts of the Metabolic 
Screening Bundle in 
the preceding 12 
months increased from 
baseline audit through 
the Quarter 4 audit: 
BMI 5% to 44%; BP 
4% to 39%; Fasting 
glucose 15% to 55%; 
Fasting lipid panel 
14% to 55% 
No randomisation, 
no control group 






notes that may 
have been 
reviewed by the 
resident but not 
remarked on in the 
progress-note 
Unclear whether 
gains made with 
intervention and 
cohort of residents 
can be sustained 
without a dedicated 




al. 2014 (10) 
UK 335 SU on the 
primary care 




training on how 









Annual physical health 
review (systolic BP, BMI, 
high-density lipoprotein: 
cholesterol ratio, smoking 
status) performed in primary 









health check  
23% SU with a 
computerised template 
review had data rich 
QRisk2 compared 
QRisk2 scores above 
20% seen in 3.9% of 
template-based 
reviews 
Use of template 
increased detection 
risk for cardiovascular 
disease 
No randomisation, 
no control group 
Method dependent 
on accurate record 
keeping and 
clinician behaviour 
No record of 
unrecorded activity 
taking place which 





 GPs selected 


































UK 95 SU with 
schizophre
nia living in 
care homes  
Patient education 
and education of 
care home staff 
Physical health monitoring 
(blood workup, liver function 
test, urea and electrolytes, 
full blood count, fasting blood 




measurement, BMI, WC) 
offered during Care 
Programme Approach review 
(held every six months to one 
year) 
Screening done by GPs 
  
QI - PDSA16 cycle Improvement in culture 
within care home 
where staff and SU 
actively participated in 
physical health 
monitoring  
BP and weight 
measured in 68% of 
patients compared to 
10% and 0 at baseline 
55% of SU had pulse 
measured compared 
to 0 at baseline 
68% had bloods done 
compared to 0 at 
baseline 
No randomisation, 




as in later PDSA 
cycles the 
interventions did 
not target only the 
patient group 
included in the 
results 













assigned to either 









23 screening indicators from 
the U.S. Preventive Services 
Task Force guidelines includ-
ed across four domains: 1) 
physical examination (BP, 
eye, height/weight, oral, 
breast, mammogram and 
pelvic) 
2) screening tests 
(cholesterol, faecal blood, 
HIV, sigmoid and 
tuberculosis)  
3) vaccinations (influenza, 
hepatitis B, measles, mumps, 
RCT  12-month FU evalu-
ation: intervention 
group received 
average 58.7% of 
recommended pre-
ventive services 
compared with 21.8% 
in usual care  
Significantly higher 
proportion of evidence-
based services for 
cardio-metabolic 
conditions (34.9% 
versus 27.7%)  
Low risk of bias 
(Performance bias 
as control group – 
treatment as usual 
– not blinded) 
Broad entry criteria 
limited the 





conducted in a 
single site so 
 
15 Average blood glucose (sugar) levels for the last two to three months 











barriers to primary 
medical care 
and rubella, pneumococcal 
bacterial infection, tetanus-
diphtheria and varicella) 
4) education (exercise, self-
examination, smoking, 
nutrition and weight) 
Care managers (registered 
nurses) supported SU to get 
screened by providing 
communication and 
advocacy with medical 
providers, health education 
and support in overcoming 
system-level fragmentation 
and barriers to primary 
medical care 
Higher likelihood to 





improvement on SF-36 
mental component 
summary (8.0% 
[versus a 1.1% decline 
in the usual care 




better in intervention 
group (6.9%) than 
usual care group 
(9.8%) 
replication would be 
needed to fully 
assess 
generalisability to 
different types of 
community mental 













response rate of 
SU and diabetes 
patients to an 
invitation 
appointment letter 
to attend a 
primary care 
health check 
Patients with SMI 
sent an 
appointment at a 
predetermined 
time and date. 
Annual health 
check for SU 
followed the HIP 
guidance 
SU were sent an 
appointment letter 10 days 
before the appointment 
inviting them to attend a 
primary care health check 
(HIP) with a predetermined 
date and time. Screening 





66% service users with 
SMI attended 
appointment  
81% service users with 
diabetes attended 
appointment Service 
users with diabetes 2.2 
more likely to attend 
health check  
No randomisation, 
no control group 
 
Unclear if sample 
reflects whole 















(n = 158 in 
1995–2001 









in which staff of 
drop-in centre 
accompanied 
small groups of 
women for 
mammography 
visits at weekly 
pre-arranged time 
A staff member of the drop-in 
centre accompanied small 
groups of women aged 50–
70 for mammography visits 
at a pre-arranged time. A 
family physician working at 
the drop-in centre served as 
the referring physician 






intervention year  
Increase from average 



















Latoo et al. 
2015 (15) 
UK 52–55 SU 
receiving 
antipsychoti















assessment (serum lipid 
profile, blood glucose, body 
weight, height, BMI and BP) 
Other information was 
collected such as smoking, 
diet, exercise, sexual health, 
sleep, dental and optical 
health, electrocardiograms 
and other routine blood 
checks. Notification list 
alerted on the computer 
when screening was due 
Screening took place in 
primary care and physical 
health clinics 
Access to blood tests was 
established to help facilitate 
prompt access to blood 
results 
Retrospective 




monitoring   
 
Screening and 
monitoring of six 
parameters: 
At 4 weeks 29 patients 
recorded screening, 19 
(66%) of which had six 
types of screening 
At 24 months, out of 
16 patients who had 
their screening 
recorded, 15 (95%) 
had 6 types of 
screening  
No control group 
No randomised 







UK  152 
community-




address needs of 
MS audit of 152 community-
based SU to quantify their 
physical health problems. 
Database set up to record 
Mixed Methods: 
pilot study, audit 
and satisfaction 
survey  
Heavy burden of 
physical health 
problems identified in 
Phase One (66% 
No randomisation, 
no control group 
Generalisability 











medication   
this population by 
monitoring 
physical health 
and providing FU 




within the clinic 
Results collected and 
appropriate FU was 
organised through primary 
care or specialist services  
Health Screening Clinic 
included three main types of 
clinical investigations:  
1) physical examination, 
electrocardiogram, and blood 
screening  
2) rating scales with medical/ 
drug histories and  
3) diet and lifestyle advice  
Nursing staff were trained in 
bloodletting, measuring BP 




obesity, 60% elevated 
cholesterol, 32% 
hypertension) 
Of the first 100 
patients audited: 
33% had metabolic 
syndrome  
99% agreed health 
screening important  
65% reported lifestyle 
change  












UK 121 SU 
under the 
care of a 
community 
mental 













smoking, BP, random blood 
glucose and lipids) 
Intervention established 
system to monitor whether 
cardiovascular disease 
screening had occurred for 
community-based SU and 
sent prompts to primary and 
secondary care staff if 
screening had not occurred 
The nurse offered screening 
to cover SU who still had not 
received the complete 
battery of cardiovascular 
disease screening 
Within intervention arm, 
approximately half the 
screening was performed in 
Cluster 
Randomised 
Feasibility trial  
 
After the trial 
cardiovascular disease 
screening increased in 
both arms but 
participants from 
intervention arm were 
significantly more likely 
to have received 
screening for BP (96% 
vs 68%), cholesterol 
(66.7% vs 26.9%), 
glucose (66.7% vs 
36.5%), BMI (92.5% vs 
65.2%), smoking 
status (88.2% vs 
57.8%) and have 10-
year cardiovascular 
disease risk score 
calculated (38.2% vs 
10.9%) 
Low risk of bias 
Response rate in 
the recruitment for 
outcome data was 
main limitation  
Recruitment was 
time-limited 
because of funding  
Participants who 
provided outcome 
data may have 






results is difficult 
96 
 
general practice and half by 
the trial registered general 
nurse with previous 
experience of providing 
cardiovascular screening 
Rosenbau



















Over a nine-month period, 
file-based reminder for 
nurse-assessed WC 
measurement of mental 
health inpatients within a 
private psychiatric facility 
Screening performed by 
mental health nurses 
Pre-post audit of 








nurses of WC from 0–
58% WC was higher in 
these patients than 
general population 
19% had BMI within a 
healthy range, 37% 
smoked, 31% were 
hypertensive 
No randomisation, 
no control group 
Not all staff were 
able to receive 
intervention 
Thompson 




























Weight and metabolic 
monitoring (height and 
weight to estimate BMI, 
systolic and diastolic BP, WC 
and hip circumference (to 
obtain waist-hip ratio), fasting 
blood glucose, full fasting 
blood lipid profile (including 
total cholesterol, low- and 
high-density lipoprotein and 
triglycerides), number of 
cigarettes smoked daily and 
level of daily exercise 
Equipment required to 
undertake monitoring (e.g. 
scales, tape measures, BP 
cuffs) located in each 
psychiatrists’ room 
Stamps indicating necessary 
blood tests for monitoring 
placed in psychiatrists’ rooms 
to aid ordering and 
completion of the correct 
blood investigations 





monitoring of four 
metabolic indices at 
the post-intervention 
time point 
Individual rates were 
higher for screening 
(74.4% to 84.9%) than 
monitoring outcomes 
(24.4% to 41.6%) 
Rates ranged between 
17.4% for blood lipids 
and 34.9% for obesity 
measures 
No randomisation, 




Metabolic screening within 
six months of being 
prescribed an antipsychotic 
and metabolic monitoring 
one-six months following 
initiation of antipsychotic 
medication 
Regular review of an SU’s 
metabolic status was built 
into the clinical review 
process which occurs on a 





UK 66–72 SU 






























Annual physical health check 
(weight, BP, blood sugar, 
lipids, electrocardiogram 
(only done if patient at high 
risk due to young patient 
age), full blood count, urea 
and serum electrolytes, liver 
function tests and prolactin)  
Mental health clinicians 
address physical health with 
SU during clinical practice 
and letters ] sent annually to 
GPs to remind them to 
conduct the physical health 
checks (study audited this 
process) 
Screening took place in 
primary care 
Pre-post audit  Number of SU having 
at least one annual 
physical health check 
increased from 20% to 
58%  
Patients who had 
undergone physical 
health check at re-
audit, a record of 
some/all of the checks 
was available in the 
notes for 75% of 
patients 
No randomisation, 
no control group 
Focuses on Early 
Intervention so 
many people do not 
have a formal 
diagnosis of SMI 
e.g. schizophrenia 
Only 7 months 
between audits; 
therefore, a very 




















(including fasting blood 
glucose, lipids, BMI, girth) 
occurs in May and November 
QI  
Mixed Methods  
 
Completion rates of 
metabolic monitoring: 
69.2% at first month 
and 65.1% at second 
month 
No randomisation, 
no control group 
Limited possibility 
of generalisation 


















monitoring for all 
eligible patients 
Service protocols 
were revised to 
require metabolic 




(designed as ‘physical health 
months’) 
In the months preceding May 
and November, investigation 
order forms were attached to 
charts for provision by 
administrators, written 
information about 
investigations was provided 
to SU during consultations, 
and necessary equipment 
was placed in consulting 
rooms 
In May and November, a 
proforma for recording test 
results and lifestyle 
assessments (smoking, 
exercise, alcohol intake) 
were attached to charts, and 
clinic appointments were 
extended from 20 to 30 
minutes 
Limited evidence of 
actions post-results  
 
and very specific 
population 
 



























Cancer services included the 
following tests/procedures: 
mammogram, cervical 
screening, prostate specific 
antigen test, digital rectal 
exam, faecal occult blood 
test and flexible 
sigmoidoscopy or 
colonoscopy 
Metabolic profile included 
BP, height and weight, 
cholesterol and blood sugar 
for diabetes 




use of preventive 
services   




less likely to use 
preventive non-cancer 




Primary Care unit 
associated with higher 
overall service 
utilisation than a 
community mental 
health team  
No randomisation, 
no control group 
Unable to adjust for 
confounding factors 






immunisation, Hepatitis C 
Virus and HIV tests 
Psychiatrists made referrals 
to primary care doctors for 
screening in routine clinical 
practice 
Screening was undertaken 
by various clinical staff and 
took place in primary care 
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3.3.7 Intervention type 
Based on the type of intervention tested, three clusters of interventions to 
facilitate screening were identified: screening template, staff education and 
training and computer/paper prompt for staff. Five clusters of interventions 
for health service delivery changes were also identified, namely: staff 
education and training, invitation letter to physical health screening, 
improving access to monitoring resources, integrating care across health 
settings and staff accompaniment to appointments. Most interventions were 
multi-faceted, so they appeared in more than one cluster. Barriers and 
enablers to the successful implementation of the interventions were 
identified; these are presented in the tables below (Tables 3.3–3.5). 
Identified barriers to the successful implementation of interventions to 
facilitate screening can be clustered into categories of resource constraints, 
environmental barriers, unclear boundaries around the professional role and 
a perceived lack of professional skills and training.  
 
Authors of several studies (2-4,8-10) noted a number of logistical and 
resource constraints to the successful collection of measurements that were 
related to limited staff time (2,5,6,9) and difficulty accessing monitoring 
equipment (such as specific waist circumference tool for obese patients and 
access to blood pressure monitors in community mental health clinics). Staff 
also reported difficulties capturing monitoring results onto the tool (1,6,9,10) 
(e.g. complicated guidelines to follow). Other barriers included transportation, 
cultural and language barriers to access phlebotomy clinics, arranging an 
appointment and patient resistance to exploring sensitive topics, such as 
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sexual health. Some of these barriers are also reported in the literature 
review of barriers to the uptake of and/or access to cancer screening 
specifically (section 5.1). An example of a specific barrier that overlaps 
screening for any physical condition and screening for cancer is feeling 
stigmatised by health professionals. 
 
Identified enablers to the successful implementation of interventions to 
facilitate screening relate to staff feeling invested and having a sense of 
‘responsibility’ in physical health monitoring (2,7,8,10), as well as staff 
flexibility around taking measures by using alternative (e.g. less invasive) 
equipment and tests (2,10). From an organisational perspective, having a 
clinical psychiatric pharmacist on the ward (3,8) to support mental health 
professionals (e.g. by providing the relevant guidelines and precautions to 













Table 3.3 Barriers and enablers to using data collection tools (by cluster). 
 
Cluster 1: Screening template1,2,4,6,7-10 Cluster 2: Staff education and 
training1,2,5,9,10 
Cluster 3: Computer or paper prompt for staff3,4,8,10  
Evaluation of the effectiveness of using a tool to 
increase screening uptake and raise staff 
awareness of physical health screening 
Staff training as a component of the 
intervention17 
Testing of a computer- or paper-based prompts to support 
clinicians to monitor and screen physical health indicators 
Barriers Enablers Barriers Enablers Barriers Enablers 
Difficulty entering 
monitoring results onto 
the tool1,6,9,10  
 




Workload issues2,5,9  ‘Booster’ 
education and 
team meetings2 
Technical constraints in 
terms of collecting 
measurement results3,10  
Having a clinical 
psychiatric pharmacist on 
the ward to remind 
clinicians to request 
investigations such as 
blood tests when 
appropriate and to provide 
the relevant guidelines 




‘Social desirability bias’1,7 
(patients self-report their 
health behaviour in an 
overly positive picture in 
an effort to please their 
keyworkers) 
 
Investment of staff in 
physical health 
monitoring2,7,8,10 
Lack of objective 
verification that waist 
circumference 
measurements 
taken by health 
professionals adhered 
to the intervention 
protocol1  
Investment of 
staff in physical 
health 
monitoring2,10  
Limited access to equipment 
and resources4,8   
 
Low uptake of data 
collection on sensitive 
topics7  




 Low uptake of test 
measurements e.g. waist 
circumference8 and fasting 
blood glucose3,8  
 
Staff reluctant to see 
metabolic syndrome 
screening as their 
responsibility2,4,6 
   Lack of expertise from 
mental health professionals 







17 No author described the content or format of education interventions in detail. 




   Unclear communication 
channel between primary 
and secondary care4,8  
 
Lack of integration with 
primary care for treatment 
or referral2,8,9  
   Low uptake of test 
measurements e.g. waist 
circumference8 and fasting 
blood glucose3,8 
 
Inability to attend 
appointment2,6 leading to 
data missing in the 
template (e.g. missing 
data on waist 
circumference2 and 
fasting blood glucose2,6) 
     
Lack of expertise in 
mental health 
professionals to interpret 
physical health results4,8 
     
Workload issues2,6,9       
Refusal by some patients 
to undergo physical 
measurements (e.g. waist 
circumference and blood 
tests)8 
     
Reluctance by some staff 
to have physical contact 
with patients9 
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Barriers to the successful implementation of health service delivery changes are 
clustered into three areas: environmental barriers, unclear boundaries around the 
professional role and patient resistance. Environmental barriers include resource 
constraints (3,12,15), lack of coordination across the primary and secondary care 
interface (15,17,19,22) and difficulty for patients and staff to obtain a screening 
appointment (2,14). In relation to staff, authors note staff turnover (18,19), resistance 
to change (2,11,17,18), lack of time (2,3,11), limited clarity over who is responsible 
for screening (15,21), and not perceiving physical health screening as a priority 
(15,18). In relation to patients, areas of concern were reluctance to engage with 
screening due to lack of motivation/scepticism in the screening process (15,18), 
inability to attend appointments (2,14,20) and particular resistance to invasive tests 
(18,20).  
 
Staff enablers include having team ‘champions’ or a key worker to encourage 
screening, staff who feel invested with regard to physical health screening 
(2,3,11,14,15,20) and established trust between patients and staff (2,12,14). 
Organisational enablers include stakeholder involvement (11,14,16,20) and having 
strong links to primary care and specialist services (2,14,17,20-22), including at-
home phlebotomy services.  
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Table 3.4 Barriers and enablers to using interventions for health service delivery change (clusters 1–2) 
 
Cluster 1: Staff education and training11,17-21: Patient and staff (working in 
primary and secondary care) education 
Cluster 2: Staff accompaniment to appointments2,11,12,14: Accompaniment of service 
users to appointments as part of each intervention to address potential difficulties in locating 
and visiting unfamiliar places 
Barriers Enablers Barriers Enablers 
Staff time constraints11,21  Team’s ownership of training11,20  Staff workload issues2,11  Staff feeling invested/having a sense of ownership 
regarding physical health screening2,11,14  
Poor communication across 
primary and secondary care 
clinical teams17,19  
Team ‘champions’ to encourage 
screening11,20  
Difficulty engaging staff2,11  Having access to primary care/in-home 
phlebotomy services2,12,14  
Lack of clarity over scope of 
practice21  
High visibility/structure around monitoring 
and better liaison with primary care20,21  
Patient reluctance to undergo 
screening2,14  
Trust between patients and staff2,14 
 
Patient resistance to invasive 
tests18,20  




Staff resistance to change11,17,18   





Table 3.5 Barriers and enablers to using interventions for health service delivery change (clusters 3-5) 
 
Cluster 3: Invitation letter to physical health 
screening11,13,20: Using an invitation letter from 
primary care to encourage patients to attend 
screening as part of a physical health check-up 
Cluster 4: Improving access to monitoring 
resources15,18,19,21:  Testing interventions developed 
to improve the collection of physical health data to 
increase screening 
Cluster 5: Integrating care across health 
settings11,12,14,16,17,20,22: Evaluation and 
reduction of the fragmentation of care 
between different care providers. New clinics 
to improve physical healthcare were set up 
and evaluated14,16,22, two trials12,17 evaluated 
nurse-led care management and two studies 
audited improvement in awareness20 and 
communication11 within the multidisciplinary 
care coordination team 
Barriers Enablers Barriers Enablers Barriers Enablers 
Patient resistance to 
invasive tests20 
Team’s ownership of 
screening11,20 
Patient resistance and 
lack of motivation in the 
screening process15,18  
High visibility and 
structure around 
monitoring21  
Lack of coordination 
across the primary 
and secondary care 
interface17,22 




Staff resistance to 
change11 
Team ‘champions’ to 
encourage screening11,20 
Patient resistance and 
lack of motivation in the 
screening process15,18  
Having a key worker 
system with key workers’ 
duties involving 
screening15  





and trust between 
patients and staff to 
help them obtain 
screening12,14 
 Getting stakeholders 
involved11,20 
Inadequate links with 
primary care15,19  
 Staff resistance to 
change11,17  
 
Availability of primary 
and specialist 
care14,17,20,22 Living in a suburban 
(rather than urban) 
area13  
 No clarity about who takes 
responsibility for 
screening15,21 
Lack of a prescribing 
provider12 
 
Staff turnover18,19   
Staff not perceiving 
physical health screening 
as a priority15,18  
Time and resource 
(screening equipment) 
constraints15,21  
Poor recording and 
knowledge of screening 







3.3.8 Outcome measures 
In this review, interventions to increase uptake of screening (or change 
patient behaviour with respect to uptake of screening) are defined as 
interventions that support health professionals with screening for physical 
health conditions (1-12,17-21). Interventions to increase access to screening 
are defined as interventions that are targeted at health professionals or 
health service delivery which facilitate the availability of screening (13-
14,16,22). 
 
3.3.9 Intervention effects 
All studies reported sub-optimal screening and monitoring at baseline, with 
improved levels of screening and monitoring post-intervention (Tables 3.1–
3.2). This appeared to be independent of screening type or study design. 
However, limited evidence of actions occurring as a result of these 
improvements was reported. As most studies were rated as being of low or 
moderate quality, it was difficult to assess whether findings of improvements 
in rates of screening are valid. The effect size was not reported for any study, 






3.4.1 Summary of findings 
The review sought to explore what works, in what setting, for whom and why 
to increase the uptake of or access to physical health screening interventions 
by adults with SMI. However, this overall objective was not achieved since 
no studies tested every parameter. Several potentially useful intervention 
approaches were identified, however, such as staff accompanying service 
users to appointments or having a ‘team champion’ or key worker to 
encourage screening. In addition, the review identified specific barriers and 
enablers to screening uptake or access in people with SMI. These findings 
could be used to target components of future screening interventions, as 
each intervention may target different aspects of screening and different 
barriers and enablers may apply.  
 
All but one study considered metabolic monitoring. Cancer screening 
uptake/access was included in two studies (14,22), while three studies 
(1,7,13) referred to the health improvement profile, which has a section on 
cancer screening uptake. No cancer screening intervention was developed in 
collaboration with service users to ensure that it was acceptable and usable 
to them, nor was any intervention underpinned by behaviour change theory. 
 
As part of this review, a large international body of work was identified, with 
diversity in the number of physical health conditions and clinical settings 
studied. The challenges involved in increasing uptake of physical health 
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screening and monitoring in people with SMI were not unique to a single 
country, setting or health service configuration. This review illustrates that 
people with SMI receive care from a variety of clinicians from different health 
services and that systems are not always in place to allow different teams to 
communicate effectively, leading to gaps in patients’ care pathway, including 
treatment and referral post-diagnosis (2,4,8,9).  
 
Flaws relating to the reliability of findings or the generalisability of results 
were highlighted in all studies (Tables 3.1–3.2); these data suggest that 
findings concerning the size of effect should be considered with caution 
because the quality of data has been identified as being generally low. 
Overall, there is no strong evidence to ascertain whether an intervention to 
increase uptake of screening would be more effective in primary or 
secondary care. Two of the key barriers were that mental health staff were 
reluctant to see metabolic syndrome screening as their responsibility (2,6), 
leading to resistance to engagement in this activity, and a perceived lack of 
expertise on the part of mental health professionals to interpret physical 
health results (4,8). The low uptake (2,3,6,7,8,9) and lack of training to 
collect waist circumference data in a uniform way was reported, as was 
unawareness of a potential ‘social desirability bias’ (1,7), factors that 
contribute to the risk of unreliable results. Lastly, mechanisms to establish 
and maintain strong links between primary care/screening clinics and mental 
health services to ensure that patients attend screening appointments 
appear to be central to monitoring patients’ physical health. One US study2 
illustrates this barrier: the aim of the intervention was to make annual 
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metabolic syndrome screening a ‘routine responsibility’ for the mental health 
team; however, it also acknowledged that the team cannot refer patients to 
primary care for follow-up.  
 
3.4.2 Limitations of the review 
There is inconsistency within the published literature around how terms such 
as ‘screening’ and ‘monitoring’ are used, which makes comparisons across 
studies difficult. The candidate’s use of these terms may differ to that of 
others who may use different terms and include different studies. To 
compensate for this, and in line with the realist review methodology, a broad 
and inclusive study identification process was used, which was adapted 
iteratively through the study selection process, as described above (section 
3.2.1). The quality of data was identified as being generally low; therefore, it 
is not possible to determine the size of effect any intervention may have. 
Given the high level of heterogeneity and the limited quality of evidence 
included in this review, it is not possible to draw firm conclusions. 
Nonetheless, this review has highlighted the variety of physical health 
screening interventions for people with SMI across several countries. A wide 
range of studies was identified with varied participants, settings, interventions 
and outcomes. A narrower review may provide answers which are more 
applicable to specific situations; however, the lack of good-quality evidence 






3.5.1 Implications for policy and practice  
Improving uptake of and access to screening in people with SMI requires 
changes both at the system and individual levels. Strategies to improve 
coordination between primary and secondary care are needed, as are 
guidelines to clarify professional role boundaries of who holds responsibility 
for screening. Resource constraints, such as workload issues and lack of 
monitoring equipment in mental health settings, need to be addressed.  
 
3.5.2 Implications for research 
There were no studies that reported a follow-up at any time other than at the 
immediate post-intervention time point. Therefore, this review is unable to 
clarify whether screening was maintained post-intervention and whether the 
increase in uptake is sustainable or if it is a consequence of the Hawthorne 
effect, whereby health professional behaviour changes as a result of being 
observed. Longer follow-up is needed after interventions are funded, and 
published evaluations of routine care are needed after research studies to 
see whether effects are sustained. The description of interventions in 
publications is often extremely vague, which limits the implementation and 
replicability of interventions, and the studies included in this review are no 
exception. With the aim of improving intervention reporting and ultimately 
their replicability, the Template for Intervention Description and Replication 
(TIDieR) checklist and guide was developed by an international expert group 
(Armstrong et al, 2015). Future studies should report interventions using the 
12-item TiDieR checklist (brief name, why, what (materials), what 
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(procedure), who provided, how, where, when and how much, tailoring, 
modifications, how well (planned), how well (actual)) (Armstrong et al, 2015; 
Hoffmann et al, 2014). Future studies should also refer to the MRC guidance 
(Anderson, 2008), to make explicit how the components of complex 
interventions may work. The use of behaviour change theory was considered 
in only one intervention design (19). Some studies acknowledged that it was 
not considered – which provides no insight into what might have impacted on 
staff and service user behaviour to increase uptake. Few interventions were 
designed in collaboration with service users, and the users’ preferences were 
not explored. 
 
Performing ’in-house’ screening in mental health services rather than in a 
primary care context warrants further research, including what training and 
equipment this would require. Interventions to reduce patient and health 
professionals’ reluctance to screening which are informed by behaviour 
change theory should be developed and tested. Involving service users in 
the intervention design and testing would ensure that it is both acceptable 
and usable to them, for example by identifying their preferences for location, 
frequency and type of support.  
 
3.5.3 Implications for tool development 
Results from this realist review have shown that clinicians’ workload, as well 
as lack of integrated care between primary and secondary settings are 
significant barriers to implementation. The tool developed for this study will 
be aimed at the individual – service user – level, rather than as a shared 
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decision-making tool (though it may be discussed with their health 
professional and/or relative). This review has highlighted that behaviour 
change theory should be used in the development phase of any intervention. 
Chapter Five addresses how the tool is theoretically informed and its testing 
with service users and mental health clinicians to ensure its acceptability 
(Chapter Six) and usability (Chapter Seven).  
 
Chapter summary 
As discussed in Chapter One, screening attendance requires an individual to 
make an informed choice. This realist review found no informed-choice tool 
available that aims to increase uptake of or access to physical health 
screening, including cancer screening, for people with SMI. The review 
identified a knowledge gap regarding the evidence on the effectiveness of 
informed-choice tools for people with SMI, and the methods used for their 
design. A review that explores the development and effectiveness of 
informed-choice tools for people with SMI was therefore needed. This (Study 




Chapter Four – Identifying the evidence base: A systematic 
review of the design and evaluation of informed-choice tools 
for people with SMI 
 
This chapter reports on a systematic review of the design and evaluation of 
informed-choice tools for people with SMI, which was conducted to inform 
the development of the tool. It completes the realist review (Study One) 
which identified a knowledge gap regarding interventions to increase the 
uptake of or access to cancer screening among individuals living with an 
SMI. The principal aim of this systematic review is to determine the optimum 
design of an informed-choice tool for people with SMI, based on the available 
evidence. This review is in line with step one of the MRC guidance for 
complex interventions (Development phase). A modified version of this 
chapter was published in a peer-reviewed journal (Lamontagne-Godwin et 
al., 2020).  
 
4.1 Background 
In healthcare, there has been a gradual shift from a paternalistic model, 
whereby the clinician holds the power, towards a model that involves greater 
patient autonomy and control (Barry and Edgman-Levitan, 2012; Kaba and 
Sooriakumaran, 2007). In several countries, including Australia, Canada, 
New Zealand, the US and UK, promoting choice has been regarded as a 
significant factor for modernising health and social care services and has 
formed part of governments’ delivery plans (Coulter, 2010), such as Creating 
a Patient Led NHS in the UK (Department of Health/NHS, 2005) and the 
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evolution of Standard Two – Partnering with Consumers within the National 
Safety and Quality Health Services Standards in Australia (Trevena et al., 
2017). In mental health services in the UK, this includes providing informed 
choice of service or treatment and care pathway (Samele et al., 2007). There 
is a shift towards providing information to the individual in a way that helps 
them make an informed ‘choice’, rather than simply obtaining informed 
‘consent’, which is more passive (Coulter et al., 2011; King and Moulton, 
2006; Liu et al., 2018; Woolf et al., 2005).  
 
In recent years, there has been increasing emphasis on empowering those 
offered healthcare to make informed choices (Michie et al., 2004). To make 
an informed choice, information must be understood and presented in a 
balanced way so as not to suggest a right or wrong option (Hope, 2002; 
Jepson et al, 2005). In addition to having the relevant information, 
clarification of one’s personal preferences and values is needed to make a 
good choice. Uncertainty about which course of action to take when choice 
among competing options involves risk, regret, loss, or challenge to personal 
life values is termed ‘decisional conflict’ (Leblanc et al., 2009). Decisional 
conflict was defined in Chapter Two (section 2.5) as an individual’s 
uncertainty about which course of action to take when faced with a choice 
among competing options (Janis and Mann, 1977). It is generated by 
inadequate knowledge and support, unclear values and the perception that 




The need for further research on the use of decision-making tools in 
populations with lower literacy was identified in a systematic review of 
decision aids (Stacey et al, 2017). Many individuals with SMI have limited 
literacy rates (Lincoln et al., 2017), which may impede their ability to use an 
informed-choice tool. In addition, this group may face additional barriers to 
using such a tool, such as difficulty with concentration; these were discussed 
earlier in Chapter One (see section 1.5). A systematic review of interventions 
that aimed to enhance informed choice to undergo health screening 
(including cancer screening) reported that for most interventions, the 
acceptability of the information needs to be systematically reviewed by 
experts but, equally importantly, also by the target population (Biesecker et 
al., 2013). In addition, the usability of the intervention, namely the literacy 
level, format and presentation of the information, needs to be taken into 
account to ensure that the intended participants can understand the 
information (Biesecker et al., 2013). The optimal design and steps to follow 
when developing an informed-choice tool for people with SMI is currently 
unknown. The literature was therefore systematically reviewed to answer the 
following questions: (1) how effective are informed-choice tools for people 
with SMI in reducing their decisional conflict and (2) what methods and 





4.2.1 Study selection 
The inclusion criteria used in this review were as follows: 
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 Studies concerning any informed-choice tool specifically for use by 
adults with an SMI, whose method of design and/or evaluation is 
described, and where the aim of the tool was to improve decision-
making 
 No restrictions on study design  
 Studies with populations involving people with mental disorders other 
than those defined as severe above (e.g. obsessive compulsive or 
anxiety disorders) only if more than 50% of participants had a 
diagnosis of SMI, or if data limited to those with SMI were available  
 Study participants were adults (18 years or over) of any gender with 
an SMI, however diagnosed and being treated in any setting. The 
definition of SMI used throughout this research was applied here (see 
Chapter One, section 1.1) 
 Studies where participants were defined by authors as having an SMI, 
even when specific diagnoses were not provided 
 The study was reported in English  
 The full text was published in a peer-reviewed journal 
 
The exclusion criteria included: 
 Shared decision-making tools that could not be used by people with 
SMI independently of a healthcare professional  
 Studies of participants with severe depression without psychotic 
symptoms – there is evidence that their behaviour around screening 




 Articles published before 1996, since this coincides with the 
introduction of the evidence-based medicine movement, which 
highlights the importance of understanding research evidence when 
making health decisions (Sackett et al., 1996)  
 
Studies involving participants with substance abuse disorders co-morbid with 
SMI were eligible, as were those with participants with SMI who reported a 
physical illness 
  
4.2.2 Search strategy  
This systematic review is reported in accordance with the 2009 PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 
statement (Moher et al., 2009). The review protocol (Lamontagne-Godwin et 
al., 2017) is registered on the international prospective register of systematic 
reviews (PROSPERO Registration number: CRD42017083507). The 
completed PRISMA checklist is contained in Appendix 3. 
 
4.2.3 Data sources 
A search of Cochrane Central Register of Controlled Trials, EBSCOhost, 
Web of Science, Academic Search Elite, MEDLINE, Embase, CINAHL and 
PsycINFO was conducted for studies published between 1996 and January 
2018. An update was conducted in March 2020. The grey literature was also 
systematically searched, including conference abstracts through Open Grey 
and the Grey Literature Report, and the reference lists of included studies 
and relevant review articles were reviewed. No geographical limits were 
imposed. The literature search was restricted to English-language 
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publications. The first author of the included studies was contacted to find 
relevant unpublished work. To identify relevant studies, the search strategy 
used a combination of subject headings. The final strategy included relevant 
synonyms and incorporated appropriate search tools to ensure maximum 
sensitivity. A list of key search terms is published in the protocol 
(Lamontagne-Godwin et al., 2017).  
 
4.2.4 Selection of studies 
Titles and abstracts were independently screened by one reviewer [the 
candidate] to identify studies that potentially met the eligibility criteria. A 
second reviewer [a chartered psychologist] screened 10% of the titles and 
abstracts. Agreement on screening results was 80%; differences were 
reconciled with a third reviewer [a chartered psychologist with expertise in 
health psychology]. The full text of potentially eligible studies was assessed 
by three reviewers [the candidate, a chartered psychologist and a chartered 
psychologist with expertise in health psychology]. Disagreements were 
resolved through discussion with a fourth [a health psychologist] and fifth 
reviewer [a psychiatrist and health services researcher]. 
 
4.2.5 Study quality assessment 
The Integrated quality Criteria for the Review Of Multiple Study designs 
(ICROMS) was used to assess the quality of the included studies (Zingg et 
al., 2016). ICROMS allows reviewers to attribute points to a study when it 
successfully meets a quality criterion. The quality criteria for each study are 
assessed using seven dimensions (e.g. managing bias in outcome 
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measurements and blinding, managing bias in sampling or between groups), 
with criteria allocated to each dimension. Scores are applicable to each 
criterion: Yes (criterion met): 2 points; Unclear: 1 point; No (criterion not met): 
0 points. The sum of points attributed to each criterion represents the global 
quality score for that study. A minimum global score threshold is attributed 
for each study design. Studies were not excluded based on quality, but 
assessments of quality informed the data synthesis and interpretation of 
results. The study quality assessment was shared with the third and fourth 
reviewers; each reviewer scored two-thirds of the studies. Any discrepancies 
in scoring were resolved by discussion. 
 
4.2.6 Data extraction  
Data extraction forms were piloted to develop a framework, which was then 
reviewed by two reviewers [a chartered psychologist with expertise in health 
psychology and a chartered research psychologist]. Papers were divided into 
two categories: 1) those describing the development of a tool (Table 4.1) and 
2) those describing the evaluation of a tool (Table 4.2). Some papers 
described both. The following data were extracted and synthesised for each 
category of studies: 1) participants (response rate, sample size, 
demographics, setting), intervention development (tool development, 
description of tool, use of behaviour change theory) and study weaknesses 
(Table 4.1); 2) participants (demographics setting), intervention evaluation 
(design, outcomes, results) and main study weaknesses (Table 4.2). All the 
data were extracted by one reviewer [the candidate]; one reviewer [a 
chartered psychologist with expertise in health psychology] verified half the 
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extracted data, while another reviewer [a chartered psychologist] verified the 
other half. 
 
4.2.7 Approach to synthesis  
A narrative synthesis of the findings was produced from the included studies, 
structured according to intervention type and method of development (Popay 
et al., 2006). Methods of intervention development were described. Data 
concerning all reported outcomes were included in the synthesis. Changes in 
scores for decisional conflict and knowledge are key indicators of 
improvement in decision-making. Both indicators were selected to assess the 
effectiveness of the intervention (Stacey et al., 2017). Changes in decisional 
conflict were compared with and, where possible, related to process 
variables and modifiers, such as the theory used to guide development or 
participant characteristics. Meta-analysis was not possible due to insufficient 
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Hispanic: n = 12 
Other/multiple races: n = 4 
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n = 74 reported 
quitting smoking for 
at least one day 
over six-month 
follow-up period  
Average length of 
self-reported 
abstinence among 
quitters was 18 days 
 n = 36 sustained 
abstinence for at 
least 7 days 
n = 9 persisted in 
their abstinence and 
provided a breath 
CO<10ppm at six-
month follow-up  
Participants’ scores 
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n = 81  
Control group (n = 23; 11 
female) 
Ethnicity: 
White: n = 20 
Black: n = 2 
Other: n = 1 
Diagnosis: 
Schizophrenia/affective 
disorders: n = 9 
Mood/anxiety disorders: n = 
14 
Intervention group (n = 30, 
10 female) 
Ethnicity: 
White: n = 17 
Black: n = 9 
Other: n = 4 
Diagnosis: 
Schizophrenia/affective: n = 
12 
Diagnosis mood/anxiety: n = 
18   
Intervention group - 
Computerised National 
Cancer Institute Education 
– (n = 28, 9 female) 
Ethnicity: 
White: n = 16 
Black: n = 10 
Other: n = 2 
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Schizophrenia/affective: n = 
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4.3 Results  
 
4.3.1 Search results 
The search results are summarised in the PRISMA Flow Diagram (Moher et 
al., 2009) (Figure 4.1). Papers were identified from the database search (n = 
883) and using the other methods, as described in section 4.2.3 (n = 48). 
Duplicate articles were removed (n = 164) and the inclusion and exclusion 
criteria applied. The full text of 13 potentially eligible papers was assessed. 
Four papers were excluded: one described a shared decision-making tool 
designed to be used with a health professional, one did not specify the target 
audience and two did not include participants with an SMI diagnosis. Nine 
papers were included in the synthesis (two from England, one from Germany 
and six from the United States).  
 
The included studies described three tools; detailed information on these is 
presented in Tables 4.1 and 4.2.  
Tool 1 – disclosure tool 
Paper-based decision aid (A4/12 pages) 
Entitled CORAL [Conceal Or ReveAL] 
Developed and trialled in England to assist people with SMI with reaching 
decisions regarding disclosure of their mental health status in the 
employment context (Brohan et al., 2014a: Henderson et al., 2013). 
Tool 2 – smoking cessation tool 
Web-based decision support system  
Entitled Let’s Talk About Smoking  
Developed and trialled in the United States to stimulate motivation in 
people with SMI to quit smoking (Brunette et al., 2011, 2013, 2017; 




Figure 4.1 PRISMA Flow Diagram (Moher et al., 2009) 
 
 
4.3.2 Assessment of study quality  
A main aim of the review was to analyse the methods used to develop 
informed-choice tools for people with SMI. The ICROMS framework was 
Tool 3 – treatment choice tool 
Web-based patient decision aid 
Available on: www.psychenet.de  
Developed in Germany to encourage patients to participate in decision-
making about treatment by providing information about the pros and cons 
of treatment options for bipolar disorder; it has not been evaluated 
(Liebherz et al., 2015). 
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used to assess the study quality of development and evaluation studies, but 
quality per se was not an eligibility criterion. Using the matrix to calculate a 
‘global quality score’ for each study, three of the four studies describing the 
development of the informed-choice tools produced a score below the 
threshold used to define ‘adequate quality’: 21/221, 15.5/223 and 20.5/224. 
These low scores are not a reflection of their quality; the design and sample 
size selected by the authors for the development studies was appropriate for 
initial testing with cognitive debriefing. Rather, these low scores reflect that 
ICROMS is more appropriate for certain types of studies, while other design 
categories were not recognised by the framework. One study9 met the 
minimum quality score and the remaining five scored above it2,5-8. The main 
study weaknesses are described in Tables 4.1 and 4.2. The most common 
weaknesses involve a small sample size and lack of generalisability. On 
balance, notwithstanding these limitations, the overall body of evidence was 
considered to be sufficiently reliable for conclusions to be drawn, since the 
quality of evidence for developmental studies was rated moderate overall 
and the evidence for the evaluation studies was rated good overall.  
 
4.3.3 Evidence of effectiveness 
The disclosure tool was evaluated in a pilot and in an exploratory 
randomised controlled trial (RCT)1,6. The smoking cessation tool was 
evaluated in a pilot study using a quasi-experimental design7, an RCT8, using 
secondary analysis of data4 from the RCT8. The tool was also evaluated after 
a six-month follow-up of the RCT9 and in a pilot trial comparing the smoking 
cessation tool to the computerised smoking education tool from the American 
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National Cancer Institute (ANCI)2. No effectiveness data are available for the 
treatment choice tool5. Reported outcomes are included in Table 4.2 and 
summarised in sections 4.3.5 and 4.3.6. 
 
4.3.4 Development and design of informed-choice tools  
Three studies (smoking cessation: n = 71, disclosure: n = 15, treatment 
choice: n = 210) described the informed-choice tools’ development1,5,7 and 
data on these are summarised in Table 4.1. Based on the current 
synthesised evidence from several studies1-5,7, a preliminary list of steps that 
interventionists may wish to follow when developing informed-choice tools for 
people with SMI is listed in the box below.  
 
 
The following section details each step. 
 
1) Step one: Identify barriers to decision-making 
Method: Conduct a (systematic) review of the literature 
 
Barriers to decision-making were identified by study authors who conducted 
a literature search prior to the development of their respective tools1,3,5. 
Step one: Identify barriers to decision-making 
Step two: Theoretically underpin the intervention  
Step three: Involve service users in the development of the tool  
Step four: Test usability of the intervention 





Authors of the disclosure (Brohan et al., 2012) and treatment choice 
(Liebherz et al., 2015; Tlach et al., 2014) tools conducted a systematic 
review, while authors developing the smoking cessation tool reviewed the 
research on smoking cessation interventions for adults with SMI3. Authors of 
the disclosure tool also conducted a qualitative study to explore disclosure of 
decision-making (Brohan et al., 2014b).  
 
2) Step two: Theoretically underpin the intervention  
Method: Identify a theory of behaviour change and refer to the Ottawa 
decision support framework. 
 
The Ottawa decision support framework is a three-step process used by 
interventionists developing decision aids to guide users through making 
health or social decisions (O’Connor et al., 1999). The first step involves the 
assessment of client and practitioner determinants of decisions to identify 
decision support needs; the second is to offer decision support tailored to 
client needs using counselling, decision tools/coaching; the last one is to 
evaluate the decision-making process and outcomes. 
 
The development of the disclosure and treatment choice tools was based on 
this framework. Authors of the disclosure tool1 included an integrated 
disclosure framework developed from their systematic review and earlier 
qualitative work as the theoretical basis for the disclosure tool (Brohan et al., 
2012, Brohan et al., 2014b). The disclosure and smoking cessation tools 
used the Theory of Planned Behaviour (Ajzen, 1991) to inform content 
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development1,3. This ensured that the tools were theoretically underpinned 
and enabled evaluation of the process of change (Moore et al., 2015).  
 
3) Step three: Involve service users in the development of the tool  
Method: Collect feedback from service users on the content of the tool using 
semi-structured interviews/online survey. Use the think-aloud method to 
collect feedback on usability and acceptability of the tool. 
 
People with an SMI were involved in the development phase of every tool in 
order to explore their needs when faced with making a particular decision5 
and to test the usability and acceptability of the tool1,3. Ease of use was 
tested for both the smoking cessation2-4 and disclosure1 tools (see below). 
Feedback from people with SMI was collected using semi-structured 
interviews1,3. Questions focused on their general opinions on the tool, other 
information/experiences which they felt should be included and any 
amendments to existing information1. Feedback was also collected using an 
online cross-sectional survey5 and the think-aloud method3. This method was 
used to test an intervention that was used in a similar study for people with 
SMI (Vilardaga et al., 2016) and is described in more detail in section 8.1. 
 
4) Step four: Test usability of the intervention 
Method: Use the Perceived Usefulness and Ease of Use Scale (Davis, 1989) 
and refer to the usability guidelines for people with schizophrenia (Rotondi et 
al., 2007) and people with cognitive deficits (United States Department of 




Ease of use was tested in four studies, three relating to the smoking 
cessation tool2,3,8 and one to the disclosure tool1. Changes implemented 
following service user feedback on the smoking cessation and disclosure 
tools showed positive effects on ease of use for both tools. Most participants 
testing the smoking cessation tool (n = 124) reported high levels of 
satisfaction with the first and second (revised) versions of the tool: 75% were 
very satisfied and 98% agreed that the way the information was presented 
was good (28.2%), very good (28.2%) or excellent (41.6%)8. Participants (n = 
15) testing the disclosure tool found the tool to be quick to use (60%) and 
relevant (60%) and they were neutral (40%) or positive (40%) on the ease of 
use of the tool1.  
 
The Perceived Usefulness and Ease of Use Scale (Davis, 1989) was 
adapted and used in one evaluation of the smoking cessation tool to assess 
participants’ perceptions of the usefulness and ease of operating the tool. 
Items included the statement ‘the smoking program gave me too much 
information’3. Results showed an increased ease of use from the first to the 
last version of the online tool, which was reflected in participants’ reduction in 
unproductive clicking and fewer questions being asked about how to use the 
tool3. 
An evaluation study of the smoking cessation tool compared it with the 
computerised ANCI tool2. Users described that although they felt that both 
the tool and the ANCI tool were ‘easy to use’, 10.7% of ANCI education 
users versus 3.3% of users of the smoking cessation tool felt it was ‘hard to 
understand’. In terms of satisfaction, 71.4% of the ANCI education users and 
139 
 
83.4% of users of the tool described the intervention as ‘good’ or ‘very good’. 
About 95% of both groups said they would recommend the intervention to 
their peers2. 
 
For the smoking cessation intervention, suggested improvements included 
integrating a mouse tutorial, using a flat interface, increasing font and button 
sizes, using a blank background with a simple border graphic and using text-
to-speech software. To ensure usability of the smoking cessation tool, 
authors consulted previous research on usability for people with 
schizophrenia (Rotondi et al., 2007) and applied usability guidelines for 
people with cognitive deficits (United States Department of Health and 
Human Services, 2010). Changes implemented following service user 
feedback on the smoking cessation and disclosure tools showed positive 
effects on ease of use for both tools.  
 
5) Step five: Assess readability levels 
Method: Use the Flesch-Kincaid readability tests (Flesch Reading Ease and 
the Flesch–Kincaid Grade Level (Flesch, 1948; Kincaid et al., 1975). 
 
The readability level of participants with SMI were checked during the 
development phase of the disclosure and smoking cessation tools1,3. Authors 
of the disclosure tool refer to the Flesch-Kincaid readability tests (Flesch 
Reading Ease and the Flesch–Kincaid Grade Level). Following feedback 
from participants, the interventionists developing the tools revised the 
readability of their tools to a revised Flesch-Kincaid grade level of 8.4 i.e. to 
be understandable by the average US 8th – 9th grader (aged 13–15 years) 
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and from an 8th grade to below a 5th grade reading level, respectively1,3. 
Further feedback concerning the format and design layout of tools suggested 
that providing definitions, simplifying language, ‘breaking down’ the 
information and including ad verbatim quotes or videos from peers are all 
helpful.  
 
4.3.5 Evaluation of impact of the tools on primary outcomes 
Disclosure tool: The impact on decisional conflict was measured using the 
validated Decisional Conflict Scale (O’Connor, 1993 – updated 2010)1,6. A 
before and after study (n = 15) found a reduction in decisional conflict, 
indicating improvement (mean difference -16.5 (SD: 17.5)1. Statistical 
significance was not tested, as the sample size was too small for significance 
to be meaningfully interpreted. This result was supported by an RCT (n = 79) 
that compared the tool users’ group to a control group receiving usual care 
(mean improvement at three months: intervention group -22.7 (SD: 15.2); 
control group -11.2 (SD: 18.1), p = 0.005)6.  
 
Smoking cessation tool: The impact of the tool on knowledge was measured as 
an outcome in one study, which tested the effect of carbon monoxide 
feedback as an additional component to the smoking cessation tool8. At a 
two-month follow-up, participants testing the smoking cessation tool in the 
carbon monoxide intervention group (n = 58) reported increased knowledge 
about the risks of carbon monoxide compared to the control group. However, 
rudimentary knowledge about the health consequences of smoking was quite 




4.3.6 Evaluation of the Impact of the tools on other outcomes 
Other outcomes tested in the evaluation studies included:  
A) Stage of Change 
Disclosure tool: The stage of change (Donovan et al., 1998), which is the 
participant’s perceived degree of readiness to change their behaviour, was 
measured in two studies (n = 15 and n = 79). The Stage of Decision-Making 
scale (1-5) (O’Connor, 2000 – updated 2003) was used, which measures an 
individual’s readiness to engage in decision-making1,6. In one study, the 
mean stage of decision-making scores increased (indicating improvement) 
pre- and post-use of the tool from 4.3 to 4.6, though the sample size was not 
powered to detect statistically significant change1. In the other study (i.e. 
feasibility trial), there was much less evidence of movement in stage of 
decision-making, with no significant change between groups and no 
significant differences between groups at follow-up, although the change 
between immediate and three-month follow-up was in a positive direction; 
the median increased from 4 (IQR 3–5) to 5 (IQR 3–6)6.  
 
Smoking cessation tool: the stage of change scale was also used to assess 
the impact of the smoking cessation tool. The stage of change (i.e. readiness 
to quit smoking) was used in three studies (n = 124, n = 135 and n = 124)4,8,9 
and was measured by one question – Are you seriously thinking about 
quitting? – at baseline and after using the smoking cessation tool using a 
four-point scale (DiClemente et al., 1991; Donovan et al., 1998). Measures of 
stage of change at baseline and after using the tool were tested and not 
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reported for two studies4,8. Authors of the third study reported an increase in 
the stage of change score (indicating improvement) pre- and post-use of the 
tool from 1.82 to 2.759.  
The impact of the tools on behaviour was also measured with the following 
instruments. 
 
B) Self-efficacy outcome 
Disclosure tool: One study tested whether the tool led to a significant 
improvement on the power–powerlessness and the self-esteem–self-efficacy 
subscales of the Empowerment Scale (Rogers et al., 2010). This scale is a 
product of the Center for Psychiatric Rehabilitation at Boston University. 
Unadjusted and adjusted comparisons of the mean changes in the power–
powerlessness subscale showed a significant reduction in scores, indicating 
improvement. No significant improvement was recorded in the mean 
(adjusted and non-adjusted) self-esteem–self-efficacy subscale score 
(unadjusted: mean difference 0.13 (SD: 0.40) compared with 0.04 (SD: 
0.28)).  
 
Change in attitudes and beliefs was tested in the following ways: 
 
C) Behavioural withdrawal 
Disclosure tool: One study tested whether the tool led to a lower rate of 
behavioural withdrawal in response to stigma using five items (e.g. secrecy) 
from the withdrawal scale (Link et al., 1989). The latter is based on the 
original nine-item subscale of the Stigma Coping Orientation scales (Link et 
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al., 2001) that measures social withdrawal6. There was no significant 
improvement in behavioural withdrawal and no significant differences 
between groups at follow-up.  
D) Behavioural motivation 
Smoking cessation tool: Four studies assessed whether the smoking 
cessation tool had any impact on behaviours indicative of motivation to quit 
smoking4,7-9, however, one study9 is a secondary analysis of data from a 
parent study8 so these data were reported twice. Behaviours indicative of 
motivation were measured using the Behavioural Motivation Index7. 
Participants who used the tool were significantly more likely than the control 
group (67% versus 35%) to show any behavioural motivation to quit smoking 
(e.g. meet with a health professional to discuss cessation)7. The effect of the 
tool remained significant in an analysis that controlled for baseline group 
differences. In a separate evaluation, authors of the trial assessed 
participants’ smoking behaviours and other quitting behaviours two months 
after use of the tool, finding that more than half (52.9%) of the participants 
engaged in at least one cessation behaviour8. During the six-month follow-up 
of the trial, 55.6% of participants engaged in a cessation behaviour and 
nearly 40% (n = 49) initiated at least one type of evidence-based cessation 
treatment9.  
 
E) Self-reported smoking cessation 
Smoking cessation tool: Initiation of verifiable smoking cessation treatment 
was tested in three out of six evaluations of the smoking cessation tool, and 
rates of cessation varied across the studies. In their evaluation, authors from 
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two studies4,8 reported that about 30% of the group had initiated cessation 
treatment by discussing treatment options with a smoking cessation 
specialist. In another evaluation, treatment was initiated by 32% of 
participants8. In the final evaluation, about 6% of participants who received 
the smoking cessation tool accessed a verifiable cessation treatment over 
the three-month follow-up period2. 
 
F) Self-reported abstinence 
Smoking cessation tool: Self-reported abstinence was tested in two studies. 
Authors9 reported in their study (n = 74) that almost 60% of participants 
abstained from smoking for at least one day over the six-month follow-up 
period. The mean length of self-reported abstinence among quitters was 18 
days. Sustained abstinence was recorded for 29% of participants for at least 
seven days, while 7% persisted in their abstinence and provided a breath 
CO<10ppm18 at six-month follow-up9. Another evaluation assessed whether 
the rate of treatment initiation and cessation behaviours would be higher 
among users of the tool in comparison to users of the computerised 
American National Cancer Institute (ANCI) education tool on smoking 
cessation. Almost 15% of participants who used the smoking cessation tool 
met the study’s definition of biologically verified abstinence at the 14-week 
follow-up, whereas none of the smokers in the ANCI education group or 
comparison condition achieved smoking abstinence2. 
 
 
18 The British National Institute for Health and Care Excellence (NICE) stipulates that a non-
smoker is identified by a reading of less than 10ppm CO [carbon monoxide] 
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G) Importance of quitting smoking 
Smoking cessation tool: This was tested in one study. Following use of the 
smoking cessation tool, participants rated the importance of quitting highly 
(mean 5.7 ± 1.4 on a 1–7 scale); however, intentions to use cessation 
treatments were relatively low (mean 3.6 ± 1.9 on a 1–7 scale)2. 
 
4.4 Discussion  
 
4.4.1 Summary of key findings 
This systematic review has identified that there are few available informed-
choice tools that people with SMI can use to make decisions about their 
health without requiring support from a professional. Nevertheless, the 
available data suggest that such tools may facilitate a reduction in decisional 
conflict, improved knowledge and movement in stage of change towards 
decision-making. As stated in the protocol (Lamontagne-Godwin et al., 
2017), the MRC guidance for developing and evaluating complex 
interventions provides a broad description on how to achieve this in four 
phases: development, feasibility/piloting, evaluation and implementation 
(Craig et al., 2008). This review has identified a clear list of key 
methodological considerations for the development of future informed-choice 
tools for people with SMI.  
 
The findings suggest that such tools are effective, as was reported in an 
earlier systematic review of decision aids for people facing difficult treatment 
or screening decisions (Stacey et al., 2017). The findings of the review by 
Stacey (2017) indicate that in the general population, in comparison to usual 
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care, decision aids increase knowledge (MD 13.27/100; 95% CI = 11.32-
15.23; 52 studies; n = 13,316; high-quality evidence) and reduce decisional 
conflict (MD −9.28/100; 95% CI = −12.20 to −6.36; 27 studies; n = 5707; 
high-quality evidence). Congruency between informed values and care 
choices was also found to increase (RR 2.06; 95% CI 1.46 to 2.91; 10 
studies; n = 4626; low-quality evidence). However, these outcomes have not 
been tested in people with SMI. The review by Stacey (2017) therefore 
provided a strong rationale for testing these outcomes in people with SMI. 
 
Although the present review has identified methods that can improve the 
acceptability and ease of use of the tools by people with SMI, challenges 
remain. For instance, feedback from people with SMI, collected using a 
range of methods, indicates difficulties with readability. Authors of the 
disclosure and smoking cessation tools1,3 sought to increase readability by 
providing definitions, simplifying the language and breaking down the 
information. Further simplification of the disclosure tool may have been 
required for some users, but it was thought that this could risk diluting the 
complexity of the disclosure decision-making, thus lowering the effectiveness 
of the tool1. Authors of the treatment choice tool acknowledged that 
adaptations may be needed for people with low literacy levels5. Adaptations 
might include adding a button for audio for each section of text. 
 
Data from semi-structured interviews with study participants identified a 
desire for specific information to be included. Participants who responded to 
the survey for the treatment choice tool specified general information 
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searches as their most relevant information need5. When asked what could 
be improved about the smoking cessation tool, 23% of participants wanted 
more detailed information about health effects of smoking and 3%–9% 
wanted more knowledge about electronic cigarettes and the social impact of 
smoking2. Participants of the study evaluating the disclosure tool wanted 
more information on the legal implications of disclosure1; however, this 
aspect was beyond the scope of the tool.  
 
As recommended by the MRC guidance for developing complex 
interventions, deciding on which information to include can be partly 
addressed through an a priori review of the literature describing the barriers 
to performing the behaviour. This was addressed by the developers of every 
tool explored in this review. However, the feedback and interview data 
indicated that this may be insufficient on its own and that tools should be 
developed and tested in stages and informed by the target audience. This 
may be a drawback of the methodology used to develop the three tools, 
which advocates for service user involvement rather than a co-production 
model. Research is needed to evaluate whether a co-production 
methodology (Slay and Stephens, 2013) would be more effective for 
developing such interventions.  
 
As reported in section 1.7.3, informed-choice tools aimed at the general 
public have been published by healthcare organisations e.g. the cervical and 
breast screening decision aid [‘Helping you Decide’] leaflets from Public 
Health England or the smoking education tool from the ANCI. Authors of one 
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study included in this review2 randomised participants with SMI to compare 
the smoking cessation tool with the computerised standard education from 
the ANCI for the general population. Findings were in favour of the smoking 
cessation (i.e. SMI-specific) tool: those who received it were more likely to 
have biologically verified abstinence from smoking and other tobacco product 
use at the 14-week assessment than those who received the ANCI tool 
(14.8% vs. 0%)2. This finding supports the need for tools that are tailored to 
people with SMI, who may face specific barriers associated with their mental 
illness diagnosis (Clifton et al., 2016). While the review found no studies of 
routine use, it is worth noting that the smoking cessation and disclosure tools 
were felt to be easily deployed and implemented without significant resource 
implications in their respective settings (routine vocational services1 and 
mental health treatment settings2).  
 
This review has also highlighted gaps in the evidence base for the 
development and utilisation of informed-choice tools for people with SMI. For 
instance, there was little evidence of the use of theoretical frameworks in tool 
development. Use of theoretical frameworks, such as the Behaviour Change 
Wheel Framework, has been reported during the developmental phase of 
decision support interventions for the general population (Elwyn et al., 2011; 
Michie et al., 2011) and for interventions for people with SMI (Mangurian et 
al., 2017; Osborn et al., 2018). These may therefore be useful to consider in 




This review identified one paper-based1 and two web-based tools3,5, though 
no study directly compared the two formats. For the purposes of this 
research, before investing in the expense of a digital version, a paper 
informed-choice tool was developed as a first step. Leaflets are commonly 
used in health care and can be uploaded by different stakeholders. 
Alternative formats to this intervention are discussed in Chapter Ten (section 
10.5). It is nonetheless worth noting that there is some evidence that 
changing the format (e.g. a video, computer programme or leaflet with a 
decision tree) of an informed-choice intervention from a well-prepared leaflet 
does not increase test uptake, knowledge or satisfaction with the decision 
(Biesecker, et al., 2013). Further research is needed to establish whether 
access to and acceptability of internet and digital technology is widespread 
among this group, although there has been a recent systematic review that 
investigated the acceptability of mobile phone- and online- delivered 
interventions for people with SMI (Berry et al., 2016). Authors of the review 
(Berry et al., 2016) advise researchers to use qualitative methods to assess 
acceptability at each phase of intervention development and testing. Other 
authors of a systematic review (Batra et al., 2017) that explored the use of 
digital health technology for patients with SMI concluded that short-term use 
of digital technologies seems to be feasible.  
 
One included study noted that 61% (n = 82) of participants reported having 
used a computer more than five times in their life, while 22% (n = 30) had no 
computer experience (Ferron et al., 2012). Other studies have pointed to 
increased adoption and value of digital technology interventions by people 
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with SMI (Biagianti et al., 2017; Robotham et al., 2016). A survey was 
conducted in London in 2011 (n = 121, including n = 49 with psychosis) and 
2016 (n = 241, including n = 121 with psychosis) to explore rates of digital 
exclusion for people with SMI and found that digital exclusion rates declined 
over time. In 2016, fewer than 1 in 10 participants were considered ‘digitally 
excluded’ (n = 24), although within that subsample, more than 80% (n = 20) 
had psychosis. In comparison to participants who were ‘digitally included’, 
those who were ‘digitally excluded’ were significantly older (included: mean 
36.8, SD: 12.7 years and excluded: mean 45.7, SD: 9.7 years). Participants 
from the ‘digitally excluded’ group had accessed mental health services for 
longer (included: mean 8.7, SD: 8.3 years and excluded: mean 14.1, SD: 9.2 
years). Factors associated with exclusion were psychosis, being older, 
having used mental health services for longer and being part of a BAME 
group (Robotham et al., 2016). More research is needed to collect long-term 
effectiveness data to demonstrate digital technologies’ usefulness and 
acceptability for people with SMI (Batra et al., 2017). 
 
In March 2020, the original search was updated, and an additional 
intervention was identified: a decision aid (booklet) for patients with bipolar II 
disorder and their families making decisions about treatment options to 
prevent relapse (Fisher et al., 2018a). The intervention was developed in 
Australia and the feasibility study protocol for a Phase II RCT of the decision 




4.4.2 Strengths and limitations of this review 
This is the first systematic review to explore the development and evaluation 
of informed-choice tools for people with SMI. It includes heterogeneous 
interventions from different settings and mental health systems, though 
sample sizes were often small with no effect size available, so findings 
should be interpreted cautiously. The generalisability of the findings may be 
reduced, as a narrow definition of severe mental illness (psychosis) was 
applied, which excluded studies focusing on other mental health conditions 
such as anxiety disorders or PTSD. Despite overlap in terms of barriers, 
people with other mental health disorders may face different challenges that 
may not be relevant to those diagnosed with psychosis. It is unlikely that any 
one tool would be suitable for a diverse population.  
 
A strength of this review is that ICROMS, a robust framework, was used to 
assess study quality; however, a limitation is that it was not fully able to 
capture the design of the descriptive studies. 
 
4.4.3 Chapter summary and implications for the development of the tool 
Few informed-choice tools exist for people with SMI. Though the review did 
not identify a definite method, the findings provide useful guidance for the 
development of informed-choice tools for people with SMI, using a clear list 
of key methodological considerations. For instance, the development of such 
tools should proceed in stages and include the views of people with SMI at 
each phase. Attention should be paid to readability and use of a theoretical 
framework could assist in determining how interventions may work best to 
inform adjustments. In terms of the format, although a digital version may be 
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acceptable to this group, for this research, a paper version of the tool was 
developed as a first step. The work to develop the tool in this thesis is 




Chapter Five – Conception and design of the tool 
 
This chapter provides a description of how the tool was developed. The first 
step was to collect the evidence regarding barriers and enablers to cancer 
screening, followed by selecting the appropriate theoretical framework to 
develop the tool, and finally, completing the steps identified in the systematic 
review reported in Chapter Four. The contents of the initial draft of the tool 
are also presented here. This chapter addresses the first two objectives of 
the overall thesis. An illustration of how these objectives map onto the MRC 
phases and the development steps for informed-choice tools identified in the 




Box 1: Development of the tool 
 
Objectives of the research that this chapter addresses (in bold): 
Objective one: To develop an informed-choice tool for women with SMI 
which addresses some of the barriers to screening attendance 
Objective two: The tool should be theoretically underpinned 
Objective three: Acceptability and usability of the tool by stakeholders should be 
tested 
Phases of the MRC guidance 
Development: Identifying the evidence base 
Development: Identifying/developing theory 
Feasibility/Piloting: Testing procedures 
Evaluation: Understanding change process 
Steps to follow when developing an informed-choice tool for people with SMI 
 
Step one: Identify barriers to decision-making 
Step two: Theoretically underpin the intervention  
Step three: Involve service users in the development of the tool 
Step four: Test usability of the intervention 






5.1 Understanding the barriers and enablers to cancer screening uptake in 
people with SMI. 
 
In line with the MRC guidance (Craig et al., 2013), the antecedents of 
behaviour and the causal determinants of change (i.e. barriers to screening) 
first need to be appropriately identified and targeted by the intervention 
(Hardeman et al., 2005; Michie and Abraham, 2004; Michie et al., 2008). A 
literature review of the barriers and enablers to cancer screening uptake by 
people with SMI was therefore conducted (Abrams et al., 2012; Aggarwal et 
al., 2013; Clifton et al., 2016; Howard et al., 2010; Kahn et al., 2005; 
MacAttram and Chinegwundoh, 2014; Martens et al., 2009; Miller et al., 
2007; Owen et al., 2002; Werneke et al., 2006; Xiang, 2015). The eligibility 
criteria used in this review were as follows: 
 
 No restrictions on study design 
 Studies reporting on the barriers and/or enablers to cancer 
screening in people with SMI 
 No date restriction was applied in the search 
 Studies where participants were defined by authors as having an 
SMI (even when specific diagnoses were not provided) 
 The full text was published in a peer-reviewed journal 
 The study was reported in English.  
 
The following search terms were used: barriers, enablers, facilitators, levers; 
cancer screening, cervical screening, smear test, pap test, bowel screening, 
colorectal screening, breast screening, mammography, prostate cancer 
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screening; severe mental illness, SMI, serious mental illness, schizophrenia, 
bipolar disorder, psychotic depression and psychosis. 
 
Studies were identified from a number of high-income countries (n = 1 
Australia (Sydney); n = 2 Canada (Manitoba region and Toronto); n = 3 
England (including n = 2 London); n = 1 Hong Kong; n = 2 Japan; n = 2 
United States (including n = 1 in Boston); n = 1 multiple high-income 
countries). A systematic review explored the disparities in breast and cervical 
screening uptake in women with SMI and other mental health disorders 
(Aggarwal et al., 2013). Some studies identified in the Aggarwal (2013) 
review overlapped with studies identified in this literature review (Martens et 
al., 2009; Miller et al., 2007; Owen et al., 2002; Tilbrook et al., 2010). The 
literature review found that some studies focused solely on cervical 
screening (Martens et al., 2009; Tilbrook et al., 2010), while others included 
barriers to breast and cervical screening (Miller et al., 2007; Owen et al., 
2002; Woodhead et al., 2016; Xiang, 2015). Other studies explored barriers 
to bowel, breast and cervical screening (Clifton et al., 2016; Fujiwara et al., 
2017; Inagaki et al., 2018; MacAttram et al., 2014; Mo et al., 2014); in 
addition to these screening programmes, some studies also incorporated 
prostate examination (Mo et al., 2014) and lung and gastric cancer screening 
(Fujiwara et al., 2017; Inagaki et al., 2018).  
 
The barriers and enablers to cervical screening that were identified in the 
literature review are reported in Tables 5.1 and 5.2. The barriers and 
enablers were extracted from the review studies (n = 11) and then the 
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barriers were grouped into three clusters. The first encompasses 
environmental and systemic factors, such as not receiving invitations to 
screening or cancer testing kits if admitted to hospital or forensic services. 
The second category comprises the individual’s belief system, e.g. fear that 
the test could trigger flashbacks of sexual violence/trauma. The third group 
relates to symptoms of the individual’s mental illness; e.g. noisy screening 
environments can aggravate mental health symptoms. The enablers were 
categorised into two clusters: environmental and systemic factors, e.g. open-
ended appointments system in sexual health clinics, and the individual’s 









Table 5.1 Barriers to cervical screening uptake by people with SMI. 
 
Environmental and systemic factors: The individual’s belief system: Symptoms of the individual’s mental illness: 
Not being registered with a GP (in the UK, lack of primary 
care registration implies being effectively ‘excluded’ from 
health screening) 
Fear of pain associated with the 
procedure 
Fear of entering noisy or crowded places (e.g. getting on 
the bus to attend a screening appointment or a busy GP 
surgery waiting room) 
Lacking access to transport to attend screening Fear of receiving a cancer diagnosis Neglect or poor level of self-care  
Lacking reminders/having too many reminders to attend a 
screening appointment 
Fear that the test could trigger 
flashbacks of a traumatic event (e.g. 
Sexual violence or female genital 
mutilation/cutting (FGM/C)) 
Underreporting of physical symptoms 
Lacking familiar care providers Adverse prior experiences of 
screening/physical health monitoring 
Denial of physical symptoms 
Low income (this barrier is relevant in health systems where 
there is a cost to attending a screening appointment) 
Embarrassment Poor insight into the importance of preventive care  
Not receiving invitations to screening or cancer testing kits if 
admitted to hospital or forensic services (forensic services 
are for people who may pose a risk to others and who may 
have been involved in the criminal justice system) 
Feeling like a burden on health services Poor insight into the potential significance of symptoms 
Health professionals deciding not to screen due to diagnostic 
overshadowing  
Cancer fatalism Inability to follow through with appointments 
Health professionals feeling they lack training in mental 
health (clinicians who are not mental health professionals 
e.g. sonographer, practice nurse) 
 Difficulties with booking an appointment (e.g., having a 
difficult relationship with receptionist staff at the GP 
practice) 
Health professionals fearing they will be misunderstood 
regarding an invasive procedure 
Mistrust of the health system 
Health professionals being uncomfortable to screen people 
with poor levels of hygiene 
Feeling stigmatised/judged by health professionals 
Health professionals deciding not to screen due to high time 
demand for treating acute mental illness 
Delusions and paranoia (e.g. sitting in waiting rooms for 




Health professionals having a negative attitude towards 
people with mental illness, which may discourage people 
from getting screened. 
Having an impaired ability to communicate needs and 
symptoms (additional support may be available, but this 
places the onus on the service user to make a request 
for help, which may be difficult for some without formal 
systems for reasonable adjustments in place). 
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Table 5.2 Enablers to cervical screening uptake by people with SMI. 
 
Environmental and systemic factors: Individual’s belief system: 
Familiar location Wanting to be informed 
Reminder letters and texts  Past positive experience 
Open-ended appointments system in 
sexual health clinics  
Being anxious to avoid further health 
problems 
Staff knowledge of mental illness Feeling ‘health conscious’ 
Staff being understanding Understanding of benefits of screening 
Encouragement from friends, family or 
health professionals 
 
Good relationship with GP 
Good relationship with the practice nurse 
Continuity of care (e.g. being 
accompanied by a mental health worker 
to the appointment) 
 
These barriers and enablers inform the development of the components of 
the tool. Each component of the tool with its corresponding barrier(s) and 
enabler(s) is described in section 5.2.3 (Tables 5.5 and 5.6).  
 
5.1.1 Gathering service user feedback on the barriers and enablers to cancer 
screening 
 
A workshop was led by the candidate in spring 2018 at City, University of 
London with a service user group of people who have lived experience of 
mental illness (SUGAR, Service User and carer Group Advising on 
Research). Participants (n = 10) were presented with the full list of barriers 
and enablers to cancer screening that were identified in the literature review 
reported in section 5.1. Participants were asked to score each barrier and 
enabler in terms of importance to them in their cervical screening behaviour 
(1 = most important, 5 = least important). Male members of the group (n = 2) 
were asked to complete the exercise as if it related to prostate cancer 




Table 5.3 Ranking of barriers to cancer screening uptake by members of a 








Not at all 
important 
Fear of receiving a cancer diagnosis 6 1 2 1 0 
Unfriendly/negative attitude of staff 6 1 2 1 0 
Having experienced trauma (including 
sexual/domestic violence) 
6 0 3 1 0 
Having experienced FGM/C (female 
genital mutilation/cutting)19 
6 0 2 0 0 
Long waiting times in waiting areas are 
problematic (e.g. when suffering from 
paranoia) 
5 2 3 0 0 
Mental health staff prioritise mental 
health over physical health 
5 2 2 1 0 
Difficult relationship with staff at GP 
practice (e.g. receptionist unwilling to 
rebook an appointment) 
5 2 2 1 0 
Mental health stigma of staff at GP 
practice/sexual health clinic 
5 1 3 1 0 
Not acting on physical symptoms [e.g. 
irregular bleeding] 
 
5 1 3 0 0 
Adverse prior experience(s) of 
screening/physical health check 
4 3 3 0 0 
Embarrassed by the procedure 4 4 2 0 0 
Fear of pain associated with the 
procedure 
3 4 2 1 0 
Lack of reminders [you would not be 
invited for screening if you are in 
hospital/not registered with a 
GP/admitted to forensic services] 
3 1 5 1 0 
Mistrust of the health system 3 3 2 0 0 
Does not believe smear test applies to 
them 
2 4 1 2 0 
Feeling overwhelmed with existing health 
and social care appointments 
2 3 3 2 0 
Feeling like a burden on health services 2 1 2 3 2 
Lack of transport/transportation cost 0 3 5 2 0 
Received too many reminders (letters, 
texting) 
0 2 3 4 1 
 




Table 5.4 Ranking of enablers to cancer screening uptake by members of a 








Not at all 
important 
Ask the nurse to explain procedure and 
ask to touch and feel the instruments 
6 0 1 0 1 
Bring a carer with you to the appointment 
for support  
4 2 1 1 1 
Request a smaller speculum (tool used to 
perform smear test)20 
4 1 2 1 0 
Request a practice nurse you feel 
comfortable with 
3 2 3 0 1 
Ask GP for Diazepam prescription 
(medication to reduce anxiety) before the 
procedure 
2 5 1 0 1 
If you do not want to discuss history of 
abuse/trauma, write it on a piece of paper 
and pass it to the nurse 
2 3 3 0 0 
Request a ‘double’ (i.e. longer) 
appointment at your GP practice 
2 2 3 0 1 
Request a reminder from your GP practice 2 1 3 2 1 
Request the last appointment of the day at 
your GP practice 
1 2 3 1 1 
Bring earphones and music device (to 
help you relax) 
0 1 2 6 0 
 
Barriers to screening which scored highest were fear of receiving a cancer 
diagnosis, negative attitude of staff and having experienced trauma 
(sexual/domestic violence or FGM/C). Enablers with the highest ranking 
were asking the nurse to explain the procedure and being able to touch/feel 
the instruments, requesting a smaller speculum (tool used to perform the 
test) and bringing a carer to the appointment for support.  
Following this exercise, a discussion among the SUGAR members on 
cervical screening uptake for people with SMI was facilitated by the 
candidate. The idea of a cervical screening informed-choice tool for women 
 
20 Not ranked by male members of the group 
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with SMI was well-received by the group. The group asked whether the tool 
could be sent out prior to the appointment and whether translations of the 
tool were planned (e.g. in Arabic), as English may be a barrier for some 
women. The enabler ‘Ask GP for Diazepam prescription (medication to 
reduce anxiety) before the procedure’ triggered a debate within the group. 
Some felt it was important to reduce anxiety before the test, while others felt 
it could be risky, given some people’s history of substance misuse with 
prescribed medication. The group discussed suggestions to include in the 
tool, such as requesting the first appointment of the day to avoid long waiting 
times in a crowded GP surgery. The full list of suggestions is contained in 
Appendix 4; these were incorporated into the draft tool, which was then 
checked for clinical accuracy (Chapter Six) and tested with service users and 
health professionals for acceptability and usability (Chapters Seven and 
Eight). 
 
Additional barriers were discussed by participants; several of these 
overlapped with those identified in the literature review (section 5.1): 
 
 Hygiene problems can make you feel embarrassed  
 Not wanting to share health problems with people that hardly know 
them 
 ‘If I am, say, psychotic, I may believe that an invasive procedure is 
tantamount to assault’ 
 Anxiety about travel and going to new places  
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 Focus on weight/speaking about weight whenever someone goes to 
the GP (e.g. if someone has a history of an eating disorder) can put 
people off any appointment to the GP practice 
 Some women may have a different anatomy and be embarrassed 
 Unfair that inpatients/people without a GP miss out on screening 
 Getting the leaflet to the people who need it the most may be 
challenging 
 Paranoia is an issue (waiting room can cause anxiety, also fear that 
you might get infected with something during your smear or someone 
inserts a chip to keep track of you).  
 
Some of the above barriers relate to systemic or societal barriers to 
screening, which cannot be addressed by this tool (e.g. ‘unfair that 
inpatients/people without a GP miss out on screening’). Suggestions from the 
service user group were incorporated into the draft tool, which was then 
revised to ensure clinical accuracy (see Chapter Six) and acceptability with 
service users (see Chapter Seven). The next section covers the theoretical 
frameworks used to develop the tool. 
 
5.2 Identifying theoretical framework(s) to underpin the development of tool 
Cancer screening uptake is described as a behaviour to protect health 
(Michie et al., 2017). Screening itself is not considered a homogeneous 
behaviour (Marteau, 1993); cervical screening attendance can be described 
as a complex protective behaviour, since it requires several steps to achieve 
the behaviour (Sheeran and Orbell, 2000). It is therefore important to 
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understand the theoretical construct of this behaviour, namely cervical 
screening uptake and the determinants of behaviour change in this context. 
There are several relevant theories, concepts and techniques to be 
considered when developing a theoretically underpinned tool. The tool was 
developed using several theoretical frameworks; the rationale for their use 
will be discussed in the following section.  
 
5.2.1 The Theory of Planned Behaviour  
 
First, the theoretical construct of an individual’s behaviour in the context of 
cervical screening was explored using the Theory of Planned Behaviour 
(TPB) (Godin and Kok, 1996; Schifter and Ajzen, 1985). The TPB is based 
on the premise that an individual’s ‘cognitive determinants’, namely attitude, 
subject norms and perceived behavioural control, together determine their 
behavioural intentions and behaviour (Michie et al., 2004). Within this model, 
attitude is defined as an individual’s positive or negative evaluation of 
performing the behaviour. Subjective norms reflect an individual’s 
perceptions of social approval for performing the behaviour, while perceived 
behavioural control suggests being able to perform the behaviour in the face 
of ‘internal’ and ‘external’ barriers. The TPB posits that people form an 
intention in advance of behaviour (Ajzen, 1985, 1991). Each cognitive 
determinant makes an independent contribution to the intention to perform a 
behaviour, the latter then makes an independent contribution to performing 
the behaviour (Michie et al., 2004). These constructs of the TPB in the 





Figure 5.1 Theory of Planned Behaviour as applied to cervical screening 
attendance for women with SMI (Azjen, 1991).  
 
 
The TPB has been applied to decision-making scenarios and been used as a 
theoretical framework for decision-making tools (Kasper et al., 2012; Krones 
et al., 2010; Sivell et al., 2013), and it has been shown to predict a range of 
health-related behaviours (Armitage and Conner, 2001; Johnston et al., 
2004), including uptake of cancer screening tests (Ogilvie et al. 2013; 
Roncancio et al., 2013; Rutter, 2000; Sheeran and Orbell, 2000; Sieverding 
et al., 2010; Tolma et al., 2006). In addition, the TPB was identified in Study 
Two, the systematic review of informed-choice tools for people with SMI 
(Chapter Four) as a relevant model for informing content development, 
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thereby ensuring that the informed-choice tools were theoretically 
underpinned. For the reasons stated above, the TPB was selected for this 
research, and a critical appraisal of this theory is discussed in Chapter Ten 
(see section 10.3). The TPB links a person’s beliefs and behaviour (Godin 
and Kok, 1996; Schifter and Ajzen, 1985). Research has shown that an 
individual’s belief system is a variable that could affect their intention to 
attend screening (Roncancio et al., 2013). For women with SMI, the range of 
beliefs that can act as barriers or enablers to uptake of cervical screening 
were listed in the previous section (Tables 5.1 and 5.2). The preliminary data 
analysis (see Chapter Nine, section 9.4) will borrow some of the constructs 
of the TPB (see Figure 5.1) to categorise the impact of the tool on 
participants’ decision-making. 
 
5.2.2 The Theoretical Domains Framework 
The Theoretical Domains Framework (TDF) was the selected framework to 
underpin the tool (Cane et al., 2012). Informed by 128 explanatory constructs 
from 33 theories of behaviour, the TDF has been used in several contexts to 
understand health behaviour and design theoretically informed interventions 
(Cane et al., 2012; Francis et al., 2012; French et al., 2012; Michie et al., 
2005). The TDF covers 14 domains, comprising the main evidence-based 
factors influencing behaviour change, such as knowledge about the 
behaviour, beliefs about the consequences of the target behaviour, social 
influences such as the attitudes of relatives, and the environmental context. 
The TDF was selected in a qualitative study to explore the cancer screening 
behaviours of people with SMI (Clifton et al., 2016); the chosen domains are 
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listed in Tables 5.5 and 5.6. As part of the Clifton et al. (2016) study, health 
and screening professionals were also interviewed to explore their 
experience of offering and providing cancer screening to people with SMI. 
Through triangulation of data from service users and health and screening 
professionals, authors were able to identify five overarching themes or 
factors influencing cancer screening behaviour for which there was at least 
partial agreement:  
 
1) Knowledge of screening programmes and processes,  
2) Knowledge of and attitudes regarding mental illness,  
3) Health service delivery factors,  
4) Beliefs and concerns of people with SMI regarding screening and  
5) Practicalities for people with SMI. 
 
The barriers and enablers, which could be associated with the different 
stages of screening, were identified. Authors of the Clifton et al. (2016) study 
coded each barrier and enabler to a TDF domain; based on those findings, 
each component of the tool was mapped out using the identified barriers and 
enablers, underpinned by the TDF (Cane et al., 2012). A critical appraisal of 
the TDF in relation to the development of the tool is presented in Chapter 
Ten (see section 10.4). 
 
Some of the identified barriers could not be targeted by the tool, as they 
required change at the provider or societal level (e.g. service users who are 
barred from GP practices) (Clifton et al., 2016), while this research focused 
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on individual determinants of health behaviour. The following section 
describes how the components of the tool were developed to overcome the 
barriers and enhance the enablers to screening uptake by women with SMI 
(French et al., 2012).  
 
5.2.3 Component behaviour change techniques 
To develop the components of the tool, the taxonomy of behaviour change 
techniques (Michie et al., 2015) was used. A behaviour change technique 
(BCT) can be defined as one of the ‘active ingredients’ (or components) of an 
intervention that is ‘an observable, replicable, and irreducible component of 
an intervention designed to alter or redirect causal processes that regulate 
behaviour’’ (Michie et al., 2013: 23). The MRC guidance for developing and 
evaluating complex interventions recommends specifying the ‘active 
ingredients’ as a required step to establish how an intervention can be 
effective across its target population group and setting (Craig et al., 2008). 
Behaviour change techniques (BCTs) are classified in a taxonomy of 93 
hierarchically-clustered techniques and grouped into 19 categories (Michie et 
al., 2015). Every BCT is numbered and given a title (e.g. 4.1 Information on 
how to perform the behaviour). The taxonomy maps the BCTs to the 14 
domains of the TDF (Cane et al., 2014; French et al., 2012; Michie et al., 
2008). Each TDF domain has BCTs allocated to it, for example ‘Behavioural 
Regulation’ (TDF domain 14) had 68 BCTs assigned to it.  
 
To develop the components of the tool, behaviour change techniques (Michie 
et al., 2015) were selected in conjunction with the domains of the TDF that 
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had been identified in earlier research (Clifton et al., 2016); these are listed in 
Tables 5.5 and 5.6. Each BCT was selected and tailored to be used in the 
tool and to promote change (Michie and Prestwich, 2010; Michie et al., 2008; 
Rothman, 2004). Using BCTs to develop the tool facilitates further 
exploration of the links between the components of the intervention and its 
desired effects (Michie et al., 2009). The BCTs were coded by two 
researchers [the candidate and a chartered psychologist with expertise in 
health psychology], who independently linked each BCT to the barrier(s) or 
enabler(s) components of the tool (themselves underpinned by the TDF), 
and this coding exercise was verified by a third researcher [a health 
psychologist]. A summary is presented for the barriers and enablers to 
cancer screening in Tables 5.5 and 5.6, respectively. Some BCTs were 
originally coded and subsequently removed following a discussion within the 
coding team. These are displayed in Appendix 5 to demonstrate the thought 





Table 5.5 Coding of component behaviour change techniques to identified 
barriers underpinned by the TDF.  
 
Barrier to cancer screening 
(Clifton et al., 2016) 
TDF Domain (Cane et al., 
2012) 
Component behaviour change technique(s) 
(Michie et al., 2015) 
Not knowing what to expect 
or what to do  
Knowledge [of condition] 4.1 Information on how to perform the 
behaviour 







Difficult to process 
information 
Memory, attention and 
decision processes 
[Cognitive overload, 
tiredness, attention control] 
11.3 Conserving mental resources 
Additional burden Goals [goal priority]  1.3 Goal setting (outcome) 
1.4 Action planning 
9.3 Comparative imagining of future 
outcomes 
Mental health symptoms 
reduce motivation for self-
care 
Goals 1.3 Goal setting (outcome)  
1.4 Action planning  
3.3 Social support (emotional) 
 
Stigma of mental illness Emotion 3.3 Social support (emotional) 
11.3 Conserving mental resources  
 
 
Past negative experience Emotion 3.3 Social support (emotional)  
Embarrassment Emotion 12.6 Body changes 
3.3 Social support (emotional) 
 
Traumatising Emotion 3.3 Social support (emotional) 
5.4 Monitoring of emotional consequences 
11.2 Reduce negative emotions 
Fear of bad news Emotion 3.3 Social support (emotional) 
11.2 Reducing negative emotions  
13.2 Framing/reframing 
Lack of understanding of 
mental illness in screening 
professionals 





aggravates mental health 
symptoms 
Behavioural regulation 3.3 Social support (emotional) 
5.4 Monitoring of emotional consequences 
6.1 Demonstration of the behaviour 
12.2 Restructuring the social environment  
Staff can be rushed Behavioural regulation 3.3 Social support (emotional) 
12.2 Restructuring the social environment 
Staff can be rough Behavioural regulation 3.3 Social support (emotional) 
Exclusion from GP 
registers 
Behavioural regulation No BCT was identified 
 
Appointment booking Environmental context and 
resources 
4.1 Instruction on how to perform behaviour 
11.3 Conserving mental resources 
Transport difficulties Environmental context and 
resources 
4.1 Instruction on how to perform behaviour 
11.3 Conserving mental resources 
Difficulty remembering 
appointments 
Environmental context and 
resources 
6.1 Demonstration of the behaviour  
11.3 Conserving mental resources 
Difficulty leaving the house 
due to mental health 
problems  
Environmental context and 
resources 
3.3 Social support (emotional) 
11.2 Reduce negative emotions 
Taking time off Environmental context and 
resources 
No BCT was identified 
Made to feel like a burden 
on health service 
Emotion 3.3 Social support (emotional) 
Poor relationship with GP Emotion 12.2 Restructuring the social environment 





Table 5.6 Coding of component behaviour change techniques to identified 
enablers underpinned by the TDF.  
 
Enabler to cancer 
screening (Clifton 
et al., 2016) 
TDF Domain 
(Cane et al., 2012) 
Component behaviour change technique(s) (Michie et 
al., 2015)  
Wanting to be 
informed 
Knowledge 4.1 Instruction on how to perform a behaviour 




Knowledge 5.1 Information about health consequences 
Encouragement Social influences 3.2 Social support (practical)  
3.3 Social support (emotional) 
6.1 Demonstration of the behaviour 
11.3 Conserving mental resources 
15.1 Verbal persuasion about capability 
Feeling ‘health 
conscious’ 
Goals 1.3 Goal setting (outcome) 
5.1 Information about health consequences 
Being anxious to 
avoid further health 
problems 
Goals 1.1 Goal setting (behaviour) 
1.3 Goal setting (outcome) 
2.3 Self-monitoring of behaviour 
Physical symptoms  Goals 1.3 Goal setting (outcome) 
1.4 Action planning  









3.3 Social support (emotional) 




No BCT was identified 
Familiar location Environmental 
context and 
resources 




6.1 Demonstration of the behaviour  
7.1 Prompt/cues 
Good relationship 
with GP  
Emotion 3.3 Social support (emotional)  
Good relationship 
with Practice Nurse  
Emotion 3.3 Social support (emotional)  
Continuity of care Emotion 3.2 Social support (practical) 
3.3 Social support (emotional) 
 
These component behaviour change techniques were used to develop the 
draft components of the tool; an example of how a behaviour change 
technique facilitated the development of each component of the tool is 




5.2.4 Draft components of the tool 
The tool was formatted as an A5 paper colour leaflet. The table of contents of 
the initial draft of the tool (Version 0.1, Appendix 6) is provided in the box 
below. The following section details how the draft content of each component 
was developed and lists which barriers and enablers it addresses. An 
example of how a BCT was used to develop the content of the draft tool for 




Title: Thinking about cervical screening (smear test) 
Why this leaflet was developed 
Why am I invited for cervical screening? 
What happens on the day? 
Common questions and anxieties 
Tips for booking your appointment 
Getting ready for your appointment 
Your appointment day 




‘Why this leaflet was developed’ 
This page provides a brief context as to why the tool was developed and who 
it is intended for. This first section also outlines that the purpose of the tool is 
to help women make a decision whether to attend screening and can be 
used to plan their appointment.  
 
Component one: ‘Why am I invited for cervical screening?’  
 
Description of content 
This component outlines: 
• who is eligible for screening, 
• what cervical screening is for and  
• the benefits of attending and what happens if you test positive for HPV  
 
This page was later revised to include more information on the risks of non-
attendance (see Chapter Seven, section 7.3.2). 
 
Rationale for content 
This component addressed the following barriers: unsure of need for 
screening, fear of bad news (see Table 5.1). 
 
This component incorporated the following enablers: understanding of 
benefits of screening, feeling ‘health conscious’, being anxious to avoid 






The selected BCTs included: 1.1 Goal setting (behaviour), 1.3 Goal setting 
(outcome), 3.3 Social support (emotional), 5.1 Information about health 
consequences, 11.2 Reducing negative emotions, 13.2 Framing/reframing.  
 
Application of a BCT to the development of this component 
Behaviour change technique 5.1 Information about health consequences is 
defined as ‘Provide information (e.g. written, verbal, visual) about health 
consequences of performing the behaviour’ (Michie et al., 2015). This section 
highlighted the positive health consequences of attending the screening 
appointment (e.g. ‘Having a smear test lowers your chances of getting 
cervical cancer’ and ‘If you have cancer, getting it diagnosed and treated 
early can save your life’).  
 
Component two: ‘What happens on the day’  
Description of content 
This component lists each step of a cervical screen test (e.g. ‘The nurse or 
doctor will ask you to undress from your waist down and lie on a bed with 
your knees bent and apart’ and ‘A small brush (like a long cotton bud) will be 
used to take a sample from the surface of your cervix’).  
 
Rationale for content 
This component addressed the following barriers: not knowing what to expect 




This component incorporated the following enablers: wanting to be informed. 
 
Theory used 
Selected BCTs: 4.1 Instruction on how to perform the behaviour and 5.1 
Information about health consequences. 
 
Application of a BCT to the development of this component 
Behaviour change technique 4.1 Instruction on how to perform the behaviour 
is defined as ‘Advise or agree on how to perform the behaviour’ (Michie et 
al., 2015). This section of the tool describes the steps that a woman needs to 
take in order to be screened.  
 
Component three: ‘Common questions and anxieties’ 
Description of content 
This component includes quotes from service users from the Clifton et al. 
(2016) qualitative study (e.g. ‘It’s hard for me to leave the house’ and ‘I have 
a poor relationship with my GP/nurse’). It also includes an action planning 
text box where users can write down what would help them attend their 
appointment and suggests thinking of reasons why they might want to go and 
why they think it is important.   
 
Rationale for content 






This component incorporated the following enablers: Past positive 




Selected BCTs: 1.3 Goal setting (outcome), 1.4 Action planning, 9.3 
Comparative imagining of future outcomes, 15.3 Focus on past success. 
 
Application of a BCT to the development of this component 
Behaviour change technique 1.4 Action Planning is defined as ‘Prompt 
detailed planning of performance of the behaviour (must include at least one 
of context, frequency, duration and intensity). Context may be environmental 
(physical or social) or internal (physical, emotional or cognitive) and includes 
‘implementation intentions’’ (Michie et al., 2015).  
 
Currently in England, women receive an open invitation for cervical 
screening, which requires them to think not only if, but also when, how, and 
where they will attend their appointment and possibly whom/what to bring to 
the appointment. It is necessary for them to make an appointment to 
successfully enact the cancer screening behaviour. One way to reduce this 
‘gap’ between intentions and performing the behaviour (i.e. screening 
attendance) is to form implementation intentions (Gollwitzer, 1993). This 
would involve a woman outlining the various steps required to perform the 
behaviour. The tool is structured around the five steps required to perform 
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the screening behaviour. For each step, a list of tips/support available is 
provided as an action plan to form an implementation intention to perform the 
behaviour. 
 
Step one: Make an informed decision whether to attend, which may include 
getting informed on what support is available.  
Relevant components: What is cervical screening, Booking your 
appointment, Tick-box page and Getting Support. 
 
Step two: Book the appointment.  
Relevant component: Booking your appointment. 
 
Step three: (Possibly) plan a set of actions to prepare for the appointment. 
Relevant components: Before your appointment, ‘Action plan’ boxes and 
Tick-box page.  
 
Step four: travel to your appointment.  
Relevant component: Before your appointment. 
 
Step five: attend the appointment.  
Relevant component: During your appointment. 
 
Component four: ‘Tick box page’ 
 
Description of content 
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This component is presented as an optional list of statements to tick. Each 
box represents a service user’s barrier to cancer screening. It was developed 
as a ‘disclosure aid’ to support women who may find it hard to discuss their 
issue(s) with the nurse. This component is designed to be shown to the 
nurse before the test, so he/she becomes aware of the barrier/issue(s) 
without having to discuss them. This ‘tick box page’ may also help elicit 
understanding and empathy from the screening professional by providing 
context for the patient’s personal circumstances. It may also help emotional 
regulation by removing the necessity for the person being screened to 
disclose a painful episode or something she finds embarrassing. 
Below are some examples of ‘tick box options’: 
 
 I am a voices hearer and get distressed during a physical exam 
 My medication makes me shake 
 I have visible cutting scars 
 I survived a traumatic experience 
 
Rationale for content 
This component addressed the following barriers: difficult to process 
information, mental health symptoms reduce motivation for self-care, stigma 
of mental illness, past negative experience, embarrassment, traumatising, 
lack of understanding of mental illness in screening professionals, screening 
environment aggravates mental health symptoms, staff can be rushed, staff 
can be rough, difficulty leaving the house due to mental health problems, 




This component incorporated the following enablers: staff being 




Selected BCT: 3.3 Social support (emotional), 5.4 Monitoring of emotional 
consequences, 6.1 Demonstration of the behaviour, 11.2 Reduce negative 
emotions, 11.3 Conserving mental resources, 12.2 Restructuring the social 
environment, 12.6 Body changes. 
 
Application of a BCT to the development of this component 
Behaviour change technique 6.1 Demonstration of the behaviour is defined 
as trying ‘to provide an observable sample of the performance of the 
behaviour, directly in person or indirectly e.g. via film, pictures, for the person 
to aspire to or imitate’ (Michie et al., 2015).  
 
Empty text boxes were included throughout the draft to include quotes 
extracted from forthcoming service user interviews in order to demonstrate 
the behaviour that is being highlighted in a particular section. There is some 
evidence that integrating a ‘narrative communication’ (e.g. ‘And I’d feel awful 
if my kids got sick because I didn’t get them vaccinated’) within a health 
intervention can be an active ingredient to encourage a particular behaviour 
(Brewer, 2016; Hinyard and Kreuter, 2007). This technique has also been 
used in the context of cancer screening (Bailey et al., 2000; Erwin et al., 
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1996, 1999) and is suggested as a step (Chapter E: Using personal stories) 
to follow when developing a patient decision aid (Bekker et al., 2012).  
 
5) Component five: ‘Tips for booking your appointment’ 
 
Description of content 
In this section, a list of things to ask the receptionist when booking an 
appointment is provided, further to feedback received from the SUGAR 
service user group. Examples of items to let the staff know include: 
 
• ‘Want to be seen by a female or male member of staff’,  
• ‘Would like to receive a reminder’, 
• ‘Need a double appointment’, 
• ‘Get anxious in waiting rooms. Ask for the first or last appointment of 
the day’. 
 
Rationale for content 
 
This component addressed the following barriers: additional burden, 
screening environment aggravates mental health symptoms, staff can be 
rushed, appointment booking, difficulty remembering appointments. 
This component incorporated the following enablers: reminders. 
 
Theory used 
Selected BCTs: 3.3 Social support (emotional), 4.1 Instruction on how to 
perform behaviour, 6.1 Demonstration of the behaviour, 7.1 prompt/cues, 
183 
 
11.3 Conserving mental resources, 12.2 Restructuring the social 
environment. 
 
Application of a BCT to the development of this component 
Behaviour change technique 6.1 Demonstration of the behaviour is defined 
as trying ‘to change, or advise to change the social environment in order to 
facilitate performance of the wanted behaviour or create barriers to the 
unwanted behaviour (other than prompts/cues, rewards and punishments)’ 
(Michie et al., 2015). The tips provided in this section of the tool may help 
change the service user’s social environment (e.g. by booking the first 
appointment of the day), which can reduce the risk of the environment 
triggering mental health symptoms, such as auditory hallucinations and 
anxiety. 
 
Component six: ‘Getting ready for your appointment’  
 
Description of content 
This section provides a list of tips, based on feedback from the SUGAR 
group and a consultant nurse working for the My Body Back21 charity. These 
suggestions may help to improve women’s screening experience such as: 
 
 Planning your travel to the appointment (e.g. checking bus times) 
 Bringing something comforting or relaxing (e.g. music player) 
 Wearing a skirt or dress (thereby avoiding having to fully undress) 
 
21 Specialist cervical screening clinic for women who have experienced sexual violence. 
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 Speaking to the nurse beforehand (e.g. if you require a pessary 
prescription) 
 Asking someone to accompany you on the day [this may encourage 
continuity of care if the woman asks her mental health worker to 
accompany her to the screening appointment] 
 Planning something nice and relaxing after the appointment (e.g. 
going for a walk in the park with a friend) 
 Write down and bring to the appointment a list of things that bother 
you about the test (e.g. parts of the body to avoid touching, whether 
you want the door locked or unlocked) as well as words that can 
trigger a panic attack. Suggestion to list alternative safe words 
instead. 
 
Rationale for content 
This component addressed the following barriers: additional burden, mental 
health symptoms reduce motivation for self-care, embarrassment, screening 
environment aggravates mental health symptoms, transport difficulties, 
difficulty remembering appointments, difficulty leaving the house due to 
mental health problems. 
 
This component incorporated the following enablers: encouragement, 





Selected BCTs: 1.3 Goal setting (outcome), 1.4 Action planning, 3.2 Social 
support (practical), 3.3 Social support (emotional), 4.1 Instruction on how to 
perform behaviour, 6.1 Demonstration of the behaviour, 9.3 Comparative 
imagining of future outcomes, 11.2 Reduce negative emotions, 11.3 
Conserving mental resources, 12.6 Body changes, 15.1 Verbal persuasion 
about capability.  
 
Application of a BCT to the development of this component 
Behaviour change technique 3.3 Social support (emotional) is defined as 
trying to ‘advise on, arrange, or provide emotional social support (e.g. from 
friends, relatives, colleagues, ‘buddies’ or staff) for performance of the 
behaviour’ (Michie et al., 2015). The example given in the taxonomy was 
identical to the suggestion provided in the tool in relation to cervical 
screening: ‘Ask the patient to take a partner or friend with them to their 
colonoscopy appointment’ (Michie et al., 2015).  
 
Component seven: ‘Your appointment day’ 
 
Description of content 
This section provides a list of suggestions to help women feel more relaxed 
and in control during the screening test. The list is based on feedback from 
the SUGAR group and a consultant nurse working for the My Body Back 
charity. Suggestions include: 
 
 A reminder that you can ask the nurse to stop at anytime 
 Ask for sedation from your GP if you think this may be necessary 
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 Agree with the smear taker on a clear signal to stop if you need to 
 Ask for a thinner/narrower speculum and more lubricant if you think it 
may hurt. 
 
Rationale for content 
This component addressed the following barriers: staff can be rushed, lack of 
understanding of mental illness in screening professionals, traumatising, past 
negative experience. 
 
This component incorporated the following enablers: past positive 
experience, good relationship with GP, good relationship with practice nurse, 
staff being understanding. 
 
Theory used 
Selected BCTs: 3.3 Social support (emotional), 5.4 Monitoring of emotional 
consequences, 11.2 Reduce negative emotions. 
 
Application of a BCT to the development of this component 
Behaviour change technique 11.2 Reduce negative emotions is defined as 
trying to ‘advise on ways of reducing negative emotions to facilitate 
performance of the behaviour’ (Michie et al., 2015). This section of the tool 
lists several suggestions (e.g. agreeing with the smear taker on a stop signal) 
to reduce the risk that the smear test elicits painful memories from a 
traumatic event. 
 




Description of content 
This section explains what happens after the test. The contact details of Jo’s 
Cervical Cancer Trust are provided if they need support after the test. A list 
of the symptoms to be aware of in between cervical screening appointments 
(e.g. ‘bleeding between your periods, after sex, or after the menopause’ and 
‘pain or discomfort during sex’) is presented. This section explains what to do 
if symptoms appear. 
 
Rationale for content 
This component addressed the following barriers: not know what to expect or 
what to do, fear of bad news, unsure of need for screening, additional 
burden, mental health symptoms reduce motivation for self-care, 
embarrassment. 
 
This component incorporated the following enablers: wanting to be informed, 
understanding of benefits of screening, feeling ‘health conscious’, being 
anxious to avoid further health problems, physical symptoms. 
 
Theory used 
Selected BCTs: 1.3 Goal setting (outcome), 1.4 Action planning, 2.3 Self-
monitoring of behaviour, 3.3 Social support (emotional), 4.1 Instruction on 
how to perform the behaviour, 5.1 Information about health consequences, 




Application of a BCT to the development of this component 
Behaviour change technique 2.3 Self-monitoring of behaviour is defined as 
trying to ‘establish a method for the person to monitor and record their 
behaviour(s) as part of a behaviour change strategy’ (Michie et al., 2015). 
Part of this section explains what a woman should do if she has unusual 
symptoms (e.g. irregular bleeding), which includes being aware of the 
symptoms, not waiting for the next screening appointment and speaking with 
a health professional if symptoms appear. 
 
Component nine: ‘Additional information’  
 
Description of content 
Considering the high rate of trauma in this group, a review of less-invasive 
alternatives to cervical screening was conducted, which is reported in 
Chapter Six (section 6.2.2). This last component includes the option of 
ordering an HPV ‘home testing’ kit, if women feel that they cannot go through 
with cervical screening. 
 
Organisations women can get in touch with if they need someone to talk to 
are provided; these can provide specialist support or advice on cervical 
screening. The contact details of Jo’s Cervical Cancer Trust are provided if 
they need support or encouragement to attend their appointment.  It also 
includes the contact details of the ‘My Body Back Project’ which is a 
specialist cervical screening clinic in London and Glasgow for women who 




Rationale for content 
This component addressed the following barriers: past negative experience, 
traumatising, fear of bad news, difficulty leaving the house due to mental 
health symptoms, poor relationship with GP. 
 
This component incorporated the following enabler: encouragement. 
 
Theory used 
Selected BCTs: 3.2 Social support (practical), 3.3 Social support (emotional), 
5.4 Monitoring of emotional consequences, 6.1 Demonstration of the 
behaviour, 11.2 Reduce negative emotions, 11.3 Conserving mental 
resources, 12.1 Restructuring the physical environment, 12.2 Restructuring 
the social environment, 15.1 Verbal persuasion about capability. 
 
Application of a BCT to the development of this component 
Behaviour change technique 12.1 Restructuring the physical environment is 
defined as trying to ‘change, or advise to change, the physical environment in 
order to facilitate performance of the wanted behaviour or create barriers to 
the unwanted behaviour (other than prompts/cues, rewards and 
punishments)’ (Michie et al., 2015). For women who have experienced 
sexual violence and find it hard to attend their cervical screening 
appointment, a specialist clinic exists to support them (the My Body Back 
charity, with clinics in London and Glasgow). Including the contact details of 







This section has detailed how each component of the tool was theoretically 
underpinned using the BCTs and barriers and enablers to cancer screening 
uptake, which are mapped to the TDF. An example of how a BCT was used 
to develop the content of the draft tool was provided for each component. 
Use of the barriers and enablers to cervical screening identified in the 
literature review (reported in section 5.1), as well as the relevant component 
behaviour change techniques (section 5.2.3), ensured that the development 
of the tool was theoretically underpinned. This fulfils the first and second key 
objectives of this PhD research, namely that the tool be developed using 
identified barriers to cancer screening for this group, and that it be 
theoretically underpinned. Using these techniques, a draft of the tool 
(Version 0.1, Appendix 6) was developed.  
 
In the following three chapters, the data collection pertaining to the tool is 
reported. Verification of the tool’s clinical accuracy is reported in the next 
chapter (Six), followed by testing its acceptability (Chapter Seven) and 
usability (Chapter Eight) with key stakeholders. 
191 
 
Chapter Six – Conception and design of the tool: Stakeholder 
involvement 
 
In this chapter, the process of involving stakeholders to refine the tool is 
described. A list of key stakeholders and the importance of their input in the 
development of the tool is provided. This step was important for ensuring 
acceptability and usability of the tool by both women with SMI and health 
professionals. Stakeholders were involved at every stage of the development 
of the tool. During the initial phase, they informed the development of a 
version appropriate for acceptability testing, including ensuring that the 
content was clinically accurate and unambiguous. 
 
6.1 Stakeholder involvement 
 
As reported in Chapter Five, a first draft of the tool (Version 0.1) was 
produced. As per recommendations from the systematic review (Chapter 
Four), stakeholders were to be involved at every step of the development of 
the tool. For this research, stakeholders include women with SMI and service 
user groups, health professionals, public health policymakers and third sector 
organisations, such as cancer and mental health charities. Including these 
groups was essential to ensure women with SMI had a voice and that the 
tool was usable and acceptable both to them and their health professionals. 
In addition, all stakeholders provided useful suggestions on how and where 
to disseminate the tool. In terms of the relative importance of stakeholder 
input, feedback from women with SMI was given the most weight, followed 
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by that from the health professionals (working in primary and secondary 
care). Women with SMI who access secondary mental health care and 
health professionals who work in that setting were later recruited to test the 
acceptability and usability of the tool; this is reported in Chapters Seven and 
Eight, respectively. The ‘co-production’ model is founded on the principle of 
equity within the relationship between the researcher and the PPI (Patient 
and Public Involvement) participant, which is an approach to service design 
and shared decision-making (Involve, 2012; Slay and Stephens, 2013). This 
model was not selected for this research, as it would have been difficult to 
find the necessary resources for one person to put in the considerable 
amount of time required for such an approach. In addition, the candidate 
sought to gain experience of having primary responsibility for designing this 
research, as well as collecting and analysing the data, with the aim of 
acquiring the necessary skills towards becoming an independent researcher.  
 
A multi-disciplinary expert group of stakeholders – thereafter key informants 
group – was established at the beginning of the process to inform the 
development of the tool in an iterative manner. Convenience sampling plus 
snowball sampling was used to identify stakeholders, namely individual 
experts and relevant organisations who would likely be knowledgeable about 
the topic. Initial contact with Jo’s Cervical Cancer Trust, the national cervical 
cancer charity, was established on social media during Cervical Cancer 
Prevention Week in January 2018; this resulted in the charity joining the 
stakeholder group and the candidate being introduced to experts working in 




Representatives from Public Health England (PHE) joined the stakeholder 
group after being informed about the project. Two service user groups and 
several health professionals who were contacted for this research had been 
involved with the candidate for prior research on diabetes care for people 
with SMI (McBain et al., 2016, 2018; Mulligan et al., 2017, 2018). Having 
displayed a research interest in the physical health of people living with SMI, 
they were contacted for the purpose of this project and agreed to give 
feedback on the tool. Members of the key informants group were clustered 
into five categories, which are listed below:  
 
 Service user groups (n = 4): a group with lived experience of cervical 
cancer and mental illness (jointly funded by Mind and MacMillan in 
Middlesbrough), Ealing Mental Health Forum22 (funded by the 
Community and Voluntary Service charity), the National Survivor User 
Network23 (NSUN) and the Service User and carer Group Advising on 
Research24 (SUGAR) based at City, University of London 
 
 Specialised cervical screening clinics (n = 4): East London clinic for 
women who have experienced FGM25, My Body Back project26 (for 











women with SMI, drug misuse and learning disabilities) and a Well 
Woman clinic for patients on an inpatient mental health ward28 
 Charities (n = 2): Healing our Way CIC29 (specialist training to help 
professionals improve their understanding of trauma/sexual violence) 
and Jo’s Cervical Cancer Trust30 
 National public health stakeholders (n = 2): Public Health England: 
different teams within NHS screening programme and UK Department 
of Health and Social Care: Research Programme Manager 
 NHS clinicians/clinical academics with an interest in the physical 
health of people living with SMI (n = 5): a GP working in a mental 
health setting and a GP with expertise in SMI (Newham CCG), a GP 
with dual training in psychiatry based in London, a psychiatric nurse 
with expertise in cancer screening in SMI (Nottingham University 
Hospitals NHS Trust) and a professor of mental health nursing based 
in London. 
 
PPI (Patient and Public Involvement) comprised six rounds, which included 
every stage of the development of the tool (see Figure 6.1 below). Round 
one consisted of feedback collected on the draft protocol and research 
materials prior to the submission of the candidate’s application to the NHS 
Research Ethics Committee (REC) to recruit service users and NHS health 
professionals. The results of round one are reported in Chapter Seven (see 








aspects of the research and the fieldwork materials. Round two, previously 
reported in section 5.1.1, consisted of feedback collected on the barriers and 
enablers to cancer screening with a service user group (SUGAR). Round 
three of stakeholder involvement is described in this chapter. Rounds four 
(Chapter Seven) and five (Chapter Eight) consisted of email feedback from 
members of the key informants group, as well as service users and health 
professionals who access and work in secondary care. The final round of 
stakeholder involvement consisted of feedback from the key organisations 






Figure 6.1 Rounds of stakeholder involvement in the development of the tool. 
 
Figure 6.1 lists the different stages of stakeholder involvement in 
chronological order. ‘Round one’ is presented in Chapter Seven (see section 
7.1.2), which describes service user feedback on the NHS ethics application 
to recruit service users and health professionals. Chapter Five includes 
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‘Round two’; section 5.1.1 reports the feedback from a service user group on 
the initial components of the tool. 
 
6.2 Round three – Verifying the clinical accuracy of the tool 
 
6.2.1 HPV primary testing 
Before the tool could be tested with service users, verification that it complied 
with current NHS cervical screening guidelines was ascertained (NHS, n.d.; 
PHE Screening, 2019). During this PhD research, a novel method for cervical 
screening cytology – ‘primary HPV testing’ - was introduced across the NHS. 
In 2016, it was announced that primary HPV screening would be 
implemented into the NHS Cervical Screening Programme. From December 
2019, primary HPV screening has been fully rolled out and is being offered 
across England as part of the NHS Cervical Screening Programme (PHE, 
2019). To receive this screening, women still need to make an appointment 
to have a smear test. The difference between the two tests concerns the 
examination of the collected cells (cytology). While previously cytology 
identified cellular changes associated with precancerous cervical lesions, 
primary HPV screening identifies the infection that triggers these cellular 
changes. Ample evidence has shown that infection with high-risk types of 
HPV is a requisite step to develop cervical cancer or pre-cancerous lesions 
(Walboomers et al., 1999).  
 
Increasing evidence has shown that cervical screening with primary HPV 
testing coupled with cytology triage is more effective than cervical screening 
with cytology triage at detecting relevant precancerous lesions and 
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decreases cervical cancer incidence (Bains et al., 2019; Lew et al., 2017; 
Ogilvie et al., 2013). Over 200 types of HPV have been identified (Burd, 
2003); the approach for screening is to use hr (high-risk) HPV testing as a 
primary screening test, with cytology reserved only for triage of women who 
test positive for HPV. This change had to be reflected in the tool. Thus, a 
definition of HPV and its causal link with cervical cancer was included in the 
draft tool; this triggered a discussion with members of the key informants 
group, which is discussed below. 
 
6.2.2 Collection and analysis of feedback on the clinical accuracy of the tool 
Version 0.1 of the tool was emailed in July 2018 to health professionals who 
are members of the key informants group (excluding the service user groups 
to avoid providing them with potentially inaccurate information) to verify the 
clinical content of the tool. A content analysis of the feedback received (by 
email) was conducted (Hsieh and Shannon, 2005; Owen, 2012). Content 
analysis is defined as a research method that seeks valid inferences from 
qualitative data to the context or environment in which they were produced 
(Downe-Wambolt, 1992; Krippendorff, 2004). It consists of two steps: first, to 
quantify and analyse the presence, meanings and relationships of words and 
concepts, and second, to elicit meaning from the data collected and to draw 
realistic conclusions from it. Such an analysis can be useful to pre-test and 
improve an intervention prior to its launch (Abroms et al., 2011). 
 
The clinical content of the tool was reviewed by Jo’s Cervical Cancer Trust 
and Public Health England. In addition, feedback was received from health 
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professionals working with the population of interest, and/or vulnerable 
groups where there may be overlap. These include a GP with expertise in 
SMI, as well as health professionals working in specialist cervical screening 
clinics for the following groups: women who have experienced sexual 
violence (feedback from n = 1 clinician), women who have survived FGM/C 
(n = 2), women who have SMI and/or a history of substance misuse (n = 1) 
and women on a mental health inpatient ward (n = 1).  
 
The fully coded content analysis for this phase is contained in Appendix 7. 
The rationale for including and rejecting the requested changes and 
suggestions was discussed with the supervisory team; decisions were 
guided by current NHS cervical screening guidelines (NHS, n.d.; PHE 
Screening, 2019). Examples of requested revisions to one section of the 











Table 6.1 Revisions made to the ‘Why am I invited for cervical screening?’ section of the tool by group (Version 0.1, Appendix 6). 
Requested revision: Revision requested by (n = ) Decision made: 














I think this section should say, 
more explicitly, that screening can 
pick up changes that, if left 
untreated, might eventually lead 
to cancer 
 1   Wording amended to 
reflect this 
 
Is it a bit confusing saying they 
will be invited for a test to see if 
they have HPV rather than a 
smear? Also, the smear doesn’t 
look for cancer it looks for pre-
cancerous cells 
   1 Wording amended to 
reflect this  
 
People may not always get their 
smear done at a GP surgery, so 
you may want to include 
alternative arrangements (some 
sexual health clinics and STI 
clinics do smears, and so do 
some gynae clinics, especially for 
patients who require adjustments) 
 1   Wording amended to 
reflect this 
 
We need to highlight that this is a 
test for detecting an often-silent 
cancer  
 1   The extent to which the risks of non-uptake of 
cervical screening should be highlighted in 
the tool will be discussed with health 
professionals and service users. Results are 
reported in Round four of stakeholder 
involvement (section 7.3.2).  
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Important to emphasise that 
women should go for regular 
screening 
 1  1 This comment was 
incorporated into this 
sentence: ‘Going for 
cervical screening 
when invited is the 




HPV can be confusing for some 
people; it has an association with 
sex and can be confused with HIV 
– best to avoid mentioning in the 
tool 
   1 Wording amended to 
reflect this 
 
‘Staying healthy’ message – focus 
on prevention rather than 
mentioning ‘cervical cancer’ 
   1 The extent to which 
the risks of non-
uptake of cervical 
screening should be 
highlighted in the tool 
is discussed with 
health professionals 
and service users in 





This may read better by putting 
the sentence ‘It is not a test for 
cancer’ at the start 
 1   Wording amended to 
reflect this 
 
Why ‘Why am I invited for cervical 
screening?’  Are they receiving 
this at the time of a letter? Should 
it be ‘why have I been…?’ 
1    This sentence was 
removed 
 
Need to include ‘if I am not 
sexually active now or ever or 
never do I need the cervical 
screening test’ 
   1 This sentence was 
added: ‘If you’re not 
sure whether you 
need a test, talk to 




‘if you have a cervix and are 
between 25 and 64’ is confusing, 
reword 
   1 This section was 
revised to: ‘To be 
invited for cervical 
screening you must: 
- be registered with a 
GP as female 
- be between the 
ages of 24 and 64’  
 
I would maybe list the places a 
woman can go to get a cervical 
smear. It is largely provided by 
primary care and an explanation 
about the process may be helpful. 
Like mentioning that the GP will 
send you a letter every 3 years to 
invite you, so making sure your 
patient details are up to date 
would be good. Some sexual and 
reproductive health clinics will 
opportunistically too but that may 
get confusing to mention because 
it is opportunistic 
   1 This section was 
revised to: ‘Your GP 
surgery will invite you 
for cervical screening 
if your contact details 
are up to date (…) In 
some areas, you 
may be able to 
arrange your 
appointment at a 
sexual health or well 
woman clinic instead 
of your GP surgery.’ 
 
Could give more info about HPV; 
Very positive page – if this leaflet 
is to help people to decide, should 
it have the pros and cons? 
Probably need to say it’s not just 
about checking for cancer as that 
isn’t clear 
1    The extent to which 
the risks of non-
uptake of cervical 
screening should be 
highlighted in the tool 
is discussed with 
health professionals 
and service users in 





If the focus of this booklet is tips 
for people with SMI, just do an 
overview of cervical screening 
here then signpost out. Getting 





into HPV will make it very 
complicated 
Eligibility age for screening: ‘25-
64’ rather than ‘24-64’. It’s better 
to stick with the screening ages 
here to avoid confusion. 
1    Wording amended to 
reflect this 
 
Offer alternative sources of 
information as not everyone has 
access to a computer or the 
internet 
  1   Research shows this 
group has access to 




Given the high incidence of sexual trauma in people with SMI (see Chapter 
One, section 1.3.2) and the barriers to their accessing primary care (see 
Chapter Five, section 5.1), less-invasive alternatives to cervical screening 
were reviewed (Gravitt et al., 2011; Kitchener and Owens, 2014; Madzima et 
al., 2017; Pathak et al., 2014; Sancho-Garnier et al., 2013; Szarewski et al., 
2011; Virtanen et al., 2011). Alternatives to cervical screening include self-
sampling (whereby a kit is sent to your home) or urine sampling. Using a 
self-sampling HPV test kit (Gravitt et al., 2011) or self-administered urine test 
(Pathak et al., 2014) were suggested in the tool as alternatives to the current 
speculum examination of the smear test, which is more invasive and requires 
a visit to a GP practice or sexual health clinic.  However, the option of using 
urine sampling or self-sampling kits to check for the presence of HPV was 
removed further to advice received from the Cervical Screening Programme 
at PHE Screening:  
 
‘At present, HPV self-sampling is not offered by the NHS Cervical 
Screening Programme so it would be inappropriate to mention it in a 
leaflet aimed at women attending for NHS screening. The UK National 
Screening Committee will be reviewing the evidence on these devices 
in the near future’. 
 
6.2.3 Implications for the development of the tool 
The clinical content of Version 0.1 of the tool was amended following 
revisions requested from members of the key informants group. The title and 
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certain sections were reworded for clarity (see Table 6.2). In addition, Jo’s 
Cervical Cancer Trust provided support with formatting.  
 
Table 6.2 Rewording of the sections of the tool (Round three of stakeholder 
involvement). 
 
Version 0.1 Version 0.2 
Title: Thinking about cervical screening 
(smear test) 
Title: Support available for cervical 
screening (smear test) 
Why this leaflet was developed What is in this leaflet? 
Why am I invited for cervical screening? What is cervical screening? 
What happens on the day? 
 
During your appointment 
Common questions and anxieties 
 
Content from ‘Common questions and 
anxieties’ has been incorporated into other 
sections 
Tick box page Tick box page 
Tips for booking your appointment 
 
Booking your appointment 
Getting ready for your appointment 
 
Before your appointment 
Your appointment day 
 
Content from ‘Your appointment day’ has 
been incorporated into the section ‘During 
your appointment’ 
What happens next? 
 







This chapter described the iterative process of involving stakeholders in the 
development of the tool. It focused on one particular step of this process, 
which involved gathering feedback on the clinical accuracy of the tool.  
The revised31 version of the tool (Version 0.2) was presented to service 
users and health professionals to assess its acceptability. This is reported in 
the following chapter.   
 
31 A sample page of Version 0.2 of the tool is provided in Appendix 8 
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Chapter Seven – Tool development: Assessing the 
acceptability of the tool 
 
This chapter describes Study Three, which consisted of assessing the 
acceptability of the tool (Version 0.2) with stakeholders, thus dealing with one 
of the two parts of Objective 3 of the research. This study addresses part of 
Objective 3 of the research, which is highlighted in Box 2 below. Acceptability 
testing is defined as assessing the perception among stakeholders that an 
intervention is agreeable to them (Peters et al., 2013). Service users and 
health professionals were recruited for this purpose from two NHS Trusts 




Box 2: Development of the tool (continued) 
 
Objectives of the research that this chapter addresses (in bold): 
Objective one: To develop an informed-choice tool for women with 
SMI which addresses some of the barriers to screening attendance 
Objective two: The tool should be theoretically underpinned 
Objective three: Acceptability and usability of the tool by 
stakeholders should be tested 
Phases of the MRC guidance 
Development: Identifying the evidence base 
Development: Identifying/developing theory 
Feasibility/Piloting: Testing procedures 
Evaluation: Understanding change process 
Steps to follow when developing an informed-choice tool for people with SMI 
 
Step one: Identify barriers to decision-making 
Step two: Theoretically underpin the intervention  
Step three: Involve service users in the development of the tool 
Step four: Test usability of the intervention 
Step five: Assess readability levels 
Stakeholder involvement to develop the tool 
Round one (February – March 2018) 
Round two (May 2018): covered in Chapter Five 
Round three (July – August 2018): covered in Chapter Six 
Round four (September – November 2018) 
Round five (December 2018 – March 2019) 





The acceptability of the tool (Version 0.2) was tested with service users who 
access secondary care and health professionals who work with them. The 
method to recruit these participants is described below. This same version of 
the tool was emailed to members of the key informants group for iterative 
feedback in September 2018. Data are reported together with results from 




7.1.1 Design and setting 
This was a qualitative, individual interview study. There were two study 
settings: outpatient mental health clinics (CMHT) within the West London 
NHS Trust (thereafter West London Trust) and Dorset HealthCare 
University NHS Foundation Trust (thereafter Dorset Trust). Recruiting from 
two Trusts ensured some variation in population experience (one Trust was 
urban and the other was mixed rural/urban) and in demographic 
characteristics of the population, including socioeconomic status, age 
structure and ethnicities. 
 
7.1.2 Ethical considerations 
This research involved a group that is often excluded from research (Bucci et 
al., 2015; Humphreys et al., 2015). In addition, the selected topic, cervical 
screening, is both a sensitive subject and one which can trigger the memory of 
painful experiences, such as childhood abuse or loss of a loved one from 
cancer. During the interviews, several service users disclosed painful and 
often traumatic personal experiences; the candidate always ensured that the 
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participant was able to discuss her experience in a safe and empathetic space 
and ensured the participant was not in distress when the interview ended. To 
mitigate the risks of potential distress to participants, a gatekeeping 
recruitment process with psychiatrists was set up to ensure that only women 
who were deemed well enough were invited to take part (see Chapter Seven, 
section 7.1.4). Collecting participant views was both challenging in terms of 
the complexity of recruiting in mental health services (see Chapter Seven, 
sections 7.1.3-7.1.5) and rewarding, as participant feedback significantly 
improved the final output. Though no safeguarding issues were encountered, 
a safety protocol for the benefit of the candidate was in place during the data 
collection phase, as detailed in the REC-approved protocol. For example, 
interviews only took place in community mental health team offices. During 
PhD supervision, the candidate discussed several difficult cases with her 
supervisors (two of whom are psychologists and the third a consultant 
psychiatrist), who were thus able to provide a safe space and offer support 
and guidance. The candidate allowed herself time to process the painful 
disclosures in between interviews. 
 
The study received a favourable assessment from the University of West 
London Ethics Committee on the 7 December 2017 (Reference: 
UWL/REC/CNMH-00301). Prior to the submission to the National Research 
Ethics Service, Patient and Public Involvement (PPI) was sought at the 
design stage of the research proposal. Feedback was given on the draft 
protocol and research materials by a service user researcher; this was round 
one of stakeholder involvement (January–February 2018). Feedback led to 
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changes in the terminology and length of the document, as well as the re-
ordering of certain sections of the research materials to improve the 
accessibility and user-friendly nature of the documents. The full list of 
feedback is contained in Appendix 9; some of the feedback was removed to 
preserve anonymity of the service user researcher. One suggestion was to 
‘invite people’s suggestions about the content of the information [to be 
included in the tool] before you put a draft together and present it to them. 
You will probably get a more genuinely user-centred leaflet in that way’. This 
suggestion was implemented; round two of stakeholder involvement (see 
Chapter Five, section 5.1.1) consisted of a workshop with a service user 
group (SUGAR) that included a general discussion on the content of the tool 
(barriers and enablers to cervical screening) and the format of the tool prior 
to acceptability testing (see Appendix 4).  
 
The study received a favourable opinion from the National Research Ethics 
Service (Ref: 18/SC/0123) on the 16th April 2018. Research and 
Development letters of access were obtained on the 18th May 2018 for 
Dorset Trust and the 20th August 2018 for the West London Trust.  
 
7.1.3 Participant recruitment criteria 
Eligible women (and trans men) were those who were (a) diagnosed with 
SMI including: schizophrenia, schizotypal and delusional disorders, bipolar 
affective disorder, or severe depressive episodes with or without psychotic 
episodes (NICE, 2016), (b) able to read English and (c) currently receiving 
adult (aged 18–65 years) outpatient mental health services in either Dorset or 
West London Trust. Women with SMI were excluded if they were considered 
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by their clinical team to lack capacity to consent or to be currently too 
unwell to take part. Eligible health professionals included those who were (a) 
working in secondary mental healthcare (doctor, clinical psychologist, nurse, 
social worker or nurse working as a care coordinator), (b) currently working 
for either Dorset or West London Trust. 
 
Given the uncertainty around mental illness classifications and diagnoses, 
the frequency of co-morbidity and because the tool is likely to be used across 
population groups, the focus was on individuals who are currently accessing 
community mental health services (secondary care) as opposed to people 
with an SMI diagnosis using only primary care. The aim was to recruit people 
with a degree of mental illness that is likely to have an impact on their daily 
lives. Recruiting mental health service users without referring to a specific 
diagnosis has been a successful recruitment method (Brown et al., 2019; 
Clifton et al., 2016). 
 
7.1.4 Sampling and recruitment procedure 
Sample size justification: Sample sizes of n = 10 for each type of participant 
(women and healthcare professionals) were based on the estimated number 
required for theoretical saturation informed by previous similar research 
(Knowles et al., 2016; Roos et al., 2016). For women with SMI, convenience 
sampling was used. For health professionals, convenience sampling plus 
snowball sampling was used to identify health professionals who would be 
likely to be knowledgeable about the topic. That is, participants were asked 
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to identify further individuals whom they believed would provide useful 
information (Goodman, 1961).  
 
Recruitment procedure: Women diagnosed with SMI 
 
Recruitment was supervised by consultant psychiatrists and Trust Research 
Leads. The candidate was invited to attend several Trust team meetings (n 
= 1 in Dorset and n = 2 in West London) to present the research study to 
health professionals and to clarify any questions about the recruitment 
procedure. Psychiatrists and one clinical psychologist working in community 
mental health teams (CMHT) acted as gatekeepers for the research study by 
suggesting participants who were eligible and well enough to take part.  
 
Psychiatrists (or a clinical psychologist) screened eligible participants during 
their outpatient clinics and notified the candidate when potential participants 
had expressed an interest to participate in the study. The candidate was 
contacted by the psychiatrists or the clinical psychologist by email or, if she 
and the service user were already in the clinic, in person. The candidate 
was available to speak to each potential participant (either over the 
telephone or in person) to discuss the study and agree a date and time to 
meet. In all cases, when the participant spoke in person with the candidate 
about taking part in the study, they agreed for the interview to take place 
immediately. Interviews were conducted face-to-face in a private space in 
community mental health clinics (n = 1 site in Dorset, n = 4 sites in West 
London), audiotaped with consent and transcribed verbatim. To preserve 
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anonymity, an alphabetical letter was attributed to each recruitment site. 
 
Prior to the start of every interview, the candidate referred to an 
independent source, i.e. a member of the participant’s clinical care team 
(psychiatrist or clinical psychologist), to ensure that the participant had 
capacity to participate. This was to ensure that the participant was able to 
give their written consent to participate and able to retain information long 
enough to make the decision and to make the decision at the point when it 
needed to be made. The consent form (Appendix 10) was signed by the 
candidate and the participant. The candidate explained the information 
sheet (Appendix 11) to the participant prior to the interview. This was to 
ensure that the participant understood the purpose and nature of the 
research, what it involves, its risks and burdens and the alternatives to 
taking part.  
 
Recruitment procedure: Health professionals 
 
Posters about the research study were emailed to the study gatekeepers, to 
be placed in community mental health team waiting rooms, staff meeting 
rooms and inpatient wards. The candidate attended several Trust team 
meetings to present the research study to health professionals. Participant 
information sheets (Appendix 12) and informed consent forms (Appendix 
13) were distributed during the meeting, and members of staff (n = 3) with 
an interest in physical health recommended colleagues who they thought 





The tool used for this study was Version 0.2 (a sample page is provided in 
Appendix 8).  
Demographic and clinical questionnaire for women with SMI (Appendix 14): 
Participants were asked to complete a demographic and clinical 
questionnaire. Information requested included demographic characteristics 
(gender, year of birth, ethnic group) and clinical information (mental health 
diagnoses, duration of illness(es), whether participants have been for one or 
more cervical screening appointment(s) in the past and, if so, when the most 
recent appointment took place). These data were collected since past 
screening experience has previously been shown to impact upon future 
uptake (Clifton et al., 2016; Roncancio et al., 2013).  
 
Health professional demographic and professional questionnaire (Appendix 
15): Participants were asked to complete a demographic questionnaire. 
Information requested included demographic (year of birth, gender and ethnic 
group) and professional characteristics (profession, length of time in current 
role, work setting and length of time qualified). 
 
The interview schedule for women with SMI (Appendix 16) includes 
questions relating to what the participant thinks about the tool, any 
suggestions about the content of the tool and in what context (both in 
terms of setting and in collaboration with whom) the participant would use 
the tool. Interviews lasted up to 45 minutes; they were audio recorded and 
transcribed verbatim. Participants were given the tool and then given some 
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time alone to read it. Some women wanted the candidate to talk them 
through it. 
 
The interview schedule for health professionals (Appendix 17) explores 
what participants think of the tool, whether there is any content they feel 
should be included, excluded or changed, and the context in which they 
think the tool should be introduced. Interviews lasted between 30 and 45 





The demographic and health data were summarised using descriptive 
statistics, such as standard deviations and means. A content analysis of the 
transcripts was conducted (Hsieh and Shannon, 2005; Owen, 2012). Data 
from service users and health professionals, alongside iterative feedback 
from members of the key informants group, represents round four of 
stakeholder involvement (see Figure 6.1). Data from these three 
stakeholder groups were combined. Each requested revision was coded 
line by line into two categories: ‘Modification Accepted’ and ‘Modification 
Declined’. If a service user feedback contradicted professional feedback, 
priority was given to suggestions from service users, as they are the primary 
target group, provided it did not contradict NHS cervical screening 
guidelines (NHS, n.d.; PHE Screening, 2019). The candidate discussed 
every action with her principal supervisor (who is a nurse and health 
psychologist) and, where relevant, with a member of Jo’s Cervical Cancer 
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Trust to ensure clinical accuracy. Any query requiring further deliberation was 
discussed with the candidate’s second and third supervisors (a consultant 
psychiatrist and chartered psychologist). The rationale for accepting or 




7.3.1 Sample profile 
Women with SMI  
A total number of n = 18 women with SMI were approached by their clinician 
to take part in this study, 10 of whom took part. A total of n = 8 women 
refused to take part in the study. Several women (n = 5) gave a reason for 
declining to take part: history of trauma which they did not want to discuss: n 
= 2; bad cervical screening experience: n = 1 and refusing to go for cervical 
screening (no reason given): n = 2. The majority of participants (n = 7) had 
attended cervical screening more than once in the past (though one had not 
been for 13 years), one participant had never attended cervical screening, 
one had attended once but declined further invitations due to a bad cervical 
screening experience and one was not yet of eligible age (aged 23). Her data 
were included in the analysis as her perception of what cervical screening 
entails was highly valuable to the development of the tool.  
 






Table 7.1 Demographic characteristics of study participants (service users) 
(n = 10). 
 






Age, years: mean (SD) 42 (SD: 7.99) 
Recruitment sites 3 
Ethnicity (grouped), n (%) 
White – all 
Black/Black British – all 















Had cervical screening n (%) 
More than once 
Once 
Never 






Last cervical screening n (%) 
In the last 5 years 
Over 5 years ago 
Never 








Table 7.2 Demographic characteristics of study participants (health 
professionals) (n = 10). 
 
 
7.3.1. Overall feedback on the tool 
The fully coded content analysis is contained in Appendix 18. Some revisions 
to the tool were requested (n = 8 changes requested from service users and 
n = 35 from health professionals). Overall feedback on the tool from service 
users and health professionals was positive. Positive feedback (n = 28 from 
health professionals and n = 54 from service users) was recorded, displaying 
acceptability of the tool with key stakeholders. Example quotes of positive 
feedback are listed below:  
 
‘The leaflet would be helpful to women who don’t go [to screening]’ (service 
user #5), 
 








Age, years: mean (SD) 43.5 (SD: 9.12) 
Recruitment sites 4 
Ethnicity (grouped), n (%) 
White – all 
Black/Black British – all 





Work setting (grouped), n (%) 









Profession (grouped), n (%) 









Length of time in current role, years: mean (SD) 6.03 (SD: 4.66) 
Length of time since initial qualification, years: mean (SD) 12.6 (SD: 7.68) 
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‘I think it’s brilliant (…) you’ve put everything in the leaflet’ (service user #6). 
 
‘It would be good if [the tool] got sent out into the post, you know when you 
have the letter for the reminder, so they [women] can have a look at the 
leaflet, so it prepares them, it would give them more faith to book this test’ 
(service user #2). 
 
Similarly, health professionals found it to be of value:  
 
‘I think it’s really thoughtful, and really sensitive, you can tell a lot of thought 
has gone into it, and I think the wording is very good, it captures quite difficult 
things but in an easy to understand way’ (Psychiatrist, West London Trust), 
‘I think it’s great, really fantastic’ (GP, West London Trust), 
 
‘Very useful to have this leaflet to hand out and then to follow-up with at the 
next appointment (…) It gives people a tool if they need extra help, it’s written 
in the leaflet what they can ask for (…) leaflet is great, it’s one of those things 
like sexual dysfunction for men on antipsychotics, don’t always think to 
check, so leaflet is useful’ (psychiatric nurse, West London Trust). 
 
An example of a requested revision is provided here. During feedback on the 
first draft of the tool (Version 0.1), a member of the key informants group 
suggested including a sentence in the tool ‘to ask for a tranquiliser if you are 
feeling very anxious before the test’. This change was implemented in 
Version 0.2. During the acceptability testing phase, one of the participants (a 
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GP working in a mental health setting) felt that benzodiazepine medication 
(tranquilisers) should not be suggested to participants as a way of reducing 
their anxiety, as this may lead to adverse reactions for patients on 
antipsychotic medication. This sentence was therefore removed.  
 
Examples of requested revisions to a component of the tool (the ‘Tick box 
page’) are shown in Table 7.3. The rationale (seconded by the supervisory 
team) for accepting or rejecting each change was included in the table.  
 
 







Table 7.3 Revisions made to the ‘Tick box page’ section of the tool by group (Version 0.2 of the tool). 
Revision: Revision requested by (n = ) Decision made: 















Ensure service users understand 
that filling out this page is optional 
2   1  Women would not 
have to bring the tool 
to their appointment, 
so it is optional by 
nature 
[Participant had a previous bad 
experience with practice nurse, 
candidate asked whether it would 
it be clearer if the tool includes: ‘I 
had a previous bad smear test 
experience’ rather than: ‘I had a 
previous bad experience’]: 
‘maybe, it’s clearer’ 
1    Change made to 
distinguish any type of 
trauma from ‘a previous 
bad smear test 
experience’, which is 
more specific 
 
‘This is good [the tick box page] 
as long as it’s all kept confidential’ 






You may also want to add points 
related to people from 
marginalised communities, e.g. 
women who identify as lesbian, 
  1   We had already 
included ‘I am a 




bisexual or transgender and 
women from BAME communities 
with particular cultural issues 
mutilation/cutting 
(FGM/C)’. Jo’s Trust 
are developing a 
separate tool for 
LGBTQIA community 
‘I think it would be useful to 
suggest having the opportunity (a) 
to let the nurse know beforehand 
about these issues and (b) to talk 
through with him/her beforehand 
(i) how a particular issue affects 
your feelings about a smear test 
and (ii) what would help you’ 
  1   Due to time 
pressures in primary 
care, it is not 
possible for practice 




All words need to be spelt out fully 
e.g. examination not exam 
  1  Wording amended to 
reflect this 
 
‘I may react in an unexpected 
way’: nurse may ask ‘so what are 
you gonna do?!’ in a not very 
helpful way, so it’s better to have 
a line where the person can write 
down how they think they may 
react 
1    Change made; the option 
‘Other: _____’ was added 
 
You could add ‘I have an issue 
with my GP’ as a barrier 
 1    The option was 
added: ‘I have had a 




with a health 
professional 
I wonder whether there should be 
a space for (optionally) writing ‘my 
mental health 
conditions/diagnoses are...’ so 
that the tool can be shown to the 
health professional doing the test. 
The nurse/Dr may not have 
access to medical records at the 
   1 ‘I have a mental illness’ 
was replaced with ‘I have 





time of the test, and it might make 
it easier for the patient  
Obesity is an issue with this 
group: could add ‘I am 
embarrassed by my body shape’ 
 1   The option was added: ‘I 
am embarrassed by my 
body’ 
 
‘I am a voices hearer and get 
distressed during a physical 
exam’: split into two different 
categories 
 1   The options were added: 
‘I hear voices’ and ‘I get 
distressed during a 
physical examination’ 
 
The option ‘I have other health 
issues’ isn’t clear, could be 
replaced by ‘I find it hard to 
maintain a healthy weight’ 
   1 The option ‘I have other 
health issues’ was 
removed. It was replaced 
by ‘I am embarrassed by 
my body’ 
 
Instead of just pass out, add ‘faint’    1 The option was added: ‘I 




A key consideration that emerged early in the interviews was the importance 
of supporting women who have experienced trauma. As reported earlier 
(section 1.3.2), people living with SMI are at substantially increased risk of 
domestic and sexual violence than those in the general population (Khalifeh 
et al., 2015). For physical abuse, the prevalence in SMI has been found to be 
47% compared with 21% in the general population and 37% in SMI versus 
23% in the general population for sexual abuse (Mauritz et al., 2013). 
Including tips and adjustments throughout the tool was noted by most service 
users and health professionals as relevant, innovative and helpful. Every 
health professional interviewed acknowledged that having a history of abuse 
or trauma is likely to be a substantial barrier to any type of cancer screening. 
Seven out of ten service users interviewed openly disclosed that they were 
survivors of rape or childhood abuse:  
 
‘There’s loads of people that have survived traumatic experiences and don’t 
want to go for smear tests for that reason’ (service user #6),  
 
‘I was raped about 20 years ago, and it [cervical screening] definitely brings it 
back’ (service user #10).  
 
A member of a service user group also disclosed how her experiences made 
her feel during a smear test:  
 
‘It’s not just embarrassment, or bad self-esteem, for crying out loud, it is a 
vulnerable part of the body and somebody is attacking it, often causing quite 
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considerable pain and if you complain they have a go at you, making you feel 
bad because you ‘can’t relax’. Then other people start telling you you’re 
stupid and a complete ‘wuss’ if you complain’. 
 
Deciding whether to disclose a history of trauma to the screening 
professional was discussed with several participants. Other than one health 
professional (care coordinator #2, West London Trust), no participant was 
familiar with the My Body Back project (charity offering cervical screening for 
women who have experienced sexual violence), which is mentioned in the 
‘Getting Support’ section, indicating value to retain it in the tool:  
‘ah that’s useful’ (service user #10).  
 
The tick box page was commented on by every service user and health 
professional. Most service users felt that this page would help them to 
disclose their traumatic event (or other issue) and any reactions (e.g. fainting, 
freezing up, or crying) they anticipate when being screened:  
‘I wish I’d had it [the tool] when I had my appointment because I could have 
ticked the boxes’ (service user #6). 
 
One woman reported avoiding screening due to her fear of the nurse’s 
reaction to the scarring on her legs caused by self-harm. She welcomed the 
tool’s tick box page to help her disclose her history of self-harm:  
‘I have deep scars on my legs (…) so I don’t like to take my trousers off and 
show my legs to a doctor’ (service user #7). 
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Another said the tool gave legitimacy to her worries (hearing voices) 
‘because it’s on your tick box page’ (service user #10).  
 
Service users appreciated the fact that they would not have to discuss their 
issue with the screening professional, but could simply show them the page 
to make them aware:  
 
‘it’s brilliant, because then you don’t have to explain that you have a mental 
health condition, so if you behave a bit strangely, they’re understanding, 
rather than brush you off or treat you like an idiot’ (service user #1). 
 
One service user admitted she would not use the tick box pages: 
‘that would probably make me more anxious than having to say it, and I 
would assume my nurse would have that information anyway’ (service user 
#3). 
 
Though the nurse would, in most instances, not have access to this 
information, it is an interesting finding that someone would believe that to be 
the case. 
 
All health professionals and members of the key informants group felt that 
this was an innovative and useful section of the tool:  
 
‘It looks a nice leaflet and we particularly like the part with the tick boxes of 
why they find it difficult to attend’ (Public Health England), 
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‘In a clinic, asking open-ended questions can sometimes be overwhelming 
for the patient (e.g. are you anxious about anything?), having the ‘tick box’ 
page is helpful’ (psychiatric nurse, West London Trust). 
 
7.3.2 Main contentious issues 
Two main contentious issues were raised during the interviews, one 
regarding the terminology around SMI, and the other whether to focus on the 
benefits of cervical screening or the risks of non-attendance. In line with 
content analysis, the coding categories were derived directly from the 




During feedback collected on the first draft of the tool (Version 0.1), one of 
the members of the key informants group commented on the lack of clarity of 
who the target audience of the tool is:  
 
‘It’s slightly confusing as to who the reader is supposed to be. I would have a 
sub-heading which reads ‘A comprehensive guide to support people with 
mental health issues’ (not sure what term is being used)’ (Jo’s Cervical 
Cancer Trust). 
 
The charity felt that there was little reference to severe mental illness in the 
tool. Their preference was for ‘SMI’ or ‘people who are anxious about 
screening’ to be included in the title of the tool, and to explicitly mention the 
target audience throughout. At the beginning of every interview with service 
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users and health professionals, the candidate discussed the extent to which 
references to mental illness should be included in the tool and whether an 
alternative title to ‘Support available for cervical screening (smear test)’ 
should be adopted. The consensus across service users was that making a 
specific reference to SMI was unnecessary:  
 
‘The title is clear’ (service user #5), ‘I like the title’ (service user #6) and  
 
‘On p.3 and elsewhere, it would be helpful to avoid using purely medical 
language for mental distress (e.g. ‘a mental health condition’ here and on 
p.10, ‘mental health symptoms’ (p.6), ‘symptoms’ (p.10); (…) a problem for 
considerable numbers of us is the interpretation of mental distress via a 
clinical model. If people are unhappy with the use of purely medical language 
in the leaflet, it may well impact on their reactions to the leaflet as a whole’ 
(member of service user group, feedback received by email on 29/11/18). 
Similarly, health professionals worried that an over-emphasis on ‘SMI’ might 
deter women attending, who may either feel that the tool is irrelevant to them, 
or that they are being stigmatised:  
 
‘One of the beauties of the leaflet is that it doesn’t go out of the way to state 
mental health, it’s a really useful leaflet for everybody actually (...) we need to 
be connecting with them as people (...) it would turn some people off if it 
became focused on SMI (...) as professionals we categorise them, but the 
person walking in the street isn’t thinking ‘I have SMI’, so we need to give 
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them information in a way that gives them better access to available 
screening’ (Psychiatrist, Dorset Trust). 
 
2) Balancing the risks and benefits of cervical screening in the tool 
 
The second contentious issue that emerged was how to strike a balance 
between the risks of non-attendance and giving women a choice of whether 
to attend cervical screening. Several participants and members of the key 
informants group were in favour of emphasising a ‘loss framed’ message: 
‘Don’t be afraid to be explicit about the risks involved if they don’t go, don’t be 
scared to use the word ‘cancer’’ (Psychiatric nurse, Dorset Trust), 
 
‘In the sentence where you say ‘it is not a test for cancer’ I think a natural 
conclusion might be ‘why bother then?’. I think it should say, more explicitly, 
that it can pick up changes that, if left untreated, might eventually lead to 
cancer’ (doctor with dual training as a GP and Psychiatrist, member of the 
key informants group), 
 
‘Need to be factual, don’t shy away from using the word ‘cancer’’ (Nurse 
prescriber, Dorset Trust), 
 
‘We need to highlight that this is a test for detecting an often-silent cancer – I 
am a bit worried that saying it’s up to you (without people knowing the facts 
that this is a test for cancer) may not emphasise the importance of this test’ 




This preference to focus on the risk of non-attendance contrasts with 
research which reports that ‘gain-framed messages’ may be more 
appropriate (Cooke and French, 2008). To increase cancer screening 
attendance, authors recommend that screening organisations would be best 
advised to send people information designed to generate positive attitudes 
(Cooke and French, 2008). A number of participants and members of the key 
informants group were in favour of focusing on a ‘gain-framed’ message: 
‘It can be scary if you read this list [of cervical cancer symptoms], you may 
think you have cancer but it can be lots of different things like thrush (…) 
discharge can also be thrush, not cancer (…) so list can be scary, important 
to explain it can be other things’ (service user #7), 
 
‘Reword: ‘it is still important to be aware of cervical cancer symptoms’ to 
something like: ‘if you experience any of these symptoms it is important to 
see your doctor straightaway. It might not be cancer, but it is important to 
have them checked’’ (service user group with lived experience of mental 
illness and cervical cancer), 
 
‘Should we be talking about cancer so early on in the leaflet? Could make 
people more anxious … it is important, but it might put some people off, 
maybe better to talk about the practical things first, that’s what’s really 




‘The word ‘cancer’ appears too much, you might scare people off ... (…) word 
‘abnormalities’ doesn’t sit well with me and I guess also for people who have 
SMI’ (Care coordinator (2), West London Trust), 
 
‘There is too much mention of the word ‘cancer’, might worry someone who 
has paranoia or health anxiety and they might think ‘I’d rather not know’’ 
(Care coordinator, West London Trust), 
 
‘‘Staying healthy’ message – focus on prevention rather than ‘it’s a cancer 
test’’ (Consultant nurse, member of the key informants group), 
‘I don’t like the bit about cancer developing, as that would make me very 
anxious’ (Jo’s Cervical Cancer Trust). 
 
Following feedback from participants, an effort was made to balance the risks 
of non-attendance with the benefits of screening throughout the tool. Cancer 
prevention was highlighted in the ‘What is cervical screening?’ section (e.g. 
‘If not monitored or treated, some changes may eventually develop into 
cervical cancer’ (page four). The health promotion message to emphasise 
the benefits of screening appears in different sections of the tool, e.g. ‘Going 
for cervical screening when invited is the best way to protect yourself against 
cervical cancer’ (page four, ‘What is cervical screening?’) and ‘These 
symptoms don’t mean you have cancer and are often caused by other things, 




Changes were incorporated to ensure acceptability of the tool with key 
stakeholders; this became Version 0.3 (a sample page is provided in 




Objective three (reported in Chapter Two, section 2.2) is defined as testing 
the acceptability and usability of the tool by stakeholders. Acceptability of the 
tool was demonstrated with key stakeholders and any changes to the content 
were incorporated in Version 0.3. This version was then used to test the 
usability of the tool with stakeholders (service users, health professionals and 





Chapter Eight – Tool development: Usability testing of the 
tool 
 
This chapter describes Study Four, which was conducted to test the usability 
of the tool. Work to this point had ensured that the tool was acceptable to 
stakeholders. It was now important to test whether the tool could be used by 
its intended users to fulfil the third objective of this research (see Box 3 
below). The think-aloud method (van Someren et al., 1994) was used for the 
purpose of usability testing. The readability of the tool (Versions 0.2 and 0.3) 
was assessed and final changes were made to obtain ‘sign-off’ of the tool 




Box 3: Development of the tool (continued) 
Objectives of the research that this Chapter addresses (in bold): 
Objective one: To develop an informed-choice tool for people with SMI 
which addresses some of the barriers to screening attendance 
Objective two: The tool should be theoretically underpinned 
Objective three: Acceptability and usability of the tool by stakeholders 
should be tested 
Phases of the MRC guidance 
Development: Identifying the evidence base 
Development: Identifying/developing theory 
Feasibility/Piloting: Testing procedures 
Evaluation: Understanding change process 
Steps to follow when developing an informed-choice tool for people with SMI 
 
Step one: Identify barriers to decision-making 
Step two: Theoretically underpin the intervention  
Step three: Involve service users in the development of the tool 
Step four: Test usability of the intervention 
Step five: Assess readability levels 
Stakeholder involvement to develop the tool 
Round one (February – March 2018) 
Round two (May 2018) 
Round three (July – August 2018) 
Round four (September – November 2018) 
Round five (December 2018 – March 2019) 






The usability of the tool Version 0.3 was tested with service users who 
access NHS mental health services and health professionals who work there. 
The method to recruit these participants is described below. In addition, this 
version of the tool was emailed to members of the key informants group for 
iterative feedback in December 2018. These data are reported in section 8.3 




Some of the study’s methodological elements (ethical considerations, 
participant recruitment criteria and recruitment procedure), are identical to 
those used in Study Three and have been reported in detail (see Chapter 
Seven, section 7.1). Thus, only the methodological elements that are specific 
to this study are described below.  
 
8.1.1 Design and setting 
The think-aloud method was used to collect feedback on the design and 
layout of the tool (Version 0.3). The rationale for using the think-aloud 
method stems from findings from the systematic review (Study Two, 
Chapter Four), suggesting using this method to test the usability of an 
intervention. The think-aloud method is a validated method of qualitative 
inquiry (van Someren et al., 1994) that is used to assess user experience 
and usability of interventions and allows observation of the actual reactions 
of the participant taking part in an intervention/using a particular tool 
(McDonald et al., 2016). This method has been used successfully to test 
smoking cessation interventions with participants with SMI (Ferron et al., 
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2011; Vilardaga et al., 2016). The Ferron (2011) study used the think-aloud 
method to develop the smoking cessation tool described in Chapter Four, 
whereas the Vilardaga et al. (2016) study reported the results of a user 
experience evaluation of a National (US) Cancer Institute smoking cessation 
app, QuitPal, and provided user-centred design data (e.g. using large 
buttons on the interfaces, breaking down the smoking cessation behaviour 
into smaller steps, maximising the consistency of the design) that 
researchers can use to tailor smoking cessation interventions for this 
population.  
 
Participants were instructed to ‘think aloud’, that is, they were encouraged to 
communicate any thoughts, comments or suggestions they had about the 
design or layout of the tool while they interacted with it. If the participant 
paused while going through the tool, the candidate would ask what they are 
thinking, and would respond to comments about the design elements of the 
tool, for instance by asking participants to elaborate and by making 
suggestions for changes on which participants could comment.  
 
The settings (West London NHS Trust and Dorset Healthcare University 
NHS Foundation Trust), sampling technique and recruitment criteria and 
procedure are identical to those used for Study Three and described in 
section 7.1.  
 




The recruitment criteria are identical to those reported in section 7.1.  
 
8.1.3 Sampling and recruitment procedure 
Sample size justification: Studies testing the usability of an intervention 
usually suggest a minimum of five participants to ensure the identification of 
usability issues (Macefield, 2009). Studies reporting usability testing using 
the think-aloud method with adults who have SMI used similar numbers of 
participants: n = 5 (Vilardaga et al., 2016), two cycles of n = 5 to test and 
verify usability of an app (Whiteman et al., 2017). Sample sizes of n = 8 for 
service users and n = 6 for health professionals were selected, based on the 
estimated number required for theoretical saturation informed by previous 
similar research (Vilardaga et al., 2016; Whiteman et al., 2017). The 
sampling technique was identical to the one reported in Chapter Seven (see 
section 7.1). 
 
The recruitment procedure is identical to that reported in section 7.1.  
 
8.1.4 Materials  
 
Version 0.3 of the tool was used for this study. 
The demographic questionnaires for women with SMI and health 
professionals are identical to the ones reported in 7.1 (Appendices 14 and 
15). Sample participant information sheets and consent forms are contained 
in Appendices 10-13. 
 
The interview schedule for women with SMI includes questions about what 
the participant thinks of the overall layout and design of the tool, whether 
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there is anything that should be changed or added or removed, whether the 
wording is clear and how easy it was to go through the tool. All participants 
were asked to provide feedback on what health professionals and health 
services might do that would make it easier for people with SMI to decide 
whether to go for cancer screening. The interview lasted up to 35 minutes. 
 
The interview schedule for health professionals includes questions on what 
the participant thinks of the overall layout and design of the tool, whether 
there is anything that should be changed, added and/or removed, whether the 
wording is clear and how easy it is to go through the tool. The interview 




The same data analysis was conducted as reported in section 7.2: the 
demographic and health data were summarised using descriptive statistics 
and a content analysis of the transcripts was conducted (Hsieh and 
Shannon, 2005; Owen, 2012). In addition to email feedback from members 
of the key informants group, a service user group (SUGAR, n = 12) 
commented on Version 0.3 of the tool during a workshop at City, University 
of London in January 2019. This feedback, alongside usability testing with 
service users and health professionals, consists of round five of stakeholder 






8.3.1 Sample profile  
Women with SMI  
A total of 17 women with SMI were approached by their clinician to take part 
in this study, eight of whom consented. Of the nine women who refused to 
take part, six gave a reason for declining to take part: history of 
trauma/abuse: n = 2; bad cervical screening experience: n = 1 and refuses to 
go for screening (no reason given): n = 3.  
 
Every participant had been for cervical screening more than once (between 
2012 and 2018, though one could not remember the last time she went). A 
summary of the results from the questionnaires are shown in Tables 8.1 and 
8.2. Participants are different individuals from those recruited in Study Three. 
To assess participants’ usability of the tool, the think-aloud method was 
applied to interviews conducted with women with SMI who access (n = 8) 




Table 8.1 Demographic characteristics of study participants (service users) (n 
= 8) 
 






Age, years: mean (SD) 47 (SD: 7.98) 
Recruitment sites 2 
Ethnicity (grouped), n (%) 
White – all 
Black/Black British – all 

















Had cervical screening n (%) 
More than once 
Once 
Never 






Last cervical screening n (%) 
In the last 5 years 
Over 5 years ago 
Never 









Table 8.2 Demographic characteristics of study participants (health 
professionals) (n = 6) 
 
The tool was designed using the Dyslexia Friendly Guide (British Dyslexia 
Association, 2018). The guide recommends using a dyslexia-friendly font 
(Arial was selected), avoiding the use of a white background and using a font 
size of a minimum 12 point (14 was selected based on feedback from 
SUGAR, one of the service user groups from the key informants group).  
 
8.3.2. Overall feedback on the tool  
Overall, feedback on the design of the tool was positive: 
 
‘I think the colours are really good, it’s quite friendly and opening, and it is 
quite informative, and I don’t think it makes it too scary, which is nice because 
obviously when you mention the word cancer or screening, it’s like OMG, and 
then people don’t want to go but not the way you’ve done it (…) it’s normally 








Age, years: mean (SD) 42 (SD: 4.36) 
Recruitment sites 4 
Ethnicity (grouped), n (%) 
White – all 
Black/Black British – all 





Work setting (grouped), n (%) 
Community mental health team 
Recovery team 





Profession (grouped), n (%) 









Length of time in current role, years: mean (SD) 5.83 (SD: 4.74) 
Length of time since initial qualification, years: mean (SD) 11.07 (SD: 6.16) 
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one page, or a boring booklet in black and white’ (service user #17) 
. 
Several changes were requested. These are listed in Table 8.3, which 
categorises the revisions requested from each group and the rationale for 
accepting/rejecting the change. The rationale (seconded by the supervisory 
team) for including and rejecting the requested changes and suggestions and 
is included in the table. Although feedback during this phase pertained to the 
design/layout of the tool, occasionally participants made suggestions relating 
to the content of the tool. These revisions were incorporated, provided they 
did not contradict NHS cervical screening guidelines (NHS, n.d.; PHE 
Screening, 2019).   
 
Table 8.3 Revisions made to the tool by group (Version 0.3 of the tool). 
 


















[On translations of the 
leaflet] Is there anything 
you can put at the end 
[of the leaflet], I don’t 
know if you have the 
resources, about getting 




    Funding will 






Increase the font for 
page numbers 
1  1  Change made: 
font size was 
increased to 14 




Maybe insert the word 
‘your’ to the [front cover] 
title: ‘Support available 
for your cervical 
1    Change made  
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screening, I think it 
makes it slightly clearer 
and also slightly more 
personable like it’s not 
an abstract thing that 
some people have and 
some people don’t, it 
applies to everyone 
WHAT IS CERVICAL SCREENING 
A picture of the cervix 
and the different parts of 
the vagina might be 
helpful 
 
1  3  Change made; 
diagram 
included on 




phases of data 
collection with 
service users  
 
BOOKING YOUR APPOINTMENT 
Change the background 
colour for this section 
(too dark) 
1    Change made 
(very pale blue) 
 
BEFORE YOUR APPOINTMENT 
Make the tips section 
more like a 
flashcard/punchy bullet 
points rather than 
expanding and going 
into too much detail  
 4 2  This section was 
revised to avoid 
overwhelming 
service users 
with too much 
text 
 
ACTION PLANNING PAGE32 
Cannot write on the blue 
sections – issue with 
colour contrast 
  3 1 Change made to 
a much lighter 
blue  
 
Doesn’t like the action 
planning page: ‘It’s 
important for me to go 
because … other ideas’: 
sounds a bit like school, 
would people fill it out? 
 1    This was not 





Add a space for women 
to ask questions before 
their appointment 
   1 Change made  
TICK BOX PAGE 
This page has a lot of 
text, it would be better 
suited on two pages 
   1 Change made  
Bring this page to the 
beginning as it’s the 
most useful and clears 
service user mental 
blocks 
 1 1   The tick box 
pages are 
most visible 
in the middle 
of the leaflet 
 
32 Three action planning boxes were included in the tool to allow women to write down their thoughts: 
‘This would help me go to my appointment’, ‘It’s important for me to go because’ and ‘Other ideas’ 
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Maybe perforate the tick 
box page so people can 
rip it out? The printers 
will just perforate that 
page, or you can 
perforate all the pages if 
you like 








The background colour 
of the tick box page is 
too dark, cannot write on 
it 
1  Group 
feedback 
2 The background 
colour was 
changed to lilac 
 
AFTER YOUR APPOINTMENT 
Put in bold: 
‘Remember, having an 
abnormal result does 
not mean that you have 
cancer’, because 
women do panic and go 
into complete 
meltdowns 
1    Bold font was 
used for this 
sentence  
 
Use a diagram to 
describe ‘hip bones’ 
  2   There was 







Three contentious issues were raised during the think-aloud sessions: the 
length of the tool, the front cover image and the order of certain sections. In 
line with content analysis, the coding categories were derived directly from 
the transcribed data. These are discussed in the following section. 
 
8.3.3 Main contentious issues 
1) Length of the tool 
The main negative feedback on the tool was its length (14 pages), an issue 
that was raised by several service users and health professionals during both 
phases of testing:  
 
‘the booklet is too long/wordy’ (n = 3 SUGAR members), 
 
‘Concentration is an issue with this group of patients, could we cut it down a 
little?’ (Psychiatric nurse, West London Trust). 
 
However, several people stated that every page was of value:  
 
‘Perhaps the leaflet is a little long, might be overwhelming for patients who 
are quite anxious, but having said that there are no sections I would remove 
and also you don’t want to undersell the importance of the test’ (Doctor, West 
London Trust). 
 
The rationale for not shortening the tool was for readability purposes, to 
avoid pages displaying too much information:  
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‘Avoid too much writing – it can be overwhelming’ (service user group funded 
by Mind/Macmillan), 
 
‘I can’t read it [font was too small], sorry my eyesight is so bad’ (service user 
#11), 
 
‘The tick box page would be better suited on two pages’ (participant at Ealing 
Mental Health Forum). 
 
Following feedback from service users that the tick-box page was too 
condensed when it was on a single page, it was reformatted onto two pages. 
This was also to give more prominence to this section, which aroused 
significant interest with service users, professionals and public health 
stakeholders. 
 
2) The front cover page 
Revisions to the front cover image 
 
Figure 8.1 Front cover of the tool 
(Version 0.3 of the tool). 
The draft front cover image (shown 





‘Question mark on the first page is to produce some interest in the leaflet? Or 
is it about questions answered? Purpose of the question mark image is 
unclear’ (Psychiatrist, West London Trust). 
 
Some service users made suggestions for a new image:  
‘Face of a young person would be better on the first page’ (SUGAR 
member), 
 
‘Illustrate groups of people most at risk of not attending in order to attract 
those groups’ (SUGAR member), 
 
‘Personally, I’d prefer silhouette of a face, feeling relieved, rather than blank’ 
(service user #12), 
 
‘you can put two people on it [front cover image], and it’s like little [speech] 
bubbles, and they are having a conversation and it’s like (…) ‘no don’t be 
embarrassed’, like a supportive friend, so there’s two women talking and one 
is whispering to the other, coz that’s how it starts, it has to be someone really 
clued on that says ‘come on I’ll take you there’‘ (service user #18), 
 
‘If I had that leaflet I would share it with another person like a friend, I would 
say ‘oh look at this it’s got a bit of information and that might help you’, 
obviously I would share it if someone was coming with me to the 





Based on the suggestions received from service users #2, #18 and a 
SUGAR member, the front cover image was revised. An illustrator was 
commissioned to conceptualise the image, which illustrates three women of 
different ages and ethnicities having a conversation on a couch about going 
for cervical screening. During a clinic in a CMHT (site C), the candidate 
asked service users (n = 3) and health professionals (n = 2) to give feedback 
on the image. Service users (n = 3) requested a larger font size for the 
speech bubbles in the image. This change was incorporated. 
 
Figure 8.2 Revised cover image (Version 0.4 of the tool). 
 
3) Order of sections of the tool 
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The order of certain sections in the tool was discussed:  
‘I like the bit about getting extra support, appropriately put at the back [of the 
tool]’ (Psychiatrist, West London Trust), 
 
‘It’s relevant for people to know what to get checked between appointments. 
I’m thinking, though, that this section might be better near the end of the 
leaflet. As people are likely to be nervous before going for a smear test at all, 
it’s probably not helpful to mention too early on what problems may arise 
even after one has gone for an appointment’ (member of a service user 
group). 
 
Based on the feedback received from the member of the National Survivor 
User Network, the list of cervical cancer symptoms was removed from the 
‘What is cervical screening’ section and became a separate section entitled 
‘Looking after your health’, which is the penultimate section of the tool. 
 
Two suggestions were discussed but subsequently rejected as they had not 
been raised by any service user: 1) one health professional suggested 
moving the tick box pages to the beginning as they considered them to be 
the most useful section; 2) another health professional suggested changing 
the order of every section:  
 
‘Not 100% sure about this, but it seems more logical to describe the 
appointment and then offer tips, rather than giving tips before knowing what 




‘First give information about what cervical screening entails, then give tips, 
might work better to capture the interest, set the scene. Once the person 
knows what the appointment entails, she can then think about what 
support/tips she needs, and what is obstructing them’ (Psychiatrist (2), West 
London Trust). 
 
The revised tool, which incorporated the revisions, became Version 0.4 (a 
sample page is provided in Appendix 20). 
 
8.4 Assessing readability of the tool 
 
Assessing and adjusting the readability levels of the tool was identified in the 
systematic review (Study Two, Chapter Four, section 4.3.4) as a step to 
follow when developing an informed-choice tool for people with SMI. People 
living with SMI may periodically face chronic executive function issues, 
including drowsiness or cognitive blunting (Castillo et al., 2015; Le et al., 
2017). In order to ensure accessibility of the tool for this group, who may 
have lower than average reading levels, the readability of the tool (Versions 
0.3 and 0.4) was assessed using the Flesch Reading Ease and Flesch-
Kincaid scales (Flesch, 1948; Kincaid et al., 1975). These scales were 
identified in the systematic review (Chapter Four) as having been used in 
other studies to assess the readability of a decision aid for people living with 
SMI (Brohan et al., 2014a). Those authors revised their decision aid to be 
understood by US 8th or 9th graders (between 13 and 15 years of age). The 




The Flesch Reading Ease scale generates a score, a number from 0 to 100. 
A higher score indicates easier reading and lower numbers mark passages 
that are more difficult to read. The formula for the Flesch reading-ease score 
test is the following:  
206.835 -1.015 (total words/total sentences) – 84.6 (total syllables/total 
words).  
 
The Flesch–Kincaid Grade scale produces a score as a US grade level, 
reflecting the number of years of education generally required to understand 
this text. For example, a score of 8.4 indicates that the text is understood by 
an average student in 8th grade (13–15 years old). The grade level is 
calculated using the following formula:  
0.39 (total words/total sentences) + 11.8 (total syllables/total words) – 15.59 
Scores can be interpreted as shown in the table below. 
 










US school level Reader’s age Explanation 
100.00–
90.00 
3–5 5th grade 7–9 year olds Very easy to read 
90.0–80.0 5–6 6th grade 9–11 year olds Easy to read 
(conversational 
English) 
80.0–70.0 6–7 7th grade 11–13 year olds Fairly easy to 
read 
70.0–60.0 7–8 8th and 9th grade 13–15 year olds Plain English 
60.0–50.0 8–10 10th to 12th grade 15–17 year olds Fairly difficult to 
read 
50.0–30.0 - College 17–19 year olds Difficult to read 
30.0–10.0 - College graduate University 
graduates 
Very difficult to 
read 
10.0–0.0 - Professional University 
graduates 
Extremely difficult 




8.4.1 Assessment of readability of the tool 
Readability levels were assessed twice using versions 0.3 and 0.4 of the 
tool (which includes changes from the usability testing phase). User testing 
enabled the tool to be revised, including refining use of language to 
increase readability, such as providing a definition and diagram for the word 
‘cervix’ as described above. The scores from the readability scales of 
Version 0.3 are reported in Table 8.5 below.  
 
Table 8.5 Initial readability scores using the Flesch Reading Ease and 
Flesch-Kincaid scales (Version 0.3 of the tool). 
 






Reader’s age (in 
years) 
Explanation 
Who is this leaflet for? 61.9  7.02 13–15 Plain English  
What is cervical 
screening?  
74.3  7 11–13 Fairly easy to 
read 
Booking your appointment 68.02  6.48 13–15 Plain English 
Before your appointment 70  
 
7.7 12–14 Plain English 
Tick box page(s) 80.31  3.92 8–9 Very easy to read 
During your appointment 87.3  3.2 8–9 Very easy to read 
After your appointment 72.4  6.6 11–13 Fairly easy to 
read 
Symptoms page 64.84  6.33 13–15 Plain English 
Getting support 50  7.84 15–17 Difficult to read 
 
To increase readability, several revisions were made to Version 0.3. The 
‘Getting Support’ page was ranked ‘fairly difficult to read’ during the initial 
score (see Table 8.5). This was due to the description of the charities which 
were listed on this page, which reduced the readability of that section. Each 
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charity was contacted and the simplified language that was provided was 
incorporated into the tool e.g. Jo’s Cervical Cancer Trust suggested 
replacing ‘eradicating cervical cancer’ with ‘eliminating cervical cancer’. 
These changes improved the readability of that section when final scores 
were calculated for Version 0.4. The reader’s age decreased (meaning 
readability of the tool increased) from 15–17 to 10–11. The scores from the 
readability scales of Version 0.4 are reported in Table 8.6 below. The 
sections of the tool with an improved reader’s age are highlighted in bold. 
 
Table 8.6 Final readability scores using the Flesch Reading Ease and 
Flesch-Kincaid scales (Version 0.4 of the tool). 
 









Who is this leaflet for? 71.816 6.47 13–15 Plain English 
What is cervical 
screening?  




74.1 5.7 10–11 Easy to read 
Before your 
appointment 
78.7 5.5 11–13 Fairly easy to 
read 








77.7 4.8 10–11 Easy to read 
Symptoms page 67 6.5 11–13 Fairly easy to 
read 
Getting support 56.3 6.6 10–11 Easy to read 
 
Final reading capability levels improved from the initial score for another four 
sections of the tool: Booking your appointment (reader’s age decreased from 
13–15 to 10–11), Before your appointment (12–14 to 11–13), After your 
appointment (11–13 to 10–11) and Looking after your health (13–15 to 11–
13). The following changes were made: the length of sentences was reduced 
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[‘What time will you need to get up and leave the house?’ was removed] and 
complicated words [e.g. ‘diagnostic’; ‘cervix’] were either removed or 
replaced. The remaining sections maintained the same reader’s age (13–15 
or below). The changes described, therefore, achieved the original aim (see 
Chapter Eight, section 8.4) of developing an intervention that was (as a 
minimum) readable to an age group of 13–15 years.  
 
8.5 Sign-off of the tool 
 
Version 0.4 was emailed in April 2019 to each organisation cited in the tool 
as a source of support: Jo’s Cervical Cancer Trust, My Body Back Project, 
Samaritans, SANE. In addition, the University of West London (which 
provided the PhD studentship) and the two Trusts where recruitment took 
place (West London NHS Trust and Dorset HealthCare University NHS 
Foundation Trust) were emailed the tool. The University of Surrey was added 
to the back page of the tool, as the principal supervisor of the candidate 
moved to that institution during the project.  
 
The West London NHS Trust queried whether translations and/or other 
formats of the leaflet were planned. The candidate answered that an East 
London council is looking into funding to translate the leaflet into Arabic. The 
candidate acknowledged that while no funding is currently available, this will 
be sought for subsequent versions of the tool. Requested changes are listed 
below. This feedback represents the final round (six) of stakeholder 




Table 8.7 Changes requested to obtain the sign-off of the tool. 
Change requested Change requested by Change made 
Version control West London NHS Trust The following sentence was 
added to the back cover of 
the tool: ‘This leaflet was 
printed in 2019. Version 1.0. 
The information in this 
leaflet was correct at the 
time of publication.’ 
Removal of all logos from 
the back page (the list of 
logos was confusing as to 
which organisation owns 
the leaflet) 
West London NHS Trust The logos were removed 
from the back page and 
were replaced by the name 
of the organisations 
Include the NHS logo on the 
front cover 
West London NHS Trust The tool was not 
commissioned by NHS 
England, so the NHS logo 
could not be included on the 
front cover 
Include Jo’s Cervical 
Cancer Trust logo on the 
front cover 
Jo’s Cervical Cancer Trust The logo was included on 
the front cover 
Include the ‘Creative 
Commons Non-Commercial 
licence’ image on the back 
cover 
University of West London The logo was included on 
the back page 
Include the acronym ‘HPV’ 
on page 4 to comply with 
‘Primary HPV screening’ 
which is being introduced 
across the NHS 
 
Consultant nurse (member 
of the key informants 
group) 
The following sentence was 
modified to include HPV: 
‘Cervical screening is a free 
health check that looks for 
HPV or cell changes 
(abnormal cells) on your 
cervix’ 
 
These changes were incorporated into Version 0.4 of the tool. The amended 
version was emailed once again to stakeholders in June and final sign-off 
was approved in August 2019. The completed version of the tool became 
Version 1.033; a sample page is provided in Appendix 21. The front cover of 













Table 8.8 Content of the signed-off version of the tool (Version 1.0 of the tool). 
 
Section (pages) Content (summary) Image/text box included Barrier(s) addressed Enabler(s) addressed 
Title page (1) Title: Support available for your cervical 
screening (smear test) 
 
 
Image of three women 
discussing whether to go for 
screening  
 
Logo of Jo’s Cervical Cancer 
Trust 
- - 
Who is this leaflet 
for? (2) 
Explanation of who the leaflet is for, and how it 
can help you plan your appointment 
- - - 
What’s in this 
leaflet? (3) 
Lists every section and includes page numbers - - - 
What is cervical 
screening? (4-5) 
• who is eligible for screening 
• the different health settings where 
screening is available 
• what cervical screening entails  
• the benefits of attending and risk of not 
attending 
• definition of the cervix 
Image of the female 
reproductive system  
 
Service user quote  
 
Unsure of need for 
screening, fear of bad 
news, poor relationship 
with GP. 
Understanding of benefits of 
screening, feeling ‘health 
conscious’, being anxious to 




A list of things to ask the receptionist is provided, 
including: 
• chaperone  
• preference for a female nurse  
Action planning text box is 
provided so women can 
optionally include the 
reason(s) why they have 






health symptoms, staff 





• reminder before your appointment is due 
• longer appointment 
• first appointment of the day, if you feel 
anxious in waiting rooms 







List of tips which may help to improve the 
screening experience such as: 
• Planning your travel to the appointment 
(e.g. checking bus times) 
• Bringing something comforting or 
relaxing (e.g. music player) 
• Wearing a skirt or dress (so you don’t 
need to fully undress) 
• Speaking to the nurse beforehand (e.g. if 
you require a pessary prescription) 
• Asking someone to accompany you on 
the day 
Action planning text box is 
provided for women to 
optionally include what would 
help them go to the 
appointment and what would 
they like to ask the nurse 
 
Additional burden, 
mental health symptoms 









leaving the house due to 
mental health problems 
Encouragement, reminders, 
continuity of care 
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• Planning something nice and relaxing 
after the appointment (e.g. going for a 
walk in the park with a friend). 
 
Tick box pages 
(8-9) 
Optional list of boxes to tick. Each box 
represents a service user barrier to cancer 
screening (Clifton et al., 2016). Developed as a 
‘disclosure aid’ to support women who may find it 
hard to discuss their issue(s) with the nurse. Aim 
of this component to show the tool to the nurse 
before the test, so nurse becomes aware of the 
issue(s) without having to discuss them. 
Examples of tick box options include: 
 I hear voices 
 My medication makes me shake 
 I have scars 
 I am a survivor of sexual violence 
 
- Difficult to process 
information, mental 
health symptoms reduce 
motivation for self-care, 




traumatising, lack of 
understanding of mental 




symptoms, staff can be 
rushed, staff can be 
rough, difficulty leaving 
the house due to mental 
health problems, made 
to feel like a burden on 
the health service 
 
Staff being understanding, 
good relationship with GP, 





Lists each step of a cervical screen Reminds the 
reader that they can ask the nurse to stop at any 
time 
Image of someone having a 
smear test (cervical screen) 
 
Service user quote 
Not knowing what to 
expect or what to do, 
traumatising 
 





Explanation of what happens after the test 
List of suggestions of who to contact if you need 
support after the test  
 
Service user quote Not know what to expect 
or what to do, fear of 
bad news 
Wanting to be informed, 
understanding of benefits of 
screening, feeling ‘health 
conscious’ 
Looking after 
your health (13) 
List of the symptoms to be aware of in between 
cervical screening appointments (e.g. unusual 
bleeding) is presented 
Explains what to do if symptoms appear 
 
Image of a nurse Unsure of need for 
screening, additional 
burden, mental health 
symptoms reduce 
motivation for self-care, 
embarrassment, fear of 
bad news 
Wanting to be informed, 
feeling ‘health conscious’, 
being anxious to avoid further 




List of organisations women can get in touch with 
if they need someone to talk to 
It also includes the contact details of 
organisations which can provide specialist 
support or advice on cervical screening 
 
Logos of Jo’s Cervical 




traumatising, fear of bad 
news, difficulty leaving 
the house due to mental 
health symptoms, poor 
relationship with GP 
Encouragement 
Back cover page 
(16) 
Lists who supported the development of the 
leaflet and provides links to websites for further 
information 
Version control 
A Creative Commons Non-







At the end of this work, a theory-informed tool on cervical screening for 
people living with SMI was created. The tool was produced in collaboration 
with key stakeholders and met established criteria for readability relevant to 
the target audience. The tool was guided by several theories and frameworks 
and developed using the two systematic reviews (Lamontagne-Godwin et al., 
2018, 2020) and barriers to cancer screening uptake identified by service 
users in a qualitative study which was underpinned by the TDF (Clifton et al., 





Chapter Nine – Evaluation of the tool 
 
This chapter reports Study Five, which consisted of conducting a preliminary 
evaluation of the tool’s impact on cervical screening decision-making with 
women with SMI. A cervical screening informed-choice tool had been 
developed which was readable, acceptable and usable to key stakeholders. 
The next step was to evaluate the proof of concept of the tool. Two validated 
scales were selected for the evaluation: The Stage of Decision-Making scale 
(O’Connor, 2000 – updated 2003) and the Decisional Conflict Scale 
(O’Connor, 1993 – updated 2010). Underpinned by the TPB, the data from 
this study were used to elaborate on the qualitative data collected as part of 




Some of the study’s methodological elements (ethical considerations, 
participant recruitment criteria and recruitment procedure) are identical to 
those used in Study Three and have been reported in detail in Chapter 
Seven (see section 7.1). Thus, only the methodological elements that are 
specific to this study are described below. 
 
9.1.1 Design and setting 
This was a quantitative, proof-of-concept study (to obtain an initial 
demonstration of the feasibility of the tool) using a convenience sample of 
women with SMI (n = 25). This study is in line with the ‘Evaluation’ phase 




9.1.2 Sampling and recruitment procedure 
Sample size justification: The selected sample size was based upon previous 
similar studies, for instance: pre-post intervention study (repeated measure), 
which evaluated a breast cancer prevention decision aid, recruited 17 higher-
risk women (O’Connor et al., 1999; Scariati et al., 2015); a preliminary 
evaluation of a decision aid to support people with mental illness to reach 
disclosure decisions enrolled 15 service users (Brohan et al., 2014a), a 
conservative approach was used and (n = 25) women were recruited to test 
the feasibility and potential effectiveness of the tool. The recruitment 
procedure is identical to the one reported in section 7.1. 
 
9.1.3 Materials 
The demographic questionnaires for women with SMI and health 
professionals are identical to the ones presented in section 7.1 (Appendices 
14 and 15). Sample participant information sheets, and consent forms are 
contained in Appendices 10-13. 
 
Instruments: As recommended by the Ottawa decision support framework 
(O’Connor et al., 1999), the validated Decisional Conflict Scale (O’Connor, 
1993 – updated 2010) and the Stage of Decision-Making scale (O’Connor, 
2000 – updated 2003) were selected to assess decisional conflict and an 
individual’s readiness to engage in decision-making respectively. These are 
contained in Appendices 22 and 23. These instruments are normally used 
with decision aids. Though the primary aim of this research is to develop and 
test an intervention that aims to surmount or reduce the impact of barriers to 
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cervical screening in women with SMI, these instruments were selected for 
this proof of concept study as the outcomes they measure are relevant to this 
research, namely whether the tool has any impact on participants’ decision-
making to attend screening.  
 
The Decisional Conflict Scale (DCS) (O’Connor, 1993 – updated 2010) exists 
in four versions. It consists of four or five subscales depending on the 
version:  
 
 Informed subscale (three items): Do you know which options are 
available to you, do you know the benefits of each option and do you 
know the risks and side effects of each option, 
 Values clarity subscale (two items): Are you clear about which 
benefits matter most to you and are you clear about which risks and 
side effects matter most to you, 
 Support (three items): Do you have enough support from others to 
make a choice, are you choosing without pressure from others and do 
you have enough advice to make a choice, 
 Uncertainty (two items): Are you clear about the best choice for you 
and do you feel sure about what to choose, 
 Effective decision (no items for this version).  
 
The DCS measures an individual’s personal perceptions of three factors of 




1. uncertainty in choosing options;  
2. modifiable factors contributing to uncertainty (such as feeling 
uninformed, being unclear about personal values and feeling 
unsupported in decision-making); and  
3. effective decision-making (other than for the ‘low literacy’ DCS) such 
as feeling the choice is informed, values-based, likely to be 
implemented and expressing satisfaction with the choice.  
 
The ‘low literacy’ version of the Decisional Conflict Scale (DCS-LL) that is 
recommended for individuals with limited reading or response skills was 
selected for this study to mitigate any cognitive impairment of participants. 
The scale has two components: Part A of the scale asks the participant 
which treatment/screening option they prefer: Option 1/2/3 or Unsure. Part B 
is composed of four subscales: Informed (three items), Values clarity (two 
items), Support (three items) and Uncertainty (two items). The response 
format is yes, no, unsure. The scoring and interpretation for part B is as 
follows: for each item [e.g. ‘Are you clear about the best choice for you?’], the 
participant responds with either ‘No’ (four points), ‘Unsure’ (two points) or 
‘Yes’ (zero points). The mean score of the items is determined for each 
subscale (feeling uninformed; feeling uncertain, having unclear values; 
feeling unsupported) and multiplied by 25. The mean score of all items is 
also determined and multiplied by 25 to create a ‘global’ score of decisional 
conflict. A summary score of zero suggests no decisional conflict or an 
overall good decision process; a score of 100 suggests extremely high 
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decisional conflict. Improvement is therefore indicated by a reduction in 
score.  
 
One published study – a cancer screening study with men eligible for 
prostate cancer screening – has investigated the psychometric properties of 
this version of the DCS (Linder et al., 2011). In this study, Cronbach’s alpha 
for the total scale was ≥ 0.83, which demonstrated adequate internal 
consistency (Nunnally, 1978).  
 
In terms of psychometric properties, The DCS-LL has been used (Henderson 
et al., 2013) and validated (Bunn and O’Connor, 1996) with people 
diagnosed with schizophrenia. The scale had adequate internal consistency 
(Cronbach’s alpha values ranging between 0.78 and 0.84) and significant 
discrimination (p < 0 to 0.037) between service users who expressed 
certainty and uncertainty regarding decisions to continue with psychiatric 
treatment (Bunn and O’Connor, 1996). 
 
The second scale used in this study is the Stage of Decision-Making; this 
scale (O’Connor, 2000 – updated 2003) measures (1) an individual’s 
readiness to engage in decision-making, (2) progress in making a choice, 
and (3) receptivity to considering or re-considering options. The scale 
consists of four statements indicating increasing levels of readiness (I have 
not yet thought about the options; I am considering the options; I am close to 
choosing one option; I have already made a choice). Participants indicate 
their agreement with one of the statements by ticking that option. The scale 
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should be presented to the participant pre- and post-intervention. It can be 
used to screen out participants who may not benefit from an intervention; it is 
an important covariate in determining who benefits most from a decision 
support intervention. In terms of the psychometric properties of the scale, no 
validity data are available; early stages (statements one and two) correspond 
to higher decisional conflict (i.e. less readiness to make the decision) and 
later stages are associated with reduced decisional conflict (O’Connor, 2000; 




Each participant was asked to fill in the demographic questionnaire and to 
complete the Decisional Conflict Scale and Stage of Decision Making 
(O’Connor 1993, 2000). Following this task, the participant engaged with 





Pre- and post-intervention, data from the Decisional Conflict Scale and Stage 
of Decision-Making Scale (O’Connor 1993, 2000) were analysed using SPSS 
(Statistical Package for Social Sciences, Version 24). Because scores were 
not normally distributed, a Wilcoxon signed-rank test, a non-parametric test, 
was used to compare women’s decision-making regarding cervical screening 
before and after using the tool. It is used to test the null hypothesis that the 
median of a distribution is equal to some value. The effect size (r) of the 
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change was also calculated, as this is more meaningful for smaller samples 




9.3.1 Impact of the tool on decision-making 
Forty women were approached by their clinician to take part in this 
evaluation study, of these, 15 women refused. Several women (n = 9) gave a 
reason for declining to take part: history of trauma: n = 2; bad cervical 
screening experience: n = 3; refuses to go for screening (no reason given): n 
= 3 and does not want to discuss cancer screening: n = 1. 
 
A sample of 25 women aged 19–57 who accessed the two community 
mental health teams agreed to participate in the study between June and 
September 2019. Most participants (n = 17) reported having attended 
cervical screening more than once in the past (though two had not been for 
over five years), two participants had been once but had declined further 
invitations and three participants had refused to attend any cervical 
screening.   
 
Three participants were aged 23 and 24 (eligible to take part in the study 
though not yet eligible for screening), though one had very recently received 
her invitation. The second disclosed she was unlikely to attend once she 
became eligible due to her history of trauma, while the third disclosed 
experiencing painful physical symptoms and for this reason was interested to 
take part in a cancer screening study to find out more about the test. Data 
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from these three women were included, as each had expressed an interest in 
taking part in the study and appeared to benefit from the information included 
in the tool. The demographic and health data were summarised using 
descriptive statistics such as standard deviations and means. A summary of 
the results from the demographic and clinical questionnaires is shown in 
Table 9.1 below. 
 
Table 9.1 Demographic characteristics of study participants (service users) (n 
= 25) 
 






Age, years: mean (SD) 42 (11.3) 
Ethnicity (grouped), n (%) 
White – all 
Black/Black British – all 













Depression and PTSD 









Had cervical screening n (%) 
More than once 
Once 
Never 






Last cervical screening n (%) 
In the last 5 years 










Table 9.2 Decisional Conflict Scale - Difficulty in making this choice [Part A]  
 
Which cervical screening option to you prefer?  Before using the tool 
 n           %  
After using the tool 
 n             %   
Option 1: I will attend my cervical screening 
appointment 
14         56 
 
21           84 
Option 2: I will not attend my cervical screening 
appointment 
5           20 3             12 
Option 3: Unsure 6           24 1              4 
 
Results from Part A indicated that the direction of change is towards having 
screening. There was a statistically significant reduction in decisional conflict 
regarding which cervical screening option participants preferred after using the 
tool (Z = -2.42, p = 0.016, r = -0.34). 
 
Table 9.3 Decisional Conflict Scale scores (median) pre- and post- use of the 
tool [Part B] 
 
Category Median (IQR34) 
before using the 
tool 
Median (IQR) 
after using the tool 
Statistica 




6 (34) 0 (50) Z = -1.34, p = 0.18, r = 
-0.19 
Informed subscale 15 (30) 3 (68) Z = -1.63, p = 0.102, r = 
-0.23 
Values clarity subscale 10 (28) 4 (46) Z = -1.34, p = 0.180, r = 
-0.19  
Supported subscale 11 (46) 4 (67) Z = -1.60, p = 0.109, r 
=-0.23  
 
a Wilcoxon Signed-Rank Test 
 
Decisional conflict scores (Table 9.3) improved (reduced) for all subscales 
post-use of the tool. The global and individual subscale decisional conflict 
scores were all below 25; scores below 25 are associated with making 
decisions (O’Connor, 1993 – updated 2010). A statistically significant overall 
 
34 IQR, interquartile range. 
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reduction in decisional conflict after using the tool (Z = -2.81, p = 0.005, r = -
0.39) was also indicated. The direction of change is positive for each of the 
decisional conflict subscales: feeling uncertain (Z = -1.34, p = 0.18, r = -
0.19), feeling uninformed (Z = -1.63, p = 0.102, r = -0.23), feeling unclear 
about values (Z = -1.34, p = 0.18, r = -0.19) and feeling unsupported (Z = -
1.60, p = 0.109, r =-0.23); however, these reductions are not statistically 
significant.  
 
Table 9.4 Stage of Decision-Making. 
 
How far along are you with your [cervical screening] 
decision? 
Pre-intervention                            Post-intervention 
n                    % n                 % 
a. I have not yet thought about the options 2                     8 0                 0 
b. I am considering the options 1                     4 4                 16 
c. I am close to choosing one option 1                     4 1                  4 
d. I have already made a choice 21                   84 20               80 
e. Total 25                  100 25              100 
 
Results from the Stage of Decision-Making scale indicated that some women 
had begun to think about their options and/or consider another choice. The 
direction of change of participants’ overall stage of decision-making on 
screening attendance after using the tool was positive, though changes were 
not statistically significant (Z = -0.17, p = 0.86, r = -0.03).  
 
9.4 Preliminary analysis of the broader impact of the tool on participants 
 
In order to obtain a broad understanding of the impact of the tool on women’s 
attitudes towards attending screening, the results of all empirical data were 
taken into account. The qualitative data collected in studies three and four 
were used to support the interpretation of the quantitative data. As reported 
in Chapter Five (see section 5.2.1), some of the constructs of the Theory of 
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Planned Behaviour (TPB) were used to categorise the different ways the tool 
may have impacted participants. The first stage of analysis was therefore 
deductive, as this approach involves beginning with a theory, in this case the 
Theory of Planned Behaviour; the final level of analysis was therefore 
interpretive. The analysis was conducted using the quantitative data from this 
evaluation (n = 25) as well as qualitative data from service user groups (n = 
4) and service user data (n = 18) reported in Chapters Seven and Eight.  
 
In order to maximise the trustworthiness of the data, a reflective stance was 
taken to consider the ways in which the candidate may have influenced what 
is communicated, e.g. participants may have assumed that I was in favour of 
cervical screening due to my research interest, which may have led some to 
state that they were attending screening or that they had no difficulty 
attending in order to avoid a discussion on why they were declining their 
invitation. Field notes were also considered. The candidate had no prior 
involvement with either NHS Trust before commencing the research, so 
there was no conflict of interest in terms of her role as a researcher to collect 
the data. A potential risk of bias was that the candidate both developed and 
collected feedback on the tool. To mitigate this risk, the multidisciplinary 
supervisory team helped with the analysis.  
 
Four preliminary categories of impact the tool had on participants were 
identified from the data, all supported by both qualitative and quantitative 
data. Each one is presented below; some service user feedback appears in 
more than one category, as each one is not mutually exclusive. 
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1) Category one: Impact of the tool on participants’ knowledge of cervical 
screening and cervical cancer symptoms 
 
Two subscales from the Decisional Conflict Scale related to knowledge 
around screening (the Informed and Supported subscales) and for both, 
scores had dropped below 25 after using the tool. Scores below 25 are 
associated with implementing decisions (O’Connor, 1993 – updated 2010).  
These scores are concordant with the qualitative feedback, in that they both 
indicated improvement in knowledge of cervical screening and cancer 
symptoms. 
 
Several women reported that the tool was ‘informative’ (service users #17 
and #9). Some participants reported their knowledge of cervical screening 
increased after having used the tool:  
 
‘Thought it was like a swab? [The candidate asked whether the tool has 
clarified what cervical screening entails] yeah it’s clarified it’ (service user 
#7), 
 
‘I have enough advice to make a choice, but for my daughter [26 years old], I 
feel there isn’t enough information out there, so the booklet is good for her’ 
(service user #14) and, 
 
‘That’s good [referring to this sentence in the tool: ‘having an abnormal 
result does not mean you have cancer’], because I thought it did, you know I 
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was in such a panic by the time my appointment came through, I was a 
nervous wreck, coz I thought I had cancer’ (service user #6). 
 
Some participants found it helpful to know that they can request certain 
adjustments:  
 
[after I explained what a chaperone is] ‘I would use a chaperone’ (service 
user #7), 
‘I didn’t know I could ask for a smaller speculum. I have an inverted uterus so 
it hurts’ (service user #13). 
 
Some women commented that although they knew what cervical screening 
entailed, they felt the tool was useful as it reminded them of the benefits of 
cervical screening:  
 
‘I remember now that it’s important to go, even though I really don’t like it’ 
(service user #2).  
 
Some participants found the ‘Looking after your health’ section of the tool, 
which describes possible symptoms of cervical cancer, useful: 
‘this page [Looking after your health section] has clarified what the symptoms 
of cervical cancer could be. I didn’t know that [these symptoms] could be 




Other participants commented on the usefulness of the ‘Getting Support’ 
section, which includes the contact details of several organisations: 
 
‘I’m very concerned about my daughter [who displayed a lot of the symptoms 
described on the page]. Didn’t know Jo’s Trust, will contact them. Think it’s 
great to have the charity contact details in the leaflet’ (service user #12) and 
[on including the cervical screening clinic for survivors of sexual violence – 
the My Body Back project – in the ‘Getting Support’ section]: ‘ah that’s useful’ 
(service user #10). 
 
2) Category two: Impact of the tool on participants’ attitudes towards cervical 
screening  
 
Changes in three subscales (Values clarity, Supported and Uncertainty) of 
the Decisional Conflict Scale indicated more positive attitudes towards 
screening following interaction with the tool. From examination of the 
qualitative data, it was possible to determine that the tool may improve the 
cervical screening experience of some women who either already attend or 
are unsure about attending. It is also evident that some women with SMI may 
be at increased risk of having a negative screening experience compared to 
women in the general population. Research has shown that such a screening 
experience may reduce a woman’s inclination to attend in the future (Clifton 
et al., 2016). Though most participants reported attending cervical screening 
(and wanted to continue attending), it became apparent during interviews 
that some women feared the appointment (e.g. that it might trigger 
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distressing memories and/or worried about the nurse’s reaction if they 
responded in an unexpected way during the test). The tool might therefore 
be helpful to women who have had a negative screening experience in 
helping to address their anxiety. Some women might have felt judged by the 
practice nurse or experienced significant pain during the test. One participant 
disclosed a bad experience with the nurse, which had led the participant to 
decline cervical screening thereafter. The candidate asked whether the tool 
had changed her decision:  
 
‘Maybe, something that I will probably think slightly differently, this whole 
leaflet, with me I already feel a little differently about it [going for screening]’ 
(service user #9). 
 
The tool might also improve the experience of women who find it hard to 
overcome feelings of shame, embarrassment or anxiety. Several participants 
alluded to how the tool might support them in that way:  
 
[on the tick box pages] ‘it’s brilliant, because then you don’t have to explain 
that you have a mental health condition, so if you behave a bit strangely, 
they’re understanding, rather than brush you off or treat you like an idiot’ 
(service user #1), 
 
‘I would find the tick box page useful’ [to disclose her history of child sexual 




‘Waiting, and waiting [in GP surgery waiting room], I start shaking, I could 
easily get panic attacks (...) Definitely would be easier for me [to go] if I don’t 
have to spend time in waiting rooms, if that could be as it says here first 
appointment, that would help’ (service user #9). 
 
3) Category three: Impact of the tool on participants’ intended behaviour   
 
Results from Part A of the Decisional Conflict Scale [‘Which cervical 
screening option do you prefer?’] showed that for some participants, the tool 
had a positive impact on their intention to attend screening. All participants 
who, before the use of the tool, were unsure whether to attend cervical 
screening (n = 6) had decided to attend after using the tool. Of those (n = 5) 
who refused to attend before using the tool, three still refused after viewing 
the tool, one decided she would attend, and one was now unsure. This 
suggests that it may be harder to change intention among women who are 
clear about refusing to attend screening compared with those who are 
unsure.  
 
For some women who already attend, while their decision to go for screening 
had not changed, the tool may improve their screening experience. The tool 
may be beneficial to them in various ways, for instance by supporting them to 
plan their appointment. As reported in Chapter Five (section 5.2.1), an 
implementation intention would involve a woman outlining the various steps 
required to perform the cervical screening behaviour. The ‘Booking your 
appointment’, ‘Before your appointment’ and ‘Getting support’ pages were 
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considered useful by some women to book and attend their appointment 
(e.g. tips on what to wear so as not to feel so exposed, whom or what they 
could bring for support, who they could contact before/after if they needed to 
discuss their anxiety):  
 
‘If I had that leaflet I would share it with another person like a friend, I would 
say ‘oh look at this it’s got a bit of information and that might help you’, 
obviously I would share it if someone was coming with me to the 
appointment, I would show it to them to give them an insight (…) [women] 
can have a look at the leaflet, so it prepares them, it would give them more 
faith to book this test’ (service user #2) and, 
 
‘I like the sentence ‘treat yourself to something nice’, I think that might be 
good because if you’ve had an experience that you’re not happy with and 
then you treat yourself, it will help you to forget your bad experience (...) 
maybe treat myself to some lunch somewhere or something’ (service user 
#4). 
 
Lastly, the ‘tick box pages’ section, which can act as a disclosure aid, may 
improve women’s intention to attend screening: 
 
‘[On using the tick box page during the appointment]: I would consider going 




[following disclosure of trauma]: ‘If I had the leaflet, I would make an 
appointment straight away. I love the tick box page, it gives you a voice, it 
makes you feel that your fears are legitimate. The test mimics what 
happened to me, it’s something that is there in your body that you don’t want. 
I cry after my appointment’ (service user #11). 
 
4) Category four: When the tool may not help  
 
It was unclear whether the tool enabled some women to make a more 
informed decision. Results from the Stage of Decision-Making scale 
indicated that for the majority of participants (n = 21 pre- and n = 20 post-
intervention), the tool did not affect, either way, their intended behaviour 
regarding cervical screening attendance. Some women reported attending 
their appointment with no issues. Exploring participants’ experience of 
screening (including any difficulty with attending) was not an aim for any of 
the studies; however, during the interviews several participants (n = 3) 
explained that they already understood the benefits of screening and did not 
identify any barriers to going. They indicated that they attended their 
appointment on a regular basis to avoid putting their health at risk:  
‘I do not have shame about my body, I go for my health. I wouldn’t use the 
tick box page’ (service user #8) and, 
 
‘It’s a very straightforward appointment, I make my appointment and go’ 




Other women, however, reported that while the tool was informative, there 
was nothing that could make them reverse their decision to decline 
screening:  
 
‘I wouldn’t use the leaflet because I don’t want to go for screening (...) there 
is nothing that would make me go’ (…) the leaflet hasn’t changed my mind 
about going for screening’ (service user #4) and, 
 
‘Nothing could make me change my mind’ (service user #13). 
 
Some women did not give a reason why this decision was taken. Several 
participants shared their experience of fluctuating mental illness and 
disclosed that when their mental health symptoms became worse (for 
instance, making it hard to leave the house or experiencing delusions), no 
amount of support could make them attend. Although, in principle, they 
agreed that it was important to attend cervical screening, they were unwilling 
to book an appointment during that time and would often forget to do so 
when they felt better again. One woman explained how being ‘bombarded’ 
(service user #3) with reminder letters during this time was unhelpful. It 
appeared that a positive screening experience in the past could be 
overshadowed by the current presentation of their mental illness:  
 
‘The nurse was lovely [during her previous cervical screen] but I don’t feel 




‘Last time I had cervical test I had unpleasant experience and then test 
hasn’t been finished and actually after that I just couldn’t bring myself to do it 
again, that’s one of the reasons, the other reason, it is my mental health, I 
find it difficult to go’ (service user #9). 
 
Some feedback suggests that these women’s refusal to attend is due to their 
belief that they will be diagnosed with cancer:  
 
‘The nurse will find cancer’ (service user #6) and, 
 
‘Fear of the unknown can also be a factor which stops women from going: if I 
do go then it’s more likely that I have it [cancer], so people think if I don’t go 
and I’m alright now, maybe I shouldn’t go because if I do go then something 
might happen’ (service user #4). 
 
For women (n = 10) who either reported declining cervical screening or had 
not been in over five years, the ‘anticipated regret’ (Rosenbaum et al., 2014) 
of having missed/delayed a cancer diagnosis due to non-attendance seemed 
to have little or no influence on their decision. The section on the benefits of 
attendance and the risks of non-attendance (tool pages 4–5) did not appear 
to alter their decision. 
 
Some women reported that they did not require additional support during 





‘Personally I don’t read leaflets even if they are handed to me (…) I find it 
easier to have a face to face conversation (…) [on the tick box pages:] It 
would probably make me more anxious than having to say it, and I would 
assume my nurse would have that information anyway’ (service user #3), 
‘I wouldn’t call a mental health professional or a charity [if the appointment 
made her feel anxious], I’m just glad when it’s over and done with’ (service 
user #5), 
 
‘It [the tick box pages] would be useful but me personally, I am a mental 
health person but I am very private person, I don’t like people to know that I 




9.5.1 Summary of key findings 
The change between pre- and post-utilisation of the tool in decisional conflict 
was overall in a positive direction. The change between pre- and post-
utilisation of the tool in stage of decision-making was in a positive direction 
(16% of participants were considering the options in comparison to 4% 
before using the tool). The tool appears to have helped some women make 
an informed decision to attend, while for others, the tool made them reflect 
on their decision to refuse screening, also making their choice more 
informed. For several women, there was no movement in their decision to 
decline screening; some may need a separate intervention to help them 
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attend. For the reasons stated above, the preliminary data that were 
gathered demonstrate that the proof of concept of the tool was achieved.  
Looking at the various ways the tool could impact upon women’s decision-
making exemplified that this informed-choice tool can positively influence a 
woman’s intention or attitude towards cervical screening.  
 
The tool appeared to address some of the barriers identified in each of the 
three categories where the tool had an impact (such as how to disclose a 
history of trauma, what support is available during the appointment or feeling 
anxious in waiting rooms). The tool might be beneficial in terms of patient 
engagement and satisfaction with care, for example by starting a dialogue 
between the patient and the smear taker. This study has illustrated the 
complexity of the cervical screening decision-making process for some 
women with SMI, which goes beyond the dichotomy of whether to attend or 
decline the invitation. There are several ways to decrease decisional conflict, 
including becoming informed about choices for screening, feeling supported 
in the screening decision, knowing personal priorities around the decision 
and feeling certain about the decision. The positive direction of change from 
the subscales of the Decisional Conflict Scale and the relevant qualitative 
data showed that the tool addressed every aspect of the decision-making 
process. 
  
A determinant of inconsistency between a person’s attitude and the uptake of 
the test may be barriers, objective or perceived, to undergoing a test such as 
cervical screening (Michie et al., 2004). As discussed in Chapter Five (see 
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section 5.1), performing any of the steps related to cervical screening uptake 
can prove prohibitive to women with SMI. Previous studies have found that if 
an individual has, in the past, engaged in a health behaviour, they are more 
likely to continue performing that behaviour in the future (Norman and 
Conner, 1996; Ronis et al., 1989; Sutton, 1994). In addition, research has 
shown that having had a positive screening experience increases the 
intention of attending in the future (Roncancio et al., 2013). For some women 
with SMI, this decision-making process may be more complex. If the 
screening invitation is sent when the woman is unwell, she may refuse to 
attend even if she had a positive screening experience in the past. Further 
research is needed to address the following barriers to screening for women 
with SMI identified in the Clifton et al. (2016) study: ‘My mental health 
symptoms reduce motivation for self-care’ and ‘I find it difficult leaving the 
house due to mental health problems’. The tool may not be appropriate for 
this group as they may not be in a position to make an informed decision; 
they may need more support than a leaflet (see Chapter Ten, section 10.5).  
 
Owing to the infrequent and sensitive nature of the test, women may start a 
new decision-making process every time about whether to be screened. An 
individual’s attitude towards cervical screening uptake is therefore not ‘static’ 
and is likely to be influenced by several factors (Clifton et al., 2016). The tool 
may support some ‘lapsed attenders’ (i.e. screening categories ‘late’ and 
‘very late’) to build implementation intentions. While all the participants in the 
study knew what cervical screening entailed, some were unaware of the 
adjustments they can request (e.g. asking for a smaller speculum or a 
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chaperone) or where they can access support. The tool seemed to have 
increased their knowledge in this regard. Qualitative data illustrated how the 
tool may provide some reassurance to women who usually attend their 
appointment but find it difficult to disclose any issue(s) they are struggling 
with (e.g. how to disclose that they are survivors of sexual trauma). These 
difficulties may put some women at higher risk of a negative screening 
experience; the tool may reduce the possibility of such an experience 
occurring and improve their attitude to screening.  
 
Lastly, fear of cervical screening and/or cervical cancer, indicated by 
avoiding or not attending, seemed to have played a role in some women’s 
decision-making process. It is unclear to what extent the information 
provided in the tool was able to reduce their fear, thereby allowing them to 
make a more informed choice. Further research is therefore warranted to find 
ways to overcome this barrier, for example by supporting them to reduce 
their anxiety, either through counselling or other intervention, such as urine 
sampling (see Chapter Ten, section 10.5). 
 
9.5.2 Strengths and limitations 
To our knowledge, this is the first study to evaluate an intervention’s impact 
on cervical screening decision-making for women with SMI (Barley et al., 
2016). Initial evidence has been gathered on the complexity of the decision-
making process for some women living with SMI. The sample size was not 
powered to detect a statistically significant difference, as this study was 
designed to assess proof of concept only, so findings should be interpreted 
with caution. Nonetheless, though the findings from this study cannot be 
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generalised due to the small size of this convenience sample, the cohort 
was diverse in terms of demographics, type of site (both rural and inner city) 
and screening participation, so findings are likely to be applicable to a wider 
population. This evaluation study has highlighted the potential impact that 
the various barriers to cervical screening can have on women’s choice 
whether to attend screening, and how the tool may be able to help.  
 
In terms of the proof of concept, the Decisional Conflict Scale and Stage of 
Decision-Making Scale (O’Connor, 1993, 2000) were relevant instruments for 
measuring the immediate post-intervention outcomes. The quantitative study 
captured changes in participants’ decision-making, but the data were unable 
to illustrate the full impact that the tool may have had on participants. 
However, this limitation of the quantitative data was offset by including the 
interview data in the analysis. The qualitative data were able to capture the 
impact of tool on some participants, such as how it may improve their future 
experience of screening, or how it has improved their awareness of cervical 
cancer symptoms. For instance, though some women maintained their 
decision to attend screening before and after using the tool, they disclosed 
feeling more confident about attending their appointment, knowing what 
adjustments they can request. The qualitative data were therefore useful to 
support the interpretation of the quantitative data and demonstrates that the 
tool supported informed decision making. 
 
A limitation of this study is the risk of social desirability bias, which refers to 
the tendency of research subjects to over-report socially desirable attitudes 
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and behaviours instead of choosing responses that reflect their true feelings 
(Paulhus, 2002). This effect may have led to an over-reporting of past and/or 
future intentions regarding cervical screening attendance among participants, 
possibly to avoid discussing why they refuse to attend cervical screening. 
Lastly, it was not possible to verify whether those participants who were 
overdue for cervical screening and disclosed an intention to book an 
appointment did so following use of the tool; this should be explored in future 
work.  
 
Chapter summary  
 
This chapter has reported the results of a preliminary evaluation of the tool, 
which showed a positive direction of change in relation to feeling informed 
about their decision. The data analysis of the impact of the tool on study 
participants, using some of the TPB constructs, identified four categories of 
impact. The tool may have an impact on knowledge and attitudes to 
screening, as well as improving the experience of women who attend their 
appointment but who may be at risk of a bad screening experience. Further 
research is warranted to develop interventions that seek to remove some of 
the barriers to screening which could not be addressed by this tool. The next 
and final chapter highlights these areas of future investigation and the 
contribution of this research to research, policy and practice. 
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Chapter Ten – Discussion and conclusions, future research 
and dissemination 
 
This final chapter summarises the main findings from the research. A 
reflection on its unique contribution to knowledge is presented. The 
methodological strengths and limitations of developing the tool are also 
provided here. Lastly, the tool’s implications for clinical practice and possible 
future research directions are considered. 
 
10.1 Summary of the research findings 
 
This research provides specific information on how limited resources could 
be utilised to improve health outcomes using a population-specific informed-
choice tool. The tool was developed following the identification of a 
knowledge gap which was highlighted by previous research (Barley et al., 
2016; Clifton et al., 2016), that is, the lack of any intervention to support 
women with SMI to attend cervical screening in the face of barriers specific 
to this group. All three objectives that were set out for this PhD research 
have been achieved. A theory-informed tool developed in collaboration with 
key stakeholders that meets established criteria for readability relevant to the 
target audience has been produced (objective one). The development of the 
tool was guided by the MRC framework (Craig et al., 2013) and the Theory of 
Planned Behaviour (Azjen, 1991), and was underpinned by the Theoretical 
Domains Framework (Cane et al., 2012); the tool’s components were 
developed using behaviour change techniques (Michie et al., 2015). This 
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fulfils objective two, namely that the informed-choice tool should be 
theoretically underpinned. Lastly, the acceptability and usability of the tool 
was tested with key stakeholders (objective three). Stakeholder involvement 
ensured that the voices of women with SMI were heard, allowing the tool to 
be developed in line with their preferences, where this did not contradict NHS 
cervical screening guidelines (NHS, n.d.; PHE Screening, 2019). 
  
PPI participants (including mental health service users, health professionals, 
as well as members of the key informants group: policy makers, clinicians, 
clinical academics, service user groups, charity workers) were consulted at 
every stage of this research (see Figure 6.1). PPI participation ensured the 
informed-choice tool was relevant and addressed issues of importance to the 
target group (Ashcroft et al., 2016). PPI feedback was also sought on the 
dissemination of the tool; this highlighted the importance of it being available 
in non-clinical settings (e.g. Recovery Colleges), in addition to primary and 
secondary NHS health care. Recovery colleges offer educational courses 
that focus on mental health and recovery; courses are ‘co-produced’ and ‘co 
delivered’, whereby service users, carers and staff collaborate to develop 
courses. A cancer-screening module within a Recovery College curriculum is 
currently in the early stages of development (see section 10.4.1).  
 
Results from the preliminary data analysis show that the tool may impact 
women in several ways. While the tool may not impact women’s decision-
making if they already attend screening, some participants reported 
improved knowledge regarding cervical screening and cervical cancer 
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symptoms (Category one: Impact of the tool on participants’ knowledge of 
cervical screening and cervical cancer symptoms). Several participants 
became aware of the kinds of adjustments they can request (such as asking 
for a chaperone or requesting a smaller speculum), which in turn may 
improve their experience. In addition, regardless of whether women decided 
to attend screening, the list of symptoms associated with cervical cancer 
displayed in the tool was also deemed beneficial by some participants, some 
of whom appeared to be unaware of them. The tool may thus have the 
added benefit of acting as a health promotion tool, as it encourages women 
to speak to their health professional if any of the symptoms appear. 
Becoming aware of which adjustments they can request and what the 
symptoms of cervical cancer are two examples of how the tool increased 
participants’ informed choice about screening. 
 
Some participants reported a positive change in attitudes regarding 
screening (category two: Impact of the tool on participants’ attitudes towards 
cervical screening). These findings highlight the need for an intervention to 
support women who find it hard to disclose a traumatic event or previous 
negative screening experience. By sharing their stories, participants 
highlighted the specific issues needing to be addressed within the tool to 
increase the likelihood of impact (e.g. how to reduce the risk of re-
traumatisation). Several women disclosed such experiences, which were also 
raised as the reasons for non-participation by other women. The tool – in 
particular the tick-box pages – has the potential to reduce the burden on 
women to disclose a painful experience, such as a sexual assault, or relate 
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some of the symptoms of their mental illness, such as hearing voices or 
scarring from self-harm. Support with disclosure may in turn reduce the risk 
of having a negative screening experience. Though the findings are from a 
relatively small sample, and so should be interpreted with caution, given the 
significant prevalence of sexual violence in this group, this tool may also be 
useful for some women without SMI who have experienced trauma.  
 
The results also showed that while some women had already decided that 
they would attend screening, the tool may improve their screening 
experience (Category three: Impact of the tool on participants’ intended 
behaviour). The tool may assist them with planning their appointment – to 
build an implementation intention – by listing tips and suggestions to help 
them feel more comfortable and supported before, during and after their 
appointment.  
 
It was unclear whether the tool enabled some women to make a more 
informed decision (category four). Some had already decided to attend (they 
disclosed having no difficulty with screening), while others had maintained 
their decision to decline screening, due to prior adverse experiences or their 
beliefs of what screening entails; this second group may require further 
support (see section 10.5). For women in this category, although the 
quantitative data showed no change in their decision pre- and post-use of the 
tool, the tool may have solidified their informed decision to either refuse or 
attend cervical screening. Further research would be needed to explore 
whether the tool had any impact on this group (see section 10.5). Lastly, 
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some women reported that they did not use leaflets; therefore, another 
format may help (see section 10.5). 
 
10.2 Reflections on conducting this research 
  
Cervical screening uptake is a personal choice. During the data collection 
process, although I highlighted the benefits of cervical screening as well as 
going for a check-up if worrying symptoms appeared, a conscious effort was 
made to keep an open mind so as not to influence participants’ decision-
making when the option of non-uptake was discussed during interviews. Some 
women disclosed gynaecological issues during the three data collection 
phases, such as having very painful periods, irregular bleeding or pain after 
sex. In these instances, I encouraged the service user to make an 
appointment with her GP, or to discuss it with her trusted mental health 
professional for assistance on seeking medical help.  
 
Upon reflection, I made three assumptions at the outset of the interviews. The 
first was that women with SMI may need additional support during and/or after 
the appointment. The feedback received was that often women would benefit 
from support before their appointment. Participants explained that they often 
felt anxious in the days leading up to or the night before the appointment and 
would appreciate talking to someone who would motivate or reassure them, 
like a friend or their mental health worker. The second assumption was that 
women who have experienced sexual trauma would be likely to reject or delay 
cervical screening uptake. While this was raised by some participants and 
given as a reason why others refused to take part in an interview, some of the 
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women who disclosed a history of trauma chose to attend screening, but often 
had a negative experience as it caused them distress and anxiety. Becoming 
aware of their resilience to attend a health check that can cause them 
significant psychological harm, coupled sometimes with disregard for their own 
wellbeing was a very humbling experience. Thirdly, I assumed that mentioning 
the word cancer (or the risk of cancer) in the tool might have a negative effect 
on their decision to attend screening. This worry was also raised by several 
members of the key informants group and interviewed health professionals 
(see Chapter Seven, section 7.3.2). Though the sample does not allow us to 
generalise whether this would be the case for most women, this concern was 
not raised by service users; it may reflect the paternalistic or ‘overprotective’ 
behaviour of some health professionals towards their patients (Marwaha et al., 
2009; Slade, 2009). This research has highlighted the importance of giving 
these women a voice. 
 
Lastly, collaborating with a variety of different stakeholders from clinical, 
policy and academic backgrounds, each one with a different agenda, posed 
both rewards and, at times, challenges. Producing an informed-choice tool 
that is being used in clinical settings (see Chapter Ten, section 10.4.1) has 
been a hugely gratifying experience. While the cancer charity supported this 
project’s concept of developing a tool for women with experience of mental 
illness as part of an academic exercise, there were at times differing views 
(see Chapter Seven, section 7.3.2), such as the extent to which the tool 
should explicitly target women with mental illness, or which logo should 
appear on the front cover. In addition, the charity’s agenda to launch this tool 
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(as soon as possible) was at odds with the PhD timeline, which required 
developing the tool with academic rigour. This research has increased my 
skills to collaborate and negotiate with stakeholders with differing interests.  
 
10.3 Limitations of the research 
 
The research has several limitations, which are listed below.  
 
First, the tool may not be applicable to all women with SMI. Certain 
populations remained inaccessible during the development of the tool, such 
as service users on forensic and inpatient wards, or homeless people who do 
not access primary care, so the leaflet may not be acceptable or usable to 
them. In addition, the literature review of barriers and enablers identified no 
studies from low and middle-income countries. It is possible that this may 
have led to certain barriers being overlooked, though this appears unlikely, 
as the literature review of the barriers to screening was inclusive of any 
health setting. Furthermore, some study participants had spent time on 
inpatient wards, and health professionals who took part in this research and 
members of the key informants group work in multiple settings, so their 
perspectives may have partly offset this limitation. Second, some of the 
systemic barriers to accessing cervical screening pertain to the healthcare 
system, which this tool could not address. 
 
With regards to the intervention, developing a paper colour leaflet has its 
limitations. Though the tool can be read and downloaded free of charge and 
is available on several websites and NHS portals, printing costs can be a 
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barrier to its dissemination and visibility. In addition, some people do not read 
leaflets. The content is available online and could easily be adapted to 
another format. 
 
Most theories applied to public health interventions tend to emphasise health 
as a matter of individual choice and capability and, by implication, a personal 
responsibility (Davis et al., 2015; Holman et al., 2018). Health behaviour 
interventions have sometimes been criticised for side-lining the issues of 
context and social factors (Davis et al., 2015). While use of the TPB is 
widespread, one of its limitations is the assumption that individuals 
systematically use the information available to them to make rational 
decisions about how to behave (de Vries and van der Pligt, 1998; Sandberg 
and Conner, 2008). Cancer screening is a complex behaviour, which entails 
personal, social and environmental factors, yet the TPB fails to acknowledge 
the influence of affective processes (Conner and Armitage, 1998). The TPB 
does not reflect the extent to which the decision to attend cervical screening 
is influenced by non-rational factors, such as values, morals and other 
reasons unrelated to self-interest (Armitage and Conner, 2001; Roncancio et 
al., 2013).  
 
This research builds on previous studies, which have highlighted that 
emotional outcomes are taken into consideration during one’s decision-
making process (Michie et al., 2004; van der Pligt et al., 1998). Affective 
processes are particularly relevant for this population, who have been 
estimated to have a lifetime incidence of trauma and abuse of 69% 
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(Anderson et al., 2016). Last, while there has been interest in anticipated 
regret in recent years (Rosenbaum et al., 2014), none of the leading theories 
of health behaviour, including the TPB, yet incorporate this important 
construct (Brewer et al., 2016). 
 
The TDF is widely considered to be the most comprehensive framework for 
designing implementation interventions, as it provides a broader coverage of 
potential change pathways than any single theory (French et al., 2012). It 
provided a number of benefits to the development of the tool, as it 
highlighted the relevant domains that can either hinder or enhance the 
screening behaviour for this group. The behaviour change techniques were 
selected in accordance with the relevant TDF domains, thus enabling the tool 
to be theoretically underpinned. However, several limitations have been 
mentioned (Francis et al., 2012). In the context of interview studies when the 
TDF is used as a coding framework, inter-coder agreement can be low; this 
may be due to the difficulty within some research teams to clarify the 
boundaries between domains (Francis et al., 2009, 2012). The second 
limitation relates to the fact that interview-collected data may reflect what 
participants perceive to be influencing their behaviours, rather than ‘actual’ 
causes (Weiner, 1985). Third, an interview topic guide based on the TDF 
may be considered too constricting, which may cause participants to respond 
to questions on the topic in ways that fit into the framework, thereby missing 
valuable nuances (Francis et al., 2012). However, a study on the barriers 
and enablers to hand hygiene, which compared results when methods were 
based on the TDF versus atheoretical methods, concluded that using a 
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theoretical framework may elicit barriers that may not ordinarily be identified, 
but which can have an important impact on behaviour (Dyson et al., 2011). 
Lastly, critics of the TDF have reported that the full range of meaning of the 
domains may not be evident to researchers without training or experience in 
behavioural sciences, so the TDF may be poorly or superficially applied; 
thus, including a health psychologist within the research team is advised 
(Francis et al., 2012). A health psychologist and a chartered psychologist 
(who is a full member of the UK Division of Health Psychology) were 
supervisors to the candidate to ensure the TDF was correctly utilised in the 
context of this research.  
 
10.4 Implications for practice 
 
The principal implication for practice is that the tool may help people make 
an informed choice whether to attend cervical screening. Since cervical 
screening is beneficial and the tool addresses barriers to attendance, the tool 
may also translate into more women attending, thus saving lives and 
reducing the burden of needing cancer treatment.  
 
This research has other specific implications for practice at different points of 
the cervical screening journey. Prior to the test appointment, the tool may 
impact on the way in which clinicians discuss screening uptake with their 
patients, for example it might facilitate a discussion of why the patient is 
struggling to attend. The tool may also act as a reminder/trigger to the health 
professional to discuss screening during a consultation. During the cervical 
screening appointment, if the patient shares the ‘tick box pages’ with the 
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smear taker, this may have an impact on the way staff view screening 
through the lens of someone who has mental illness and/or had a traumatic 
experience. Having a better understanding of a patient’s set of 
circumstances might in turn modify their behaviour towards other patients. 
The tool might have an impact on how patients and smear takers interact 
during the screening appointment, for example any words to avoid using or 
asking for a narrower speculum. Following the appointment, patients may 
feel more comfortable discussing their screening appointment with a member 
of their mental health support team. Service users may also feel more 
confident to ask their trusted mental health professional to accompany them 
to the appointment. These implications for practice require further 
investigation (see section 10.5). 
 
10.4.1 Dissemination of the tool and outreach 
Considerable effort has been made to disseminate the tool; uptake has been 
achieved by so many services and across different settings, indicating its 
perceived value by health professionals. In April 2019, funding was received 
from the University of Surrey to develop a webpage on this project where the 
tool could be hosted. In addition to details about this research, information 
was collated on other resources and specialist clinics throughout the UK, 
which aim to support people who find it hard to go for screening. The weblink 






The leaflet is available on SystmOne, a clinical computer system currently 
used in GP practices, community services, prisons, hospitals, social care and 
mental health. It is also available on Jo’s Cervical Cancer Trust36 website, 
NHS Trust physical health portals and some local EMIS (Egton Medical 
Information Systems) Health37 portals, NHS websites such as the Northern 
Cancer Alliance38 or third sector organisations such as HealthWatch 
Ealing.39 The leaflet is being downloaded by CCGs and secondary care 
Trusts and distributed in community mental health teams, trauma and 
forensic services, primary care and sexual health clinics, as well as specialist 
clinics and charities working with women who have experience of mental 
illness and/or trauma. A print-run of the tool was funded by the West London 
Trust (n = 500) and the University of West London (n = 500) following a 
press release.40 Distribution is currently under way in specialist cervical 
screening clinics and community mental health teams, following a temporary 
pause due to the COVID-19 pandemic in spring 2020. Imperial College 
Health Partners have written a blog about this research, which is hosted on 
their website.41 In addition, the tool continues to be downloaded by 




37 EMIS Health supplies electronic patient record systems and software used in primary care, 










The tool is being used as part of two separate training packages on cancer 
screening in two mental health Trusts and as part of a module that is 
currently being developed on cancer screening for a Recovery College. 
Funding was received from the West London NHS Trust, the University of 
West London and Dorset Healthcare University NHS Foundation Trust to 
develop a 90-second animated video, created by Sci Ani (Science 
Animated),42 which illustrates the key points of the tool. The video is 
available on Jo’s Cervical Cancer Trust,43 YouTube44 and the project website 
hosted by the University of Surrey.45 It was included alongside the tool in the 
December 2019 Newsletter of the Faculty for Homeless and Inclusion 
Health.46 
 
Oral and poster presentations of various stages of this research were given 
at the Annual Division of Health Psychology Conference in 2018, the Annual 
Public Health Conference in 2019, the Behavioural Science and Public 
Health Network Annual Conferences in 2018 and 2019 (poster was runner-
up in 201847) and the Annual Doctoral Conference at the University of West 
London every year from 2017–2020 (first prize awarded for the oral 
presentation in May 2019). The candidate was invited to present her 
research findings at the West London Trust Research Day (June 2019) and 
Physical Healthcare Steering Group Meeting (January 2020), UCL (July 










of a presentation is contained in Appendix 24. An article48 entitled ‘Cervical 
cancer screening resources aimed at addressing mental health disparities’ 
appeared in the Journal of Mental Health Practice (Jones-Berry, 2020) to 
highlight the tool and animated video and showcase its benefits and use in 
an NHS trauma service. The journal is distributed to all mental health nurses 
who are affiliated with the Royal College of Nursing. 
 
Requests have been made to adapt the tool to different settings and 
populations. Funding permitting, the tool may be used as a prototype to 
develop another tool for women with anxiety in collaboration with Public 
Health England. A Clinical Commissioning Group has enquired about 
adapting the tool to their local services. Funding to translate the tool into 
Arabic and/or Somali is being sought by an East London council. The tool 
has had international reach. Lastly, following a presentation at the French 
National Cancer Institute49 in October 2019, the national public health 
agency is currently seeking funds to translate and adapt the tool to its 
healthcare system for use in clinical settings.  
 
10.5 Future research directions 
 
As reported above, the tool is being disseminated in settings accessed by 
women who may not have a mental illness diagnosis, such as homeless 
populations and specialist cervical screening clinics for women who have 







practices and sexual health clinics for the public. There is a need to evaluate 
its use in these other groups. The ‘tick box pages’ were acceptable to women 
with SMI to act as a ‘disclosure aid’; these could be adapted to other physical 
health checks such as dental appointments or hearing/eyesight tests. 
Whether the information contained in the leaflet in other format, such as a 
mobile app, would increase its benefits could also be tested. Similar 
interventions for this population may be useful for breast, bowel and prostate 
screening. Though there is currently no national screening programme for 
lung cancer in the UK, the NHS has been offering ‘Lung Health Checks’ in 
some parts of England since Autumn 2019 (NHS England – National Cancer 
Programme, 2019). Given the high rate of smoking within this population, 
such an intervention may warrant further investigation. 
 
It was unclear whether the tool enabled some women to make a more 
informed decision (category four); more research may be needed to 
ascertain whether the information provided in the tool improved their 
informed choice to attend or refuse screening. The risk of reliving the trauma 
by going for screening was deemed too great by some participants, so 
further research with this group on the acceptability of alternatives to a 
cervical swab, such as self-testing or urine sampling (possibly collected in 
community mental health teams during a physical health clinic) is worth 
consideration. For some women, the fear of receiving a cancer diagnosis 
was a factor in refusing to be screened; this group may need additional 
support to manage their anxiety. The leaflet only addresses one aspect of 
the screening journey – additional interventions may be required. Some 
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women with SMI who require further tests (for example if a positive HPV 
result is received), or oncological treatment following a cancer diagnosis, 
may need further support. High mortality rates from cancer in this group, as 
reported in Chapter One, warrant exploring which interventions might be of 
value since none specific to people with SMI are currently available. Lastly, 
some women receive the letter when they are mentally unwell. They may 
need a separate intervention to help them attend; coordinating screening and 
mental health services would help to ensure that the invitation to screening is 
not sent out when women are unwell. 
 
There are systemic barriers to accessing cervical screening pertaining to the 
healthcare system, which this tool could not address, such as being excluded 
from a GP practice or not receiving the invitation for screening if admitted to 
forensic services. How to overcome these barriers warrants further research. 
Training of health professionals (e.g. nurses working in primary care and 
sexual health clinics) on barriers to screening in this group to reduce some of 
the stigmatising attitude women with SMI may experience should be 
investigated. A separate intervention using secondary care records to ensure 
women are not invited when they are unwell, e.g. if they are in hospital, 
should also be explored.  
 
An external scoping review of the tool’s pathways for dissemination across 
NHS services was conducted by Imperial College Health Partners in 
September and October 2019. All stakeholders interviewed ‘felt that a 
quantitative evaluation was unnecessary for this type of intervention, given 
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that it is low cost, likely to be of some benefit, and the fact that other 
innovations of a similar type do not undergo this level of evaluative rigour’. 
Instead, some qualitative feedback on acceptability at the point of use from 
service users and health workers delivering the tool was suggested as a 
more appropriate route. This could be the subject of a future research project 
focused on implementation. 
 
The potential impact of the shift to HPV primary testing on the tool should 
also be highlighted. In addition, HPV vaccinations may in the long-term 
reduce the need for the number of cervical screening appointments; 
however, these will still be required, as well as regular follow-ups, if a woman 
tests positive. HPV self-testing is being trialled in two London sites (Pike, 
2019), and the sensitivity of urine sampling to detect CIN2+ (moderately 
abnormal cells found on the surface of the cervix) is being compared to 
vaginal and cervical samples (Sargent et al., 2019). Any adoption by Public 
Health England of an alternative to cervical screening would require the tool 
to be updated, for example if women are offered the opportunity to provide a 
urine sample in a mental health setting in lieu of cervical screening in primary 
care.  
 
Lastly, the psychological impact on women with SMI of testing positive for 
HPV deserves further investigation. Even though HPV may have been 
acquired many years prior to screening, and HPV is qualitatively different 
from other sexually acquired infections due to its high prevalence and long 
latency, relaying of ‘positive’ results will create significant challenges both for 
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health professionals and for patients (Ogilvie et al., 2013). Research has 
been conducted on the potential for anxiety and distress for women in the 
general population following receipt of results from routine HPV primary 
testing; health professionals will need to explain the context for HPV 
infections and manage emotional responses to positive results (McBride et 
al., 2020). While some qualitative research (n = 27) has found the emotional 
impact of HPV testing to be modest, with the primary concern relating to 
abnormal results (O’Connor et al., 2014), other work has reported that the 
sexually transmitted nature of HPV infection can cause psychological 
distress (McCaffery et al., 2006; Waller et al., 2004). Women also report 
concern about communicating positive test results to sexual partners, stigma 
and shame associated with having a sexually transmitted infection and 
anxiety that it might be misinterpreted as infidelity as well as the impact of 
positive HPV results on relationships with partners (McCaffery et al., 2003). 
The shift of cervical screening from an oncological to a communicable 
disease paradigm may create a novel barrier to cervical screening uptake for 
women with SMI. How this population of interest will react to receiving 
cervical screening results in the context of a positive or negative HPV test 
warrants further investigation. 
 
10.6 Contribution to knowledge 
 
This is the first cervical screening informed-choice tool for women with SMI 
that has been developed to address some of the specific barriers faced by 
women with SMI. Findings from this research contribute to the scientific 
literature as previous community-based research identified low cervical 
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screening rates in this population. This project has highlighted how women 
with SMI might use a cervical screening informed-choice tool and what 
information they would like included. To our knowledge, this is the first 
literature review that has been conducted on the barriers and enablers to all 
types of cancer screening in people with SMI. The systematic reviews have 
been published and the protocols are included on the PROSPERO website, 
so updates to the reviews can be conducted by other researchers, thereby 
building on the existing body of knowledge. The review on the design and 
development of informed-choice tools for this population has synthesised a 
list of steps that researchers might apply when developing an informed-
choice tool for people with SMI. While some steps overlap with the MRC 
guidance (e.g. both recommend identifying barriers as a first step), this list 
nonetheless contributes to the evidence base on developing interventions 
specifically for people with SMI (such as assessing readability of the tool).  
 
This research has developed and evaluated a novel intervention with the 
input of a population often excluded from research (Bucci et al., 2015; 
Humphreys et al., 2015). Very few interventions for people with SMI have 
been tested using the think-aloud method; this research adds to the literature 
on methods that can be used for this group to assess the usability of an 
intervention. The publication (Lamontagne-Godwin et al., 2018) based on the 
realist review of interventions to increase uptake of or access to screening 
for people with SMI, has already been cited in the academic literature (n = 13 
citations as of October 2020) and generated concerted interest on social 
media. A final publication on the development and preliminary evaluation of 
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the tool is in preparation. Looking beyond the PhD, I would like to continue 
developing interventions that aim to improve the physical health of people 
with SMI. Potential future areas of investigation include screening for other 
types of cancer and metabolic syndrome, given my prior research interest of 
working on improving diabetes care in people with SMI (Jones et al., 2016; 
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Appendix 1. Completed PRISMA checklist (Moher et al., 2009) 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3-4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
4 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
4 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
4 




Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
5 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
5 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 





Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
6 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  N/A 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
N/A 
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
6 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 




Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
Tables 1 
and 2 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Tables 1 
and 2 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
N/A 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  Tables 1 
and 2 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
10-12 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 





Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  12-13 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
13 
 





Appendix 2. Full electronic search strategy for one database (MEDLINE)  
 
The following terms will be used in all data sources: (cardiovascular OR vascular OR 
CVD OR ‘chronic heart disease’ OR ‘coronary heart disease’ OR CHD OR diabetes 
OR metabolic OR aneurysm) OR cancer OR neoplasm OR carcinoma OR maligna* 
OR *tumour OR tumor OR breast OR mammogra* OR bowel OR cervical OR pap*) 
OR (dental OR dentist OR tooth OR teeth) OR (eye OR retinopathy) AND (‘mass 
screening’ OR surveillance*) OR “Screening Test” OR ((cholesterol OR fecal OR 
faecal OR blood OR HIV OR sig¬moid OR tuberculosis) AND test*) OR “health 
check*” AND (letter OR mail* OR phone OR telephone OR ‘reminder system*’ OR 
‘videotape recording*’ OR ‘audiotape recording*’ OR questionnaire* OR strateg* OR 
alert* OR hotline OR community OR media) AND (intervention* OR goal OR ‘behav* 
change’ OR ‘implementation intention*’ OR plans OR planned OR planning OR plan 
OR educat* OR campaign* OR barriers OR intention* OR ‘behav* outcome’ OR 
outcome OR ‘lifestyle change’ OR longitudinal OR ‘follow up’ OR motivation*) AND 
(satisf* OR dropout* OR ‘drop out’ OR attrition OR uptak* OR adher* OR compliance 
OR complie* OR comply* OR ‘patient acceptance of health care’ OR encourag* OR 
improve* OR improving OR increas* OR promot* OR particip* OR nonattend* OR 
‘non attend’ OR accept* OR attend* OR attitud* OR utilisation OR utilization OR 
refus* OR respond* OR respons* OR reluctan* OR nonrespon* OR ‘non respon*’ OR 
incidence OR prevalence OR prevalence OR satisfaction OR cooperat* OR ‘co 
operat*’) AND (‘severe mental illness’ OR ‘mental illness’ OR schizophrenia OR 
catatonic OR paranoid OR disorganized OR disorganised OR bipolar OR manic OR 




Appendix 3. Completed PRISMA checklist (Moher et al., 2009) 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and 
implications of key findings; systematic review registration number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  3-4 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
4 
METHODS   
Protocol and registration  5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
4 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
5-6 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
5 




Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
6 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes 
for obtaining and confirming data from investigators.  
7 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
7 
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 





Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  N/A 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I2) for each meta-analysis.  
8 
Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
7 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
N/A 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
8 and 
Figure 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
Tables 1 
and 2 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  9 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Tables 1 
and 2 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  9 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  N/A 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to 
key groups (e.g., healthcare providers, users, and policy makers).  
17-19 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
19 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  19-20 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
20 




Appendix 4. Service user group feedback on the draft content of the tool (Round two 
of stakeholder involvement) 
 
Feedback received on the draft contents of the tool during a workshop with a service 
user group (May 2018):  
• Request first appointment of the day (20 minutes maximum is helpful in the waiting 
area)  
• Let people know about the “My Body Back” charity (screening clinic in London and 
Glasgow for women who have experienced sexual violence) although they are 
inundated with referrals!  
• Question yourself why you may not want to attend the appointment and try to 
overcome this [this was developed into an action planning text box]  
• Nurse could be informed previously (about history of trauma/abuse)  
• Bringing music may help you relax before the procedure, not during the procedure: 
“If I was the practitioner I would want the person to hear me (be able to 
communicate)”  
• Language/non-verbal communication used by health professionals is important  
• Do not be afraid to ask the nurse what is going to happen during the procedure  
• Some people might need an interpreter/translator  
• Need visual aids/diagrams of equipment used, genitals and position used for the 
procedure  




• All staff involved say “hello my name is…” and introduce themselves clearly  
• Explain why I need a smear if I am not diagnosed with cervical cancer  
• Explain how long you need to wait for the result  
• Explains what happens if you get a positive/negative result  
• Are there any side effects to having a smear? These need to be explained  
• Do you need to give a reason if you ask for a double (i.e. longer) appointment?  
• If you feel comfortable with your GP, can you ask him/her to perform the smear?  
• Suggestion for non-verbal disclosure: use a paper card [to show the nurse] to 
disclose something they do not want to discuss. Something interactive within the tool 
would be ideal – space for people to write down/think about own barriers, then take it 
to the GP.  
• Be specific in mentioning people can request a female nurse  
• Explain why some people may need more frequent smears (e.g. if they have a STD 
(sexually transmitted disease))  
• One person said it is important to bring the carer to the appointment but not in the 
room during the test  
• Resource should acknowledge that access to screening is not just an issue for 
people with SMI – general problem  
• Important to explain importance of cervical screening  
• Make it clear that cervical screening is a choice and acknowledge people may not 




• Staff need to respect people’s wishes about whether or not they want to talk about 
their mental illness/experiences  
• Emphasise importance of cervical cancer: but might explanation of risks put people 
off?  
• Need to be clear that being asked to go for cervical screening does not mean you 
have cancer  















coded by Reviewer 
#1 [the candidate] 
Component behaviour 
change techniques (BCT) 
coded by Reviewer #2 
[psychologist with 
expertise in health 
psychology] 
Coding verification 
by Reviewer #3 
[health 
psychologist] 
Section(s) of the tool 
that address(es) the 
barrier 
Not knowing 
what to expect 
or what to do  
Knowledge [of 
condition] 





4.1 Information on how 
to perform the 
behaviour 
4.1 Information on how to 
perform the behaviour 
Agreement During your appointment  
After your appointment 




















Agreed to include 11.3 
Conserving mental 
resources  
11.3 Conserving mental 
resources 
Agreement Every page 
 





1.3 Goal setting (outcome) 
1.4 Action planning 
9.3 Comparative imagining of future outcomes 












Goals 1.3 Goal setting (outcome)  
1.4 Action planning  
15.4 Self-talk: [REJECTED following discussion with 
Reviewer #2] 
3.3 Social support (emotional) 
Feedback from 
Reviewer #3:  
Are we asking them 
to set a goal (e.g. 
smart goal with date 
and time etc.) or is 
attending screening 





Before your appointment 
Tick box pages 
Stigma of 
mental illness 
Emotion 3.3 social support (emotional) 





Reviewer #3:  
Not quite clear how 
these specifically fit 
with the next column 
[Following feedback 
from Reviewer #3, 
the decision by 
Reviewers #1 and 
#2 was made to 
keep 3.3 and 11.3.] 
Tick box pages 
Past negative 
experience 







imagining of future 
5.4 Monitoring of emotional 
consequences 
[REJECTED following 
discussion with Reviewer 
#1] 
9.3 Comparative imagining 
of future outcomes 
[REJECTED following 
Feedback from 
Reviewer #3:  
Not quite clear how 
these specifically fit 
with the next column 
[5.4 and 9.3 were 
removed further to 
feedback from 








with Reviewer #2] 
3.3 Social support 
(emotional)  




Reviewer #3 and a 
discussion between 
Reviewers #1 and 
#2] 
 
Embarrassment Emotion 3.3 Social support (emotional) 
12.6 Body changes 
Agreement Tick box pages 
 
Before your appointment 
 
Traumatising Emotion 3.3 Social support (emotional) 
5.4 Monitoring of emotional consequences 
11.2 Reduce negative emotions 
Agreement Tick box pages 
 




Fear of bad 
news 
Emotion 3.3 Social support (emotional) 
11.2 Reducing negative emotions  
13.2 Framing/ reframing 
Agreement What is cervical 
screening 
 



















3.3 Social support 
(emotional) 
5.4 Monitoring of 
emotional 
consequences 
3.3 Social support 
(emotional) 
5.4 Monitoring of emotional 
consequences 
6.1 Demonstration of the 
behaviour 
Feedback from 
Reviewer #3:  
Perhaps the 
rationale for 12.2 
Booking your 
appointment 
Before your appointment 




6.1 Demonstration of 
the behaviour 
11.2 Reduce negative 
emotions 
12.2 Restructuring the 
social environment  





11.2 Reduce negative 
emotions 
12.2 Restructuring the 
social environment  
 
needs to be 
stronger 




3.3 Social support (emotional) 




Reviewer #3:  
 
Perhaps the 
rationale for 3.3 




Tick box pages 









12.1 Restructuring the physical environment 







Not sure this is how 
I would interpret this 
barrier [Following 
feedback from 
Reviewers #2 and 












4.1 Instruction on how to perform behaviour  
11.3 Conserving mental resources 







4.1 Instruction on how to perform behaviour 
11.3 Conserving mental resources 
 
 








4.1 Instruction on how 




6.1 Demonstration of 




6.1 Demonstration of the 
behaviour 
11.3 Conserving mental 
resources 
 
Agreement Booking your 
appointment 
Before your appointment 
Difficulty leaving 
the house due 





3.3 Social support (emotional) 
11.2 Reduce negative emotions 
Agreement Before your appointment 
Tick box pages 
Getting support 
Taking time off Environmental 
context and 
resources 
No BCT was identified Agreement - 
Made to feel like 
a burden on 
health service 
Emotion 3.3 Social support (emotional) Feedback from 
Reviewer #3: 
 
Perhaps explain the 
value of 3.3 in the 
final column 












Emotion No BCT was identified Agreement - 









coded by Reviewer 
#1 [the candidate] 
Component behaviour 
change techniques (BCT) 
coded by Reviewer #2 
[psychologist with expertise 
in health psychology] 
Coding verification 
by Reviewer #3 
[health psychologist] 
Section(s) of the tool that 
address(es) the barrier 
Wanting to be 
informed 
Knowledge 4.1 Instruction on how to 
perform a behaviour 











prevention of cancer 
and risks if 
screening not 
attended? As below 
During your appointment 
 
After your appointment 
 
Looking after your health 
Understanding 
of benefits of 
screening 
Knowledge 5.1 Information about 
health consequences 
Agreement What is cervical 
screening 
 
After your appointment 
Encouragement Social influences 3.2 Social support 
(practical)  
3.3 Social support 
(emotional) 
6.1 Demonstration 
of the behaviour 
3.2 Social support (practical)  
3.3 Social support 
(emotional) 
6.1 Demonstration of the 
behaviour 









11.3 Conserving mental 
resources [INCLUDED 
following a discussion with 
Reviewer #1] 





Goals 1.3 Goal setting 
(outcome) 
















 1.3 Goal setting (outcome) 
1.4 Action planning 
[REJECTED following a 
discussion with Reviewers #1 
and #3] 
5.1 Information about health 
consequences [INCLUDED 




Reviewer #3:  
 
Not sure “Feeling 
‘health conscious’” 
is really goal setting 
or action planning 
 
 
What is cervical 
screening 
 
After your appointment 
 
Looking after your health 
Being anxious 
to avoid further 
health problems 
Goals 1.1 Goal setting 
(behaviour) 
1.3 Goal setting 
(outcome) 
 
1.1 Goal setting (behaviour) 
1.3 Goal setting (outcome) 
2.4 Self-monitoring of 
outcome of behaviour 
[INCLUDED following a 
discussion with Reviewer #1] 
 
Agreement What is cervical 
screening 
 













1.3 Goal setting (outcome) 
4.1 Action planning 
[INCLUDED following a 
discussion with Reviewer #1]  
5.1 Information about health 
consequences 
7.1 Prompt/cues [INCLUDED 
following a discussion with 
Reviewer #1] 
Agreement Looking after your health 
Past positive 
experience 





3.3 Social support (emotional) Feedback from 
Reviewer #3:  
 
 
The tick box pages 
aim to increase staff 
empathy/understand
ing so you could 
perhaps include 3.3. 
 
Tick box pages 
Staff knowledge 
of mental illness 
Behavioural 
regulation 
No BCT was identified Agreement - 
Familiar location Environmental 
context and 
resources 
No BCT was 
identified 
12.1 Restructuring the 
physical environment 
[INCLUDED following a 
discussion with Reviewer #1] 





No BCT was 
identified 
6.1 Demonstration of the 
behaviour  
[INCLUDED following a 
discussion with Reviewer #1] 
Agreement Booking your 
appointment 
 





[INCLUDED following a 




Emotion 3.3 Social support (emotional)  Feedback from 
Reviewer #3:  
 
The tick box pages 
aim to increase staff 
empathy/understand
ing so you could 
perhaps include. 
 
Tick box pages 
Good 
relationship with 
Practice Nurse  
Emotion 3.3 Social support (emotional)  Feedback from 
Reviewer #3:  
 
The tick box page 
aims to increase 
staff 
empathy/understand
ing so you could 
perhaps include 3.3. 
 
Tick box pages 
Continuity of 
care 
Emotion 3.2 Social support (practical) 
3.3 Social support (emotional) 
 
Feedback from 
Reviewer #3:  
 
Suggestion to go to 
the appointment 
with a health 
professional/social 
worker may help 
with this barrier. 
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Not sure what 
to expect?  




          
Page 
 
Why this leaflet was developed       
                    
Why am I invited for cervical screening? 
       
What happens on the day           
                             
Common questions and anxieties   
                                 
Tips for booking your appointment                    
 
Getting ready for your appointment                            
 
Your appointment day                                                            
 
What happens next?                                                             
 
Additional information                                                           
 




Why this leaflet was developed 
 
It is up to you to decide whether to attend 
your smear test or not.  
 
There are lots of reasons why this decision 
might be difficult to make.  
 
This leaflet provides clear information and 
addresses common questions and anxieties.  
 
This leaflet was based on experiences of 
people who found it difficult to attend their 
appointment.  
 
The leaflet isn’t designed to persuade you 
either way. It’s here to help you make a 
decision and let you know what help and 
support is available. 
 
You can use this leaflet to plan your 




Why am I invited for cervical screening?  
 
HPV (Human Papilloma Virus) is responsible 
for most types of cervical cancer.  
 
If you have a cervix and are between 25 and 
64, you will be invited to test if you have HPV.  
 
This is called a smear test (also called 
cervical screening or ‘Pap test’).  
 
The smear test saves as many as 5,000 lives 
from cervical cancer a year in the UK.  
 
Having a smear test lowers your chances of 
getting cervical cancer.  
 
If you test positive for HPV, this does not 
mean you have cancer, but you may be more 
at risk of developing it. Further tests may be 
necessary.  
 
If you have cancer, getting it diagnosed and 




What happens on the day 
The nurse or doctor will ask you to undress 
from your waist down and lie on a bed with 
your knees bent and apart.  
 
A device - called a speculum - will be put into 
your vagina and then used to open it gently.  
 
This allows the nurse or doctor to see your 
cervix.  
 
A small brush (like a long cotton bud) will be 
used to take a sample from the surface of 
your cervix.  
  
The sample is sent to a laboratory to see if 









This leaflet supports the NHS leaflet Cervical 
Screening: Helping you decide and Cervical 
Screening: Easy Guide. 
 
This website has lots of videos to explain what 
















‘It’s hard for 
me to leave 
the house’ 














Think of reasons why you might want to go and why 
you think it’s important.  

















‘I had a bad 
experience’  







‘It’s difficult to book an appointment’ 
‘I’m not sure I 
need screening’ 
FFFFFFFFDDD 





Below are some issues that have been 
raised: 
Tick all boxes that apply to you I can talk 
about this 
I don’t want 
to talk about 
this today 
I survived a traumatic experience – 
sexual/domestic violence – abuse 
  
I have a mental illness   
I am a survivor of FGM   
I have visible cutting scars   
I am afraid I may pass out or react in an 
unexpected way 
  
I am a voices hearer and get distressed 
during a physical exam 
  
I have other health issues   
I am embarrassed by parts of my body    
My medication makes me shake   
I had a traumatic birth and find the smear 
test uncomfortable  
  












Tips for booking your appointment 
 
Let the staff know if you: 
 
A) Get anxious in waiting rooms. Ask for the first 
or last appointment of the day.  
 
B) Want to be seen by a female or male member 
of staff. 
 
C) Want to be seen by your GP.  
 
D) Would like to receive a reminder for your 
appointment (text-message, postal or 
telephone reminder). 
 
E) Need a double appointment. 
 
F) You may feel more comfortable having a first 








Tips on getting ready for your 
appointment 
 
A) Things to pack that you might find comforting: 
 
o Something from home to cover yourself (like 
a blanket or shawl)  
 
o A music device and earphones to help you 
relax before your appointment 
 
B) Wear a loose-fitting skirt on the day  
 
C) Ask a trusted person to accompany you on 
the day – ask them to take the morning or 
afternoon off 
 
D) Organise transport to and from your 
appointment in advance  
 
E) Plan something nice after your appointment, 
like going to the cinema, or going for tea and 






F) There may be things that bother you about the 
smear test. Write them down if it’s easier. This 
could be:  
 
o parts of your body not to touch 
o whether you prefer a soft or firm touch,  
o whether you want the door locked or 
unlocked,  
o any reactions that you may predict that you 
would prefer the health professional to know 
about in advance. 
 
G) There may be words which could trigger 
anxiety or flashbacks. List alternative 'safe' 










“I am in control 
and can say 






Your appointment day 
 
A) You can have an impartial observer (a 
‘chaperone’) if you would like one. A 
chaperone can be a friend, family member or 
a trained healthcare professional such as a 
practice nurse. You do not have to accept the 
person who is offered to you as a chaperone. 
If you have asked for one but there is no-one 
immediately available you can reschedule 
your appointment.  
B) The smear test is a collaboration between you 
and the nurse/doctor. Agree on a signal to 
stop if you need to do so at any stage. 
C) Ask the nurse/doctor to warn you before they 
touch you and to explain what they will be 
doing.  
D) Speak to your doctor about sedation or 
medication to reduce your anxiety on the day 
if you think it would help. 








What happens next?  
 
You should receive a letter explaining your 
results within two weeks of your 
appointment. 
 
If your results, or waiting for your results, 
makes you anxious, you can contact Jo’s 
Cervical Cancer Trust (www.jostrust.org.uk) 
by calling: 
0808 802 8000  
 
The majority of people with a cervix will test 
negative for HPV. This means you have a 
very low risk of developing cervical 
cancer before your next smear test.  
 
You will receive another invitation in 3 or 5 
years (depending on your age). 
 
If you test positive for HPV, you will need to 
do more tests. 
 “I get very 
anxious 
waiting for 
my results”  
“It’s important 






Cancer can, very rarely, develop between 
regular smear tests. If you have symptoms 
such as: 
o Pain or discomfort during sex,  
 
o Bleeding between your periods, after 
sex, or after the menopause,  
 
o Unusual and/or unpleasant vaginal 
discharge 
 
o Lower back pain 
 
Don’t wait for your next smear test. Make an 
appointment with your nurse or doctor. 
Usually these symptoms won’t mean you 
have cancer. It’s best to have your symptoms 
checked out. 
  
“I made an 
appointment with my 
GP when I had 
irregular bleeding”  
“My partner 
encouraged 









Order a ‘self-testing’ kit  
Buy your kit online. It’s not available on the 
NHS. It costs between £50 and £100. The 
sample is collected by putting a swab (it looks 
like a tampon) into the vagina. The sample is 
then put into a test tube to be sent off to a 
laboratory. Discuss your results with your 
nurse or doctor.  
 
Organisations that can support you: 
 
Jo’s Cervical Cancer Trust 
Telephone: 0808 802 8000  
www.jostrust.org.uk 
 
My Body Back (London and Glasgow) 
Cervical screening clinics for women in the 
UK who have experienced sexual violence  
www.mybodybackproject.com 
 







This leaflet was developed to make sure that 
everyone with a cervix who is invited for a 
smear test has access to information to help 
you decide whether you want to attend.  
 
We would like to thank all the patients, 
service user groups, professionals and 
frontline staff who helped in the making of 
this leaflet. 
 
This leaflet is available in English, Arabic, 
French and Somalian. 
 
This work was funded by the University of 
West London. 
 
UWL / King’s logos 
Dorset and WLMHT Logos 




Appendix 7. Fully coded content analysis of the clinical accuracy testing phase (Round three of stakeholder involvement) 
 Revision requested by (n = ) Decision made: 















“Title page”       
It’s slightly confusing as to who 
the reader is supposed to be.  I 
would have a sub-heading 
which reads…a 
comprehensive guide for 
people with…, or to support 
people with mental health 
issues (not sure what term is 
being used) 
1     Service users (and 
most mental health 
professionals) 
would not want to 
use such a label for 
this group. It's our 
role to ensure the 
leaflet is tailored to 
their needs, and 
available in the 
services they 
access in primary 
and secondary 
care 
I would take out the thought 
bubbles as they are slightly 
confusing and potentially 
insensitive 
1     The format of the 
cover page was not 
the focus of this 
feedback session. 
The cover page 
was changed 







Do we need to make it clear up 
front that this is a specialised 
resource for people with SMI? 
Just wondering if a) it lets 
people know it's for them and 
b) it helps HCPs who are 
looking for a particular 
resource. Just adding a tag-
line like 'A guide for people 
with severe mental illness'. 
However, I don't know if this a 
label people would want to see 
or think it applies to them 
1     Service users (and 
most mental health 
professionals) 
would not want to 
use such a label for 
this group. It's our 
role to ensure the 
leaflet is tailored to 
their needs, and 
available in the 
services they 
access in primary 
and secondary 
care 
[Discussion around what to call 
the test: smear test? Pap test? 
Cervical screening?]: Suggest 
cervical screening (smear test) 
   1 This suggestion 
has been 
incorporated into 
the title (following 




“Why this leaflet was developed” 
Prefers the expression “found 
it difficult to attend” to “feeling 
anxious about attending” 
 
   1  Both sentences 
were included, 
because anxiety is 
a real issue service 
users can relate to: 
"This leaflet is for 
women who find it 





(a smear test). 




Add “What’s in this booklet?" 
as a title for the page 
1    Wording amended 
to reflect this 
 
Would replace "What's in this 
booklet?" with "What’s in this 
leaflet?" 
  1  Wording amended 
to reflect this 
 
You may want to add that 
people find it difficult to go 
“because they are feeling 
anxious about going for a 
smear test”, rather than just 
"because you have a mental 
illness or have had a traumatic 
experience" 
  1  Wording amended 
to reflect this 
 
I would take out the word 
‘anxieties’ of the 4th heading, 
that seems like pre-empting an 
anxiety with doesn’t seem very 
reassuring 
1     This word was not 
removed and was 
tested with service 
users during the 
acceptability phase 
This section seems a bit long 
and repetitive. It’s an ideal 
place to say who the target 
reader is and why…so what 
evidence has led to its 
development? what do we 
mean by mental health? how 
the leaflet can be used etc. 
1    Wording amended 
to reflect this 
 
I’d also probably add 
something like, many people 
who go for screening feel 
anxious and it’s ok to feel that 
    Wording amended 





way, however the information 
should help to reduce/manage 
anxiety and/or prepare you for 
a screening appointment 
I like that it covers informed 
choice, but wording could 
probably change to make it 
slightly less daunting and 
confusing.  It might be easier 
to have one sentence along 
the lines of…it’s important to 
under/know about the process 
to help you decide if you want 
to attend  - but in saying 
that…is that the purpose of the 
booklet? Or is it to reduce 
anxiety?  
1     The purpose of the 
leaflet is to support 
women make an 
informed choice. 
Reducing anxiety is 
one of the barriers 
the leaflet aims to 
address 
 
I wonder if you can make more 
of the work you’ve done with 
people with SMI here – that is 
the really special thing about it. 
Something like: ‘We worked 
closely with people with severe 
mental illness to develop this 
leaflet. Some felt anxious 
about cervical screening 
because of their mental illness, 
a previous traumatic 
experience, or for another 
reason. You will see some of 
their stories and tips 
throughout the leaflet.’ 
1    Wording amended 
to reflect this 
 
"What does this leaflet cover?" 
As a header for the contents 
list 
1    Wording amended 





“Why am I invited for screening?” 
I think this section should say, 
more explicitly, that screening 
can pick up changes that, if left 
untreated, might eventually 
lead to cancer 
 1   Wording amended 
to reflect this 
 
Is it a bit confusing saying they 
will be invited for a test to see 
if they have HPV rather than a 
smear? Also the smear doesn’t 
look for cancer it looks for pre-
cancerous cells 
   1 Wording amended 
to reflect this  
 
People may not always get 
their smear done at a GP 
surgery, so you may want to 
generalise it slightly (some 
sexual health clinics and STI 
clinics do smears, and so do 
some gynae clinics, especially 
for patients who require 
adjustments) 
 1   Wording amended 
to reflect this 
 
People may not always get 
their smear done at a GP 
surgery, so you may want to 
include alternative 
arrangements (some sexual 
health clinics and STI clinics 
do smears, and so do some 
gynae clinics, especially for 
patients who require 
adjustments) 
 1   Wording amended 





We need to highlight that this 
is a test for detecting an often 
silent cancer  
 1   The extent to which the risks of non-
uptake of cervical screening should be 
highlighted in the tool will be discussed 
with health professionals and service 
users. Results are reported in Round four 
of stakeholder involvement (section 
7.3.2).  
Important to emphasise that 
women should go for regular 
screening 
 1  1 This comment was 
incorporated into 
this sentence: 
“Going for cervical 
screening when 
invited is the best 




HPV can be confusing for 
some people, it has an 
association with sex and can 
be confused with HIV – best to 
avoid mentioning in the tool 
   1 Wording amended 
to reflect this 
 
‘’staying healthy’’ message - 
focus on prevention rather 
than mentioning “cervical 
cancer” 
   1 The extent to which 
the risks of non-
uptake of cervical 
screening should 
be highlighted in 




service users in 








This may read better by putting 
the sentence "It is not a test for 
cancer" at the start 
 1   Wording amended 
to reflect this 
 
Why "Why am I invited for 
cervical screening?"  Are they 
receiving this at the time of a 
letter? Should it be "why have I 
been…?" 
1    This sentence was 
removed 
 
Need to include “if I am not 
sexually active now or ever or 
never do I need the cervical 
screening test” 
   1 This sentence was 
added: “If you’re 
not sure whether 
you need a test, 
talk to your GP or 
nurse.” 
 
“if you have a cervix and are 
between 25 and 64” is 
confusing, reword 
   1 This section was 
revised to: “To be 
invited for cervical 
screening you 
must: 
- be registered with 
a GP as female 
- be between the 
ages of 24 and 64”  
 
I would maybe list the places a 
woman can go to get a cervical 
smear. It is largely provided by 
primary care and an 
explanation about the process 
may be helpful. Like 
mentioning that the GP will 
send you a letter every 3 years 
to invite you, so making sure 
   1 This section was 
revised to: “Your 
GP surgery will 
invite you for 
cervical screening 
if your contact 
details are up to 
date (…) In some 





your patient details are up to 
date would be good. Some 
sexual and reproductive health 
clinics will opportunistically too 
but that may get confusing to 
mention because it is 
opportunistic 
able to arrange 
your appointment 
at a sexual health 
or well woman 
clinic instead of 
your GP surgery.” 
Could give more info about 
HPV; Very positive page – if 
this leaflet is to help people to 
decide, should it have the pros 
and cons? Probably need to 
say it’s not just about checking 
for cancer as that isn’t clear 
1    The extent to which 
the risks of non-
uptake of cervical 
screening should 
be highlighted in 




service users in 





If the focus of this booklet is 
tips for people with SMI, just 
do an overview of cervical 
screening here then signpost 
out. Getting into HPV will make 
it very complicated 
1    Wording amended 
to reflect this 
 
Eligibility age for screening: 
‘25-64’ rather than ‘24-64’. It’s 
better to stick with the 
screening ages here to avoid 
confusion. 
1    Wording amended 





Offer alternative sources of 
information as not everyone 
has access to a computer or 
the internet 
  1   Research shows 
this group has 
access to the 
internet and a 
computer 
I think this whole section 
needs to be rewritten to make 
it a bit clearer and in a more 
logical order - see other 
attachment. It might be 
working a bit too hard - if the 
focus of this booklet is tips for 
people with SMI, just do an 
overview of cervical screening 
here then signpost out. Getting 
into HPV will make it very 
complicated 
1    Wording amended 
to reflect this 
 
“What happens on the day” 
The Easy Guide hasn't been 
updated since 2013! I am 
biased, but can I suggest our 
EasyRead guide which was 
updated in June 2018? It's also 
more comprehensive 
 
1    Wording amended 
to reflect this 
 
Could what happens on the 
day be a cartoon and show 
pictorially? 
1    An image of the 
examination was 
later introduced in 
the leaflet 
An Easy Guide 
already exists 
Is it worth having some 
pictures? Eg of the speculum - 
some people may not know 
what it is 
 
1    An image of the 
examination was 
later introduced in 
the leaflet 





‘Point 3’: Is it worth mentioning 
that "they would remain 
covered at all times, not 
exposed when undressed" 
   1 Wording amended 
to reflect this 
 
Might be an idea to change the 
wording slightly to make it a bit 
softer for someone who may 
be anxious about the process 
– could talk about different 
sizes of the speculum…that 
they can ask for a different 
size, that the Nurse/GP is 
trained in doing them and 
understands that is can be a 
difficult process for some 
people for a variety of reasons 
    Wording amended 
to reflect this 
 
It will usually be a nurse doing 
smear test! [rather than GP] 
   1 Wording amended 
to reflect this 
 
I actually like this section, it’s 
clear and factual, this should 
probably come up a lot earlier 
in the leaflet 
1     Usability testing of 
the leaflet will 
determine if this 
section should be 
moved 
It might be an idea to explain 
what a cervix is if it’s going to 
be mentioned 




introduced in a 
later version of the 
leaflet 
 
“Common questions and anxieties” 
I think you could add a few 
more interactive tools like [One 
column asking the person to 
write down what they are 
   1 Wording amended 





concerned about, what would 
help and then why they will 
go/why it’s important], then this 
leaflet becomes a tool 
professionals can use to assist 
someone to weigh up the 
pros/cons and potential 
suggestions to take to an 
appointment that will make 
their visit more comfortable. It 
would feel, hopefully, to the 
patient like they have been 
consulted with, they have co-
produced the way their 
consultation will go and they 
feel respected and valued 
‘Common questions and 
worries’ [barriers] can be 
merged to “Support for people 
who are anxious about the 
smear test” table, also I think a 
different format is needed here 
spelling myths and answers 
   1 These two sections 
have been merged 
 
There is a lot on this page, it’s 
actually slightly overwhelming, 
may need to think about 
layout.  Could thought bubbles 
just be bullet points instead? 
1    This page has 
been merged with 
the tick box page 
 
I love this way of presenting 
people's concerns. Perhaps it 
can be a little cleaner - see 
attached 
1    Formatting 
amended to reflect 
this 
 
“Tick box page” 
[we can talk about this/I don’t 
want to talk about this]: rather 
   1  The various 




than these, I would be happier 
if it is one column saying what 
are the corresponding 
solutions of their problem 
leaflet offer tips, 
but these are not 
included on this 
page 
 
There is some repetition in the 
"tick box" page and the page 
before which has suggestions 
for women who have 
experienced sexual violence. 
Some of the suggestions on 
this page (e.g. "do you prefer a 
soft/firm touch, do you want 
the door un/locked") could be 
moved to the "tick box" page 
  1  These two sections 
have been merged 
to avoid repetition  
 
I am a female to man/trans 
man and I am feeling anxious: 
Just saying 'trans man' is 
better 
1     This sentence has 
been removed as 
was out of the 
scope of this 
project 
Instead of just pass out, add 
"faint" 
  1  Wording amended 
to reflect this 
 
The option "I have other health 
issues" isn’t clear, could be 
replaced by "I find it hard to 
maintain a healthy weight" 
  1  Wording amended 
to reflect this 
 
I'm not sure about this, but I 
wonder whether there should 
be a space for (optionally) 
writing 'my mental health 
conditions/diagnoses are...' so 
that the leaflet can be shown 
to the health professional 
doing the test. The 
nurse/doctor may not have 
 1   This suggestion 
was included and 








access to medical records at 
the time of the test, and it 
might make it easier for the 
patient. Or not. Something to 
ask the service users, I guess 
Is it worth saying it is optional 
to fill this [tick box page] out? 
   1  The leaflet would 
only be used if the 
individual chose to 
bring the leaflet to 
the appointment 
I’m confused by page 7, is the 
idea to show this to the person 
doing the smear?  If so I think 
that’s a whole other project in 
terms of supporting HCP’s to 
manage and support those 
with specific mental health 
issues having this process 
within the time and 
professional constraints they 
have.  I’d be keen to lose this 
page actually 
1     This page will be 
tested with service 




“Tips for booking your appointment” 
I would remove the option to 
be seen by your GP- nearly all 
practices have nurses doing 
the smears and it may be 
disappointing for patients to 
ask for something that the 
practice cannot provide- GPs 
are not best placed to do 
smears these days and some 
are not up to date with training! 
 1   Wording amended 
to reflect this 
 
The last appointment may be 
result in a longer wait if the 
  1  Wording amended 





clinician has run over in their 
previous appointments.  Is 
there evidence that supports 
the last appointment having 
sorter wait times? 
It would be a bad idea to book 
the last appointment of the day 
as these are very often late 
 1   Wording amended 
to reflect this 
 
The patient may not get a 
double appointment on 
request, this would be up to 
the nurse to rebook if the 
patient was anxious- by setting 
out incorrect patient 
expectations we may lose trust 
 1   Wording amended 
to reflect this 
 
With regard to chaperones - a 
family friend is not a 
chaperone - CQC define a 
chaperone as a neutral party 
who has knowledge of the 
practical intimate procedure 
occurring to protect both 
patient and clinician- the 
patient can bring a friend or 
relative but they are not acting 
as a chaperone 
 1   Wording amended 
to reflect this 
 
“Book a double appointment”: 
what does this mean? 




“if you get anxious sitting in 
waiting rooms”: say the 
symptoms rather than label of 
anxious 
1     This will be tested 
with service users 
during the 
acceptability phase 
May have to manage 
expectation, there may not be 
1    Wording amended 





staff of required genders  
and/or they may not have 
policy for double appointments 
for screening, or ability to send 
a text message as a reminder 
– maybe need line to say "this 
may not be available in all GP 
surgeries" 
"Let the receptionist know if 
you would like to have a 
chaperone. This is a person 
working at the clinic, like 
another nurse, who can be 
there during the screening": It 
doesn’t have to be – it could 
be someone they bring and 
trust. 
 
1    Wording amended 
to reflect this 
 
“Tips on getting ready for your appointment” 
The way we talk about some of 
these things should be 
softened slightly - for example, 
rather than 'do this', we can 
say "You may feel more 
comfortable wearing a skirt or 
dress, as you will not have to 
undress from the waist down" 
1    Wording amended 
to reflect this 
 
I’d refrain from telling the 
reader to do something ‘nice’ 
afterwards…also if the person 
is socially isolated this may 
cause concern 
1     Will let service 
users determine 
whether they would 







"Make plans to treat yourself to 
something nice and relaxing 
after your appointment": this 
perpetuates the idea that 
cervical screening is 
something scary/draining – I 
think it’s just the wording. 
Maybe ‘If you will need support 
after the appointment, make 
plans that focus on self-care.’ 
 
1     Will let service 
users determine 
whether they would 




Section A could be helpful.  It 
might be an idea to have a 
range of things the reader may 
find comforting, or to reduce 
text just ask the reader to think 
about doing/taking something 
that helps them most in 
anxious situations  
1    Wording amended 
to reflect this 
 
These words can trigger an 
anxiety attack or flashbacks: 
Should we be asking people to 
list words that trigger them? Or 
should we be asking what 
words they would prefer to be 
used? 
1     This section will be 
tested with service 




In the section "things to pack 
that you may find comforting", 
in terms of suggesting 
"something from home to 
cover yourself (like your own 
blanket)", the clinic will always 
provide a blanket/sheet 
   1 Wording amended 
to reflect this 
 
I’d refrain from asking 
someone to take time off work  
1    Wording amended 





It might be worth something 
along the lines of “some 
people who attended 
screening said they felt less 
anxious about the process if 
they were able to…” 
1     We have focused 
on "what you find 
comforting" rather 
than "what makes 
you less anxious" 
 
Who is section F for? [There 
may be things that bother you 
about the smear test. Write 
them down if it’s easier] Does 
this go to the health 
professionals?  May cause 
anxiety to start writing this 
down, could just suggest 
telling the health professional 
in a way that’s most 
comfortable for them 
1    This section has 
been merged with 
the “tick box page” 
 
Sections C-E make the whole 
process sound like something 
that will be time consuming 
and traumatising.   
1     This section will be 
tested with service 
users and health 
professionals 
during the 
acceptability phase  
Not sure I would suggest the 
safe words as there is a 
reliance on the health 
professional to read this prior 
to the appointment.  
     We will keep a box 
where people can 
write down any 
words they don't 
want used - the tick 
box page can be 
brought to the 
appointment so the 
nurse will read 
them during the 
appointment 




With regards to asking for 
medication from the doctor if 
you are feeling anxious: 
sometimes the person may 
feel that the [skin] tissues are a 
bit harder [in the context of 
FGM] and it is painful and 
uncomfortable in that case I 
think GP can give them some 
medication to use to make 
tissues softer and that is 
helpful for releasing physical 
discomfort 
   1 Wording amended 
to reflect this 
 
"speak to your GP about 
medication if you are feeling 
very anxious": some GPs won't 
prescribe "benzos" 
[benzodiazepines, anxiety 
medication] and some GPs are 
very cautious about giving 
them, particularly to patients 
on strong antipsychotic 
medication: would remove this 
option, you wouldn't normally 
prescribe it to the general 
population 
 1   This section has 
been removed 
 
Remove "impartial observer" 
as an explanation of 
"chaperone" and replace with 
an example "like a healthcare 
assistant" 
  1  Wording amended 
to reflect this 
 
Needs to make clear that if a 
chaperone is wanted then this 
should be mentioned at the 
 1   Wording amended 





time of booking the 
appointment 
“What happens next” 
Again a nice clear section. I 
would probably also say they 
can speak to their GP or 
someone else they trust along 
with the charity 
1    Wording amended 
to reflect this 
 
You "may" need to have more 
tests, not "you will need to" 
    Wording amended 
to reflect this 
 
“You should receive a letter 
explaining your results within 
two weeks of your 
appointment” add: 'Sometimes 
it can take less time or longer.' 
Just in light of the massive 
delays across England… 
1    Wording amended 
to reflect this 
 
Maybe worth changing 
‘negative’ to ‘not found to 
have’, I’d shy away from 
‘normal’ 
1    Wording amended 
to reflect this 
 
I’d probably change the 3rd 
paragraph to say ‘the majority 
of people who go for 
screening’ as opposed to ‘with 
a cervix’ as it sounds a bit odd 
1    The moniker 
“people with a 
cervix” was used to 
be inclusive of 
transmen who may 
not identify with the 
title ‘woman’ but 




[You will be invited in three to 
five years] Given that we may 
change the screening intervals 
this could date the leaflet. It 
  1  Wording amended 





may be better to advise you 
will receive another invitation 
when your next test is due? 
“Symptoms” page 
Would be great to have 
something about feeling 
confident to go to the GP in the 
screening interim if they spot 
anything unusual – I don’t like 
the bit about cancer 
developing as that would make 
me very anxious, the last line 
also contradicts that sentence 
1    Wording amended 
to reflect this 
 
“Cancer can, very rarely, 
develop between regular 
smear tests. If you have 
symptoms such as …” : Can 
just say 'It is important to be 
aware of cervical cancer 
symptoms, including… 
1    Wording amended 
to reflect this 
 
Instead of “if you have any” 
suggest “if you have any 
symptoms” 
  1  Wording amended 
to reflect this 
 
“Bleeding between your 
periods, after sex, or after the 
menopause”: Separate these: 
 
'bleeding that is unusual for 
you (abnormal bleeding) - this 
may be between periods or 
after sex' 
 
'bleeding after the menopause' 
1    Wording amended 
to reflect this 
 
Before "It is important to be 
aware of these symptoms", 
  1  Wording amended 





you could add "Even if your 
cervical screening results are 
normal, it is still important..." 
‘You don’t have to wait for your 
next cervical screening 
invitation’: This should read 
that cervical screening is not a 
diagnostic test 




“Unusual and/or unpleasant 
vaginal discharge” replace with 
'Vaginal discharge that is 
unusual for you - for example, 
a different or bad smell’ 
1    Wording amended 
to reflect this 
 
Jo’s Cervical Cancer Trust are 
changing “lower back pain” to 
“'unexplained lower back pain 
that lasts a long time” 
 
1    Wording amended 
to reflect this 
 
“Don’t wait for your next smear 
test. Make an appointment with 
your nurse or doctor. Usually 
these symptoms won’t mean 
you have cancer. It’s best to 
have your symptoms checked 
out”: replace with "If you have 
any symptoms, see your 
doctor straight away. You do 
not have to wait for your next 
smear test" 
1    Wording amended 
to reflect this 
 
‘Looking after your health’: 
suggested title for this page 
1    Wording amended 
to reflect this 
 
“Additional information” 
Could we add more [support] 
organisations? I'm sure there 
1    Wording amended 





are for this group, even if not 
cervical screening specific! 
Add Samaritans, MIND, 
charities don't need to know 
much about physical health, 
it's more about getting 
emotional support if they are 
feeling anxious or a bit upset 
after their appointment 
 1   These charities will 
be contacted in 
view of including 
them in the leaflet 
 
At present, HPV self-sampling 
is not offered by the NHS 
cervical screening programme 
so it would be inappropriate to 
mention it in a leaflet aimed at 
women attending for NHS 
screening. The UK National 
Screening Committee will be 
reviewing the evidence on 
these devices in the near 
future 
  1  This section has 
been deleted 
 
I hesitate around self-testing 
where there is a cost, as not 
everyone can afford it and it 
may cause anxiety if they 
can’t, however it’s about 
informed decisions, so it would 
be their choice based on the 
information 
 
1    This section was 
removed further to 
feedback received 






I was interested in self-
sampling kits, I was going to 
look it up 
 1    This section was 
removed further to 
feedback received 








The cost of self-sampling kits 
might be a barrier for this 
group 
 1   This section was 
removed further to 
feedback received 






The cost of self-testing kits is 
high 
 1   This section was 
removed further to 
feedback received 






Cautious about this [self-
testing kits] - we can't 
recommend and the NHS 
doesn't officially endorse either 
(as far as I'm aware!). So 
maybe just need to be careful 
about wording 
1    This section was 
removed further to 
feedback received 






Would suggest taking out self-
testing as less effective than 
cervical screening 
   1 Ibid. as above  
I would be wary of highlighting 
the ability to order self-
sampling kits online. It might 
be worth picking the brains of 
the national cervical screening 
programme manager and 










advisory group for their stance 
on the evidence for those sort 
of kits first 
 
section has been 
deleted 
 
Suggestions to the whole leaflet 
Is there a reason for not 
including any pictures? 
because it is limiting to English 
speaking community… 
 





added to the leaflet 
 
Maybe a good video can be 
linked to the flyer for them to 
see if they want to 
   1 An animated video 
was commissioned 
to illustrate the key 
findings from the 
leaflet 
 
Images/illustrations should be 
included 
  1   Ibid. as above 
I think there is a lot, a lot of text 
and that using pictures would 
break this up. It seems quite 
intimidating with all the text 
even though the language is 
simple and well-spaced 
   1  Ibid. as above 
To me at the moment it is not 
giving clarity as which BCT we 
are using to bring the 
behaviour change. I don’t 
know what the phase of your 
PhD is but I would suggest 
analysing this flyer to identify 
the Behaviour change 
techniques (BCTs) according 






used, and each 
barrier/facilitator 




to the taxonomy. Following that 
you can develop/ screen the 
content in this e.g. it is 
inhibitive or initiative behaviour 
and what can facilitate that e.g. 
we want problem solving so 
this section is listing the 
problem “Support for people 
who are anxious about the 
smear test” and the column 
next to it should give the 
solution/answer to it. 
Otherwise listing problems is 
not a BCT. Same is do we 
need Goal setting? or want to 






I wonder if the info would sit 
better in chronological order - 
for example, start with the 
explanation of what cervical 
screening is > before your 
appointment (tips for booking) 
> at your appointment > after 
your appointment etc. It makes 
it easier to navigate 
 
1    The order of the 
sections was 
revised and this 
was tested during 
the usability phase 
 
Perhaps it should be aimed 
more at professionals/carers 
rather than just the people with 
SMI 
     The leaflet can be 
used with a health 
professional but it 
is aimed at 
improving decision-





Before, during and after need 
to be more summarised (…) 
It’s very long flyer and to me it 
is assuming low health literacy 
of the reader while internet 
impact is there 
   1  The length of the 
leaflet will be 
tested with service 





















Appendix 9. Feedback from service user researcher on the draft research materials 
and protocol 
 
Some thoughts about your draft research study protocol and revised 
questionnaire  
The draft protocol  
Introductory information on patient and public involvement  
It is interesting to see your plans for the involvement of women with lived experience 
in commenting on your research documents and great that you want to have this 
involvement. A couple of points:  
• Because organisation [xxx] as a whole has not been involved and because you 
have used some of my suggestions, but not others – your total prerogative as a 
researcher – I think that the extent of xxx’s involvement needs putting more 
cautiously, for example changing the sentence starting ‘Members of this group ...’ to 
‘One or two members of this group ...’ and then adding at the end of the information 
about xxxx ‘and some changes made as a result of feedback given’.  
Background  
I thought that this contains some very useful and informative material. Additional 
suggestions from a lived experience perspective would be:  
• Citing some material from women with a serious mental health diagnosis. If you 
would like to cite the comment in the email which I have sent to you with this 
 
 
attachment, let me know and I will ask the woman’s permission. There is also a 
relevant quote in my […] Project report, which I can forward to you if you would like  
• It was good to see that one or two of the articles which you reference come from 
co-produced studies. I think it would also be helpful to include studies by people with 
lived experience and to mention the importance of these (i.e. because the latter 
know from the inside what their experiences actually are and what approaches they 
and their peers find beneficial). I am not personally aware of a study about cancer 
experiences directly from people with serious mental illness diagnoses, but could 
send you references about user-led research and its value if this would be helpful  
• In the final paragraph on p.4, you mention some very relevant barriers to cervical 
screening for women with a serious mental illness diagnosis. You might want to 
include as well the sheer impact of mental distress? In the xxx Project, participants 
named this as a particularly high obstacle to their looking after their physical health. 
(This is different from the mental capacity issue that you mention on p.5.)  
Rationale  
The reason for undertaking this study came across to me as well evidenced.  
Theoretical Framework  
I found it clear that you have worked hard to ensure an adequate theoretical 
underpinning for your study. You may also want to take account of the fact that 
people with lived experience can find established frameworks unsatisfactory from 
their perspectives, because they stem from studies undertaken by researchers 
without lived experience (or studies in which people with lived experience had some 
role, but not a co-equal one)  
Research questionnaires  
 
 
Just one suggestion: I wonder whether the sentence starting ‘At the end of the 
research, we will understand what women diagnosed with a serious mental illness 
require ...’ should be put a little less strongly? As this is a single study and a 
comparatively small one, should the sentence read more along the lines of: ‘At the 
end of the research, we will have an improved understanding of what women 
diagnosed with a serious mental illness require ...’?  
Phase Four: Testing the usability of the tool  
Think-aloud testing (Study 3) A couple of questions:  
• Validated methodology is clearly important. However, for people with lived 
experience, there can be a tension between validated scales/questionnaires and 
material which they find ‘valid’ in their own experience because it is user-led. Would 
you want to make any mention of recognising the latter too?  
• You speak of taking some informal notes on participant behaviour. Will participants 
be informed that you would like to do this and will it be subject to their consent? 
Measures  
Demographic and clinical questionnaire  
Would it be helpful also to ask healthcare professionals about relevant health issues 
for them? Some professionals also experience mental distress and may have used 
mental health services themselves. In addition, it may be relevant to know which of 
them have undergone cervical screening themselves.  
Draft interview schedule for women diagnosed with a serious mental illness  
It is good to see the further increase in accessible wording. A few suggestions as 
well:  
• It is encouraging that you have decided to ask people at the UK charity dedicated 
to cervical cancer/cervical abnormality issues for suggestions about supporting 
 
 
women who have experienced sexual violence with cervical screening. Will any of 
the contributors from this charity have lived experience of a serious mental illness 
diagnosis and will views be sought from women with lived experience about other 
aspects of cervical screening which are relevant to the leaflet, before a first draft is 
produced? As I mentioned previously, not asking women with lived experience for 
their ideas about the information leaflet before an initial draft is collated limits the 
amount of influence which women will be able to have over it and could have a 
negative effect on its quality. Otherwise, might it be useful to explain your reasons for 
not obtaining ideas for the leaflet from women with lived experience before the first 
draft of it?  
• In the 4th question, you may want to invite 3 main reasons for using/not using the 
leaflet, rather than 3 main benefits: to pre-empt any bias in the question  
• I would suggest not limiting the final question to people from BAME and LB and T 
communities –these were just examples from me. There are issues for other 
marginalised groups as well, e.g. young people (under 25s) and people who have 
physical or sensory disabilities/physical health conditions in addition to their mental 
distress. You may also want to use the terminology ‘people from BAME or LB and T 
communities’ rather than ‘the BAME/LBT community’? There are a whole host of 
different communities within BAME and LB and T populations  
• I was a little unclear about the difference between the next to last question in the 
main set and the 3rd question under the heading of ‘finally’. Data analysis I like the 
emphasis on also looking at ‘deviant cases and disconfirming evidence’ and at 
dissonance between findings. I think this will be particularly important during analysis 
of data from people with lived experience who face further marginalisation because 
 
 
e.g. they belong to a BAME, or LB and T community, are under 25, or have physical 
or sensory disabilities/health conditions too.  
Inclusion and exclusion criteria  
I found these very clear. A couple of points:  
• I am very aware that many research studies exclude people who cannot read 
English rather than using translators. It does also concern me, however; exclusion 
from research studies further marginalises people who already tend to be seriously 
marginalised  
• Although there are unfortunately many precedents for a clinical team making 
decisions about the capability of someone with lived experience to give informed 
consent to participation in a study, this approach is unpopular with many people who 
have lived experience. The latter see it as a rather ‘top down’ approach and one 
which fails to recognise that they know themselves best. There are also precedents 
for taking an alternative approach; for example, I had REC approval for doing so 
when I undertook a study about the Care Programme Approach and recovery. Might 
you want to reconsider your approach to the issue? Sampling strategy for women 
diagnosed with a serious mental illness It is helpful that you are aiming to recruit as 
wide a demographic mix of participants as possible. One thought: people from BAME 
and LB or T communities and young people are very frequently under-represented 
amongst research participants, may particularly lack confidence in their views being 
heard, for instance. If you want to be sure of a good demographic mix, I think you 
may well need to do something more active than relying on the demographic areas 
in which recruitment is due to occur.  
Recruitment procedure for women diagnosed with a serious mental illness  
 
 
One thought: there can be considerable tensions between people with lived 
experience and psychiatrists, which can affect recruitment – mean that there is a 
bias because the people approached/the people who come forward do not include 
those who are unhappy with their psychiatrist. Had you thought of recruiting more 
widely? (Again, there are precedents for doing so.)  
Consent from people with lived experience  
Some really useful points are covered. In this paragraph, it might also be helpful to 
include the following issues:  
• Sending the information sheet and consent form to participants ahead of an 
interview: to add to their ability to give informed consent  
• Covering confidentiality issues during verbal explanations about the study  
• Explaining that choosing not to take part in the study/withdrawing from it will not 
affect any care which they receive  
• Explaining how the researchers will ensure that they are sensitive if they postpone 
an interview; people with lived experience often have painful experiences of rejection 
and, if the situation is not handled with considerable sensitivity, could go away 
feeling further rejected.  
Ethical and regulatory considerations  
You have some clear information about the health researchers and clinicians who 
make up the research team. It would have been good to have some service user 
researchers as well, to bring in a co-production element for the data collection. 
Service user researchers can sometimes also elicit data which researchers without 
lived experience do not, because people with lived experience may talk more freely 
with their peers. Is this something you would consider and would you have a budget 
 
 
for it? If not, I think it would be helpful if you acknowledged that research team 
members will not have lived experience expertise  
Risks and burdens  
Because women with lived experience may have been sexually abused and may 
have had bad experiences with cervical screening for that and other reasons, I think 
it would be good if you said a little more here about risks arising from these sorts of 
factors.(re-traumatisation because of such memories).  
Peer review  
For the reasons given below (for sub-section 8.4), I think it would be helpful to add at 
the end of the 2nd sentence in sub-section 8.3 ‘and some changes made as a result 
of feedback given’.  
Societal impact  
Would it be worth adding the Healthy London Partnership to your dissemination list? 
The Partnership has a current focus on physical health experiences for people 
diagnosed with serious mental illnesses and has itself produced some reports 
related to cancer and people with these diagnoses.  
The revised questionnaire  
It is helpful to see some further changes to this. A couple of additional suggestions:  
• In gender terms, the following questions are now recommended for equality 
reasons: ‘At birth, were you described as Female? Male? Intersex?’ and: ‘Which of 
the following options describes how you think of yourself now: Female? Male? In 
another way ..............................................................?’ (with tick boxes for the various 
options, of course)  
• Would it be worth using one of the standardised sets of wording for the ethnicity 
part of the questionnaire?  
 
 
• It would be good to add ‘please’ before the question ‘Tell us about your past 
experience of ...’  
• When I suggested exploring experiences of people with serious mental illness 
diagnoses who belong to LB and T, or BAME communities etc, I partly had in mind 
the demographic section of the questionnaire. In this, you are already asking 
participants about their ethnicity. If you decide to include the gender questions I have 
suggested, that will cover trans issues. If you invite people to say whether they are 
heterosexual, bisexual or lesbian, you will also know how many participants you 
have from these communities. In the data analysis, you might then be able to see 
whether there are any significantly different experiences of cervical screening for 
women with lived experience who belong to further marginalised 
communities/groups  
• If you also use the questionnaire to ask specifically about experiences for women 
with serious mental illness diagnoses who face additional marginalisation, I think 
what would be helpful is one broad question and one with some re-wording, for 
example: ‘If you think that your experiences of cervical screening have been affected 
by factors such as your ethnicity, age, sexual orientation, physical health condition or 
physical disabilities, please share it here’ (with space underneath to do so).  
Hoping that these points are of some help  
02/02/18 
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Appendix 10. Sample consent form (women with SMI) 
 
Rec ref: 18/SC/0123 
IRAS Project ID: 233934 
 
[Insert UWL and Trust logos] 
 
Participant Identification Number: __________ 
 
Short study title: Cervical screening informed choice tool for women with mental 
illness 
Name of researcher: Frederique Lamontagne-Godwin 
 
CONSENT FORM #1 
 
 Women diagnosed with a serious mental illness 
 
     
Thank you for considering taking part in this research. The person 
organising the research should have explained the project to you before 
you agree to take part. If you have any questions arising from the 
Information Sheet or explanation already given to you, please ask the 
researcher before you decide whether to join in. You will be given a copy 
of this Consent Form to keep and refer to at any time. 
 
Please initials in the boxes next to the statements you agree with 
after you have read the Information Sheet and/or listened to an 
explanation about the research.  
  
 
1) I confirm that I have read and understood the Information Sheet 
version 0.3 dated 08/03/2018 for the above study and have had 
the opportunity to ask questions. All questions have been 
answered to my satisfaction. 
 
   
2) I understand that my participation is voluntary and that I am free 
to withdraw at any time, without giving any reason, without my 
medical care, work or legal rights being affected. 
 
   
3) I understand that I will be interviewed about my views and 
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I consent to my interview being audio recorded. 
 
 
I consent to the processing of my personal information for the 
purposes explained to me. I understand that such information will 
be handled in accordance with the terms of the UK Data 
Protection Act 1998.  
 
I understand that I may be quoted anonymously (no name or 
identifying information) in reports of the results of the study. I give 
my permission for this. 
 
I understand that, if I wish, my interview can be excluded from the 
study if requested prior to 31 July 2019 (after which the final 





I understand that some parts of the data collected for the study 
may be looked at by representatives of regulatory authorities and 
by authorised people to check that the study is being carried out 
correctly. All will have a duty of confidentiality under the Data 





I agree to make my anonymised data available with the UK Data 
Service, which is funded by the Economic and Social Research 
Council (ESRC). We will use this free UK data service to store the 
qualitative data and quantitative data as open data.  
 
 
12) I agree to be contacted about the next phase in this study.  
   
 
_______________________  _____________ _________ 
Name of Participant   Date   Signature 
 
 
______________________  _____________ _________ 
Name of person taking consent Date   Signature 
(Interviewer) 







Yes / No 
 
                
 
Consent form_#1_interview_Phase 3_HCP_v0.3_08032018 
 
Appendix 11. Sample participant information sheet (women with SMI) 
 
Rec ref: 18/SC/0123        
IRAS Project ID: 233934 
 
[Insert NHS Trust and UWL logos] 
 
 
INFORMATION SHEET #3 
Women diagnosed with a serious mental illness 
Short study title: Cervical screening informed choice tool for women with mental 
illness 
This research forms part of a University of West London PhD Studentship (2017-
2020) 
PhD student/researcher: Frederique Lamontagne-Godwin, University of West 
London 
Principal Supervisor: Professor Elizabeth Barley, University of Surrey 
Second Supervisor: Dr Claire Henderson, King’s College London  
Third Supervisor: Dr Caroline Lafarge, University of West London 
Invitation paragraph  
We would like to invite you to take part in our research study. Before you decide 
whether you would like to participate, it is important for you to understand why the 
research is being carried out and what taking part would involve for you. You do not 
have to take part. If you don’t want to participate it will not impact upon the care you 
receive in any way. Please take time to read the following information carefully and 
ask the research team any questions you may have.  
Part 1 
Why are we carrying out this research? 
Screening people for some cancers can be helpful in detecting early cancer and this 
may help improve health. For this reason, in the UK there are national screening 
programmes for three types of cancer (breast, bowel and cervical). This research is 
about the decision to attend a smear test (cervical cancer screening) for women aged 
25 to 64. Evidence suggests that people diagnosed with a serious mental illness may 
be less likely to have cancer screening. One reason is the difficulty to make a decision 
on whether to attend the appointment. Decision-making can be hard because of 
factors such as: how mentally distressed people feel, past experiences of physical 
health care, difficulty remembering appointments and sexual abuse. There has been 
little research in this area.  
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What is the purpose of the research?  
The aim of the research is to develop an information leaflet to help women 
diagnosed with a serious mental illness to decide whether to attend a smear 
test. The research will explore the experience of participants (women diagnosed with 
a serious mental illness and health professionals) when using the leaflet. Our aim is 
to make the leaflet appealing and user friendly. Your participation will help us achieve 
this goal. 
Why have I been invited? 
You receive care from the xxx NHS Trust. 
Do I have to take part? 
No, participation is entirely voluntary. It is entirely up to you to decide whether or not 
to take part.  If you don’t want to take part it will not affect the care you receive in any 
way. If you decide to take part you are free to withdraw at any time, without giving a 
reason. If you withdraw from the study, this will not affect the care you receive in any 
way. 
What will happen to me if I take part?  
You will be asked to provide some details about yourself (gender, diagnosis, duration 
of illness/es, year of birth, ethnic group, whether you have ever attended a smear test 
and approximate date when it took place). You will then take part in a short interview 
with the researcher to provide any feedback you might have on the content and design 
of the leaflet. Below are example questions you will be presented with: 
• Layout: what do you think of the overall layout? Is there anything you would 
change? If so, what? 
• Clarity: was anything unclear? If so, how would you reword it? 
• Start to finish: how easy was it to go through the information leaflet? Would 
you change anything? 
• Look and feel: what did you think of the design of the information leaflet?  
• Information: Do you think there is too much/not enough information? 
• Overall: is there anything you would change/add/remove from the information 
leaflet? If so, what? 
• Is there anything else you would like to say about what health professionals 
and health services might do that would make it easier for people diagnosed 
with a serious mental illness to decide whether or not to go for cancer 
screening?   
• What could be done to make the experience of cancer screening better for 
people diagnosed with a serious mental illness? 
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Before and after you provide feedback on the leaflet, we will ask you to fill out two 
short questionnaires on how you would feel about attending a smear test. We want to 
know if the leaflet has an impact on your decision to attend a smear test in the future. 
Interviews will be recorded and last up to forty-five minutes. They will be conducted 
face-to-face in your clinic. The interview will be scheduled at a convenient time for you, 
either after your planned standard clinical care visit or, if you prefer, on another day. If 
you have incurred travel expenses that you would not have done without taking part 
in the study, we will reimburse these. You will be able to take breaks if you need to. 
You can choose to skip questions you do not want to answer or leave the session at 
any point if you are not enjoying it, without explaining why. 
Who can take part? 
We are looking for: 
• Women aged between 18 and 64 
All participants need to have: 
• A diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder or 
psychotic depression. 
You don’t need to have had cancer screening (smear test) to take part. We are 
interested in talking to a wide range of people including those who have missed or 
declined their smear test appointments, as well as those who have been screened.  
What do I do if I am interested in taking part? 
If you are interested in taking part please either: 
• Phone or email the research team using the contact details at the end of this 
sheet. To save expense, we will call you straight back OR 
• Ask another person, such as a health care worker, friend or relative to pass 
your details on to us and we will contact you. 
Expenses and payments 
You will not receive any payment for participating in the study. Neither your health 
professional nor the hospital are being paid to participate in this study. If you have 
incurred travel expenses that you would not have done without taking part in the study, 
we will reimburse these. 
What are the possible risks of taking part? 
The main disadvantage to you is giving up your time to take part in the research study. 
Talking to the researcher about cancer screening may remind you of difficult feelings 
or unpleasant experiences and could cause you to feel distressed. If you find the 
interview distressing, you can take a break.  
What are the possible benefits of taking part? 
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In similar studies some participants have told us that they found it interesting talking 
to a researcher about the interview topics. You will be involved in research which will 
help to increase understanding about uptake of cancer screening in people diagnosed 
with a serious mental illness diagnosis. The study might not help you directly, but your 
involvement may help improve attendance of smear tests by women diagnosed with 
a serious mental illness.  
What will happen if I don’t want to carry on with the study?  
If you change your mind and decide that you do not want to participate in the study, 
you can withdraw at any time by asking us to stop recording. You do not need to give 
a reason and your legal rights will not be affected. If you withdraw from the study, we 
will completely remove your collected information from our records.  
Will my taking part in this study be kept confidential?  
Your identity and all the information about your participation will be kept confidential. 
We will choose a unique code number for you and use that instead of your name in all 
future documents. Recording and transcriptions will be encoded and stored on our 
secure University of West London server and protected with a password. Any 
document with your identifiable information (e.g. consent sheets) will be kept in a 
locked filing cabinet in the researcher’s office at the University of West London. The 
only circumstances in which a researcher would not maintain confidentiality is if you 
told a member of the research team something which made us believe there was a 
serious risk to your or someone else’s safety. In those circumstances, we would 
discuss our concerns with your care coordinator or speak to the duty clinician on the 
team, who would decide whether any further action was required. 
 
We will register the study with the UK Data Service to store our anonymous interview 
data and numerical data as accessible data. We will make all data available in this 
way within three months of acceptance by a scientific journal of the main study 
publications. If you do not wish to have your anonymised data registered on this 
platform, you can opt out on your Informed Consent Form. 
PART 2 
Who is organising and funding the research? 
This study is funded by a University of West London PhD Studentship (2017-2020) 
and sponsored by the University of West London. 
Who has reviewed this study? 
This study was reviewed and approved by the South Central - Hampshire B Research 
Ethics Committee on the 16/04/2018. This study has been reviewed and given 
favourable opinion by the University of West London Ethics Committee on the 
07/12/2017. 
What if there is a problem?  
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You can contact the researcher who will do her best to answer your questions. You 
can also contact the Chief Investigator, Professor Elizabeth Barley, at the University 
of West London (Elizabeth.barley@uwl.ac.uk or 020 8209 4117). If you remain 
concerned and wish to complain formally, you can do this through the NHS complaints 
procedure. Any complaint about the way you have been dealt with during the study or 
any possible harm you might suffer will be addressed. You can contact the Patient 
Advice and Liaison Service (PALS) at the xxx NHS Trust in the following way: 







You do not have to take part in this study. If you do take part you are free to withdraw 
at any time without giving a reason. You may withdraw any interview data already 
collected if you tell the researcher before 31/08/2019. After that, your data will have 
been analysed.  
Harm 
In the unlikely event that something goes wrong and you are harmed during the 
research and this is due to someone’s negligence, you may have grounds for a legal 
action for compensation against the School of Human and Social Sciences at the 
University of West London, but you may have to pay legal costs.   
Independent Contact Point 
You can contact INVOLVE, a national advisory group which supports active public 
involvement in the NHS, if you seek general advice about taking part in research.  




023 8059 5628 Alpha House, University of 
Southampton Science Park, Chilworth, 
Southampton, SO16 7NS 
involve@nihr.ac.uk 
Who will have access to my personal data? 
Only the research team have access to your personal data. Trust staff of the Research 
and Development Office may need to check data in the course of their monitoring and 
auditing work.   
What will happen to the results of the research study? 
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The results of this study may be published in scientific journals or presented at 
scientific conferences, but there will be no way of knowing who has taken part. Our 
results will be accessible by browsing the registry on this database: 
www.researchregistry.com using the study Research Registry Unique Identifying 
Number: researchregistry3816.  
Research Team Contact Details  
If you would like any further information about this study or would like to participate 
please contact: 
 






Address: University of West London 
School of Human and Social Sciences 
Paragon House Boston Manor road, Brentford, Middlesex, TW8 9GA 
Telephone: 020 8209 4117 [project mobile number] 
 
The researcher will call you back to avoid expense. 
What now? 
If you decide to participate in this study, we will ask you to sign a consent form. We 
will keep one copy, and give you another copy to keep. Thank you very much for taking 
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Appendix 12. Participant information sheet (health professionals) 
Rec ref: 18/SC/0123 
IRAS Project ID: 233934 
 
[Insert UWL and Trust logos] 
 
INFORMATION SHEET #1 - Healthcare Professional 
Short study title: Cervical screening informed choice tool for women with mental illness 
This research forms part of a University of West London PhD Studentship (2017-2020). 
PhD student: Frederique Lamontagne-Godwin, University of West London 
Principle Supervisor: Professor Elizabeth Barley, University of West London 
Second Supervisor: Dr Claire Henderson, King’s College London 
Third Supervisor: Dr Caroline Lafarge, University of West London 
Invitation paragraph  
We would like to invite you to take part in our research study. Before you decide whether you 
would like to take part, it is important for you to understand why the research is being carried 
out and what taking part would involve for you. This should take about 10 minutes. Please 
take time to read the following information carefully, and ask the research team any questions 
you may have.  
Part 1 
Why are we carrying out this study? 
Screening people for some cancers can be helpful in detecting early cancer and this may help 
improve health. For this reason in the UK there are national screening programmes for three 
types of cancer (breast, bowel and cervical). This research is about cervical screening for 
women aged 25 to 64. Evidence suggests that people diagnosed with a serious mental illness, 
such as bipolar disorder, schizophrenia, other psychoses, may be less likely to have cancer 
screening. One reason is the difficulty to make a decision on whether to attend a screening 
appointment. There has been very little research in this area. Our study aims to improve the 
decision-making process of whether to attend cervical screening by developing and 
testing a paper leaflet for women diagnosed with a serious mental illness. The research 
is being conducted by a team of researchers led by the University of West London. 
We are interviewing women diagnosed with a serious mental illness and their health 
professionals for their views and feedback on the content of the leaflet. Our goal is to make it 
appealing, intuitive and user friendly. Your participation will help us achieve this goal. 
What is the purpose of the research?  
The primary aim is, through use of an informed choice tool, to improve the ability of women 
diagnosed with a serious mental illness to come to a decision of whether to attend cervical 
screening. The research will develop an informed choice tool for women diagnosed with a 
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serious mental illness and explore participants’ experience of using the leaflet and feedback 
from health professionals.  
Why have I been invited? 
You have been invited because you are an NHS professional and are involved in delivering or 
promoting physical health in people diagnosed with a serious mental illness. We are 
conducting our study in the clinic where you work, so we are seeking your agreement to take 
part. 
Do I have to take part? 
No, participation is entirely voluntary. It is entirely up to you to decide whether or not to take 
part.  If you decide to take part you are free to withdraw at any time, without giving a reason.  
What will happen to me if I take part?  
You will be asked to provide feedback on the tool in a single feedback session. This involves 
filling out a short demographic questionnaire and taking part in a single interview with the 
researcher (also see below). You do not have to take part in a feedback session in the next 
and final phase (phase 4). Interviews will last between thirty and forty-five minutes and will be 
conducted face-to-face in your clinic. The interview will be scheduled at a convenient time for 
you. If you would like to have a break at any stage, then please tell the researcher. During the 
interview you do not have to answer anything that you don’t want to and if you are not enjoying 
taking part then you can decide to leave at any stage, without having to tell the researcher 
why. Interviews will be audio-recorded. Below are example questions you will be presented 
with:  
• What do you think of the tool? 
• Are there any experiences/information which you feel are missing and should be 
included? 
• Are there any changes which we should make to the tool? 
• How likely would you be to use it with a mental health service user to assist them in 
their decision-making on whether to attend screening? Why? 
• What do you think might be the best setting to introduce the tool to your patients? 
• Do you have any experience of using such tools? What was their experience like?  
Who can take part? 
We are looking for nurses and psychiatrists working in secondary care mental health services. 
What do I do if I am interested in taking part? 
If you are interested in taking part please phone, email or write to the research team using the 
contact details at the end of this sheet. 
Expenses and payments 
You will not receive any payment for participating in the study. If you have incurred travel 
expenses that you would not have done without taking part in the study, we will reimburse 
these. 
What are the possible risks of taking part? 
There are no foreseen risks in participating in the study. The main disadvantage to you is 
giving up your time to take part in the research study. It is possible that you might find 
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answering some of the questions difficult. If this were to occur, you can take a break or 
terminate the interview at any time.  
What are the possible benefits of taking part? 
In similar studies some participants have told us that they found it interesting talking to a 
researcher about the interview topics. You will be involved in research which will help to 
increase understanding about uptake of cancer screening in people diagnosed with a serious 
mental illness.  
Will my taking part in this study be kept confidential?  
Your identity and all the information about your participation will be kept confidential. We will 
choose a unique code number for you and use that instead of your name in all future 
documents. Recording and transcriptions will also be stored on a secure server and will be 
password protected. Any paper data with your identifiable information (e.g. consent sheets) 
will be kept in a locked filing cabinet in the researcher’s office at the University of West London.  
 
We will register the study with the UK Data Service to store our qualitative data and 
quantitative data as open data. We will make all data available in this way within three months 
of acceptance by a peer reviewed journal of the main study publications. If you do not wish to 
have your anonymised data registered on this platform, you can opt out on your Informed 
Consent Form. 
PART 2 
Who is organising and funding the research? 
This study is funded by a University of West London PhD Studentship (2017-2020) and 
sponsored by the University of West London. 
Who has reviewed this study? 
This study was reviewed and approved by the South Central - Hampshire B Research Ethics 
Committee on the 16/04/2018. This study has been reviewed and given favourable opinion by 
the University of West London Ethics Committee on the 07/12/2017.  
What if there is a problem?  
You can contact the PhD student Frederique Lamontagne-Godwin, who will do her best to 
answer your questions. You can also contact the Chief Investigator, Professor Elizabeth 
Barley, at the University of West London by email: Elizabeth.barley@uwl.ac.uk or telephone: 
020 8209 4117. If you remain concerned and wish to complain formally, you can do this 
through the NHS complaints procedure.  
Withdrawal 
You do not have to take part in this study. If you do take part you are free to withdraw at any 
time without giving a reason and your legal rights will not be affected. You may withdraw any 
data already collected if you wish if you tell the researcher before 31/07/2019, at which time 
your data will have been analysed.  
Harm 
In the event that something goes wrong and you are harmed during the research and this is 
due to someone’s negligence, you may have grounds for a legal action for compensation 
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against the School of Human and Social Sciences at the University of West London, but you 
may have to pay legal costs.   
Independent Contact Point 
You can contact INVOLVE, a national advisory group which supports active public involvement 




023 8059 5628 Alpha House, University of 
Southampton Science Park, Chilworth, 
Southampton, SO16 7NS 
involve@nihr.ac.uk 
Who will have access to my personal data? 
Only the research team have access to your personal data. Trust staff of the Research and 
Development Office may need to check data in the course of their work monitoring and 
auditing research.   
What will happen to the results of the research study? 
The results of this study may be published in scientific journals or presented at scientific 
conferences, but there will be no way of knowing who has taken part. Our results will be 
accessible by browsing the registry on this database: www.researchregistry.com using the 
study Research Registry Unique Identifying Number: researchregistry3816.  
Research Team Contact Details  
If you would like any further information about this study or would like to participate please 
contact: 




Email: Elizabeth.barley@uwl.ac.uk frederique.lamontagne-godwin@nhs.net 
Address: University of West London 
School of Human and Social Sciences 
Paragon House Boston Manor road, Brentford, Middlesex, TW8 9GA 
Telephone: 020 8209 4117 [project mobile number] 
 
What now? 
If you decide to participate in this study, we will ask you to sign a consent form. We will keep 
one copy, and give you another copy to keep. Thank you very much for taking time to consider 
being in this study. 
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Appendix 13. Consent form (health professionals) 
Rec ref: 18/SC/0123 
IRAS Project ID: 233934 
[Insert Trust and UWL logos] 
 
Participant Identification Number: __________ 
 
Short study title: Cervical screening informed choice tool for women with mental 
illness 
Name of researcher: Frederique Lamontagne-Godwin 
 
 




      
Thank you for considering taking part in this research. The person organising the 
research should have explained the project to you before you agree to take part. If you 
have any questions arising from the Information Sheet or explanation already given to 
you, please ask the researcher before you decide whether to join in. You will be given 
a copy of this Consent Form to keep and refer to at any time. 
 
Please initials in the boxes next to the statements you agree with after you have 






I confirm that I have read and understood the information sheet version 0.3 
dated 08/03/2018 for the above study and have had the opportunity to ask 
questions. All questions have been answered to my satisfaction. 
  
    
2) I understand that my participation is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my work or legal rights being 
affected. 
  
    
3) I understand that I will be interviewed about my views and feedback on an 
informed choice tool to facilitate cervical screening decision-making for women 
diagnosed with a serious mental illness. 
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I consent to my interview being audio recorded. 
 
 
I consent to the processing of my personal information for the purposes 
explained to me. I understand that such information will be handled in 
accordance with the terms of the UK Data Protection Act 1998.  
 
I understand that I may be quoted anonymously (no name or identifying 
information) in reports of the results of the study. I give my permission for this. 
 
 
I understand that, if I wish, my interview can be excluded from the study if 






I understand that some parts of the data collected for the study may be looked 
at by representatives of regulatory authorities and by authorised people to 
check that the study is being carried out correctly. All will have a duty of 








I agree to make my anonymised data available with the UK Data Service, which 
is funded by the Economic and Social Research Council (ESRC). We will use 
this free UK data service to store the qualitative data and quantitative data as 
open data.  
 
  
    
 
___________________________ _____________ _________________
   





   
Name of person taking consent  Date   Signature 
(Interviewer) 
 






Yes / No 
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Appendix 14. Demographic questionnaire for women with SMI 
 
Participant Identification Number: __________ 
Rec ref: 18/SC/0123 
IRAS Project ID: 233934       
[NHS Trust and UWL logos] 
 
Short study title: Cervical screening informed choice tool for women with mental 
illness 
Name of researcher: Frederique Lamontagne-Godwin 
 
Questionnaire for women diagnosed with a serious mental illness 
Gender 
 
At birth, were you described as:  
Female           
Male         
Intersex  
Would rather not say 
 
Which of the following options describes how you think of yourself now:  
Female          Male   
In another way.............................................................. 
Would rather not say 
 
Year of birth 
 
 
Ethnic group (Choose one option that best describes your ethnic group or background) 
White  11. Bangladeshi   
1. English/Welsh/Scottish/Northern 
Irish/British  
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2. Irish    
13. Any other Asian 




3. Gypsy or Irish Traveller   Black/ African/Caribbean/Black 
British 
 
4. Any other White background, 
please describe 
……………………………… 
 14. African   
Mixed/Multiple ethnic group  15. Caribbean  
5. White and Black Caribbean   16. Any other 
Black/African/Caribbean  
background, please describe 
          ……………………………… 
 
6. White and Black African   Other ethnic group  
7. White and Asian  17. Arab  
8. Any other Mixed/Multiple ethnic 
background, please describe 
……………………………… 
 18. Any other ethnic group, 
please describe: 
           ……………………………… 
 
Asian/Asian British   
9. Indian   
10. Pakistani   






Have you ever had a smear test? 
Never 
Once 
More than once 
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Appendix 15. Healthcare professional questionnaire 
Rec ref: 18/SC/0123 
IRAS Project ID: 233934      
[Insert Trust and UWL logos] 
 
Participant Identification Number: __________ 
Short study title: Cervical screening informed choice tool for women with mental illness 
Name of researcher: Frederique Lamontagne-Godwin 
 
Healthcare Professional Questionnaire 
Gender  
At birth, were you described as:  
 
Female           
Male         
Intersex  
Would rather not say 
 
Which of the following options describes how you think of yourself now:  
Female           
Male   
In another way.............................................................. 
Would rather not say 
Year of birth 
 
Ethnic group (Choose one option that best describes your ethnic group or 
background) 
White 11. Bangladeshi   
11. English/Welsh/Scottish/Northern 
Irish/British  
  12. Chinese   
12. Irish   13. Any other Asian 
background, please describe 
……………………………… 
 
13. Gypsy or Irish Traveller   Black/ African/Caribbean/Black 
British 
14. Any other White background, 
please describe 
……………………………… 
















Mixed/Multiple ethnic group 15. Caribbean  
15. White and Black Caribbean   16. Any other 
Black/African/Caribbean  
background, please describe 
          ……………………………… 
 
16. White and Black African   Other ethnic group 
17. White and Asian  17. Arab  
18. Any other Mixed/Multiple ethnic 
background, please describe 
……………………………… 
 18. Any other ethnic group, 
please describe: 
           ……………………………… 
 
Asian/Asian British  
19. Indian   









Length of time since your initial qualification 
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Appendix 16. Interview schedule (women with SMI) 
Rec ref: 18/SC/0123  
IRAS Project ID: 233934 
Interview Schedule #1 
 
Women diagnosed with a serious mental illness 
Feedback on the content of the smear test information leaflet 
 
The interview items are a guide for the discussion and the follow-up questions and prompts 
can be added as necessary. The order and content of the items do not need to be adhered to 
precisely.  It may be useful or necessary to adjust the wording of some questions for individual 
participants or to follow up some items using questions that appear elsewhere in the schedule.    
Before starting the interview: obtain signed consent to participate in the study and ask 
participant to complete a brief questionnaire.   
Introduction  
Thank you for agreeing to take part in our study. We are interested in exploring views of 
women diagnosed with a serious mental illness on this draft smear test information leaflet, 
which aims to improve the decision-making process of women to attend a smear test. I just 
want to ask you a few questions about your thoughts on the content. All information will be 
kept completely confidential.     
Are there any questions you would like to ask me before we start? 
Inform participant you are turning on recorder 
• What do you think of the information leaflet? 
• What suggestions do you have about the content? [Prompt: What information do you 
feel should be in/excluded?] 
• Would the information leaflet have been useful to you in making the decision to 
attend a smear test in the past? If not, why not? 
• Would you use this information leaflet in thinking about attending a smear test in the 
future? If not, why not? If yes, why (perhaps 3 main benefits) 
• Would the information leaflet be useful in making other screening decisions e.g. 
breast screening? If not, why not? If yes why?  
• Would you recommend a friend with a mental health condition to use this information 
leaflet to reach a screening decision? If not, why not? 
• Would you recommend clinicians to use the information leaflet in assisting mental 
health service users with a screening decision? If not, why not? 
• Would you prefer to go through the information leaflet alone or with someone else, 
and if so, who? 
Finally... 
 
Interview Schedule_#1_content interview_Phase 3_WDSMI_v0.1.08022018 
 
• Is there anything else you would like to say about what health professionals and 
health services might do that would make it easier for people diagnosed with a 
serious mental illness to decide whether or not to go for cancer screening?   
• And what could be done to make the experience of cancer screening better for 
people diagnosed with a serious mental illness? 
................................................................................................................................................... 
 
Thank the participant for their time and contribution. 
 
Reiterate that the audio-recording will be transcribed for analysis, then deleted with just the 
transcribed data to be used for analysis. 
 




Appendix 17. Interview schedule (health professionals) 
Rec ref: 18/SC/0123  
IRAS Project ID: 233934 
 
Interview Schedule #1 
Healthcare Professional 
Feedback on cervical screening informed choice tool for women 
diagnosed with a serious mental illness 
 
The interview items are a guide for the discussion and the follow-up questions and 
prompts can be added as necessary.  The order and content of the items do not need 
to be adhered to precisely.  It may be useful or necessary to adjust the wording of 
some questions for individual participants or to follow up some items using questions 
that appear elsewhere in the schedule.    
Before starting the interview 
Obtain signed consent to participate in the study and ask participant to complete a 
brief demographic questionnaire. Remind participant of rights to withdraw at any time, 
before, during or after the study.  
Introduction  
Thank you for agreeing to take part in our study. We are interested in exploring 
healthcare professional views of this draft informed choice tool, which aims to facilitate 
the decision-making process of whether to attend cervical screening for women 
diagnosed with a serious mental illness. I just want to ask you a few questions about 
your thoughts on the content – please answer as honestly as possible.  All information 
will be kept completely confidential.     
Are there any questions you would like to ask me before we start?  
Inform participant you are turning on recorder 
• What do you think of the tool? 
• Are there any experiences/information which you feel are missing and should 
be included? 




• Are there any changes which we should make to the tool? 
• Any other comments/suggestions about the content? 
• How likely would you be to use it with a mental health service user to assist 
them in their decision-making on whether to attend screening? Why? 
• What do you think might be the best setting to introduce the tool to your 
patients? 
• Lastly, do you have any experience of using such tools? What was their 
experience like? How does this one compare? 
....................................................................................................................................... 
Thank the participant for their time and contribution. 
 
Reiterate that the audio-recording will be transcribed for analysis, then deleted with 
just the transcribed data to be used for analysis. 
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Appendix 18. Fully coded content analysis (acceptability testing) 
 
 Revision requested by (n = ) Decision made: 
















Should we mention the leaflet 
is aimed at women with SMI? 
Perhaps we don't need to be 
so explicit… 
    Service users (and most mental health 
professionals) would not want to use such a 
label for this group. It's our role to ensure the 
leaflet is tailored to their needs, and available 
in the services they access in primary and 
secondary care 
[Image of ladies]: add text in 
bubbles (e.g. can I bring a 
friend?, I need more 
information, I'm feeling 
anxious...).  
    A professional 
illustrator was 
commissioned to 
design the front page 
cover based on service 
user feedback  
 
 
“What is in this leaflet” 
On p.3, are the sub-headings 
of 'What is cervical screening?' 
etc meant to be a contents 
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list? If so, could this be 
clarified? 
“What is cervical screening”       
“Going for cervical screening is 
the best way to protect against 
cervical cancer”: this 
contradicts above that it is not 
a test for cancer. The general 
perception is that's what it is. 
So maybe you better off giving 
details as what it is instead 
   1 Wording amended to 
reflect this 
 
Need to be more specific 
about the description of 
cervical cancer symptom 
"lower back pain": fears too 
many people will come to the 
surgery with this symptom and 
feel anxious that they have 
cancer 
 1   Wording amended to 
reflect this 
 
Could replace "these 
symptoms can all be caused 
by things other than cancer" to 
"these symptoms can all be 
caused by lots of different 
things" - maybe find another 
word for "things"; be consistent 
and replace "smear test" with 
"cervical screening" 
 1   Wording amended to 
reflect this 
 
This may read better by putting 
the sentence "It is not a test for 
cancer" at the start 
  1   This sentence was 
deleted as may be 
confusing for 
service users 
In the sentence where you say 
'it is not a test for cancer' I 
think a natural conclusion 
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might be 'why bother then?'. I 
think it should say, more 
explicitly, that it can pick up 
changes that, if left untreated, 
might eventually lead to cancer 
Word "cancer" appears too 
much, you might scare people 
off... (…) word "abnormalities" 
doesn't sit well with participant 
and guesses also for people 
who have SMI 
 1    This was not raised 
by any service user 
There is too much mention of 
the word "cancer", might worry 
someone who has paranoia or 
health anxiety and they might 
think "I'd rather not know" 
 1    This was not raised 
by any service user 
Should we be talking about 
cancer so early on in the 
leaflet? Could make people 
more anxious…it is important, 
but it might put some people 
off, maybe better to talk about 
the practical things first, that's 
what's really important 
 1    This was not raised 
by any service user 
Perhaps remove one mention 
of "cancer" by saying: "it's a 
preventative check that can 
prevent some serious illnesses 
like cancer"; when we describe 
cervical cancer symptoms, we 
can say "these things can be 
caused by things other than 
cancer"; avoid having the word 
"cancer" on its own 
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Don't be afraid to be explicit 
about the risks involved if they 
don't go, don't be scared to 
use the word "cancer" 
 1    Have tried to strike 




Need to be factual, don't shy 
away from using the word 
"cancer" 
 1    Have tried to strike 




You could add: "if you catch it 
[cervical cancer] in time you'll 
be alright" 
 1   Wording amended to 
reflect this 
 
Offer alternative sources of 
information as not everyone 
has access to a computer or 
the internet 
  1   Research shows 
this group has 
access to internet 
and a computer. 
The leaflet will be 
available as a 
paper version in 
clinics 
Is there an option for women 
younger than 24 to have the 
test if they are worried? 
1     Leaflet is designed 
to provide 
information to 
women on the NHS 
cervical screening 
programme 
This sentence "If you’ve never 
had any sexual contact, your 
risk of developing cervical 
cancer is very low.  If you’re 
not sure if you need a test, talk 
to your GP or practice nurse." 
feels a bit out of place. I would 
take it out – we don’t want to 
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actively discourage people 
from going, especially as we 
can’t link all cervical cancers to 
HPV at the moment. Saying ‘If 
you’re not sure if you need a 
test…’ is a good enough 
prompt to talk/ask questions. 
It's relevant for people to know 
what to get checked between 
appointments (p.5). I'm 
thinking, though, that this 
section might be better near 
the end of the leaflet. As 
people are likely to be nervous 
before going for a smear test 
at all, it's probably not helpful 
to mention too early on what 
problems may arise even after 
one has gone for an 
appointment 
  1  A new section (Looking 
after your health) 
towards the end of the 
leaflet was included 
which includes 




I didn't know that smear tests 
wouldn't be able to detect 
cancer 
1    Sentence was removed 
to avoid confusion 
 
“Booking your appointment” 
"If your mental health 
symptoms get worse in waiting 
rooms, ask to book the first 
appointment of the day, so you 
aren’t waiting long": This 
phrase assumes the person 
does have mental illness, but I 
didn’t get the sense from the 
start of the booklet that all 
people reading this would. 
Think it either needs to be 
   1  The leaflet should 
be tailored to their 
needs without 
having to be too 
explicit that this is 
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definite throughout, or more 
vague here. Would prefer it 
definite throughout (see 
suggestion at start).  
Double appointments are an 
issue in some practices… 
 1   Have revised to: "Ask 
the receptionist if you 
can book a longer 
appointment." 
 
A lot of GPs don't have the 
licence to do smear tests 
because they do so few and in 
some practices it's so hard to 
get a GP appointment, so it 
might be worth removing and 
just stating 'make an 
appointment with your practice 
nurse' 
 1   Wording amended to 
reflect this 
 
Patient may not get it, but they 
could "ask for" a double 
appointment 
 1   Wording amended to 
reflect this 
 
Could also suggest going to 
your GUM clinic, more of a 
female environment 
1 1   Wording amended to 
reflect this 
 
Asking for the 1st appointment 
of the day (p.6) sounds a 
helpful idea for some people 
who find it hard to wait. 
However, for others of us, the 
morning is a particularly 
difficult time of day. What 
about an alternative 
suggestion to fit this, e.g. 
asking for the first appointment 
after a surgery's lunch break? 
  1   We cannot make it 
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An appointment reminder (p.6) 
can be helpful and many 
surgeries now do this 
automatically, of course. 
However, not everyone will feel 
a need for it, so you might like 
to add the words: 'If you would 
find this helpful'? 
  1  Wording amended to 
reflect this 
 
You may want to clarify in what 
circumstances people would 
want a longer appointment? 
Many of us would just like to 
get in and out as quickly as 
possible! 
  1  Wording amended to 
reflect this 
 
[Regarding people who might 
be feeling anxious in a waiting 
room before their smear test] 
that's a confusing one, what 
does that mean, they wouldn't 
know that you're going [for a 
smear test]? [I explain that 
some people get 
anxious/paranoid sitting in 
waiting rooms, they don’t get 
anxious because they think 
other people know they are 
going for a smear. She then 
replies:] oh that is me [I get 
anxious in waiting rooms]  
1    Wording amended to 
reflect this 
 
“Before your appointment” 
“Ask someone you trust to go 
to the appointment with you. 
See if they can be free in the 
morning or afternoon off work, 
to stay with you”: I think people 
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may not know re health 
attendants or chaperones and 
we can introduce that here 
The section "Before your 
appointment" could come a bit 
earlier 
 1    This was not raised 
by any service user 
"book a double 
appointment/organise 
transport in advance" sounds 
quite prescriptive, perhaps 
replace with "you can book… 
 1   Wording amended to 
reflect this 
 
Instead of "book your transport 
in advance" you could reword: 
“If it reduces your anxiety, you 
can plan your travel the day 
before, what time do you need 
to get up, what time do you 
need to leave the house, what 
time are the trains etc” 
1    Wording amended to 
reflect this 
 
Bring a friend, relative "or your 
mental health professional" 
 1   Wording amended to 
reflect this 
 
"Bringing nicotine chewing 
gum in case you have a 
cigarette craving while you’re 
in the waiting room": Very 
specific! Has this come up a lot 
in the SMI interviews? 
   1  There is a very 
high prevalence 
rate of smoking in 
this group 
 
I'm not sure I'd find it helpful to 
list for myself why it's important 
to go (p.8) -  for me, the issue 
is getting oneself there rather 
than being unaware of the 
reasons for going. However, 
everyone is different of course 
  1   It may be useful as 
goal setting. Some 
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[box which allows you to think 
about why you find it hard to 
go, what would help you to 
go...] After point 1 – think 
about reasons - add lines for 
the thoughts or add point 2 into 
the first one. Is point 2 a 
separate question? This bit is 
confusing. It seems to be 
asking two different things with 
one only one space to write in 
  1  The formatting of this 
section has been 
revised to avoid 
confusion 
 
For some people with mental 
health problems it is very 
difficult for them to ring and 
make appointments and ask 
for the support they need. 
Could there be a sentence 
saying something like: if you 
find making an appointment 
difficult, ask a trusted relative, 
friend or your mental health 
worker to help you 
  1   There is a box 
where service 
users can fill out 
this section: "This 
would help me go 
to my appointment" 
 
“tick box page” 
Ensure service users 
understand that filling out this 
page is optional [Is it optional 
[the tick box exercise]? Do I 
get given that [leaflet] at the 
GP or?] 
 
2   1  Women can 
choose whether to 
bring the leaflet to 
their appointment, 
so it is optional by 
nature 
You may also want to add 
points related to people from 
marginalised communities, e.g. 
women who identify as lesbian, 
bisexual or transgender and 
  1   Out of scope for 
this project, though 
FGM is mentioned 
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women from BAME 
communities with particular 
cultural issues 
[Service user had a previous 
bad experience with practice 
nurse, I asked whether it would 
be clearer if I put ‘I had a 
previous bad smear test 
experience’ rather than ‘I had a 
previous bad experience’] 
maybe, it’s clearer 
1    Wording amended to 
reflect this 
 
The language used on this 
page seems traumatising - it 
makes the test sound like a big 
thing to go through.  Be careful 
of using words like ‘anxiety’, 
mentioning anxiety could 
trigger it (…) Could the list of 
things that might bother you be 
worded differently – is there 
another way to describe ‘stress 
responses’? 
  1   This was not raised 
during any service 
user interview 
The idea of being able to show 
the nurse points you may want 
her/him to understand seems 
potentially helpful. I think it 
would be useful also to 
suggest having the opportunity 
(a) to  let the nurse know 
beforehand about these and 
(b) to talk through with him/her 
beforehand (i) how a particular 
issue affects your feelings 
  1   With time 
pressures in 
primary care, it is 
not possible for 
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about a smear test and (ii) 
what would help you 
[participant had a previous bad 
experience with practice nurse, 
candidate asked whether it 
would it be clearer if the tool 
includes: ‘I had a previous bad 
smear test experience’ rather 
than: ‘I had a previous bad 
experience’]: “maybe, it’s 
clearer” 
1    Change made to 
distinguish any type of 
trauma from “a 
previous bad smear 
test experience” which 
is more specific 
 
“This is good [the tick box 
page] as long as it’s all kept 
confidential” 






You may also want to add 
points related to people from 
marginalised communities, e.g. 
women who identify as lesbian, 
bisexual or transgender and 
women from BAME 
communities with particular 
cultural issues 
  1   We had already 
included “I am a 






separate tool for 
LGBTQIA 
community 
“I think it would be useful to 
suggest having the opportunity 
(a) to let the nurse know 
beforehand about these issues 
and (b) to talk through with 
him/her beforehand (i) how a 
  1   Due to time 
pressures in 
primary care, it is 
not possible for 
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particular issue affects your 
feelings about a smear test 




All words need to be spelt out 
fully e.g. examination not exam 
  1  Wording amended to 
reflect this 
 
“I may react in an unexpected 
way”: nurse may ask “so what 
are you gonna do?!” in a not 
very helpful way, so it’s better 
to have a line where the 
person can write down how 
they think they may react 
1    Change made; the 
option “Other:……” was 
added 
 
You could add “I have an issue 
with my GP” as a barrier 
 1    The option was 
added: “I have had 




experience with a 
health professional 
I wonder whether there should 
be a space for (optionally) 
writing ‘my mental health 
conditions/diagnoses are...’ so 
that the tool can be shown to 
the health professional doing 
the test. The nurse/Dr may not 
have access to medical 
records at the time of the test, 
and it might make it easier for 
the patient.  
   1 “I have a mental illness” 
was replaced with “I 




Obesity is an issue with this 
group: could add “I am 
 1   The option was added: 
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embarrassed by my body 
shape” 
“I am a voices hearer and get 
distressed during a physical 
exam”: split into two different 
categories 
 1   The options were 
added: “I hear voices” 
and “I get distressed 
during a physical 
examination” 
 
The option “I have other health 
issues” isn’t clear, could be 
replaced by “I find it hard to 
maintain a healthy weight” 
   1 The option “I have 
other health issues” 
was removed. It was 
replaced by “I am 
embarrassed by my 
body” 
 
Instead of just pass out, add 
“faint” 
   1 The option was added: 
“I may pass out or faint” 
 
“During your appointment” 
Words like cervix can be 
difficult to understand – may 
need further explanation and 
/or diagram 
1    An image of female 
anatomy has been 
included (copyright jo’s 
Trust) 
 
Should there be diagrams to 
complement the description? 
    An image of female 
anatomy has been 
included (copyright jo’s 
Trust) 
An Easy Guide 
already exists 
 
It’s silly but…point 
three…maybe it should say “lie 
back on a bed" 
 1   Wording amended to 
reflect this 
 
Be careful about making 
suggestions of nice things to 
do. Some people may not 
enjoy what you suggest or be 
able to afford it  
  1   This was not raised 








Page 486 of 500 
aaah "treat yourself 




mention there has 
been a discussion 
about whether it’s 
necessary to give 
specific examples, 
everyone will have 
a different idea] I 
think it’s ok for her 
to leave it like that, 
for me it would be: 
“have a bubble 
bath”) 
There is not enough emphasis 
on how quick the test is / 
minimal level of discomfort / 
the experience of staff doing 
the test 
  1  This sentence was 
added: "The test only 
takes a few minutes. It 
might feel 
uncomfortable but 
should not be painful." 
 
Could mention that the ''smear 
test can be sore/uncomfortable 
but it will be over quickly" - 
however that might put people 
off! 
 1   This sentence was 
added: "The test only 
takes a few minutes. It 
might feel 
uncomfortable but 
should not be painful." 
 
"If it's uncomfortable ask for a 
smaller speculum": can we 
avoid changing the size during 
the procedure and ask for a 
smaller size at the outset? they 
might otherwise be put off and 
    This sentence was 
removed. In the 
'Booking your 
appointment' section 
the following is 
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feel traumatised if they have 
experienced pain 
the test may be 
uncomfortable, speak 
with the nurse 
beforehand. They can 
offer support." 
I'd like to know if the 
examination is at all painful, or 
if it's not painful at all (...) it 
may be handy to put it in the 
leaflet that it's not painful at all, 
that it may be uncomfortable 
but it's not painful (…) just to 
be constantly reassured that 
it's not going to be painful (…) 
Thinks more women would go 
[to smear test or other medical 
appointments] if they were 
reassured that it's not painful 
and if it hurts, how much does 
it hurt. It's uncomfortable 
especially if you're not in a 
sexual relationship and they 
might think their vagina is very 
small, they might think oh god 
is it gonna hurt (…) Pain is a 
factor that stops people from 
going 
1    This sentence was 
added: "The test only 
takes a few minutes. It 
might feel 
uncomfortable but 
should not be painful." 
 
 
Perhaps reword 'tea and cake' 
to something more generic like 
'treat yourself': such an issue 
with obesity in this group… 
 1   Was revised to: "Make 
plans after your 
appointment. You could 
treat yourself to 
something nice and 
relaxing." 
 
[queried whether we should 
take out the "tea and cake" 
 1    Was revised to: 
"Make plans after 
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suggestion] Doesn't have an 
issue with leaving in "treat 
yourself to something nice like 
tea and cake"!  
your appointment. 
You could 
treat yourself to 
something nice and 
relaxing." 
Instead of "go out for tea and 
cake" you could say "make 
sure you allow yourself time for 
a pleasurable activity", 
something that they feel happy 
with (e.g. going for a walk, 
shopping, seeing a friend) 
 1   Was revised to: "Make 
plans after your 
appointment. You could 
treat yourself to 
something nice and 
relaxing." 
 
“After your appointment” 
Could the word ‘worried’ be 
used instead of anxious? 
  1   This was not raised 
by any service user 
Could add "share your 
concerns with your mental 
health professional" 




Speak to your mental health 
professional (not nurse - teams 
are multidisciplinary) to get 
emotional support/do a debrief 
 1   Have included "mental 
health worker" (more 
inclusive in terms of 
roles) 
 
If the patient needs emotional 
support, you could add: "speak 
to your mental health nurse" 
 1   Have included "mental 
health worker" (more 
inclusive in terms of 
roles) 
 
Instead of "speak to your 
doctor" on the "Getting 
support" page, would add "or 
nurse" 
 1   Have included "mental 
health worker" (more 
inclusive in terms of 
roles) 
 
Instead of "speak to your 
mental health crisis team" 
[generally the mental health 
crisis team is for people who 
are at the point of admission], 
 1   Have included "mental 
health worker" (more 
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speak to your "community 
mental health worker/mental 
health professional" 
Would suggest adding 
"relative" [if you need support] 
1    Wording amended to 
reflect this 
 
If I was feeling anxious I would 
probably talk to one of my 
support workers, maybe go to 
CAPE [Community Activities 
Projects Ealing: http://c-a-p-
e.co.uk]. it would have to be 
someone I trust, and mainly at 
the moment the only people I 
think I could trust is the people 
in authorities so like Dr 
[psychiatrist] maybe or the 
nurse if she's alright if she's 
the same nurse but I wouldn't 
talk to a friend about it 
because I don't feel, some of 
these people, women, that I 
speak to they're just like oh it's 
one of them things, but i don't 
want to hear that, I want 
positivity I don't want negativity 
(...) I'd talk to a professional to 
be honest 
1    Have added "trust": 
"Talk to a trusted friend, 




Some people may have better 
relationships with primary care 
so take out "mental" in 
sentence "if you don't 
understand your results or 
have any questions, speak to 
your mental health 
professional" 
   1 Have added: "Talk to a 
trusted friend, relative 
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“Getting support” 
It's good to see the list of 
support agencies on pp. 13 
and 14. Many of us are not so 
keen on SANEline, though, 
because SANE is felt to be 
particularly medical model in 
ethos. You may want to 
balance this by mentioning 
another helpline with a wider 
approach? You may also want 
to add helplines for people 
from BAME communities? 
There can be particular issues 
related to institutional racism 
within the NHS, or some 
particular sensitivities, e.g. for 
some Asian women?  
  1  Samaritans was added 
(not NHS related) 
 






Add "local" to the sentence 
"Ask about support services in 
your [local] area" 
 1    The leaflet can be 
adapted to local 
services; the leaflet 
must suggest 
organisations and 
charities that are 
accessible 
nationally 
Could there be space here for 
local areas to add in 
information about other places 
to access cervical screening? 
For example, sexual health 
clinics offer this service in our 
area and we have GP 
practices signed up to be ‘No 
  1   The leaflet can be 
adapted to local 
services; the leaflet 
must suggest 
organisations and 
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Fear’ practices which offer 
additional support to women 
You could add MIND as a 
suggestion for contacting 
someone for emotional 
support, or "speak to your 
mental health professional" if 
you are anxious about results 
 1   Have included "mental 
health worker" (more 
inclusive in terms of 
roles) 
 
Mind does not 
have a line for 
emotional support 
 
Suggest taking out "these 
charities were suggested" and 
replace with "some women 
found it helpful to contact" 
   1 Have revised to: "You 
may prefer to speak to 
someone you don’t 
know. 
Pages 14 and 15 list 
helplines you can call." 
 
Have the use of these phone 
numbers been sanctioned by 
the charities? 
   1 We have approval from 
every organisation 
included in the leaflet 
 
Think having SANEline is a 
good idea [described what 
they do, help with distress, 
anxiety] coz normally it's the 
day before [that you get 
anxious], could be the evening 
before people say oh do I go 
[to the appointment], what 
should I do! (…) Samaritans is 
more if you need to chat to a 
friend, if you're lonely, so 
MIND is better, they can help 
you with your anxiety or stress 
of something 
1    Based on this 
feedback, we have 
modified the support 
page to ensure it's clear 
that women feel they 
can ask for support 




Suggestions to the overall document 
Are you able to attach first 
names to quotes? It can help 
   1 Will use pseudonyms  
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make it a bit more personal for 
the reader 
Reduce the amount of text in 
the leaflet/shorten the leaflet 
 1 1  Have tried to reduce 
wording in every 
section  
 
Perhaps the leaflet is a little 
long, might be overwhelming 
for patients who are quite 
anxious, but having said that 
there are no sections I would 
remove and also you don't 
want to undersell importance 
of the test 
 1   Have tried to reduce 
wording in every 
section 
 
Concentration is an issue with 
this group of patients, could we 
cut it down a little? 
 1   Have tried to reduce 
wording in every 
section 
 
You could run a scenario 
through people's minds [so 
and so is a teacher, and this is 
how she went about booking 
her apt etc.]: service users look 
at professionals for guidance 
 1    Not feasible for the 
leaflet but this idea 
was suggested for 
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Appendix 20. Sample page from Version 0.4 of the tool 
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A 









Jo’s Cervical Cancer Trust A national charity 
dedicated to eliminating cervical cancer. Has 
information and support about cervical 
screening, cell changes (abnormal cells) and 
cervical cancer – no question is too big or 
small. www.jostrust.org.uk 
Helpline: 0808 802 8000 
(For opening hours, visit www.jostrust.org.uk/helpline) 
Ask the Expert: www.jostrust.org.uk/ask-expert 
 
My Body Back (London and Glasgow) 
Offers support to women to reclaim control of their 
body after sexual violence. Runs specialist clinics 
offering cervical screening and STI testing in 
London and Glasgow for women and trans men 




Samaritans is available round the clock, every single day of the year. 
You can talk to them any time you like, in your own way, about 
whatever’s getting to you. 
Call free any time on 116 123 
Email jo@samaritans.org 
Find your nearest branch at www.samaritans.org 
 
SANE 
National mental health helpline offering specialist 
emotional support to anyone affected by mental 
llness. www.sane.org.uk 
SANEline: 0300 304 7000 
(Every day, 4.30pm to 10.30pm) 
 
Getting support 
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Appendix 22. Decisional Conflict Scale (O’Connor, 1993)  
 
Rec ref: 18/SC/0123  
IRAS Project ID: 233934        





My difficulty in making this choice 
 
A.  Which smear test option to you prefer? Please check ☑ one. 
 
a. ☐ Option 1: I will attend my cervical screening appointment 
b. ☐ Option 2: I will not attend my cervical screening appointment 
c. ☐ Option 3: Unsure  
 
B. Considering the option you prefer, please answer the following questions: 
 
 Yes Unsure No 
1.      Do you know which options are available to you?    
2.      Do you know the benefits of each option?    
3.      Do you know the risks and side effects of each 
option? 
   
4.      Are you clear about which benefits matter most 
to you? 
   
5.      Are you clear about which risks and side effects 
matter most to you? 
   
6.      Do you have enough support from others to 
make a choice? 
   
7.      Are you choosing without pressure from others?    
8.      Do you have enough advice to make a choice?    
9.      Are you clear about the best choice for you?    








My difficulty in making this choice 
 
C.  Which smear test option to you prefer? Please check ☑ one. 
 
a. ☐ Option 1: I will attend my cervical screening appointment 
b. ☐ Option 2: I will not attend my cervical screening appointment 
c. ☐ Option 3: Unsure  
 
 
D. Considering the option you prefer, please answer the following questions: 
 
 Yes Unsure No 
11.      Do you know which options are available to 
you? 
   
12.      Do you know the benefits of each option?    
13.      Do you know the risks and side effects of 
each option? 
   
14.      Are you clear about which benefits matter 
most to you? 
   
15.      Are you clear about which risks and side 
effects matter most to you? 
   
16.      Do you have enough support from others to 
make a choice? 
   
17.      Are you choosing without pressure from 
others? 
   
18.      Do you have enough advice to make a 
choice? 
   
19.      Are you clear about the best choice for you?    












Appendix 23. Stage of Decision Making (O’Connor, 2000) 
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Stage of Decision Making 
 
 
How far along are you with your decision? 
 
 









a.  I have not yet thought about the options. 
 
b.  I am considering the options. 
 
c.  I am close to choosing one option. 
 
d.  I have already made a choice. 
 
 
Stage of Decision Making © AM O’Connor, MJ Jacobsen, D Stacey 2002 
 
 








Appendix 24. Abstract for the West London NHS Trust R&D Conference (April 2019) 
 
Oral Presentation  
Title of presentation: The development, usability and acceptability of a cervical screening 
informed choice tool for women living with a severe mental illness and/or women who have 
experienced trauma  
Author: Frédérique Lamontagne-Godwin  
University of West London  
Supervisors:  
Professor Elizabeth Barley, University of Surrey  
Dr Claire Henderson, King’s College London  
Professor Caroline Lafarge, University of West London  
Abstract  
Purpose/Objective: People with severe mental illness (SMI) die on average 10-20 years 
sooner than the general population, including from cancer. People with SMI face barriers to 
screening uptake and have poorer survival rates following diagnosis of cancer. The aim of 
this PhD research is to develop a cervical screening informed choice tool for women with 
SMI.  
Research Questions: What are, if any, the specific design(s) and theoretical 
underpinning(s) of informed choice tools developed for people with SMI? What are service 
users’ and clinicians’ experiences of using the tool? Does the tool have any impact on 
service users’ decisional conflict to attend screening?  
Methods: A realist review of interventions to increase access to or uptake of physical health 
screening for people with SMI and a systematic review of informed choice tools for this 
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population have been conducted. A mixed-methods research design was used to develop 
the tool informed by these reviews. The usability and acceptability of the tool (paper leaflet) 
was tested by service users and clinicians in the West London NHS Trust and Dorset 
Healthcare University NHS foundation Trust, using semi-structured interviews and the think-
aloud method. In May-June 2019, a preliminary evaluation of the tool's impact on decision-
making to attend cervical screening will be conducted with service users.  
Main findings: Feedback from a national Key Reference Group, service users, service user 
groups and clinicians demonstrates acceptability and usability of the tool. A dissemination 
strategy has been planned involving CCGs, Public Health England, NHS Trusts and cancer 
and mental health charities. An animated video to illustrate key information from the leaflet 
is currently being developed.  
Significance for research and practice: The tool is designed to help women with SMI to 
make an informed decision about whether to attend cervical screening. It can be used by 
women themselves or as a tool for clinicians to help their clients. This may impact on 
screening uptake and mortality rates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
